20250623140951

Årsredovisning

för

Getinge Sterilization Aktiebolag

556031-2687

Räkenskapsåret

2024

Fastställelseintyg

Undertecknad verkställande direktör i Getinge Sterilization Aktiebolag intygar att resultaträkningen och balansräkningen i årsredovisningen har fastställts på årsstämma den 26/5 2025. Årsstämman beslutade att godkänna styrelsens förslag till resultatdisposition.

Jag intygar också att innehållet i årsredovisningen och revisionsberättelsen stämmer överens med originalen.

Halmstad den 2025-06-16

Maria Ek

20250623 14953

Årsredovisning

för

Getinge Sterilization Aktiebolag

556031-2687

Räkenskapsåret

2024

20250623140954

Styrelsen och verkställande direktören för Getinge Sterilization Aktiebolag upprättar följande årsredovisning för räkenskapsåret 2024.

Årsredovisningen är upprättad i svenska kronor, SEK. Om inte annat särskilt anges, redovisas alla belopp i tusentals kronor (Tkr). Uppgifter inom parentes avser föregående år.

Förvaltningsberättelse

Information om verksamheten

Getinge Sterilization AB bedriver tillverkning och försäljning av sterilisationsutrustning, huvudsakligen avsett för sjukvård, Surgical Workflow, och laboratorier och farmaceutisk industri, Life Science. Av totala försäljningen utgör ca 91,87% (98,16%) intern försäljning till koncernbolag. Av totala inköp utgörs ca 28,04% (27,57%) inköp från andra koncernbolag.

Ägarförhållanden

Bolaget är ett helägt dotterbolag till Getinge AB (org. nr. 556408-5032, säte i Göteborg). Getinge AB är det slutliga moderbolaget i den koncern vilken Getinge Sterilization AB ingår. Med stöd av årsredovisningslagen (ÅRL) 7 kap 2 § har inte någon koncernredovisning upprättats avseende Getinge Sterilization AB-koncernen. För information om den ekonomiska ställningen och resultatet för den koncern som Getinge Sterilization AB ingår i hänvisas till koncernredovisningen för Getinge AB.

Flerårsöversikt (Tkr)	**2024**	**2023**	**2022**	**2021**	**2020**
Nettoomsättning	516 166	692 382	810 929	731 533	714 928
Resultat efter finansiella poster	-168 767	-147 286	-106 879	168 922	-230 652
Balansomslutning	1 453 843	2 051 345	1 952 787	1 596 166	1 779 332
Antalet anställda st	367	375	371	349	338
Soliditet %	44	31	35	31	12
Avkastning på totalt kap. (%)	neg	neg	neg	12,4	neg

För definitioner av nyckeltal, se Redovisnings- och värderingsprinciper.

20250623114955

Väsentliga händelser under räkenskapsåret

Orderingången för 2024 var på en rimlig nivå, med något försvagad effekt under hösten, men som delvis kompenserades under årets sista månad. Våra goda och långvariga kundrelationer resulterade i flera återkommande beställningar från vissa stora kunder.

Projektportföljen har under året utvecklats till mer komplexa utrustningar med större tyngd på konstruktion och programmering. Detta har inneburit ett kompetensskifte i organisationen som har medfört något längre ledtider. Samtidigt arbetar vi med effektivitets aktiviteter inom vårt Manufacturing Excellence program för att korta ner ledtiderna. Volymen av intäktsredovisade projekt har minskat under året. Detta hör delvis samman med det under 2023 förändrade leveransvillkoret från exwork till dap som slog igenom fullt ut 2024, som innebär att vi intäktsredovisar projekten först vid ankomst till kund.

Vi har även tagit viktiga steg i vår långsiktiga hållbarhets- och digitaliseringsstrategi. Under året har vår nya solenergipark på tagits i drift, vilket bidrar till att minska vår klimatpåverkan. Samtidigt har vi inlett förberedelserna för implementeringen av nytt affärssystemet SAP, vilket kommer att skapa en tydligare struktur och bidra till effektivare och mer integrerade affärsprocesser framöver.

Väsentliga händelser efter räkenskapsårets slut

Efter räkenskapetsårets slut har det inte skett några väsentliga händelser för Getinge Sterilization AB.

20250623149356

Förväntad framtida utveckling samt väsentliga risker och osäkerhetsfaktorer

Trots en svag inledning i orderingången och en omvärld i förändring, så finns det goda förhoppningar om återhämtning från halvårsskiftet.

Med positiva kundrelationer ser vi fram emot att stärka vår position ytterligare. Vi planerar att fortsätta vår satsning på utvecklingsprojekt, samtidigt som vi strävar efter att förbättra vår effektivitet och öka produktionskapaciteten med målbilden att minska ledtiden och våra kostnader.

Trots våra positiva förväntningar finns det även risker och osäkerhetsfaktorer som vi måste ta hänsyn till. Tullarna till USA är en osäkerhetsfaktor som kan påverka vår export till USA.

Vi måste vara konkurrenskraftiga och ständigt jobba med effektivitetsförbättringar för att motverka effekten av kostnadsökningar och störningar i materialförsörjningen.

I övrigt utgör generella marknadsrisker den största risken som påverkar bolaget. Dessa beskrivs mer utförligt i Getinge AB:s årsredovisning. Sammanfattningsvis är det viktigt att vi förblir uppmärksamma på dessa risker och osäkerhetsfaktorer när vi planerar för framtiden och tar strategiska beslut för att säkerställa vår långsiktiga framgång

Bolaget har en pågående miljöutredning kopplad till tidigare verksamhet i Skärhamn, Tjörns kommun. Utredningen syftar till att undersöka eventuella historiska mark- och grundvattenföroreningar som kan kopplas till verksamheten som bedrevs i ett koncernbolag som har fusionerats in i Getinge Sterilization AB. Verksamheten är avslutad men föroreningarna kan resultera i ersättningskrav mot Getinge Sterilization AB. I utredningen samarbetar Getinge Sterilization AB med företaget Geosyntec Consultants AB. I juni 2023 delades resultatet från de miljötekniska undersökningarna med Tjörns kommun och i slutet på året så kommunicerades förslag på utökad provtagningsplan med kommunen. I februari 2024 mottogs svar från kommunen, dels kring rapport och förslag på ytterligare undersökningar. Baserat på en reviderad plan har Geosyntec initierat nästa steg i provtagning under februari 2025. Utredning bedrivs metodiskt i nära kommunikation med kommunen. Utfallet är fortsatt osäkert och krav kan komma att riktas mot Getinge Sterilization AB.

Forskning och utveckling

Bolaget har större forsknings- och utvecklingsprojekt som anses vara av väsentligt värde för företaget under kommande år. Utvecklingsprojekten består till största del i projekt där bolagen vill utveckla produkter med nya tekniker och prestanda för att möta marknadskraven som också blir mer kopplade till miljökrav. För att möta marknadens behov idag och i framtiden utvecklas sterilsatorer med olika sterilisationstekniker och media. I tillägg till sterilisatorer utvecklas också tillbehör och lastutrustning för att på bästa sätt effektivisera, underlätta och hjälpa kunder och användare i det dagliga arbetet.

Bolagets kostnader för forskning och utveckling uppgick under räkneskapsåret till ca 34% (19%) av de totala rörelsekostnaderna.

20250623 14957

Användande av finansiella instrument

Bolaget redovisar månatliga valutamarknadskurser avseende försäljning och inköp i respektive valuta. Getinge Treasury ingår externa kontrakt på koncernnivå och säkrar därmed framtida flöden i annan valuta än SEK baserat på de prognosticerade flöden som koncernbolagen har.

För redovisningsprinciper avseende hanteringen av finansiella instrument hänvisas till redovisningsprinciperna.

Hållbarhetsrapport

Företaget upprättar enligt ÅRL 7 kap 31a § inte någon egen hållbarhetsrapport. Moderföretaget Getinge AB, med säte i Göteborg, Sverige och org.nr 556408-5032, upprättar hållbarhetsrapport för hela Getingekoncernen där Getinge Sterilization AB ingår. Rapporten finns att tillgå på Getinge AB:s webbplats: www.getinge.com/se/foretag/hallbarhet/.

Tillstånds- eller anmälningspliktig verksamhet enligt miljöbalken

Bolaget bedriver tillståndspliktig verksamhet enligt miljöbalken. Den tillståndspliktiga verksamheten motsvarar 100% av bolagets nettoomsättning och påverkar miljön framför allt genom energianvändning, vattenförbrukning och -utsläpp, buller och kemikaliehantering. Tillståndet beviljades den 9 december 2003, följt av en ändring av bullervillkoren den 7 mars 2005 genom dom. Företagets grundvillkor att max få använda 3000 ton plåt per år har blivit inaktuellt eftersom man numera i huvudsak köper färdiga detaljer. I samråd med tillsynsmyndigheten beslutades att nytt tillstånd ej söks men redovisning innebär nu i stället det årliga antalet försålda tryckkärl. Företaget har i den årliga miljörapporten 2024 visat att företaget uppfyllde myndighetens fastställda villkor med bred marginal.

Under 2024 utfördes årlig tillsyn med representanter för tillsynsmyndigheten och från företaget. Inga avvikelser noterades vid detta möte. Inga tillbud eller driftstörningar med påverkan på miljön har förekommit under året. Inga klagomål från grannar eller andra intressenter har framförts till bolaget eller myndigheten. Ständiga förbättringar fortgår som vanligt.

Getinge Sterilization AB är sedan den 30 december 2004 miljöcertifierat enligt ISO 14001. Certifikatet är giltigt till 12 dec 2026. Revisionen 2024 genomfördes utan avvikelser eller krav på åtgärder.

Företaget använder 100% el från vattenkraft och solpaneler och 100% biobaserad naturgas. Getinge Sterilization kan därför anses som klimatneutrala vad gäller energianvändning till fastighets- och verksamhetsenergi. Bolaget arbetar ständigt med att minska miljöpåverkan utifrån ett livscykelperspektiv, till exempel genom att utveckla nya autoklaver som förbrukar så lite vatten och energi som möjligt. Bolaget har även nära samarbete med kunderna där man genom utformande minskar resursåtgång och miljöpåverkan vid användning.

20250623114958

Förändringar i eget kapital

	Aktie-kapital	Reserv-fond	Fond för utvecklings utg	Övrigt fritt eget kapital	Totalt
Belopp vid årets ingång	5 000	1 000	182 610	454 519	**643 129**
Aktivering av utvecklingsutgifter			19 260	-19 260	**0**
Upplösning till följd av årets avsrkivningar			-19 894	19 894	**0**
Årets resultat				2 178	**2 178**
Belopp vid årets utgång	**5 000**	**1 000**	**181 976**	**457 331**	**645 307**

Aktiekapitalet består av 50 000 st aktier. Kvotvärdet är 100 kronor per aktie.

Bolaget har tidigare erhållit villkorade aktieägartillskott om totalt 314 000 Tkr. Villkoret för återbetalning för aktieägartillskott är att det på ordinarie årsstämma konstaterats att bolaget har fritt eget kapital enligt fastställd balansräkning och att en sådan återbetalning inte står i strid med ABL 17 kap 3§ 2-3 st, försiktighetsregeln samt med god affärssed.

Förslag till vinstdisposition

Styrelsen föreslår att till förfogande stående vinstmedel (kronor):

balanserad vinst	455 152 895
årets vinst	2 177 636
	457 330 531
disponeras så att	
i ny räkning överföres	457 330 531
	457 330 531

Företagets resultat och ställning i övrigt framgår av efterföljande resultat- och balansräkning samt kassaflödesanalys med noter.

20250623144959

Resultaträkning
Tkr

	Not	2024-01-01 -2024-12-31	2023-01-01 -2023-12-31
Nettoomsättning	3	516 166	692 382
Kostnad för sålda varor		-535 707	-635 062
Bruttoresultat		**-19 541**	**57 320**
Rörelsens kostnader			
Försäljningskostnader		-48 172	-68 576
Administrationskostnader		-63 114	-62 631
Forsknings- och utvecklingskostnader		-53 584	-29 044
Övriga rörelseintäkter		20 517	26 655
Övriga rörelsekostnader		-11 062	-16 016
Rörelseresultat	4, 5, 6, 7	**-174 956**	**-92 292**
Resultat från finansiella poster			
Resultat från andelar i koncernföretag		59 877	0
Räntekostnader och liknande resultatposter	8	-53 688	-54 994
		6 189	**-54 994**
Resultat efter finansiella poster		**-168 767**	**-147 286**
Bokslutsdispositioner	9	170 427	115 280
Resultat före skatt		**1 660**	**-32 006**
Skatt på årets resultat	10	518	-4 983
Årets resultat		**2 178**	**-36 989**

20250623141960

Balansräkning

Tkr

	Not	2024-12-31	2023-12-31
TILLGÅNGAR			
Anläggningstillgångar			
Immateriella anläggningstillgångar			
Balanserade utgifter för utvecklingsarbeten	11	143 281	79 910
Pågående utvecklingsarbeten och förskott avseende immateriella anläggningstillgångar	12	66 859	136 676
Koncessioner, patent, licenser, varumärken samt liknande rättigheter	13	455	436
		210 594	**217 022**
Materiella anläggningstillgångar			
Byggnader och mark	14	15 988	18 683
Maskiner och andra tekniska anläggningar	15	39 855	41 292
Inventarier, verktyg och installationer	16	20 849	17 385
		76 692	**77 359**
Finansiella anläggningstillgångar			
Andelar i koncernföretag	17, 18	321 100	1 147 251
Uppskjutna skattefordringar	19	8 460	7 942
Andra långfristiga fordringar	20	3 444	1 927
		333 004	**1 157 121**
Summa anläggningstillgångar		**620 290**	**1 451 502**
Omsättningstillgångar			
Varulager m m			
Råvaror och förnödenheter		90 341	83 987
Varor under tillverkning		268 547	121 690
Färdiga varor och handelsvaror		8 162	6 690
		367 049	**212 366**
Kortfristiga fordringar			
Kundfordringar		7 510	5 164
Fordringar hos koncernföretag	21	439 609	368 562
Aktuella skattefordringar		5 110	4 982
Övriga kortfristiga fordringar		10 812	4 126
Förutbetalda kostnader och upplupna intäkter	22	3 460	4 641
		466 502	**387 475**
Kassa och bank		2	2
Summa omsättningstillgångar		**833 553**	**599 843**
SUMMA TILLGÅNGAR		**1 453 843**	**2 051 345**

20250623114961

Balansräkning

Tkr

	Not	2024-12-31	2023-12-31
EGET KAPITAL OCH SKULDER			
Eget kapital	27		
Bundet eget kapital			
Aktiekapital		5 000	5 000
Reservfond		1 000	1 000
Fond för utvecklingsutgifter		181 976	182 610
		187 976	**188 610**
Fritt eget kapital			
Balanserad vinst eller förlust		455 153	491 508
Årets resultat		2 178	-36 989
		457 331	**454 519**
Summa eget kapital		**645 307**	**643 129**
Avsättningar	23		
Avättning för pensioner och likande förpliktelser		3 444	1 927
Övriga avsättningar		2 766	2 346
Summa avsättningar		**6 210**	**4 274**
Långfristiga skulder			
Skulder till koncernföretag	24	0	826 151
Summa långfristiga skulder		**0**	**826 151**
Kortfristiga skulder			
Leverantörsskulder		60 818	59 496
Skulder till koncernföretag	21	528 112	411 477
Övriga kortfristiga skulder		13 306	29 626
Upplupna kostnader och förutbetalda intäkter	25	200 090	77 193
Summa kortfristiga skulder		**802 326**	**577 791**
SUMMA EGET KAPITAL OCH SKULDER		**1 453 843**	**2 051 345**

20250623114962

Kassaflödesanalys

Tkr

	Not	2024-01-01 -2024-12-31	2023-01-01 -2023-12-31
Den löpande verksamheten			
Rörelseresultat		-174 957	-92 292
Justeringar för poster som inte ingår i kassaflödet	26	71 563	25 886
Erlagd ränta		-53 688	-54 994
Kassaflöde från den löpande verksamheten före förändring av rörelsekapital		**-157 082**	**-121 400**
Kassaflöde från förändring av rörelsekapitalet			
Förändring av varulager och pågående arbete		-154 683	9 050
Förändring av kundfordringar		-2 346	-4 475
Förändring av kortfristiga fordringar		-21 543	-27 779
Förändring av leverantörsskulder		1 323	-22 527
Förändring av kortfristiga skulder		223 212	167 831
Kassaflöde från den löpande verksamheten		**-111 119**	**700**
Investeringsverksamheten			
Investeringar i immateriella anläggningstillgångar		-50 906	-52 488
Försäljning av immateriella anläggningstillgångar		478	0
Investeringar i materiella anläggningstillgångar		-12 151	-14 300
Försäljning av materiella anläggningstillgångar		57	37
Försäljning av dotterbolag		826 104	0
Placering i övriga finansiella anläggningstillgångar		-1 517	-211
Kassaflöde från investeringsverksamheten		**762 065**	**-66 962**
Finansieringsverksamheten			
Amortering av lån		-826 151	0
Erhållen utdelning		59 925	0
Erhållna koncernbidrag		115 280	66 262
Kassaflöde från finansieringsverksamheten		**-650 946**	**66 262**
Årets kassaflöde		**0**	**0**
Likvida medel vid årets början			
Likvida medel vid årets början		2	2
Likvida medel vid årets slut		**2**	**2**

20250623114963

Noter
Tkr

Not 1 Redovisnings- och värderingsprinciper

Getinge Sterilization ABs årsredovisning har upprättats enligt årsredovisningslagen och Bokföringsnämndens allmänna råd BFNAR 2012:1 Års- och koncernredovisning (K3). Redovisningsprinciperna är oförändrade i jämförelse med föregående år.

Utländska valutor
Getinge Sterilization AB redovisar fordringar och skulder i utländsk valuta till månatliga valuta kurser som tillhandahålls av Getinge Group. Kursdifferenser avseende rörelsefordringar och rörelseskulder redovisas inom rörelseresultatetet medan kursdifferenser på finansiella fordringar och skulder redovisas inom finansiella poster. För redovisningsprinciper avseende valutaterminskontrakt, se stycke om finansiella instrument. Transaktioner i utländsk valuta omräknas enligt transaktionsdagens avistakurs.

Rapportering av geografiska marknader
Getinge Sterilization AB bedriver tillverkning och försäljning av sterilisationsutrustning, huvudsakligen avsett för sjukvård, Surgical Workflow och laboratorier och farmaceutisk industri, Life Science. Bolaget har försäljning över hela världen. För fördelning per geografisk marknad, se not 3.

Intäkter
Varor
Intäkter har tagits upp till verkligt värde av vad som erhållits eller kommer att erhållas och redovisas i den omfattning det är sannolikt att de ekonomiska fördelarna kommer att tillgodogöras bolaget och intäkterna kan beräknas på ett tillförlitligt sätt.

Vid försäljning av varor redovisas inkomsten som intäkt när de väsentliga förmåner och risker som är förknippade med ägandet av varan har överförts från företaget till köparen.

Försäljningen redovisas efter avdrag för moms och rabatter.

Tjänster
Intäktsredovisning av tjänster sker i takt med med att tjänsterna utförs.

Leasingavtal
Samtliga leasingavtal där företaget är leasetagare redovisas som operationell leasing (hyresavtal), oavsett om avtalen är finansiella eller operationella. Leasingavgiften redovisas som en kostnad linjärt över leasingperioden. Företaget har hyresintäkter från andra företag i koncernen.

Ersättningar till anställda
Kortfristiga ersättningar
Kortfristiga ersättningar i bolaget utgörs av lön, sociala avgifter, betald semester, betald sjukfrånvaro, sjukvård och bonus. Kortfristiga ersättningar redovisas som en kostnad och en skuld då det finns en legal eller informell förpliktelse att betala ut en ersättning.

20250623 14964

Ersättningar efter avslutad anställning
I bolaget förekommer avgiftsbestämda pensionsplaner och inbetalningar till kapitalförsäkringar/direktpension.
I avgiftsbestämda planer betalar bolaget fastställda avgifter till ett annat företag och har inte någon legal eller informell förpliktelse att betala något ytterligare även om det andra företaget inte kan uppfylla sitt åtagande. Bolagets resultat belastas för kostnader i takt med att de anställdas pensionsberättigade tjänster utförts.
När det gäller inbetalning av premier till kapitalförsäkringar/direktpensioner ger dessa upphov till avsättning av framtida kostnader för särskild löneskatt. Värdering sker till marknadsvärde. Bolagen betalar den särskilda löneskatten i takt med att kapitalförsärkingen faller ut till betalning.

Ersättningar vid uppsägning
Ersättningar vid uppsägning utgår då bolaget beslutar att avsluta en anställning före den normala tidpunkten för anställningens upphörande eller då en anställd accepterar ett erbjudande om frivillig avgång i utbyte mot sådan ersättning. Om ersättningen inte ger bolaget någon framtida ekonomisk fördel redovisas en skuld och en kostnad när bolaget har en legal eller informell förpliktelse att lämna en sådan ersättning. Ersättningen värderas till den bästa uppskattningen av den ersättning som skulle krävas för att reglera förpliktelsen på balansdagen.

Inkomstskatter
Aktuella skatter värderas utifrån de skattesatser och skatteregler som gäller på balansdagen. Uppskjutna skatter värderas utifrån de skattesatser och skatteregler som är beslutade före balansdagen. Uppskjuten skattefordran avseende underskottsavdrag eller andra framtida skattemässiga avdrag redovisas i den utsträckning det är sannolikt att avdraget kan avräknas mot överskott vid framtida beskattning. Fordringar och skulder nettoredovisas endast när det finns en legal rätt till kvittning. Aktuell skatt, liksom förändring i uppskjuten skatt, redovisas i resultaträkningen om inte skatten än hänförlig till en händelse eller transaktion som redovisas direkt i eget kapital. I sådana fall redovisas även skatteeffekten i eget kapital. På grund av sambandet mellan redovisning och beskattning särredovisas inte den uppskjutna skatteskulden som är hänförlig till obeskattade reserver.

Immateriella tillgångar
Immateriella anläggningstillgångar består av balanserade utvecklingskostnader, goodwill och patent, uppkommen i samband med övertagen kammarverksamhet. Immateriella anläggningstillgångar redovisas till anskaffningsvärde minskat med ackumulerade avskrivningar och nedskrivningar. Aktiveringsmodellen tillämpas för internt upparbetade immateriella tillgångar. Avskrivningar görs linjärt över den bedömda nyttjandetiden. Avskrivningstiden för internt upparbetade immateriella anläggningstillgångar och övriga immateriella anläggningstillgångar uppgår till fem år respektive tio år.

20250623114965

Materiella anläggningstillgångar
Materiella anläggningstillgångar redovisas till anskaffningsvärde minskat med avskrivningar. I anskaffningsvärdet ingår utgifter som direkt kan hänföras till förvärvet av tillgången.
När en komponent i en anläggningstillgång byts ut, utrangeras eventuellt kvarvarande del av den gamla komponenten och den nya komponentens anskaffningsvärde aktiveras. Tillkommande utgifter som avser tillgångar som inte delas upp i komponenter läggs till anskaffningsvärdet till den del tillgångens prestanda ökar i förhållande till tillgångens värde vid anskaffningstidpunkten. Utgifter för löpande reparation och underhåll redovisas som kostnader. Realisationsvinst respektive realisationsförlust vid avyttring av en anläggningstillgång redovisas som Övrig rörelseintäkt respektive Övrig rörelsekostnad. Materiella anläggningstillgångar skrivs av systematiskt över tillgångens bedömda nyttjandeperiod. När tillgångarnas avskrivningsbara belopp fastställs, beaktas i förekommande fall tillgångens restvärde. Linjär avskrivningsmetod används för materiella tillgångar.

Följande avskrivningstider tillämpas:

Kontorsbyggnader	
Stommar	45 år
Fasader, yttertak, fönster	20-30 år
Hissar, ledningssystem	15-20 år
Övrigt	20 år
Industribyggnader	
Stommar, fasader, yttertak	30-45 år
Hissar och lyftanordningar	15 år
Övrigt	20 år
Markanläggningar	33 år
Maskiner och andra tekniska anläggningar	5-15 år
Inventarier, verktyg och installationer	3-5 år

Nedskrivningar av icke-finansiella tillgångar
När det finns en indikation på att en tillgångs värde minskat, görs en prövning av nedskrivningsbehov. Har tillgången ett återvinningsvärde som är lägre än det redovisade värdet, skrivs den ner till återvinningsvärdet. Vid bedömning av nedskrivningsbehov grupperas tillgångarna på de lägsta nivåer där det finns separata identifierbara kassaflöden (kassagenererande enheter). För tillgångar som tidigare skrivits ner görs per varje balansdag en prövning av om återföring bör göras. I resultaträkningen redovisas nedskrivningar och återföringar av nedskrivningar i den funktion där tillgången nyttjas.

Finansiella instrument
Derivatinstrument
Finansiella instrument redovisas i enlighet med reglerna i K3 kapitel 11, vilket innebär att värdering sker utifrån anskaffningsvärde. Bolaget använder valutaterminsderivat.
Derivatinstrument med positivt värde värderas löpande i enlighet med lägsta värdets princip. Derivatinstrument med negativt värde värderas till det negativa värdet. De värdeförändringar som uppkommer inom ramen för lägsta värdets princip och ändringar av negativt värde, redovisas omedelbart i resultaträkningen. Värdeförändring på valutaterminer redovisas i posten Övriga rörelsekostnader i resultaträkningen.

20250623 14966

Kundfordringar och övriga fordringar
Fordringar redovisas som omsättningstillgångar med undantag för poster med förfallodag mer än 12 månader efter balansdagen, vilka klassificeras som anläggningstillgångar. Fordringar tas upp till det belopp som förväntas bli inbetalt efter avdrag för individuellt bedömda osäkra fordringar.

Låneskulder och leverantörsskulder
Låneskulder och leverantörsskulder redovisas initialt till anskaffningsvärde efter avdrag för transaktionskostnader. Skiljer sig det redovisade beloppet från det belopp som ska återbetalas vid förfallotidpunkten periodiseras mellanskillnaden som räntekostnad över lånets löptid med hjälp av instrumentets effektivränta. Härigenom överenstämmer vid förfallotidpunkten det redovisade beloppet och det belopp som ska återbetalas.

Kvittning av finansiell fordran och finansiell skuld
En finansiell tillgång och en finansiell skuld kvittas och redovisas med ett nettobelopp i balansräkningen endast då legal kvittningsrätt föreligger samt då en reglering med ett nettobelopp avses ske eller då en samtida avyttring av tillgången och reglering av skulden avses ske.

Aktier och andelar i dotterföretag
Aktier och andelar i dotterföretag redovisas till anskaffningsvärde efter avdrag för eventuella nedskrivningar. I anskaffningsvärdet ingår köpeskillingen som erlagts för aktierna samt förvärvskostnader. Eventuella kapitaltillskott och koncernbidrag läggs till anskaffningsvärdet när de uppkommer. Utdelning från dotterföretag redovisas som intäkt.

Varulager
Varulagret har värderats till det lägsta av anskaffningsvärdet och verkligt värde. Erfordliga avdrag för inkurans har gjorts. Anskaffningsvärdet fastställs med användning av först in, först ut-metoden (FIFU). För råvaror ingår alla utgifter som är direkt hänförliga till anskaffningen av varorna i anskaffningsvärdet. För varor under tillverkning och färdiga varor inkluderar anskaffningsvärdet konstruktionskostnader, direkt material, direkt lön, andra direkta kostnader, hänförbara indirekta tillverkningskostnader samt materialomkostnader.

Avsättningar
En avsättning redovisas i balansräkningen när företaget har en legal eller informell förpliktelse som en följd av en inträffad händelse och det är sannolikt att ett utflöde av resurser kommer att krävas för att reglera åtagandet och en tillförlitlig uppskattning av beloppet kan göras. Om effekten av när i tiden betalningen sker är väsentlig redovisas avsättningen till nuvärdet av de framtida betalningar som krävs för att reglera förpliktelsen. Diskonteringsräntan utgörs av den räntesats som före skatt avspeglar aktuell marknadsbedömning av det tidsberoende värdet av pengar och de risker som är förknippade med framtida betalningar till den del riskerna inte beaktas genom att justeringar gjorts vid bedömningen av de framtida betalningarna.

Avsättningen tas endast i anspråk för de utgifter som avsättningen ursprungligen var avsedd för. Avsättningen prövas varje balansdag och eventuell justering av avsättningen redovisas i resultaträkningen.

20230623149 67

Bokslutsdispositioner
Förändringar av obeskattade reserver redovisas som bokslutsdispositioner i resultaträkningen. Koncernbidrag redovisas som bokslutsdispositioner. Koncernbidrag som lämnas till ett dotterföretag redovisas dock som en ökning av andelens redovisade värde.

Kassaflödesanalys
Kassaflödesanalysen upprättas enligt indirekt metod. Det redovisade kassaflödet omfattar endast transaktioner som medfört in- eller utbetalningar. Som likvida medel klassificerar företaget, förutom kassamedel, disponibla tillgodohavanden, som ej ingår i Getingekoncernens koncernkontosystem, hos banker och andra kreditinstitut samt kortfristiga likvida placeringar som är noterade på en marknadsplats och har en kortare löptid än tre månader från anskaffningstidpunkten. Getingekoncernens koncernkontosystem hanteras som förändring av rörelsefordran eller rörelseskulder i kassaflödesanalysen.

Nyckeltalsdefinitioner
Soliditet
Eget kapital och obeskattade reserver (med avdrag för uppskjuten skatt) i förhållande till balansomslutningen.
Avkastning på totalt kapital
Resultat före avdrag för räntekostnader i förhållande till balansomslutningen.

20250623114968

Not 2 Uppskattningar och bedömningar

Bolaget gör uppskattningar och bedömningar om framtiden. De uppskattningar för redovisningsändamål som blir följden av dessa kommer definitionsmässigt sällan att motsvara det verkliga resultatet. De uppskattningar och antaganden som innebär en risk för väsentliga justeringar i redovisade värden för tillgångar och skulder under nästkommande år behandlas i huvuddrag nedan.

Immateriella tillgångar
Bolaget aktiverar utgifter som är förknippade med projektutveckling när kriterier i K3 18.12 är uppfyllda och utgiften bedöms kompenseras av framtida intäkter som överstiger utgiften. Bolaget undersöker löpande om det finns något nedskrivningsbehov i befintliga projekt. För att göra detta gör företagsledningen bedömningar avseende exempelvis ökad effektivitet och minskade kostnader i framtida produktion. Nyttjandeperioder för utvecklingsprojekten bestäms utifrån allmänt vedertagna principer och tillämpas konsekvent.

Inkurans i varulager
Nedskrivning för inkurans i varulager sker utifrån en koncerngemensam inkuransmodell vilken baseras på historisk förbrukning de tre senaste åren för respektive artikel i varulagret. Årets resultat har försämrats med 4 532 (222) för inkuransnedskrivningar. Att fastställa nedskrivningsbehovet är en bedömningsfråga. Skillnaden mellan det bokförda värdet och det skattemässiga värdet avseende inkuransen behandlas skattemässigt som en temporär skillnad varvid en uppskjuten skattefordran uppstår.

Andelar i koncernföretag
Bolaget upprättar nedskrivningsprövning om det finns indikationer på nedskrivningsbehov av det bokförda värdet, i form av lägre bokfört värde jämfört med substansvärdet i eget kapital. Nedskrivningsprövningen utgörs av en bedömning av dotterföretagens framtida resultatintjäningsförmåga diskonterad till ett nuvärde där vissa parametrar prognosticeras, exempelvis årlig procentuell organisk tillväxt och diskonteringsränta.

20250623144969

Not 3 Nettoomsättningens fördelning

	2024	2023
Nettoomsättningen per geografisk marknad		
Sverige	92 015	62 457
Europa	304 642	274 931
Nordamerika	64 743	154 672
Asien	18 058	174 444
Sydamerika	36 686	23 401
Afrika	22	2 477
	516 166	**692 382**

Not 4 Av- och nedskrivningar enligt plan per funktion

	2024	2023
Kostnad för sålda varor	-6 052	-6 406
Försäljningskostnader	-85	-256
Administrationskostnader	-5 945	-5 018
Forsknings- och utvecklingskostnader	-57 544	-23 962
	-69 627	**-35 641**

Not 5 Arvode till revisorer

Med revisionsuppdrag avses granskning av årsredovisningen och bokföringen samt styrelsens och verkställande direktörens förvaltning, övriga arbetsuppgifter som det ankommer på bolagets revisor att utföra samt rådgivning eller annat biträde som föranleds av iakttagelser vid sådan granskning eller genomförandet av sådana övriga arbetsuppgifter.

	2024	2023
Öhrlings PricewaterhouseCoopers AB		
Revisionsuppdrag	-315	-318
	-315	**-318**

20250623114970

Not 6 Anställda och personalkostnader

	2024	2023
Medelantalet anställda		
Kvinnor	76	73
Män	291	302
	367	**375**
Löner och andra ersättningar		
Styrelse och verkställande direktör	-1 117	-916
Tantiem och liknande ersättning till verkställande direktör	-87	-168
Övriga anställda	-198 948	-197 542
	-200 152	**-198 626**
Sociala kostnader		
Pensionskostnader för styrelse och verkställande direktör	-157	-171
Pensionskostnader för övriga anställda	-25 050	-20 507
Övriga sociala avgifter enligt lag och avtal	-65 876	-66 248
	-91 083	**-86 926**
Totala löner, ersättningar, sociala kostnader och pensionskostnader	**-291 235**	**-285 552**

Verkställande direktörens pensionsförmån motsvarar gällande ITP-plan. Vid uppsägning från bolagets sida äger verkställande direktören rätt till lön under en uppsägningstid motsvarande 6 månader. Vid uppsägning från verkställande direktörens sida är motsvarande tid 6 månader.

Könsfördelning bland ledande befattningshavare		
Andel kvinnor i styrelsen	3 St	3 St
Andel män i styrelsen	4 St	4 St
Andel kvinnor bland övriga ledande befattningshavare	8 St	7 St
Andel män bland övriga ledande befattningshavare	3 St	4 St

20250623149771

Not 7 Leasingavtal

Årets leasingkostnader avseende leasingavtal, uppgår till -1 848 (-1 585).
Under perioden intäktsförda leasingintäkter, uppgår till 3 396 (3 315).

Framtida leasingavgifter, för icke uppsägningsbara leasingavtal, förfaller till betalning enligt följande:

	2024	**2023**
Inom ett år	1 519	1 284
Senare än ett år men inom fem år	2 138	1 574
	3 657	**2 858**

I bolagets redovisning utgörs den operationella leasingkostnaden i allt väsentligt av förfogande över fordon, truckar och lagerlokaler. Fordon leasas på 3 år för förmånsbilar, med möjlighet till förlängning med 1 år i taget. Avtalen löper på 1 år i taget, men kan sägas upp med omedelbar verkan, varför några icke uppsägningsbara leasingavtal inte finns. Truckar leasas på 5 år och lagerlokaler förlängs mellan 1 till 3 år. Den operationella leasingintäkten avser hyror från koncernföretag. Då avtal saknas redovisas inte några framtida förfallna leasingintäkter.

Not 8 Räntekostnader/intäkter och liknande resultatposter

	2024	**2023**
Räntekostnader till koncernföretag	-53 671	-55 005
Övriga räntekostnader/intäkter och liknande resultatposter	-17	11
	-53 688	**-54 994**

Not 9 Bokslutsdispositioner

	2024	**2023**
Erhållet koncernbidrag	170 427	115 280
	170 427	**115 280**

20250623114972

Not 10 Aktuell och uppskjuten skatt

	2024	2023
Skatt på årets resultat		
Uppskjuten skatt	518	-4 983
Totalt redovisad skatt	**518**	**-4 983**

Avstämning av effektiv skatt

		2024		2023
	Procent	**Belopp**	**Procent**	**Belopp**
Redovisat resultat före skatt		1 660		-32 006
Skatt enligt gällande skattesats	20,60	-342	20,60	4 983
Skatteeffekt av ej avdragsgilla permanenta skillnader		12 366		0
Skatteeffekt av ej skattepliktiga permanenta skillnader		-11 506		-11 576
Redovisad effektiv skatt	**-31,20**	**518**	**-20,60**	**-6 593**

Not 11 Balanserade utgifter för utvecklingsarbeten och liknande arbeten

	2024-12-31	2023-12-31
Ingående anskaffningsvärden	537 426	537 426
Årets anskaffningar	89 088	0
Utgående ackumulerade anskaffningsvärden	**626 515**	**537 426**
Ingående avskrivningar	-385 113	-362 019
Årets avskrivningar	-25 718	-23 093
Utgående ackumulerade avskrivningar	**-410 831**	**-385 113**
Ingående nedskrivningar	-72 404	-72 404
Utgående ackumulerade nedskrivningar	**-72 404**	**-72 404**
Utgående redovisat värde	**143 281**	**79 910**

20250623114973

Not 12 Pågående utvecklingsarbeten och förskott avseende immateriella anläggningstillgångar

	2024-12-31	2023-12-31
Ingående anskaffningsvärden	146 522	94 319
Årets anskaffningar	50 264	52 203
Omklassificering	-89 088	0
Utgående ackumulerade anskaffningsvärden	**107 697**	**146 522**
Ingående nedskrivningar	-9 846	-9 846
Årets nedskrivningar	-30 992	0
Utgående ackumulerade nedskrivningar	**-40 838**	**-9 846**
Utgående redovisat värde	**66 859**	**136 676**

Not 13 Koncessioner, patent, licenser, varumärken samt liknande rättigheter

	2024-12-31	2023-12-31
Ingående anskaffningsvärden	4 022	3 737
Årets anskaffningar	642	285
Försäljningar/utrangeringar	-789	0
Utgående ackumulerade anskaffningsvärden	**3 875**	**4 022**
Ingående avskrivningar	-3 586	-3 505
Försäljningar/utrangeringar	311	0
Årets avskrivningar	-146	-81
Utgående ackumulerade avskrivningar	**-3 421**	**-3 586**
Utgående redovisat värde	**455**	**436**

Not 14 Byggnader och mark

	2024-12-31	2023-12-31
Ingående anskaffningsvärden	164 153	164 252
Försäljningar/utrangeringar	0	-99
Omklassificeringar	-5	0
Utgående ackumulerade anskaffningsvärden	**164 148**	**164 153**
Ingående avskrivningar	-145 471	-142 747
Omklassificeringar	5	83
Årets avskrivningar	-2 694	-2 807
Utgående ackumulerade avskrivningar	**-148 160**	**-145 471**
Utgående redovisat värde	**15 988**	**18 682**

20250623114974

Not 15 Maskiner och andra tekniska anläggningar

	2024-12-31	2023-12-31
Ingående anskaffningsvärden	123 280	116 618
Inköp	4 848	6 831
Försäljningar/utrangeringar	-11 460	-169
Utgående ackumulerade anskaffningsvärden	**116 668**	**123 280**
Ingående avskrivningar	-81 988	-75 835
Försäljningar/utrangeringar	11 401	169
Årets avskrivningar	-6 226	-6 322
Utgående ackumulerade avskrivningar	**-76 813**	**-81 988**
Utgående redovisat värde	**39 855**	**41 292**

Not 16 Inventarier, verktyg och installationer

	2024-12-31	2023-12-31
Ingående anskaffningsvärden	45 105	45 130
Inköp	7 303	7 469
Försäljningar/utrangeringar	-1 827	-7 494
Omklassificeringar	6	0
Utgående ackumulerade anskaffningsvärden	**50 587**	**45 105**
Ingående avskrivningar	-27 720	-31 854
Försäljningar/utrangeringar	1 827	7 473
Omklassificeringar	-6	0
Årets avskrivningar	-3 839	-3 339
Utgående ackumulerade avskrivningar	**-29 738**	**-27 720**
Utgående redovisat värde	**20 849**	**17 385**

Not 17 Andelar i koncernföretag

	2024-12-31	2023-12-31
Ingående anskaffningsvärden	1 157 351	1 157 351
Försäljningar	-836 251	0
Utgående ackumulerade anskaffningsvärden	**321 100**	**1 157 351**
Ingående nedskrivningar	-10 100	-10 100
Försäljningar	10 100	0
Utgående ackumulerade nedskrivningar	**0**	**-10 100**
Utgående redovisat värde	**321 100**	**1 147 251**

20250623114975

Not 18 Specifikation andelar i koncernföretag

Namn	Kapital-andel %	Rösträtts-andel %	Antal andelar	Bokfört värde 2024-12-31
Getinge Logistics AB	100	100	1 000	321 100
				321 100

	Org.nr	Säte
Getinge Logistics AB	556547-8798	Halmstad

Not 19 Uppskjutna skattefordringar

Uppskjuten skattefordran på kostnad är återförd i beskattningen och blir avdragsgill kommande år avseende temporära skillnader. Det finns underskottsavdrag om 1 000 (20 765) som i sin helhet har beaktats vid beräkning av uppskjuten skattefordran.

	2024-12-31	2023-12-31
Varulager, inkuransnedskrivning	134	0
Avsättning, garanti	112	144
Fastighet, skillnad skattemässig avskrivning	2 901	2 922
Outnyttjat underskottsavdrag	206	4 278
Direktpension	1 097	598
Bonusreservation	4 010	0
	8 460	**7 942**

Not 20 Andra långfristiga fordringar

	2024-12-31	2023-12-31
Ingående anskaffningsvärden	1 927	1 716
Tillkommande fordringar - premie direktpension	1 517	211
Utgående ackumulerade anskaffningsvärden	**3 444**	**1 927**
Utgående redovisat värde	**3 444**	**1 927**

20250623149976

Not 21 Transaktioner med närstående

Nedan anges andelen inköp och försäljning avseende koncernföretag.

	2024-12-31	2023-12-31
Inköp (%)	28	28
Försäljning (%)	92	98

Koncernkonto
Bolaget ingår i Getingekoncernens koncernkontosystem där bolagets beviljade kredit uppgår till 500 000 (500 000). Vid årets utgång uppgick bolagets skuld till -401 626 (-298 641) och ingår i posten skulder till koncernföretag.

Uppgifter om moderföretaget
Moderföretag i den största, och minsta, koncern där Getinge Sterilization AB är dotterföretag och koncernredovisning upprättas är Getinge AB, 556408-5032, Göteborg.

Not 22 Förutbetalda kostnader och upplupna intäkter

	2024-12-31	2023-12-31
Förutbetald hyra	81	79
Förutbetald försäkringspremie	176	159
Poster för vidarefakturering	538	1 300
Övriga poster	2 665	3 103
	3 460	**4 641**

Not 23 Avsättningar

	2024-12-31	2023-12-31
Avsättningar för garantier		
Belopp vid årets ingång	1 184	6 626
Årets avsättningar	1 225	379
Under året ianspråktagna belopp	-700	-4 928
Under året återförda belopp	0	-893
	1 709	**1 184**
Pensioner och liknande förpliktelser		
Belopp vid årets ingång	1 927	1 716
Årets avsättningar - premier direktpension	1 517	211
	3 444	**1 927**
Övriga avsättningar		
Belopp vid årets ingång	567	583
Justeringar till följd av förändringar av nuvärden	490	-16
	1 057	**567**
Omstruktureringsreserv		
Belopp vid årets ingång	596	5 104
Under året ianspråktagna belopp	-596	-1 786
Under året återförda belopp	0	-2 722
	0	**596**

20250623114977

Not 24 Långfristiga skulder koncernföretag

Ingen del förfaller till betalning senare än fem år efter balansdagen.

	2024-12-31	2023-12-31
Ingående skuld	826 151	826 151
Utgående ackumulerade skulder	**826 151**	**826 151**
Amorteringar, avgående fordringar	-826 151	0
Utgående ackumulerade nedskrivningar	**-826 151**	**0**
Utgående redovisat värde	**0**	**826 151**

Not 25 Upplupna kostnader och förutbetalda intäkter

	2024-12-31	2023-12-31
Upplupna löner	12 475	11 976
Upplupna semesterlöner	31 882	30 685
Upplupna sociala avgifter	27 663	23 688
Fakturerat ej ankommit slutkund	107 152	6 867
Reserv av sena fakturor och övriga poster	20 918	3 977
	200 090	**77 193**

Not 26 Justering för poster som inte ingår i kassaflödet

	2024-12-31	2023-12-31
Avskrivningar	38 635	35 641
Avsättning, garantier	525	-5 442
Omstruktureringsreserv	-596	-4 508
Nedskrivning balanserade utvecklingsprojekt	30 992	0
Pensioner och liknande förpliktelser	1 517	211
Övriga avsättningar	490	-16
	71 563	**25 886**

Not 27 Disposition av vinst eller förlust

Förslag till vinstdisposition
Styrelsen föreslår att till förfogande stående vinstmedel (kronor):

balanserad vinst	455 152 895
årets vinst	2 177 636
	457 330 531
disponeras så att	
i ny räkning överföres	457 330 531
	457 330 531

20250623114978

Not 28 Väsentliga händelser efter räkenskapsårets slut

Efter räkenskapetsårets slut har det inte skett några väsentliga händelser för Getinge Sterilization AB.

Not 29 Eventualförpliktelser

Notera att det pågår en miljöutredning där krav kan komma att riktas mot bolaget, för mer information se förvaltningsberättelse.

	2024-12-31	**2023-12-31**
Övriga ansvarsförbindelser, förmånstagare Tullverket	24	24
Bankgaranti	50 296	0
	50 320	**24**

20250623114979

Resultat- och balansräkningen kommer att föreläggas på årsstämman för fastställelse.

Halmstad

Eric Honroth, 2025- 05-21
Ordförande

Maria Ek, 2025- 05-21
Verkställande direktör

Linda Forsberg, 2025- 05-21

Julien Albouy-Meyer, 2025- 05-21

Pontus Käll, 2025- 05-21
Arbetstagarrepresentant

Ida ~~Gustafsson~~ Ekman, 2025- 05-21
Arbetstagarrepresentant

Patrik Larsson, 2025- 05-21
Arbetstagarrepresentant

Vår revisionsberättelse har lämnats 2025-05-28

Öhrlings PricewaterhouseCoopers AB

Rebecka Alfredsson
Aukoriserad revisor

20250623114980

Revisionsberättelse

Till bolagsstämman i Getinge Sterilization Aktiebolag, org.nr 556031-2687

Rapport om årsredovisningen

Uttalanden

Vi har utfört en revision av årsredovisningen för Getinge Sterilization Aktiebolag för år 2024.

Enligt vår uppfattning har årsredovisningen upprättats i enlighet med årsredovisningslagen och ger en i alla väsentliga avseenden rättvisande bild av Getinge Sterilization Aktiebolags finansiella ställning per den 31 december 2024 och av dess finansiella resultat och kassaflöde för året enligt årsredovisningslagen. Förvaltningsberättelsen är förenlig med årsredovisningens övriga delar.

Vi tillstyrker därför att bolagsstämman fastställer resultaträkningen och balansräkningen för Getinge Sterilization Aktiebolag.

Grund för uttalanden

Vi har utfört revisionen enligt International Standards on Auditing (ISA) och god revisionssed i Sverige. Vårt ansvar enligt dessa standarder beskrivs närmare i avsnittet Revisorns ansvar. Vi är oberoende i förhållande till Getinge Sterilization Aktiebolag enligt god revisorssed i Sverige och har i övrigt fullgjort vårt yrkesetiska ansvar enligt dessa krav.

Vi anser att de revisionsbevis vi har inhämtat är tillräckliga och ändamålsenliga som grund för våra uttalanden.

Styrelsens och verkställande direktörens ansvar

Det är styrelsen och verkställande direktören som har ansvaret för att årsredovisningen upprättas och att den ger en rättvisande bild enligt årsredovisningslagen. Styrelsen och verkställande direktören ansvarar även för den interna kontroll som de bedömer är nödvändig för att upprätta en årsredovisning som inte innehåller några väsentliga felaktigheter, vare sig dessa beror på oegentligheter eller misstag.

Vid upprättandet av årsredovisningen ansvarar styrelsen och verkställande direktören för bedömningen av bolagets förmåga att fortsätta verksamheten. De upplyser, när så är tillämpligt, om förhållanden som kan påverka förmågan att fortsätta verksamheten och att använda antagandet om fortsatt drift. Antagandet om fortsatt drift tillämpas dock inte om styrelsen och verkställande direktören avser att likvidera bolaget, upphöra med verksamheten eller inte har något realistiskt alternativ till att göra något av detta.

Revisorns ansvar

Våra mål är att uppnå en rimlig grad av säkerhet om huruvida årsredovisningen som helhet inte innehåller några väsentliga felaktigheter, vare sig dessa beror på oegentligheter eller misstag, och att lämna en revisionsberättelse som innehåller våra uttalanden. Rimlig säkerhet är en hög grad av säkerhet, men är ingen garanti för att en revision som utförs enligt ISA och god revisionssed i Sverige alltid kommer att upptäcka en väsentlig felaktighet om en sådan finns. Felaktigheter kan uppstå på grund av oegentligheter eller misstag och anses vara väsentliga om de enskilt eller tillsammans rimligen kan förväntas påverka de ekonomiska beslut som användare fattar med grund i årsredovisningen.

En ytterligare beskrivning av vårt ansvar för revisionen av årsredovisningen finns på Revisorsinspektionens webbplats: www.revisorsinspektionen.se/revisornsansvar. Denna beskrivning är en del av revisionsberättelsen.

Rapport om andra krav enligt lagar och andra författningar

Uttalanden

Utöver vår revision av årsredovisningen har vi även utfört en revision av styrelsens och verkställande direktörens förvaltning för Getinge Sterilization Aktiebolag för år 2024 samt av förslaget till dispositioner beträffande bolagets vinst eller förlust.

Vi tillstyrker att bolagsstämman disponerar vinsten enligt förslaget i förvaltningsberättelsen och beviljar styrelsens ledamöter och verkställande direktören ansvarsfrihet för räkenskapsåret.

20250623114981

Grund för uttalanden

Vi har utfört revisionen enligt god revisionssed i Sverige. Vårt ansvar enligt denna beskrivs närmare i avsnittet Revisorns ansvar. Vi är oberoende i förhållande till Getinge Sterilization Aktiebolag enligt god revisorssed i Sverige och har i övrigt fullgjort vårt yrkesetiska ansvar enligt dessa krav.

Vi anser att de revisionsbevis vi har inhämtat är tillräckliga och ändamålsenliga som grund för våra uttalanden.

Styrelsens och verkställande direktörens ansvar

Det är styrelsen som har ansvaret för förslaget till dispositioner beträffande bolagets vinst eller förlust. Vid förslag till utdelning innefattar detta bland annat en bedömning av om utdelningen är försvarlig med hänsyn till de krav som bolagets verksamhetsart, omfattning och risker ställer på storleken av bolagets egna kapital, konsolideringsbehov, likviditet och ställning i övrigt.

Styrelsen ansvarar för bolagets organisation och förvaltningen av bolagets angelägenheter. Detta innefattar bland annat att fortlöpande bedöma bolagets ekonomiska situation, och att tillse att bolagets organisation är utformad så att bokföringen, medelsförvaltningen och bolagets ekonomiska angelägenheter i övrigt kontrolleras på ett betryggande sätt. Den verkställande direktören ska sköta den löpande förvaltningen enligt styrelsens riktlinjer och anvisningar och bland annat vidta de åtgärder som är nödvändiga för att bolagets bokföring ska fullgöras i överensstämmelse med lag och för att medelsförvaltningen ska skötas på ett betryggande sätt.

Revisorns ansvar

Vårt mål beträffande revisionen av förvaltningen, och därmed vårt uttalande om ansvarsfrihet, är att inhämta revisionsbevis för att med en rimlig grad av säkerhet kunna bedöma om någon styrelseledamot eller verkställande direktören i något väsentligt avseende:

- företagit någon åtgärd eller gjort sig skyldig till någon försummelse som kan föranleda ersättningsskyldighet mot bolaget, eller
- på något annat sätt handlat i strid med aktiebolagslagen, årsredovisningslagen eller bolagsordningen.

Vårt mål beträffande revisionen av förslaget till dispositioner av bolagets vinst eller förlust, och därmed vårt uttalande om detta, är att med rimlig grad av säkerhet bedöma om förslaget är förenligt med aktiebolagslagen.

Rimlig säkerhet är en hög grad av säkerhet, men ingen garanti för att en revision som utförs enligt god revisionssed i Sverige alltid kommer att upptäcka åtgärder eller försummelser som kan föranleda ersättningsskyldighet mot bolaget, eller att ett förslag till dispositioner av bolagets vinst eller förlust inte är förenligt med aktiebolagslagen.


En ytterligare beskrivning av vårt ansvar för revisionen av förvaltningen finns på Revisorsinspektionens webbplats: www.revisorsinspektionen.se/revisornsansvar. Denna beskrivning är en del av revisionsberättelsen.

Halmstad den 28 maj 2025

Öhrlings PricewaterhouseCoopers AB


Rebecka Alfredsson
Auktoriserad revisor

20250623149B2



Passion for Life

2024 Annual Report



At some point in life, everyone needs to seek care. We have a long tradition of creating innovations that improve people's quality of life – and save lives. It is one of the most important jobs in the world.

About the report

Getinge AB (publ)'s formal Annual Report and consolidated financial statements comprise the section Financial statements on pages 55–126, except for the Remuneration Report on pages 64–67, and have been audited by the company's auditor. The Corporate Governance Report comprises the section "Corporate Governance" on 32–54 and has been examined by the company's auditor. Sustainability information is integrated in the section "Strategy" on pages 12–31 and in the Sustainability Report on pages 127–168. The statutory Sustainability Report is defined on page 128. The auditor's report on the limited assurance of Getinge's Sustainability Report and statement on the statutory Sustainability Report is presented on page 168. Getinge has used artificial intelligence (AI) as a tool to assist in text production in parts of this Annual Report. Final review and approval is carried out by company employees to ensure accuracy and relevance.

Contents

Introduction | 1–11

3 This is Getinge
4–5 2024 in brief
6–7 Words from the CEO
8 Global value creation
9 Getinge as an investment
10–11 External trends

Strategy | 12–31

13–15 Getinge's strategy and vision beyond 2030
16 Targets 2024–2028
17 Growing market for Getinge products
18–19 Business areas
20–23 Acute Care Therapies
24–27 Life Science
28–31 Surgical Workflows

Corporate Governance Report | 32–54

34–48 Corporate governance structure
39–41 Board of Directors
42–44 President & CEO and Getinge Executive Team
45–46 Building blocks in the Getinge corporate governance model
47–52 Assurance framework, risks and risk management
53–54 Internal control over the financial reporting
54 Auditor's report on the Corporate Governance Report

Financial statements | 55–126

56–60 Administration Report
61–63 Guidelines for remuneration
64–67 Remuneration Report 2024
68 Proposed appropriation of profit
69–73 Group financial statements
74–111 Group notes
112–115 Parent Company financial statements
116–122 Parent Company notes
123–126 Auditor's report

Sustainability Report | 127–168

128 About the Report
129 Sustainability at Getinge
130–134 Materiality and stakeholders
135–137 Sustainability governance and management
138–149 Environment
150–159 Social responsibility
160–161 Governance
162–163 Reporting principles
164–167 GRI content index
168 Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

Other information | 169–185

170–171 The Getinge share
172–175 Multi-year overview
176–178 Reconciliation of alternative performance measures
179–181 Group companies
182–183 Definitions
184 Annual General Meeting and Nomination Committee
184 Financial information
185 Reading guide and distribution policy
185 Contact

Introduction
This is Getinge
2024 in brief
Words from the CEO
Global value creation
Getinge as an investment
External trends
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information


This is Getinge

As the world's population grows and ages, and the number of people with multiple illnesses increases, so do the challenges in healthcare. Lifestyle diseases, such as cardiovascular diseases remain among the leading causes of death globally, requiring more effective and comprehensive solutions.

At Getinge, we work globally with a shared belief that all people and societies should have access to the best possible care, with as little impact on the environment as possible.

By offering hospitals and life science institutions advanced technological solutions and expertise, we not only contribute to improved clinical outcomes, but also more efficient workflows and reduced resource utilization.

Ultimately, our work involves saving and improving lives, by making life-saving technology accessible for more people.



~12,000
Employees

~30,000
Customers

34.8 billion
Net sales 2024

>135
Sales to no. of countries

Introduction
This is Getinge
2024 in brief
Words from the CEO
Global value creation
Getinge as an investment
External trends
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information

2024 in brief


Q1

JAN 9

Maquet Ezea launched – an easy-to-use and robust surgical light

JAN 11

The Heart Surgeon's Cookbook – a world-first collaboration to help heart surgeons improve their dexterity



FEB 6

Servo ventilators get a **virtual twin**, TwinView




MAR 1

TÜV SÜD temporarily suspends the CE certificate for Cardiosave

MAR 7

Aquadis Index is launched – an intuitive high-performance multi-chamber washer-disinfector



MAR 7

We take a **giant leap forward in cardiovascular surgery** with 510(k) clearance for Vasoview Hemopro 3

MAR 21

120 years

We celebrate 120 years in medtech

MAR 31

Agneta Palmér appointed **new CFO**



MAR 28

We donate life-saving medical equipment to Ukraine

MAR 28

We extend the bioreactor portfolio with SUPR – a **larger single-use systems**

Q2


APR 11

Our covered stent system Advanta V12 **receives EU MDR approval** for use for patients with renal artery stenosis and/or aortoiliac occlusive disease (AIOD)

APR 25

With **compact design and sustainable performance** our cGMP washer redefines cleanroom efficiency





MAY 21


We introduce **DPTE-BetaBag®** with material from renewable sources

MAY 8

FDA sends a letter to US healthcare providers about Cardiosave, Cardiohelp and HLS sets

MAY 28

Our new lab sterilizer **Lancer LSS**



MAY 14

12%

Getinge's financial targets 2024–2028: Adjusted EPS growth of above 12% on average

JUN 3

We introduce **Poladus 150** – the latest innovation in low-temperature sterilization



JUNE 12

We receive FDA 510(k) **clearance from the US** for Talis+ACG Clinical Decision Support software


Introduction
This is Getinge
2024 in brief
Words from the CEO
Global value creation
Getinge as an investment
External trends
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information

2024 in brief

Q3

JUL 2

We launch **PulsioCare** – the next generation in hemodynamic monitoring



AUG 22

We acquire **Paragonix Technologies**, a leading organ transport products and services company in the US

SEP 1


We make a provision of **SEK 482 M** related to Brazilian investigation

SEP 25

Our **CE certificate** for ECLS consumables is reinstated

JUL 5

We extend and elevate our partnership with **Universeum**



Q4



OCT 9

FleetView is introduced – a web application that elevates service with connected devices


OCT 28

Paragonix Technologies receives FDA 510(k) clearance for **KidneyVault** portable renal perfusion system

NOV 7

Alexandra Holland appointed as **EVP Brand & Communications**






DEC 19

We partner with **908 Devices** to enhance bioreactor capabilities for continuous monitoring of key cell culture parameters

DEC 5


We open our new **Experience Center** in Mumbai, India



Introduction
This is Getinge
2024 in brief
Words from the CEO
Global value creation
Getinge as an investment
External trends
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Interview with Mattias Perjos, President and CEO of Getinge

"A record-breaking year for Getinge"



2024 was a record-breaking year with strong growth, more satisfied customers and successful product launches.

What are Getinge's greatest achievements this year, and what has been the key to them?

In terms of sales, 2024 was a record-breaking year for Getinge. We are continuing to grow, have more satisfied customers, our acquisitions have performed strongly and we have launched in-demand products in all business areas. This was possible due to a long-term focus on innovation, a customer-first approach and strong collaboration.

What challenges have you faced, and what have you learned from them?

During the year, we worked very intensely on continuing to improve quality, which we have regularly provided information about. These experiences have further strengthened our focus on continuous improvement and on the need to adapt quickly to meet both regulatory requirements and market expectations.

At the same time, we see the great appreciation showed by many customers for our products and employees, which can be seen in, for example, higher sales of these products. It has been impressive to see how our customers and employees have worked together to solve these challenges.

What trends are affecting medtech right now, and how are you preparing?

An ageing population, a worldwide lack of resources and economic pressures are increasing the need for cost-effective and sustainable care. We are tackling these challenges by working closely with customers, offering solutions that improve both patient care flows

Introduction
This is Getinge
2024 in brief
Words from the CEO
Global value creation
Getinge as an investment
External trends
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information

and the work environment. Our digital solutions, such as Servo TwinView, enable healthcare professionals to monitor ventilators remotely and reduce disruption to critically ill patients. With T-DOC, hospitals can automate the traceability and utilization of surgical instruments, saving time and reducing the risk of manual errors in central sterile supply departments and operating rooms. Digitalization and personalized medicines present considerable opportunities but require innovative technologies and sustainable processes, something that we are working on throughout our value chain.

How are you leveraging innovation to strengthen your position and create long-term value?

Innovation is a central part of our DNA and essential for remaining relevant to our customers. We are continuously developing new therapies and solutions and improving existing products to meet future healthcare needs and ensure long-term sustainability. Our strategy extends beyond 2030, and means that we will help double the number of lives saved, enable at least one additional surgery per OR per day, and ensure that medicines for complex diseases reach patients 25% faster. This requires advanced development of technologies, business models and digital solutions, which create higher customer value and provide us with competitive advantages. One example is our Torin OR management solution that uses AI optimization to help hospitals maximize their capacity through better scheduling and resource utilization. By automating and streamlining planning, more surgeries can be performed, leading to shorter waiting times and better access to care.

We are also open to making supplementary acquisitions that will enable us to make even more of a difference.

How is Getinge contributing to a more sustainable future?

Sustainability is the core of our vision for a future of better and more accessible care. We are working actively to reduce our environmental impact through energy efficiency and sustainable choices of materials, while helping to strengthen society by supporting healthcare providers and increasing access to life-saving technologies globally. Our strategy focuses on sustainable innovation for better health and responsible business conduct, with engaged co-workers as a foundation.

What are the main priorities moving forward?

We are continuing to focus on creating value for our customers in their important work to deliver better healthcare to more patients. A critical part of this is that we must resolve our quality challenges. In addition, we will strengthen our leading position in acute cardiopulmonary support, organ transplantation and cardiovascular surgery through continuous product development, clinical partnerships and strategic investments. We are also strengthening our position in the OR and central sterile supply departments by digitizing and optimizing workflows, increasing productivity and minimizing the risk of healthcare-acquired infections. At the same time, we are developing our capacity to support and collaborate with customers working on the vital issue of finding solutions to complex and currently incurable diseases.

What message do you want to send shareholders and other stakeholders about the future of Getinge?

We stand strong for the future with a clear direction toward sustainability, innovation and global growth. Our long-standing customer relationships and leading positions mean we are well equipped to meet the healthcare needs of the future.

Despite geopolitical uncertainty and increased protectionism, our industry has historically been resilient. Trade barriers are impacting the entire market but ultimately pose the greatest risks for patients and tax payers, a realization I hope policymakers will also arrive at. At the same time, there is a constant growing need for care, and we have already shown in 2024 that we have a strong position in our prioritized categories. With the continued willingness of hospitals and pharmaceutical companies to invest, and our strong market presence, we see many opportunities for continuing to create long-term value and make life-saving technology available for more people.

"With the continued willingness of hospitals and pharmaceutical companies to invest, and our strong market presence, we see many opportunities for continuing to create long-term value and make life-saving technology available to more people."

Introduction
This is Getinge
2024 in brief
Words from the CEO
Global value creation
Getinge as an investment
External trends
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information

We exist to make life-saving technology accessible for more people

At Getinge we strive to contribute to a more sustainable healthcare with optimized use of resources, improved medical results and reduced waiting times. Our ambition is for everyone to have access to the best possible care.

WE USE RESOURCES...

Resources & suppliers

Depending on the product, we either purchase raw materials (mainly metals and minerals), processed materials (such as plastics and electronics) or parts of products. When developing our supplier base, we evaluate a wide range of factors including impacts, opportunities and risks.

Environmental impact
Carbon emsissions arise throughout the life cycle of our products, from raw materials and sourcing to production and use. Energy consumption, water use, material extraction, use, and waste also account for negative impacts to the environment in our value chain.

TO CONDUCT OUR BUSINESS...

Own operations

For our business to evolve and to achieve our financial and sustainability targets, we depend on the expertise and diverse perspectives provided by our ~12,000 employees worldwide. By ensuring employee engagement and an inclusive culture, we can unlock their expertise and dedication to continue delivering the products that lead to improved outcomes and resource efficiency within the healthcare sector.

AND CREATE VALUE FOR CUSTOMERS AND SOCIETY

Customers & society

Healthcare
By supplying products and solutions to hospitals and life science institutions in over 135 countries, we help improve efficiency and reduce the use of resources, which benefits customers and patients.

Patient
We work actively to increase the number of lives saved, the number of operations performed per day per hospital and to reduce the time it takes to bring new medicines to market.

Society
Our products and service offerings are part of the healthcare sector's important mission to save and improve people's lives, which benefits both patients and society as a whole.
As a large global company, we also create jobs and develop skills of many employees and professionals. We comply with laws and regulations in the countries where we operate and tax income from our operations helps build and develop societies.

Employees
Engaged employees are critical to our company's success. This means that we work to create the best possible conditions for coworkers to thrive and reach their highest potential. We offer skills development and have a global approach to family leave, which set out a minimum standard offering for paid parental and caregiver leave.

For owners and lenders
It is important for us that the capital contributed by owners and lenders leads to a reasonable return on investment in relation to risk. With good potential for growth and long, close customer relationships, we create value for our owners and lenders.

Environment
We work actively to reduce negative environmental impact by setting ambitious targets, implementing improvement activities and collaborating across the value chain with suppliers, customers and other stakeholders in the pharmaceutical and healthcare industry.

Introduction
This is Getinge
2024 in brief
Words from the CEO
Global value creation
Getinge as an investment
External trends
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Getinge as an investment

3,837%

Total return from the initial public offering in May 1993

2,885%

The total return on the Stockholm Stock Exchange over the same period

11.6%

Return on invested capital (ROIC*)

MARKET LEADING POSITION AND CLOSE CUSTOMER RELATIONSHIPS

Since the company was founded 120 years ago, we have built up close customer relationships and developed innovative healthcare technologies. This has resulted in leading positions in most product segments, a high level of customer loyalty and strong competitiveness.

GROWTH POTENTIAL IN A STABLE MARKET

Demographic factors indicate a rising need for effective healthcare worldwide. Our growth strategy focuses on the product areas that have favorable prospects and includes both organic and acquired growth. The healthcare market is relatively unaffected by economic fluctuations, which provides stability for underlying growth.

FOCUS ON IMPROVEMENTS AND SUSTAINABILITY

Continuous improvement activities are being made to increase customer value, sales, margins and cash flow. Sustainability has top priority, focusing on quality, business conduct, engaged employees and sustainable innovations.


LONG-TERM OWNERSHIP AND VALUE CREATION

We have a stable shareholder base with a long-term perspective, with the largest shareholder holding more than 50% of the votes. This lends stability and creates the conditions for continuous value creation for our shareholders, customers, patients and society as a whole.

The total return includes both price growth and dividends. An investor who bought shares for SEK 10,000 in connection with the 1993 listing and reinvested the dividends had increased the value of their investment to SEK 393,700 by the end of the year.

It is important for us that the capital contributed by owners and lenders leads to a return that is higher than the cost of the same capital (e.g. interest expense for loans). Our return for 2024 was higher than the cost of capital, which means that we generate added value for our owners and increase our scope for action thanks to a financially stronger position.

* Rolling 12 months adjusted EBIT/invested capital. Invested capital is defined as Equity + Net debt (excluding pension commitments) and is calculated as (opening balance + closing balance of operating capital) divided by 2.




Introduction
This is Getinge
2024 in brief
Words from the CEO
Global value creation
Getinge as an investment
External trends
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information

External trends

Agility in a changing

We operate globally, and although the conditions between markets may differ, many of the external influences are the same.





Market requirements

MORE COST EFFICIENT HEALTHCARE

The need for accessible and sustainable healthcare is increasing with a growing global population and longer life expectancy. Technological and digital innovations are crucial for meeting demand, yet can also be costly. Global challenges such as conflict, supply chain problems and inflation are putting further pressure on funding for the healthcare sector.

ATTRACT AND RETAIN SKILLED HEALTHCARE STAFF

Staff shortages in the healthcare sector are growing and burnout is a challenge. Attracting and retaining skilled staff requires efficient workflows and a sustainable working environment.

Our solutions

We are addressing these needs in close cooperation with our customers to create effective care solutions. We support purchasing organizations and hospitals by offering attractive procurement terms, larger purchase volumes and customized financial solutions. This facilitates both improved quality of care and lower costs – without compromising patient safety. By also promoting out-of-hospital care solutions, such as ambulatory care centers, we are helping the healthcare system to become more efficient and increase accessibility.

Our Hospital Transformational Partnerships and Digital Health Solutions initiatives offer verified solutions to increase employee productivity and job satisfaction. Our innovative products and services relieve the burden on healthcare professionals, contributing to a sustainable work environment and reducing the risk of burnout. We aim to create conditions for healthcare professionals to do their job safely and effectively.



DIGITALIZING HEALTHCARE

Digitalization is revolutionizing healthcare with technologies such as telecare, AI, 3D printing and robotics. These innovations are paving the way for new business models and personalized care solutions that make healthcare more efficient and accessible.

We are developing digital ecosystems for healthcare of the future together with partners, focusing on integrated solutions for advanced care. Examples of this are our systems for controlling and streamlining hospital flows of equipment and patients, as well as connected products that enable staff to monitor patient vital signs remotely.



NEW CUSTOMIZED DRUGS

Biopharmaceutical innovation is rapidly progressing towards personalized medicines, which requires specialized manufacturing processes that can be adapted to the unique needs of patients.

We are contributing to this development through solutions that ensure biopharmaceutical processes and prevent contamination. Our advanced bioprocessing and cell and gene therapy technology support pharmaceutical manufacturers in meeting strict regulations and optimizing production. We aim to be a key partner in the ongoing development of next generation of medicines.



SUSTAINABLE SOLUTIONS IN MEDTECH

The world is facing increasing demands for resource efficiency and sustainability. One of the most critical challenges is creating a more sustainable and resource-efficient healthcare system.

We have integrated sustainability throughout our value chain, from research and development to recycling. Our operations are founded on environmental, social and ethical responsibility, with clearly defined environmental, social and governance (ESG) standpoints and policies. We aim to be a long-term and responsible player in the industry by delivering high-quality products and solutions with sustainability as a core component.

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information


Strategy

During the year, we continued to develop our strategic focus areas to create value for all stakeholders.

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Strategy and vision beyond 2030

Our ambition is to ensure long-term profitable growth. This is only possible if our customers believe that we have an offering that enables the best possible care. Our strategy to achieve this is based on the three focus areas of quality, customers and innovation. These in turn are enabled by our people, sustainability, productivity and financial performance.



Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information



QUALITY

The highest level of quality is not only a prerequisite for us to operate – we are working hard for, and are convinced, that it will be a competitive advantage for us in the future.

Quality beyond 2030 includes:

- We no longer have a Consent Decree with the FDA, we deliver high-quality products that benefit patients, and we work closely with authorities to set the standards for the future
- Our extensive quality efforts make us one of the most reliable medtech suppliers, resulting in productivity gains for us and our customers



CUSTOMERS

We already hold a leading position in the majority of our product categories. Our solutions reach approximately 30,000 customers globally, and are represented in the top ten largest hospitals in all markets. We are endeavoring to advance our position further.

Customers and patients beyond 2030 include:

- We are an acknowledged and preferred partner for our customers thanks to our comprehensive offering and our first-rate service and advisory support
- We have successfully launched new offerings, leveraged our global reach, satisfied needs in our main markets and served many of the needs in emerging markets




INNOVATION

We remain relevant to our customers through continuous innovation. This ranges from optimizing internal processes to developing revolutionary new therapies and solutions. Our historically important product launches such as Servo ventilators and DPTE-BetaBag® clearly demonstrate that innovation is part of our company's DNA.

Accordingly, innovation beyond 2030 includes:

- We carried out successful launches under our innovation and sustainability strategy and are continuously adding new projects
- Attractive digital solutions are an integral part of our offering and provide us with competitive advantages
- We have intensified our proactive M&A strategy to further strengthen our innovativeness

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information



ENABLERS

EMPLOYEES

Our approximately 12,000 employees are our most important asset. Therefore, their well-being and dedication is critical to our success.

Employees beyond 2030 includes:

- We are regarded as an attractive workplace that manages to attract top talent and continues to score highly in regular employee surveys
- We act based on three key principles: Team players, Forward thinkers and Game changers

SUSTAINABILITY

Sustainability is a central aspect of our goal to contribute to a future of better, more efficient and more accessible healthcare.

Sustainability beyond 2030 includes:

- A focus on quality, responsible business and engaged employees are the backbone of everything we do
- Sustainable innovations for better health are the driving force and pave the way for our sustainability activities

PRODUCTIVITY

Increasing productivity has been necessary to handle high levels of inflation in recent years. Our customers are under more pressure than ever to deliver more and better care with limited resources. This is where we play an important role.

Productivity beyond 2030 includes:

- Continuously improve our operating model and processes to become the most customer-centric and profitable business possible
- Continue to help our customers achieve more cost-efficient patient flows based on the leading clinical performance of our solutions and enabling resource savings

FINANCIAL PERFORMANCE

This is the consequence of how we manage the other elements of our strategy. If we implement it well, the results will follow.

Financial performance beyond 2030 thus includes:

- Having average growth and profitability at least in line with the market
- We have an efficient capital structure that facilitates attractive growth and profitability at reasonable risk
- We are considered an attractive investment in both the stock and bond markets

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Targets 2024–2028

Sustainability targets

Social	**>70%** Employee engagement	**<1.5** Audit findings /quality system audits
Environment	**-90%** Reduce Scope 1 and 2 emissions by 90% by 2030*	**-25%** Reduce Scope 3 emissions by 25% by 2030, and by 90% by 2050*
Governance	**>90%** Percentage of employees who completed training in business ethics	

*Base year 2021.

Financial targets

>12%

Average adjusted EPS growth

Adjusted earnings per share increased 27.6% during the year, mainly as a result of stronger underlying earnings in all business areas.



Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Growing market for our products

With a broad portfolio and a leading position in a number of product categories, we are working together with customers and partners to provide all people and societies with access to the best possible healthcare.

Available in the top ten hospitals in all markets


The market's annual growth is deemed to be 4–6% and the need to increase productivity and create more sustainable healthcare is greater than ever. Our company is well equipped to address these challenges with a broad portfolio in which solutions are becoming increasingly connected to facilitate the care of the future. We have a leading position in most product categories of our three business areas. These solutions reach approximately 30,000 customers in 135 countries globally, and are represented in the top ten largest hospitals in all markets. By capitalizing on our unique position in many growing segments, we have many opportunities to continue to expand the business.

Ambition to continue to grow in the US

Competition differs between each business area and product category. Just like us, most of these competitors have long experience in the industry, substantial size and market presence for their specific product segments. Some competitors primarily operate in the US market, which is a relative strength given that the price levels and margins in general are higher there. This concentration to the US is largely due to historical reasons, since several of them have their roots there. Getinge was founded in Europe, but has been growing faster in the US than in Europe for a long period of time and the ambition is to continue on the established track.

Our largest sales markets 2024

Our ten largest markets represented >70% of total sales in 2024.






Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Three business areas with world-leading positions

Our operations are organized into three business areas: Acute Care Therapies, Life Science and Surgical Workflows. Each business area has world-leading positions in most product categories. They operate in a market with annual sales of more than SEK 200 billion.



Our solutions in Acute Care Therapies helps save the lives of 10 million critically ill patients each year, the majority of whom have problems with the most fundamental aspect of body function – the circulation of oxygenated blood. The business area has a world-leading position and provides key products, therapies and training to make this possible.

- Life support during intensive care and surgery
- Cardiovascular surgery and effective management of organs for transplantation
- Comprehensive range of services, training and digital solutions



In Life Science, we partner with scientists and engineers to develop and manufacture better pharmaceutical solutions. The focus is on bioprocesses and reducing the risk of contamination through tailored, compliant and effective solutions to prevent, mitigate and cure diseases – and save lives.

- Future-proofed products and systems for efficient development and manufacturing of more advanced medicines
- Reduce the risk of contamination by using washer-disinfectors, sterilizers, isolators and sterile transfers
- Service and user support



In Surgical Workflows, we have a leading position in the global market for products and services for hospital operating rooms and central sterile supply departments.

- High quality operating room equipment such as operating tables and lights
- Products for sterile reprocessing of surgical instruments
- Digital solutions for increased efficiency, quality and safety before, during and after surgery
- Service and project management

GETINGE

2024 Annual Report

Introduction

Strategy

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business areas

Acute Care Therapies

Life Science


Surgical Workflows

Corporate Governance Report

Financial statements

Sustainability Report

Other information




[1] Excluding Group functions and other

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Innovative solutions for the future of intensive care

With our renowned Servo ventilators, we are showcasing our long-term commitment to meeting the growing demands of healthcare and creating safer, more efficient workflows. One of this year's milestones was the launch of Servo TwinView – our ventilators have a virtual twin that provides medical staff with near real-time view of the data, without having to step inside the sensitive environment of the intensive care unit.

Servo TwinView enhances both patient safety and workflows by allowing staff to monitor therapies remotely, reducing disruption to critically ill patients and improving introduction and training outside the ICU. In addition, the solution enables faster and more informed decisions by enabling remote second opinions and contributes to a more sustainable work environment by relieving healthcare professionals. Our Servo ventilators are here to stay, and we are continuing to develop them to help our customers shape the care of the future.



20250623144942

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Acute Care Therapies

Helping to double the number of lives saved among critically ill patients

QUALITY

Very high quality requirements apply to our products and we operate our business in accordance with the current regulations. Regulators around the world monitor to ensure proper implementation.

Activities in 2024

In 2024, we focused on Cardiopulmonary and Cardiac Assist, where we have experienced quality challenges originating from previous years. We have worked to increase the pace of critical product care, strengthen dialogue with regulators and ensure updates in quality registers. An analysis concluded that there are no additional systemic problems besides those already announced. The action plan has been shared with the authorities and will be implemented in 2024–2026.

During the year, we received FDA 510(k) clearance for Vasoview Hemopro 3 for endoscopic vessel harvesting, Talis' innovative digital clinical decision support software and KidneyVault, Paragonix's first perfusion technology for safe and effective kidney transport for organ transplantation. We have also made extensive progress in the EU MDR process, with all product categories having approved EU MDD extensions and ten product categories have now been approved under the EU MDR.

CUSTOMERS

Our customers work with advanced intensive care, cardiovascular surgery and organ transportation, among other things. They need to be able to rely on the safety, ease of use and advanced productivity of our products and services.

Activities in 2024

We continued our work to increase brand awareness and customer satisfaction, which generated positive results in this year's survey. We also focused on restoring customer confidence following quality challenges in Cardiopulmonary and Cardiac Assist. In parallel, we focused on the deployment of attractive technologies and addressing profitable markets, as well as launching digital offerings that help increase customer value.

INNOVATION

Our customers demand medical technologies that increase clinical efficiency and productivity, enabling more patients to be saved in a cost-effective way. This requires innovation in a variety of areas.

Activities in 2024

In 2024, we focused on product development and implementing the digital strategy, while also ensuring successful product launches in terms of customer value, regulatory requirements and growth agenda.

Launches during the year include Servo TwinView, which allows medical teams to analyze data from ventilators remotely, and Pulsiocare, which offers advanced hemodynamic monitoring with a high degree of user-friendliness.

We also acquired the US company Paragonix, which offers unique solutions for the safe transportation and storage of organs for transplantation, which fits perfectly with our portfolio from a strategic perspective. Paragonix has made significant progress after the acquisition, for example, by receiving FDA 510(K) clearance for the KidneyVault portable renal perfusion system.

Introduction

Strategy

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

Life Science

Surgical Workflows

Corporate Governance Report

Financial statements

Sustainability Report

Other information



PRIORITIES FOR 2025

- Take the next step toward excellence in quality
- Increase customer confidence through delivery stability
- Drive productivity and continuous improvements
- Accelerate the pace of innovation and implement the digital plan
- Drive employee development and commitment
- Continue to implement the sustainability approach

ENABLERS

EMPLOYEES

Thousands of dedicated employees in Acute Care Therapies work side by side to save lives every day. From sales and product development to production and support functions, everyone plays a crucial role in empowering healthcare professionals to make a difference.

Activities in 2024

We have set performance targets for all employees to strengthen key skills and increase commitment. This is achieved through transparent communication, improved decision-making, leadership accountability and promoting a growth mindset.

SUSTAINABILITY

Healthcare as a whole accounts for about 5% of carbon emissions worldwide and also generates hazardous waste. We are working intensively to reduce this impact while also improving clinical efficiency, which is positive for patients, hospital productivity and the finances of the healthcare system.

Activities in 2024

We continued to take action to achieve our sustainability targets, which also increases our competitiveness and ensures regulatory compliance. Alongside capitalizing on environmental effects, we place great importance on the contribution of our products to social and economic sustainable development. These include our new Vasoview Hemopro 3, which allows for faster treatment, shorter recovery and reduced risk of infection.

CO_2 emissions from our own production (Scope 1 & 2) for the year was reduced by 4%.

PRODUCTIVITY

We have a responsibility to our customers, investors and society around the world to conduct our operations cost efficient and to develop products and services that enhance productivity. In doing so, more patients can be helped without undermining the finances of the healthcare system.

Activities in 2024

The focus has been on reducing operating expenses to offset the effects of temporary increases in quality costs and inflation. At the same time, we have implemented improvements by making structural changes for long-term productivity.

For example, we carried out initiatives to improve the stability of purchasing and production, which increases productivity and delivery reliability, an important factor for customer satisfaction.

202506231499 3


Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

ENABLERS


Getinge's addressable market amounts to SEK **100** billion with an anticipated growth of 4–6% per year.

FINANCIAL PERFORMANCE


Business area's share of Group sales



Business area's regional distribution of sales



Net sales and adjusted EBITA margin



Market dynamics

	Advanced cardiopulmonary therapy	Cardiovascular surgery	Endovascular therapies
Products	Life-support therapies for intensive care and the OR, in the form of ECMO, heart-lung machines[1], ventilators, anesthesia systems, hemodynamic monitoring, intra-aortic balloon pumps, organ preservation and transportation[2] and digital solutions.	Products for advanced cardiac surgery in the form of endoscopic vessel harvesting products, beating heart surgery, vascular grafts and thoracic drainage systems.	Products for peripheral vascular diseases, which includes covered stents.
Share of sales within Acute Care Therapies (average 3 years)	69%	27%	4%
Market growth per year	6–8%	0–1%	8–10%
Our position	1	1	2
Our market share	~20%	40–45%	15–20%
Main competitors	Dräger, Mindray, GE Healthcare, BD, LivaNova, Medtronic, Teleflex, Transmedics, XVIVO	W. Gore, Terumo, Artivion, Medtronic	W. Gore, Bentley, BD

[1] Expected to be phased out in 2025, therefore included in 2024 figures but excluded from future market growth. [2] Paragonix was acquired in September 2024, therefore excluded from 2024 figures but included in future market growth.

Introduction

Strategy

Strategy for sustainable growth

Targets 2024–2028

Growing market for Getinge products

Business Areas

Acute Care Therapies

Life Science

Surgical Workflows

Corporate Governance Report

Financial statements

Sustainability Report

Other information



Innovative solutions for sterile transfer with renewable materials

Our latest DPTE-BetaBag® demonstrates our commitment to sterile transfer by integrating renewable materials. The newly launched Tyvek bag includes a Beta part primarily made of plastics derived from biomass waste and biological residues. This shift reduces the bag's carbon footprint while maintaining its essential functions. The new DPTE-BetaBag® has been rigorously tested to meet strict performance requirements, including sterilizing and gamma irradiation processes. In line with our EcoDesign initiatives, we have conducted a Life Cycle Assessment (LCA) of the DPTE-BetaBag® to evaluate its environmental impact and confirm a reduced carbon footprint, meeting customers' growing demand for sustainable innovations.

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Life Science

Enabling 25% more rapid development of advanced medicines

QUALITY

Our life science customers are engaged in the development and production of medicines, which means that they are subject to very strict quality requirements. Being both a supplier and partner, we are indirectly subject to the same high standards.

Activities in 2024

We continued our cultural shift to a more proactive approach, focusing on the preventive identification of potential shortcomings in products and production processes. We have restructured our quality organization by adopting a holistic approach to quality throughout the entire product life cycle. We have also implemented increased testing in production and preventive maintenance to ensure that the products and services we supply are of the highest quality. This enables a more efficient and reliable supply chain for our customers and ourselves.

CUSTOMERS

Our customers develop, manufacture and distribute medicines. These customers include some of the largest global companies, as well as many newer and fast-growing companies active in biopharma.

Activities in 2024

During the year, we worked intensively to meet the demand from companies who are expanding their capacity. Biopharma customers have started to generate higher order intakes again after a long period of focusing on reducing their inventory levels. This is most noticeable in Europe and North America and in Sterile Transfer, where we have also broadened our customer base.


INNOVATION

Our customers are seeking technologies and services that provide safer, faster and more economically efficient development production and distribution of medicines. The aim of our ongoing development activities is to help achieve this.

Activities in 2024

A great deal of our innovation takes place together with our customers. More widespread use of AI is an example of this. We launched several new products in 2024, including the GEW 888 neo – a washer that consumes up to 32% less water depending on configuration, the Lancer LSS lab sterilizer and a new version of the DPTE-BetaBag® made from renewable plastics. We also acquired INTACT™, an ecosystem of patents to create simpler and more cost-effective aseptic handling throughout the value chain. The performance of HPNE, which was acquired at the end of 2023, has also strengthened our position.

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information



PRIORITIES FOR 2025

- Drive growth through continued focus on innovation and acquisitions
- Integration and expansion of acquired companies HPNE and INTACT™
- Manufacturing Excellence that drives productivity and profitability
- Releasing capital for investments in value-adding growth
- Driving operations toward our sustainability targets
- Create high engagement among employees

ENABLERS

EMPLOYEES

Customers greatly appreciate our commitment to customer focus, innovation and collaboration. Therefore, these aspects are naturally integrated into the development of our employees and the organization as a whole.

Activities in 2024

During the year, we carried out activities to increase commitment by defining roles and responsibilities and strengthening our initiative, cooperation and decision-making ability. We also improved the technical and business proficiency of the sales organization.

SUSTAINABILITY

Our customers' commitment to sustainable development and manufacturing of medicines has increased considerably in recent years. This presents new opportunities that inspire us to develop.

Activities in 2024

We continued to identify and take sustainability action to achieve our sustainability targets and strengthen our competitiveness. This is based on a detailed roadmap and the development of EcoDesign guidelines, as well as specific activities and development efforts. Examples of this are the launch of the new Lancer LSS lab sterilizer that reduces energy consumption by up to 17% through improved control, and the cGMP washer GEW 888 neo that, depending on configuration, reduces water consumption by up to 32% and utility consumption by up to 25% compared with the product it replaces.

Emissions from our own production (Scope 1 & 2) for the year decreased with -36%.

PRODUCTIVITY

To enhance our competitiveness, we are striving to work cost-effectively and create products and services that improve productivity for our customers.

Activities in 2024

As a result of declining demand in biopharma in recent years, we have made capacity and cost adjustments to increase earnings capacity ahead of expected growth. This encompasses structural improvements that include consolidating the supplier base, reducing the cost of existing products and improving the quality of production.


Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

ENABLERS


Getinge's addressable market amounts to SEK
— 35 —
billion with an anticipated underlying growth of 9–11% per year.

FINANCIAL PERFORMANCE


Business area's share of Group sales



Business area's regional distribution of sales



Net sales and adjusted EBITA margin



Market dynamics

	Pharma production	Medical research
Products	Solutions for aseptic/sterile transfers, GMP sterilizers, GMP washers, bioreactors, automated logistics, isolators, disposables for liquid handling, pumps.	Lab washers, sterilizers and bioreactors, as well as cage washers and logistic automation.
Share of sales in Life Science	70%	30%
Market growth per year	10–12%	8–10%
Our position	1–4	2–3
Our market share	10–15%	10–15%
Main competitors	Fedegari, Steris, Steelco, Sartorius, GE, Thermo Fisher	Steris, Steelco/Miele, IWT, Sartorius, Eppendorf

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Efficient throughput and resource savings with Aquadis Index


With Aquadis Index, our new multi-chamber washer-disinfector, we combine high capacity with low resource consumption to help Central Sterile Supply Departments (CSSDs) worldwide achieve both productivity and sustainability goals. Designed for ease of use, it handles large loads efficiently, ensuring smooth throughput for CSSD teams at all experience levels. Our resource-saving technology significantly reduces water, energy, and detergent consumption. Features such as reuse tanks, dynamic water filling, optimized detergent dosing, and heat/energy recovery enhance resource efficiency while maintaining premium cleaning performance. With full connectivity, Aquadis Index enables CSSD staff to maximize uptime and ensure that the washer-disinfector is always ready for use.



Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

Surgical Workflows

One more surgery per day per OR



Our Surgical Workflows products are the backbone of a hospital's surgical operations. Accordingly, it is essential that our products and services are of the highest quality. Otherwise, the operations risk coming to a standstill.

Our customers are hospitals and clinics offering surgery and sterilization of surgical instruments. High utilization rates, productivity and quality in these operations are essential to the financial performance of the hospitals.

Our customers want technology and services that make surgical workflows safer, faster and more cost effective. Our efforts strive to meet these needs.

Activities in 2024

During the year, we strengthened our processes for customer feedback, field actions, reporting to regulators and product development. Our Quality Value Engineering efforts have raised quality and reduced costs and our First Time Pass ratio has increased significantly during the year, reducing the need for post-processing. This in turn entails faster delivery to the customer.

Activities in 2024

We want to be a partner to our customers and contribute to efficient workflows and high productivity. As a result, we offer infrastructure, machinery, consumables, service and digital tools. During the year we saw solid growth in such areas as infection control consumables and Digital Health Solutions, thanks to our leading digital tools for managing sterile reprocessing, ORs and patient flows.

Activities in 2024

During the year, we launched a large number of new features to existing offerings and some completely new products and services. These include the user-friendly and robust Maquet Ezea surgical light, the intuitive and high-performance Aquadis Index washer-disinfector and the Poladus 150 low-temperature sterilizer. At the end of 2023, we completed the acquisition of US-based Healthmark Industries, significantly strengthening our offering in Infection Control consumables and services.

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information



PRIORITIES FOR 2025

- Continue the structured efforts to ensure high quality in products and processes
- Strengthen our position in Infection Control and become a leading full-service supplier with the help of Healthmark-industries
- Launch new products and assume a stronger position in fast growing segments such as Digital Health Solutions, endoscope reprocessing and low temperature sterilization
- Increase productivity through efficient manufacturing, procurement and service processes
- Improvements in line with our sustainability targets

ENABLERS

EMPLOYEES

Meeting customer needs requires strong customer focus, innovation and collaboration. That is why we are prioritizing the development of both our employees and the entire organization.

Activities in 2024
We have a high level of employee engagement, which we aim to maintain. During the year, we accelerated our Responsible Leadership program, explained and discussed the strategy behind our priorities, and developed local action plans where necessary.

SUSTAINABILITY

Sterile reprocessing and surgery have a negative impact on the environment, which is why our customers demand products and services that minimize these effects. This is something we have been working on for a long time, which has resulted in a leading position.

Activities in 2024
During the year, we analyzed the environmental impact of selected consumables and established product environmental profiles (PEPs) for key products. We continued to map the impact of raw material and component sourcing and accelerated product development to reduce electricity and water consumption.
CO_2 emissions from our own production (Scope 1 & 2) for the year reduced with 48%.

PRODUCTIVITY

To enhance our competitiveness, we will conduct cost efficient operations and develop products and services that increase customer productivity.

Activities in 2024
We are continuing to focus intensely on reducing product costs through more efficient manufacturing and procurement. Efficient procurement helped bring about net savings in 2024 and Quality Value Engineering, which involves redesigning and replacing components, also made a positive contribution. These initiatives will continue.

Introduction
Strategy
Strategy for sustainable growth
Targets 2024–2028
Growing market for Getinge products
Business Areas
Acute Care Therapies
Life Science
Surgical Workflows
Corporate Governance Report
Financial statements
Sustainability Report
Other information

ENABLERS


Getinge's addressable market amounts to SEK

— 67 —


billion with an anticipated growth of 4–6% per year.

FINANCIAL PERFORMANCE


Business area's share of Group sales



Business area's regional distribution of sales



Net sales and adjusted EBITA margin



Market dynamics

	Sterile reprocessing department	Operating room equipment	Digital solutions for increased efficiency.
Products	Complete solutions for instrument and endoscope reprocessing, including steam and low-temperature sterilizers, washer-disinfectors, endoscope cleaners, automation solutions and consumable supplies, as well as service and clinical training.	Complete operating room solutions including modern hybrid operating rooms in combination with imaging partners, advanced operating tables, surgical lights and ceiling supply units, as well as consulting on layouts, workflows and technical service.	Advanced digital solutions to optimize hospital workflows and ensure efficiency in sterile supply chains, operating room integration and OR management.
Share of sales in Surgical Workflows	50%	44%	6%
Market growth per year	3–5%	4–6%	7–15%
Our position	1–2	1	1–5
Our market share	20–25%	15–20%	5–10%
Main competitors	Steris, SteelcoBellmed, Shinva, ASP	Baxter, Steris, Stryker, Mindray, Dräger	Steris, Karl Storz, Teletracking, Censis and local IT companies

GETINGE

2024 Annual Report

Introduction

Strategy

Corporate Governance Report

- Corporate governance structure
- Board of Directors
- President & CEO and Getinge Executive Team
- Building blocks in the Getinge corporate governance model
- Assurance framework, risks and risk management
- Internal control over the financial reporting
- Auditor's report on the Corporate Governance Report

Financial statements

Sustainability Report

Other information



Corporate Governance Report

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

Contents

33 About the report
34 Corporate governance structure
35 General Meeting
35–36 Nomination Committee
36 External auditor
36–41 Board of Directors
42–44 President & CEO and Getinge Executive Team
45–46 Building blocks in the Getinge corporate governance model
47–52 Assurance framework, risks and risk management
53–54 Internal control over the financial reporting
54 Auditor's report on the Corporate Governance Report

About the report

This Corporate Governance Report has been prepared and adopted by Getinge AB (publ)'s Board of Directors in accordance with the provisions of the Swedish Annual Accounts Act and the Swedish Corporate Governance Code. The Corporate Governance Report presents an overview of Getinge's corporate governance, including a description of the system for internal control over the financial reporting.

Information on Getinge's corporate governance is also available at www.getinge.com/int/company/corporate-governance/overview/. Information on the website does not comprise part of this Corporate Governance Report.

Responsibly, sustainably and efficiently

Getinge AB (publ) hereby submits its 2024 Corporate Governance Report that summarizes how the corporate governance is structured, how it has been carried out and how it has been developed in the Group during the 2024 fiscal year. This Corporate Governance Report is reviewed by the company's auditors. The auditor's report can be found on page 54.

Getinge always strives to ensure effective management, social and environmental responsibility, ethical business practices and optimal use of resources. As part of the efforts to continuously improve corporate governance, two of the primary focus areas during the year remained the further development of sustainability governance and the regulatory area of product quality.


In the area of sustainability, Getinge continued its work to strengthen governance during the year to ensure that the Group meets the expectations and requirements set. The overall focus has been to integrate sustainability dimensions throughout the operations and to increase cooperation on the matters between different functions in the Group. Part of this work was implementing a Sustainability Advisory Group, which works to ensure coordination between the different functions and that the varying characteristics of the business areas are taken into account in decision-making. The process of fine tuning the responsibilities and tasks of the newly established Ethics and Sustainability Committee continued during the year.

Getinge continued to work actively on ensuring proactivity, good product quality and integrated operational quality responsibility during the year, and adjustments to the Quality Compliance, Regulatory & Medical Affairs function. Examples of such measures are initiating a new process for management review and developing way of working using the global quality management system that was implemented in 2023.

During the year, the structure of the Acute Care Therapies business area was updated with the creation of the Transplant Care product segment as a direct result of the acquisition of Paragonix Technologies, an organ transport products and services company.

» As part of the efforts to continuously improve corporate governance, two of the primary focus areas during the year remained the further development of sustainability governance and the regulatory area of product quality. «

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information



Corporate governance structure

Getinge as a company

The company is a Swedish public limited liability company with the business name Getinge AB (publ). The Board of Directors is domiciled in the municipality of Gothenburg, Västra Götaland County, Sweden. The objects of the company's operations shall be to, directly or indirectly through subsidiaries, engage in the manufacturing and sale of medical technical equipment, and in any other activities compatible therewith.

The complete Articles of Association are available on www.getinge.com. The Articles of Association contain no specific provisions for the appointment or dismissal of Board members or on amendments to the Articles of Association.

External regulations

Getinge's corporate governance is based on applicable laws, regulations, good practice on the stock market and the Nasdaq Rulebook for Issuers. In addition, the Group's corporate governance is based on the Swedish Corporate Governance Code (the "Code"). Getinge follows the Code's "comply or explain" principle.

Getinge's only deviation from the Code's regulations in 2024 was from the Code's rule 2.4, that the Chairman of the Board or any other Board member is not to be Chairman of the Nomination Committee. The Nomination Committee appointed Carl Bennet (Board member and owner of the company's largest shareholder, Carl Bennet AB) as Chairman of the Nomination Committee, since the Nomination Committee found it important to have a representative of the largest shareholder to serve as Chairman of the Nomination Committee.

There were no violations of the stock market rules and no violations of good practice on the stock market reported by Nasdaq Stockholm's Disciplinary Committee or the Swedish Securities Council.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

A SHARES AND SHAREHOLDERS

The total number of shares in the company amounts to 272,369,573, of which 18,217,200 are Class A shares, each share carrying entitlement to ten votes and 254,152,373 are Class B shares, each share carrying entitlement to one vote. All shares carry the same dividend entitlement, and the Articles of Association contain no limitation on the number of votes each shareholder can cast at a General Meeting of Shareholders.

The largest shareholder, Carl Bennet AB, held 20.20% of the shares outstanding and 50.19% of all votes in the company at the end of the 2024 fiscal year, making him the only direct or indirect shareholder with a holding in the company representing over one tenth of the number of votes for all of the shares in the company.

For information about shareholders and the Getinge share, see pages 170–171 and www.getinge.com.

B GENERAL MEETING OF SHAREHOLDERS

The General Meeting of Shareholders is Getinge's highest decision-making body. Shareholders can exert their influence at the Annual General Meeting ("AGM") and, when applicable, at an Extraordinary General Meeting. The AGM, where shareholders exercise their voting rights in key issues for the company, is held within six months of the end of the fiscal year.

General Meetings of Shareholders are convened by publishing of a notice in Post- och Inrikes Tidningar (the Swedish Official Gazette) and on the company's website. An announcement is to be made in Svenska Dagbladet that the notice of the Meeting has been published. Shareholders, who want to participate in the discussions at the Meeting, must give notice of attendance to the company not later than the date provided in the notice of the Meeting. The Articles of Association also prescribe a possibility for the Board of Directors to resolve on collection of powers of attorney and to resolve that shareholders can exercise their voting rights by post. A shareholder who wishes to have a matter put forward at the General Meeting of Shareholders must submit a written proposal to the Board in a timely manner so that the proposal can be included in the notice of the Meeting.

2025 Annual General Meeting

The AGM will be held on April 22, 2025 at Kongresshallen at Hotel Tylösand in Halmstad, Sweden. Shareholders are also offered the possibility of taking part through postal voting.

Information about how shareholders can register their attendance at the AGM is available at www.getinge.com. The notice of the AGM is also available on the website, together with proposals and other relevant documentation for the AGM.

2024 Annual General Meeting

The 2024 AGM was held on April 22, 2024 in Halmstad, both physically and through postal voting. All of the members of the Board, the Nomination Committees' representatives and the auditor in charge attended the AGM. A total of 1,128 shareholders were represented at the AGM, representing approximately 82% of the votes in the company. The minutes from the AGM are available on www.getinge.com.

The decisions made by the AGM include:

- Dividend of SEK 4.40 per share for the 2023 fiscal year
- Re-election of all Board members available for re-election and the Chairman
- Re-election of Öhrlings PricewaterhouseCoopers AB as the company's auditor
- Approval of the remuneration report

C NOMINATION COMMITTEE

The Nomination Committee's task is to put forward proposals ahead of the AGM regarding the election of the Chairman of the AGM, the Chairman of the Board and other members of the Board, election of auditors, as well as fees for Board members and auditors.

At the 2020 AGM, principles were adopted for the appointment of the Nomination Committee and the instruction for the Nomination Committee, to apply until further notice. Ahead of each AGM, the Nomination Committee shall be composed of members appointed by the four largest shareholders in terms of voting rights as of August 31 of each year, and the Chairman of the Board. In addition, if the Chairman of the Board in consultation with the member appointed by the largest shareholder in terms of voting rights deems it appropriate, it shall include an, in relation to the company and its major shareholders, independent representative of the minority shareholders. The Instruction for the Nomination Committee is available in its entirety at: www.getinge.com/int/company/corporate-governance/.

Nomination Committee ahead of the 2025 Annual General Meeting

Following changes in the ownership structure of the company, Getinge's Nomination Committee ahead of the 2025 AGM comprises the company's Chairman of the Board Johan Malmquist, and representatives from the following five owners, listed by size:

- Carl Bennet AB: Carl Bennet
- Fourth Swedish National Pension Fund: Jannis Kitsakis
- AMF Pension & Fonder: Dick Bergqvist
- Carnegie fonder: Simon Blecher
- Swedbank Robur: Marianne Nilsson

Carl Bennet was appointed Chairman of the Nomination Committee ahead of the 2025 AGM (see also the section "External regulations" for information about deviation from the Code). No remuneration is paid to members of the Nomination Committee, and the members have affirmed that there are no conflicts of interest that affect their assignment on the Committee.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

C NOMINATION COMMITTEE cont.

The Nomination Committee has addressed all the matters that the Nomination Committee must address in accordance with the Code. As a basis for its work, the Nomination Committee studied the financial statements for the company's operations in 2024, the completed Board evaluation and proposals received.

When preparing its proposals on the composition of the Board, the Nomination Committee takes into account the individual expertise and experience of the proposed Board members, how well the Board will work as a whole and whether it possesses the necessary breadth in terms of background and expertise. The Nomination Committee pays particular attention to the value of diversity and the balance between the need for renewal and continuity in the Board. In its efforts to achieve diversity, the Nomination Committee gives special consideration to an even gender distribution. The Nomination Committee applies rule 4.1 of the Code as its diversity policy in preparing proposals of Board members. The aim of the policy is that the Board is to have a composition appropriate to the company's operations, phase of development and other relevant circumstances and to exhibit diversity and breadth of qualifications, experience and background, and strive for an equal gender distribution. Ahead of the 2024 AGM, the Nomination Committee stated that the gender balance is not satisfactory and expressed an intention to strive toward a more even gender balance.

The Nomination Committee has, in its own assessment, concluded that the Board is well functioning and that the Board members together hold the diversity and extensive competence, experience and background required, and are suitable with respect to the company's operations, phase of development and other circumstances, including sustainability aspects.

The proposals of the Nomination Committee ahead of the 2025 Annual General Meeting are submitted in the notice of the Meeting.

D EXTERNAL AUDITOR

Getinge AB (publ)'s auditor is elected at the AGM. The auditor performs an audit of the Annual Report, financial statements and the consolidated financial statements as well as the management by the Board and President & CEO in accordance with generally accepted auditing standards. After each fiscal year an auditor's report for the Parent Company and a Group auditor's report are presented to the General Meeting. The auditor also reviews Getinge's nine-months report. The auditor in charge and co-auditor participate in all of the Audit and Risk Committee meetings, as well as relevant Ethics and Sustainability Committee meetings, and report to the relevant committees and Board of Directors on their audit.

External auditors in 2024

At the 2024 AGM, the registered auditing firm Öhrlings PricewaterhouseCoopers AB was re-elected auditor until the 2025 AGM, which the firm has been since 2008. Authorized Public Accountant Cecilia Andrén Dorselius has been Auditor in Charge since the 2024 AGM and Authorized Public Accountant Karin Olsson was the co-signing auditor.

In addition to standard audit assignments, Öhrlings PricewaterhouseCoopers AB provides advisory services and performs assessments. Such assignments take place in accordance with the regulations determined by the Audit and Risk Committee for approval of the nature and scope of the services and the fees for such services. The performed assignments are not deemed to have given rise to any conflict of interest. Details about the amounts of remuneration paid to auditors are presented in Note 5 of the Annual Report.

E BOARD OF DIRECTORS

Composition of the Board of Directors

In 2024, Getinge AB (publ)'s Board comprised eight members elected at the AGM, of whom one is Getinge's President & CEO, as well as two members appointed by employee representative organizations and two deputy members for the employee representatives. Out of the Board members elected at the AGM, two are women and six are men (corresponding to 25% and 75%, respectively).

Independence of Board members

The Nomination Committee deemed that the composition of the Board during 2024 met the requirements for independence as stipulated by the Code. The Nomination Committee has observed that Mattias Perjos, in his capacity as President & CEO, is to be regarded as dependent in relation to the company and executive management, and that Carl Bennet and Dan Frohm, as Board members of Getinge's principal owner Carl Bennet AB, are to be regarded as dependent in relation to the major shareholders. Other Board members are deemed to be independent in relation to the company, executive management and major shareholders. A total of seven out of eight Board members are deemed to be independent in relation to the company and executive management (87.5%) and six out of eight are deemed to be independent in relation to major shareholders (75%).

Expertise of the Board

Ahead of the 2024 AGM, the Nomination Committee concluded that the Board functions well and that the Board members possess broad expertise and solid industry knowledge. For example, the Board members jointly possess solid financial background and extensive financial know-how, among other, through Board members' previous operative assignments within fields of economics and finance and other Board assignments, including work in Audit Committees. The Board also jointly possess competence and experience from the sustainability field, for example through one Board member's previous assignment as chairman of a Sustainability Committee but also through other Board members' operational assignments in

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

executive positions. Through certain Board members' previous and/or current operational assignments for Getinge and other companies, the Board members jointly possess sound knowledge of the industry and market where the company operates and of areas of relevance for the operations, such as artificial intelligence. Within the Board, there is also competence and experience from operational work within hospitals and clinical activity. In addition, the Board has solid experience from international relations and Board work, in broad sense, through Board members' previous and current operational assignments as well as Board assignments in other companies.

Responsibilities and work of the Board of Directors

Primarily, the Board is responsible for the organization of the company and the management of its affairs. In carrying out its duties, the Board must safeguard the interest of all its shareholders. The Board of Directors is to maintain and promote a good corporate culture and ensure that Getinge – on behalf of its shareholders – is led in the most sustainable, responsible and effective manner possible.

The guidelines for the Board's work are described in greater detail in the Board's rules of procedure and annual plan, which are reviewed and adopted each year. The rules of procedure include provisions on preventing disqualification and conflicts of interests for Board members, and a process for handling any transactions between Getinge and related parties.[1]

The Chairman is responsible for leading and managing the Board's work and ensuring that it is conducted in an organized and efficient manner. The President & CEO acts as rapporteur at the Board's meetings. In addition, the Group's Chief Financial Officer serves as rapporteur and the Group's Head of Corporate Legal serves as Secretary of the Board, with the exception of instances where it is inappropriate for them to attend. Other senior executives also participate when needed. The rules of procedure also contain guidelines for the work of the Board's committees. The Board decides on the members of the committees, with the aim of the committee members possessing the relevant experience and skills for the committee's work.

Board of Directors' work in 2024

In 2024, the Board held a total of 13 meetings, with an attendance rate of 97% of the members elected by the AGM.

At its ordinary meetings, the Board has addressed fixed agenda items in accordance with the Board's rules of procedure and annual plan. Accordingly, the Board has addressed the Group's long-term objectives and strategy, risks and risk management, sustainability matters, financial and investment plan, financial reports and corporate governance documents. The Board has continuously addressed its business situation and financial matters, ethics and compliance, quality and regulatory matters, succession planning and talent development, as well as organizational matters. During the year, the Board also addressed legal proceedings and acquisitions.

During the year, the Board worked in particular on matters related to:

- quality work and remediation of the communicated challenges in the area and implementation of robust processes and systems;
- sustainability efforts and ensuring that these are integrated throughout operations; and
- the Group's acquisition agenda and, in particular, the acquisition of Paragonix Technologies.

At one of its meetings, the Board met with the company's auditor without the presence of the President & CEO or any other individual from executive management. The Board also continuously evaluated the work of the President & CEO and addressed to this matter at one meeting without the presence of executive management.

The Board of Directors of Getinge AB (publ) is responsible for, among other things:

- Overall strategy, targets and organization
- That procedures are in place for financial reporting and that financial reporting is conducted in accordance with applicable rules and regulations
- An overview of the financial plan, earnings, forecasts and forward-looking statements as well as the adoption of the financial statements
- Ensuring that there are effective systems for follow ups and control of operations, financial position and risks, and well-functioning internal control
- Identifying how sustainability issues affect risks and business opportunities
- Approving guidelines and general policies for conduct in society with the aim of securing long-term value creation
- Ensuring that there are sufficient control mechanisms in place for compliance with applicable rules and regulations, as well as with internal policies and guidelines
- Ensuring that external disclosures (incl. financial reporting) are characterized by openness and objectivity, and are correct, reliable and have a high level of relevance, and that there are appropriate processes, controls and systems in place

Board of Directors' evaluation of its work

The Board carries out an annual evaluation of its work for the purpose of developing its methods and effectiveness. The evaluation in 2024 was, as in previous years, based on a survey and a tool provided by an external party. Additionally, the Chairman of the Board carried out individual interviews with the Board members. The results and analysis of this have been reported to the Board and followed up on with discussions and identification of focus areas moving forward. The Nomination Committee has taken part of the evaluation in its entirety as well as the Board's conclusions.

1) Board member's shareholdings and other assignments can be found on pages 39–41. Getinge does not collect shareholding information from suppliers or other stakeholders. Information on any transactions with related parties are presented in Note 28.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

BOARD COMMITTEES

The Board has established three committees – to focus on remuneration, audit and risk and ethics and sustainability

F REMUNERATION COMMITTEE

Responsibilities and work

The Remuneration Committee is responsible for:

- preparing the Board's resolutions concerning remuneration principles, remuneration and other employment terms and conditions for executive management;
- monitoring and evaluating variable remuneration programs for executive management;
- assisting in the preparation of the company's remuneration report;
- preparing proposals on guidelines for the remuneration to senior executives that the Board will propose to the AGM;
- monitoring and evaluating the application of the guidelines for remuneration;
- evaluating the current remuneration structures and levels in the company; and
- preparing resolutions related to succession planning and talent development.

The Committee held four meetings in 2024, and remained in contact as required. A particular area of focus was evaluating and ensuring that current remuneration levels and structures are in line with market terms.

Composition

In 2024, the Committee comprised the Board members Johan Malmquist (Chairman), Carl Bennet and Dan Frohm. The members of the Remuneration Committee are independent in relation to the company and executive management, and Johan Malmquist is also independent in relation to the company's major shareholders.

G AUDIT AND RISK COMMITTEE

Responsibilities and work

The Audit and Risk Committee is responsible for:

- meeting the requirements of the Swedish Companies Act, the Code and the EU Audit Regulation;
- contact between the Board and the auditors;
- preparing matters relating to the election of auditors and remuneration;
- monitoring the company's accounting;
- preparing the company's financial statements;
- preparing the company's finance policy;
- monitoring the effectiveness of the company's internal control, financial risk management and internal audit;
- monitoring legal disputes, internal investigations and whistleblowing cases;
- monitoring the Group's work on information and cyber security matters; and
- monitoring sustainability reporting matters that have been delegated to the Ethics and Sustainability Committee

The Committee held seven meetings in 2024, and remained in contact as required. The company's auditors participated in all meetings. Particular focus areas were internal control, monitoring remediation programs, the Group's long-term financing, procurement of audit services and digital compliance.

Composition

In 2024, the Committee comprised the Board members Johan Bygge (Chairman), Cecilia Daun Wennborg, Dan Frohm and Kristian Samuelsson. The members of the Committee are independent in relation to the company, executive management and the company's major shareholders, with the exception of Dan Frohm, who is not considered to be independent in relation to the company's major shareholders. The composition of the Committee meets the qualification criteria that is placed on accounting or auditing expertise.

H ETHICS AND SUSTAINABILITY COMMITTEE

Responsibilities and work

The Ethics and Sustainability Committee is responsible for:

- preparing strategic matters regarding the company's work on areas defined by Getinge as key areas for sustainable development;
- preparing the sustainability-related matters that the Board is required to address under the Code;
- monitoring the work of the Sustainability function;
- monitoring the work of the Ethics & Compliance function and monitoring the implementation of an effective Ethics & Compliance program;
- monitoring the work of the Quality Compliance, Regulatory & Medical Affairs function, and monitoring the implementation of the quality organization.


The Committee held six meetings in 2024, and remained in contact as required. Particular focus areas for the year were the work on the Group's materiality assessment and sustainability strategy, monitoring the process of sustainability reporting and product quality activities. Furthermore, the Committee particularly monitored the Group's work on human rights compliance programs, integration of sustainability dimensions in the acquisition process and due diligence in the supply chain.

Composition

Since the 2024 AGM, the Committee comprised the Board members Cecilia Daun Wennborg (Chairman), Malin Persson and Dan Frohm. The members of the Committee are independent in relation to the company, executive management and the company's major shareholders, with the exception of Dan Frohm, who is not considered to be independent in relation to the company's major shareholders.

Board of Directors




Name	Johan Malmquist	Carl Bennet	Johan Bygge	Cecilia Daun Wennborg
Position	Board member elected by the AGM. Chairman of the Board. Board member since 2016. Chairman of the Remuneration Committee.	Board member elected by the AGM. Vice Chairman of the Board. Board member since 1999. Member of the Remuneration Committee.	Board member elected by the AGM. Board member since 2007. Chairman of the Audit and Risk Committee.	Board member elected by the AGM. Board member since 2010. Chairman of the Ethics and Sustainability Committee. Member of the Audit and Risk Committee.
Year of birth, education and nationality	1951, B.Sc. in Business Administration, Swedish.	1951, B.Sc. in Business Administration, med. Dr. h.c., tech. Dr. h.c., honorary doctorate in economics, Swedish.	1956, B.Sc. in Business Administration, Swedish.	1953, B.Sc. in Business Administration, Swedish.
Core expertise	Industry know-how, Business management, International industry	Industry know-how, Business management, International industry	Business management, Mergers and acquisition, Finance	Medical and healthcare, Business management, Sustainability
Board assignments	Chairman of Arjo AB (publ) and Trelleborg AB (publ). Board member of Mölnlycke Health Care AB, Stena Adactum AB and Chalmers University of Technology Foundation.	Chairman of Lifco AB (publ). Vice Chairman of Arjo AB (publ) and Elanders AB (publ). Board member of L E Lundbergaföretagen AB (publ).	Chairman of Scandi Standard AB (publ), Guard Therapeutics AB (publ), Yangi AB, Arevo AB and AB Regin. Vice Chairman of Third Swedish Pension Fund (AP3). Board member of Lantmännen Ek.För CapMan OYJ and Riksbankens Jubileumsfond Foundation.	Chairman of Almi AB. Board member of Loomis AB (publ), Bravida Holding AB (publ), Oncopeptides AB (publ), Atvexa AB, Social initiative Norden AB, Gränges AB (publ), and member of Swedish Securities Council.
Professional experience, previous assignments and other information	President & CEO of Getinge 1997–2015. Former Business Area Director within Getinge, President of Getinge's French subsidiary, President of subsidiaries in the Electrolux Group. Former Chairman of the Board of Tingstad Pappers AB, and Board member of Elekta AB (publ), SCA AB (publ) and the Dunker Foundations.	CEO and Chairman of Carl Bennet AB. Former President & CEO of Getinge 1989–1997. Chairman of Getinge's Board of Directors 1997–2019. Former Board member of Holmen AB (publ).	Former Chairman of PSM International China and Nobina AB (publ), Chairman of EQT Asia Pacific, Venture Partner of Proxum AG Venture Fund, COO of EQT, Board member of Anticimex, I-Med Ltd and Praktikerjänst AB. CFO of Investor AB, Executive Vice President of Electrolux and CFO of Electrolux.	Former deputy CEO of Ambea AB, CEO of Carema Vård och Omsorg AB, acting CEO of Skandiabanken, Head of Swedish Operations at Skandia, President of Skandia Link, and Board member of Atos Medical Holding AB (publ), Hoist Finance AB (publ), Sophiahemmet, ICA Gruppen AB (publ), Hotell Diplomat AB, Eleda TopCo AB and the Oxfam Sweden Foundation.
Attendance at meetings*				
Board meetings	13/13	11/13	13/13	13/13
Remuneration Committee	4/4	4/4	–	–
Audit and Risk Committee	–	–	7/7	7/7
Ethics and Sustainability Committee	–	–	–	6/6
Independence[1]				
Dependent/independent in relation to the company and executive management and in relation to major shareholders	Independent in relation to the company, executive management and major shareholders.	Dependent in relation to major shareholders, owner and Chairman of Getinge's principal owner Carl Bennet AB. Independent in relation to the company and executive management.	Independent in relation to the company, executive management and major shareholders.	Independent in relation to the company, executive management and major shareholders.
Remuneration and holdings				
Total remuneration in 2024, SEK	1,606,200, of which 156,800 comprises fees for the Remuneration Committee.	816,600, of which 113,600 comprises fees for the Remuneration Committee.	1,016,700, of which 313,700 comprises fees for the Audit and Risk Committee.	1,013,400, of which 153,600 comprises fees for the Audit and Risk Committee and 156,800 comprises fees for the Ethics and Sustainability Committee.
Holdings in Getinge AB (publ) (own and related parties[2])	160,000 Class B shares.	Holds 18,217,200 Class A shares and 36,802,969 Class B shares through companies.	30,600 Class B shares.	18,500 Class B shares.

* Barbro Fridén stepped down as a Board member at the 2024 AGM and attended 5/5 Board meetings and 1/1 Remuneration Committee meeting prior to that.
1) See further on the independence of the Board on page 36. 2) See definition of related parties on page 41.

Board of Directors, cont.




Name	Dan Frohm	Mattias Perjos	Malin Persson	Kristian Samuelsson
Position	Board member elected by the AGM. Board member since 2017. Member of the Audit and Risk Committee, the Remuneration Committee and the Ethics and Sustainability Committee (from 2024 AGM).	Board member elected by the AGM. Board member since 2017. President & CEO.	Board member elected by the AGM. Board member since 2014. Member of the Ethics and Sustainability Committee.	Board member elected by the AGM. Board member since 2021. Member of the Audit and Risk Committee.
Year of birth, education and nationality	1981, M.Sc. in Industrial Engineering and Management, Swedish.	1972, M.Sc. in Industrial Engineering and Management, Swedish.	1968, M.Sc. in Industrial Engineering and Management, Swedish.	1977, Professor, M.D., PhD., Swedish.
Core expertise	International industry, Strategy and business development	Industry know-how, Business management, International industry	Business management, Sustainability, Technological development, R&D, Strategy and business development	Medical and healthcare, Technological development, R&D, AI/Digitalization
Board assignments	Chairman of Elanders AB (publ), Vice Chairman of Carl Bennet AB and Lifco AB (publ), Board member of Adjo AB (publ) and Swedish-American Chamber of Commerce, Inc.	Board member of EUROAPI S.A. Member of International Chamber of Commerce (ICC) Sweden's Board.	Chairman of Universeum AB. Board member of Hexpol AB (publ), Peab AB (publ), Beijers Group, Hydroscand Group AB, Stena Sessan AB, Absolent Air Care Group AB (publ) and AB Sigrid Rudebecks Skola.	Member of the Faculty Board of Sahlgrenska Academy, University of Gothenburg.
Professional experience, previous assignments and other information	CEO of DF Advisory LLC. Former management consultant at Applied Value LLC in New York.	President & CEO of Getinge. Former CEO of Coesia Industrial Process Solutions (IPS) and head of Coesia International. Senior positions at FlexLink AB including the role of CEO.	CEO and owner of Accuracy AB. Former CEO of the Chalmers University of Technology Foundation and many years' experience in major Swedish industrial enterprises such as the Volvo Group. Former Board member of Hexatronic Group AB (publ), EVRY ASA, OX2 AB (publ), Oddwork Sweden AB and Ricardo PLC.	Professor of orthopaedic surgery at the University of Gothenburg and senior consultant in orthopaedic surgery at Sahlgrenska University Hospital. Experience from healthcare with evidence-based medical research and interdisciplinary research in areas such as artificial intelligence (AI) and digitization.
Attendance at meetings				
Board meetings	12/13	13/13	13/13	13/13
Remuneration Committee	4/4	-	-	-
Audit and Risk Committee	7/7	-	-	7/7
Ethics and Sustainability Committee	3/3	-	6/6	-
Independence[1]				
Dependent/independent in relation to the company and executive management and in relation to major shareholders	Dependent in relation to major shareholders, Board member of Getinge's principal owner Carl Bennet AB. Independent in relation to the company and executive management.	Dependent in relation to the company and executive management in his capacity as President & CEO of Getinge. Independent in relation to major shareholders.	Independent in relation to the company, executive management and major shareholders.	Independent in relation to the company, executive management and major shareholders.
Remuneration and holdings				
Total remuneration in 2024, SEK	1,083,800, of which 113,600 comprises fees for the Remuneration Committee, 153,600 comprises fees for the Audit and Risk Committee and 113,600 comprises fees for the Ethics and Sustainability Committee.	-	816,600, of which 113,600 comprises fees for the Ethics and Sustainability Committee.	856,600, of which 153,600 comprises fees for the Audit and Risk Committee.
Holdings in Getinge AB (publ) (own and related parties[2])	154,999 Class B shares.	200,000 Class B shares.	18,112 Class B shares.	5,000 Class B shares.

1) See further on the independence of the Board on page 36. 2) See definition of related parties on page 41.

Board of Directors, cont.






Name	Åke Larsson	Fredrik Brattborn	Ida Ekman	Pontus Kåll
Position	Ordinary Board member appointed by employee organization	Ordinary Board member appointed by employee organization	Deputy appointed by employee organization	Deputy appointed by employee organization
Year of birth, education and nationality	1966, M.Sc. in Electrical engineering, Swedish.	1976, Swedish.	1985, B.Eng. in Chemical engineering, Swedish.	1991, Swedish.
Board assignments	-	-	-	-
Professional experience, previous assignments and other information	Specialist, Research & Development at Maquet Critical Care AB. Assignments on Getinge's Board: Ordinary Board member 2016–2018, 2020–2022 and from October 2022. Deputy 2014–2016, 2018–2020 and 2022.	Workshop technician, Manufacturing at Getinge Disinfection AB. Assignments on Getinge's Board: Deputy 2020–2021. Ordinary member from April 2022.	Manager Master Data Operations, IT at Getinge Business Support Services. Assignments on Getinge's Board: Deputy representative since 2022.	Functional tester at Getinge Sterilization AB. Assignments on Getinge's Board: Deputy representative since 2022.
Attendance at meetings				
Board meetings	13/13	13/13	13/13	13/13
Remuneration Committee	-	-	-	-
Audit and Risk Committee	-	-	-	-
Ethics and Sustainability Committee	-	-	-	-
Independence[1]				
Dependent/independent in relation to the company and executive management and in relation to major shareholders	-	-	-	-
Remuneration and holdings				
Total remuneration in 2024, SEK	-	-	-	-
Holdings in Getinge AB (publ) (own and related parties[2])	100 Class B shares.	Holds no shares.	45 Class B shares.	Holds no shares.

Definition of related parties, linked to shareholdings:

Related parties are legal entities directly or indirectly controlled by the Board member or President & CEO or by his or her related parties.
In the case of physical relatives, the spouse/cohabiting partner, children under custody and other relatives with whom households have been shared for at least one year are covered.

1) See further on the independence of the Board on page 36.
2) See also the definition of related parties above.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

PRESIDENT & CEO AND GETINGE EXECUTIVE TEAM

President & CEO

The Board of Directors has delegated the day-to-day management of Getinge and the overall management of the Group's operations to the President & CEO, including an authorization to make decisions or govern all matters that are not exclusively under the authority of the Board of Directors.

It is the President & CEO's responsibility to implement and ensure that the strategies, business plans and operational objectives that the Board adopts are carried out and that effective internal governance and control are maintained. The President & CEO also reports at Board meetings and keeps the Board of Directors and its Chairman up to date on Getinge's financial position, development, risks and opportunities, and the progress of sustainability activities. The President & CEO's role, areas of responsibility and authorizations are described in more detail in the instruction for the CEO and for financial reporting.

Getinge Executive Team

The President & CEO is supported by the Getinge Executive Team in conducting Getinge's operations. The Getinge Executive Team comprises the business area presidents, the head of the Global Sales and Service organization, the CFO and heads of the Group support functions.

The President & CEO delegates roles and responsibilities to the Executive Team, which then structures its own management teams and ensures that strategic matters, leadership, product quality, ethics and compliance, and sustainability matters are integrated into the business.

Forum at Getinge Executive Team level

Internally, Getinge has a continuous need for coordination and interaction between various functions and competencies in the global organization. Cross functional forums and meeting structures have been established at the Group level to ensure acceptance and coordination and to assist the President & CEO and the Getinge Executive Team in making well-informed decisions, and also to provide a defined structure for escalation to the Getinge Executive Team and the Board of Directors.

Getinge Executive Team 2024


At year-end 2024, Getinge Executive Team comprised ten individuals. The Getinge Executive Team held six ordinary meetings in 2024 and remained in continuous contact and alignment between meetings. The primary focus of the meetings was the Group's strategic and operational performance and monitoring of results. During the year the Getinge Executive Team addressed topics such as sustainability, the acquisition agenda, the changing global landscape and financial situation, challenges in the supply chain and other external factors. One of the major focus areas for 2024 has been the Group's quality activities, both in terms of communicated challenges in quality and remediation activities related to this, but also in terms of proactive work to strengthen processes and refine relevant systems.

Forum at Getinge Executive Team level

Forum	Responsibilities
Sustainability Board	Governance across all sustainability-related areas. This includes preparing proposals, initiatives and guiding principles for the Executive Team, the Ethics and Sustainability Committee and the Board of Directors.
Sponsorship & Donations Committee	Pre-approval of sponsorships and donations.
IT Board	Prioritizing coordination and decisions on IT activities and proposing decisions on IT investments to the Executive Team.
Ethics Committee	Follow ups of internal investigations and compliance issues and measures taken as a result. Also has decision-making powers regarding relations with third parties where specific risks have been identified.
Disclosure Committee	Previews proposed disclosures in financial reports, and makes recommendations to the Audit and Risk Committee and the Board of Directors on these.
Insider Committee	Supports the President & CEO in managing insider information issues and the disclosure of these.
STIP Steering Committee	Prepares – in relation to non-executives – the annual variable remuneration process, performance targets and any deviations or adjustments.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information


Executive Team



Mattias Perjos (1972)	Agneta Palmér (1978)	Carsten Blecker (1966)	Elin Frostehav (1982)	Stéphane Le Roy (1977)	Eric Honroth (1971)
President & CEO	Chief Financial Officer	Chief Commercial Officer	President, Acute Care Therapies	President, Surgical Workflows	President, Life Science
M.Sc. in Industrial Engineering and Management	M.Sc. in Economics	PhD in Dentistry; Doctorate in Business Administration, Bachelor in Medicine	Master of Science Program in Industrial Engineering and Management	M.Sc. in Industrial Engineering	B.Sc. in Business and Marketing
Swedish citizen	Swedish citizen	German citizen	Swedish citizen	French citizen	US citizen
Employed at Getinge since 2017	Employed at Getinge since 2018	Employed at Getinge since 2014	Employed at Getinge since 2019	Employed at Getinge since 2012	Employed at Getinge since 2018
Shareholdings (own and related parties): 200,000 Class B shares	Shareholdings (own and related parties): 2,800 Class B shares	Shareholdings (own and related parties): 7,200 Class B shares	Shareholdings (own and related parties): 4,000 Class B shares	Shareholdings (own and related parties): 5,300 Class B shares	Shareholdings (own and related parties): 1,025 Class B shares
Previous experience: Mattias Perjos has held senior positions at Coesia 2012–2017, including CEO of Coesia IPS Division and Coesia International. Previously he was CEO of Flexlink 2006–2016 where he started his career in 1998 and served as business area manager 2003–2006. Other assignments: Board member of EUROAPI S.A. Member of International Chamber of Commerce (ICC) Sweden's Board.	Previous experience: Until March 2024, Agneta Palmér held the position of Executive Vice President Operational Services and prior to that was Vice President Corporate Control at Getinge. She has previously held leading positions in finance in the Volvo Group and before that worked as a management consultant with a focus on business development, process optimization and financial control.	Previous experience: Carsten Blecker previously served as President EMEA, responsible for all of Getinge's country organizations in the region. Before that, he was Head of Biomet's Dental business for EMEA. Prior to that, Carsten was with Paler Medical as Business Unit Director. Carsten also worked for McKinsey & Company, Kimberly-Clark Healthcare EMEA and Medtronic EMEA.	Previous experience: Until March 2022, Elin Frostehav was Vice President of Critical Care, a product segment in Acute Care Therapies at Getinge. She has previously held leading global positions within Semcon in the areas of product development and digitalization. Prior to Semcon, Elin held various positions at FlexLink.	Previous experience: Stéphane Le Roy most recently served as the Regional President of South West Europe in Getinge's Global Sales organization. He joined Getinge in 2012 as country manager for Infection Control in France. Between 2006 and 2012, he was business unit manager for CT Scanners for Siemens Healthcare in France. Before that, he held several product management positions and supply chain assignments within the field of medical imaging at GE Healthcare.	Previous experience: Until March 2022, Eric Honroth was President of the North America sales region in Getinge's Global Sales organization. He has more than 20 years of experience in global leadership roles in the medical devices industry, including roles at Becton, Dickinson, CareFusion and Abbott Vascular.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

Getinge Executive Team cont.




Joanna Engelke (1960)	**Magnus Lundbäck** (1969)	**Anna Romberg** (1979)	**Alexandra Holland** (1986)
Executive Vice President, Quality Compliance, Regulatory & Medical Affairs	Executive Vice President, Human Resources	Executive Vice President, Sustainability, Legal & Compliance	Executive Vice President, Communications
MBA, B.A. in Political Science	PhD in Strategy and Organization and Technology Licentiate	PhD in Corporate Governance and Compliance, M.Sc. in Economics and Business Administration	Bachelor of Science in Communications
US citizen	Swedish citizen.	Finnish citizen	US citizen
Employed at Getinge since 2022	Employed at Getinge since 2017	Employed at Getinge since 2020	Employed at Getinge since 2024
Shareholdings (own and related parties): Holds no shares.	Shareholdings (own and related parties): 7,842 Class B shares	Shareholdings (own and related parties): 7,700 Class B shares	Shareholdings (own and related parties): Holds no shares.
Previous experience: Joanna Engelke has solid experience from areas of regulatory healthcare in international companies. She has previously held leading positions as Head of New Ventures & Chief Quality Officer for JUUL Labs, Senior Vice President Global Quality & Regulatory Affairs at Boston Scientific Corporation, Managing Director at Holloran Consulting Group and Portfolio CEO, Biospecific at PureTech Ventures among others.	Previous experience: Magnus Lundbäck was previously SVP Human Resources & Sustainability at Gunnebo Group. He has previously served as Executive Vice President Human Resources and Sustainability at Getinge and as Vice President Human Resources at Volvo Car Corporation.	Previous experience: Anna Romberg has served as VP Ethics and Compliance for Cargotec Oyj, and in various governance and compliance roles at Telia Company AB. She has also supported numerous global companies, with regards to governance and compliance matters, on a consultancy basis. She is one of the founders of the Nordic Business Ethics Initiative. Other assignments: Chairman of the Board of North House AB.	Previous experience: Until November 2024, Alexandra Holland was Vice President, Business and Culture Communications, Johnson & Johnson MedTech. She has more than 15 years of leadership experience in healthcare communications working across the consumer, medtech and corporate sectors.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

Building blocks in the Getinge corporate governance model

Getinge's operational corporate governance model consists of three main components: governing principles and documents, operational governance and legal entity governance.

Combined, these components form the building blocks for Getinge's corporate governance model and conditions for meeting targets, monitoring and control, which supports the Board's agenda.



Framework for Getinge's corporate governance.

Getinge guiding principles and steering documents

Guiding principles

Getinge's expressed vision, purpose, goals, brand promise and cultural core values are used as guiding principles for its operations. The Board of Directors establishes the general long-term strategy, which sets the direction for the coming years, as well as annual operational and financial targets. The Board also evaluates the strategy for all business areas and the Global Sales and Service organization once per year.

The President & CEO establishes the operational targets for the business, based on decisions by, and guidance from, the Board.

Steering documents – framework

The Code of Conduct – Responsible leadership – provides guidelines for how Getinge works. It can be summarized in the six principles in the figure on this page.

The Code of Conduct is based on Getinge's global policies adopted by the Board and revised at least every two years.

For each of the policy documents, more detailed and guiding directives and guidelines are issued (where appropriate) that are decided upon by the CEO or member of the Executive Team responsible for the area.

The Code of Conduct and all policy documents, directives and guidelines as well as quality steering documents are available to all employees. The Code of Conduct and several global policies are also available on Getinge's website.

GETINGE'S CODE OF CONDUCT

- Always act with honesty, fairness and integrity
- Act respectfully to protect confidentiality, privacy and information
- Take care of each other
- Take care of the world
- Stand up and speak up when something isn't right
- Act together to protect our stakeholders

Read more at the link below:
https://www.getinge.com/int/company/business-ethics/code-of-conduct/

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

Getinge's operating model

Getinge's operating model aims to create a clear structure and distribution of roles within the Group. It is based on what and how Getinge develops, manufactures, serves and sells to customers and capitalizes on the differences between the business areas. The operating model is based on decentralized decision-making under the established Group-wide frameworks and strategies.

Business areas

The operational business areas are Acute Care Therapies, Life Science and Surgical Workflows. The business areas are responsible for (i) their daily operations and integrated financial results, (ii) developing their product portfolios and offerings, and (iii) their strategic agendas. They are also responsible for ensuring that the operations are conducted in accordance with laws and rules, and for ensuring that quality and regulatory requirements are met and that sustainability topics are integrated into operations.

Global Sales and Service organization

The operational business also includes a Group-wide Global Sales and Service organization to capitalize on synergies in sales. The function coordinates larger strategic decisions with the business areas and assumes the ultimate responsibility for ensuring that sales are conducted in accordance with laws and rules and that quality and regulatory requirements are met.


Competence and support functions

Getinge has certain shared competence and support functions that are organized into two categories. Corporate functions provide steering in areas at Group level and are responsible for developing policies, guidance, processes and structures. Getinge has a centralized Ethics & Compliance function that is responsible for designing the compliance programs, providing support for implementing and monitoring such implementation. Getinge also has a separate Corporate Internal Audit function. See also page 48 for information about these supervisory functions. The group support functions are competence and support functions for coordination of a variety of areas and are more active operationally in daily activities.

Legal entity governance

Getinge comprises a large number of separate legal entities globally. Each legal entity within Getinge functions as part of an operational business area, the Global Sales and Service organization, the corporate functions or the Group support functions.

Governance of the legal entities must be effective and designed to ensure compliance with rules and intra-Group requirements.



1) Includes Strategy, M&A and Investor Relations
2) Also includes Treasury, Tax, Corporate Control, Risk Management, IT and Supply Chain Services.
3) Reports directly to the Audit and Risk Committee.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

Assurance framework, risks and risk management

Risk management framework

Getinge actively and systematically manages the risks that the Group is exposed to. In accordance with this, the Getinge Executive Team conducts an annual evaluation of material risks and effects. Based on this evaluation, the Executive Team decides and acts on measures to reduce risks and their effects. The risk evaluation is reported to the Board of Directors and serves as a key basis in determining the focus areas for Corporate Internal Audit.

Risks at Getinge are managed in accordance with the Group's decentralized structure. The three business areas and the Global Sales and Service organization are responsible for risk management in their respective areas and have their own structures for this purpose. The corporate and Group support functions support these units by providing governance, developing processes and promoting synergies in their specific areas of competence. Several established forums that focus on specific types of risks conduct regular evaluations and monitoring to ensure correct coordination and management from a Group perspective. Examples of these forums are the Ethics Committee, Sustainability Board and the Group's risk manager forum. To manage cyber risks, Getinge also has a Chief Information Security Officer (CISO) who coordinates this work via, inter alia, a Security Advisory Board and a Getinge Centre of Excellence for cyber security linked to the Group's products.

Risk assessment

By conducting quantitative and qualitative risk analyses focusing on the customer offering and operations, Getinge identifies the key risks that could prevent the achievement of business and financial targets. In addition, several of the Group's units are analyzed to gain a more detailed understanding of how existing regulations are applied in practice. The overall responsibility for identifying and managing potential risk areas lies with the Getinge Executive Team and the operations. The Ethics & Compliance function and Corporate Internal Audit assist with support, ongoing monitoring, investigations and internal audit, which help to identify risk.

In 2024, Getinge continued its efforts to strengthen the process for risk identification, preventive action and risk management in the Corporate Risk Management function, with support from Corporate Internal Audit. The risk identification process was, as in previous years, carried out as a Group-wide analysis based on consolidated input data from the three business areas, the Global Sales and Service Organization and support functions. Financial risks and opportunities from a sustainability perspective are evaluated in Getinge's double materiality assessment (DMA) process and then incorporated into the overall process. The most relevant identified risks are presented on the following pages, but do not comprise a complete account of all of the risks to which the Group is exposed. The risks are divided into three categories:

- External – risks that cannot be controlled, but that are monitored and prepared for in order to optimize outcomes and turn risks into opportunities;
- Operational – risks that can be controlled and are to be managed in a cost-efficient manner to minimize negative effects, where the company has a direct impact on the root causes; and
- Strategic – risks and opportunities that the company is exposed to and are to be managed by balancing risks and the potential for maximizing advantages.

Efforts to identify specific risks in each category and develop plans to prevent risks and mitigate the potential effects were continually conducted during the year.

Getinge's insurance program

Strategy

Getinge works actively with loss prevention activities, for example, through its extensive quality activities and by preventing interruption risks in the operations. The starting point is for Getinge to act as if the Group was uninsured. That means that Getinge continuously considers risk factors and manage them as part of the daily work. Actively monitoring incidents and correcting underlying causes means that claims related to product liability can be prevented.

Group-wide insurance program

Getinge has a Group-wide insurance program that encompasses the global operations. The program aims to protect the assets in the consolidated balance sheet and to counteract fluctuations in earnings. The aim is to cover insurable risks with adequate limits based on current risk exposure levels. Insurance policies have been entered into with insurance companies with high credit ratings and a documented ability to provide claims assistance. The joint insurance programs create economies of scale, ensure a harmonized approach to limits and deductibles and is the foundation of balanced and cost-efficient insurance policies.

Customer value

A stable and standardized insurance coverage for the Group's global operations also adds customer value since it is required in many tender and procurement processes and when commercial contracts are signed.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

Ethics & Compliance


The risk identification system and management process is supplemented by the Ethics & Compliance function. The function is responsible for the global Ethics & Compliance program, sets standards and processes, and monitors the use and implementation of these. The function also manages the Group's Speak-Up Line (whistleblower function) and performs risk assessments and internal investigations. Internal investigations and whistleblowing cases are reported to the Audit and Risk Committee, other work is reported to the Ethics and Sustainability Committee. An update is also presented to the Board in its entirety once a year. More information on the Ethics & Compliance function is presented in the Sustainability Report on page 136.

Corporate Internal Audit

Getinge's internal audit function, Corporate Internal Audit, aims to provide independent audit of operational governance in selected areas, with a focus on effectiveness and risk management. The annual internal audit plan is based on identified risks and function-specific and industry-related risk assessments. Each year, priority is assigned to a number of units, Group-wide processes or thematic areas for auditing, in which improvement areas are identified and graded based on their potential business impact. The areas are based on the annual plan but can also be adapted to issues that arise during the year. For all observations, an action plan is prepared in collaboration with each business owner. The Corporate Internal Audit function follows up on and ensures that actions plans are conducted within defined time periods.

In 2024, the work to develop the internal Corporate Internal Audit function continued under the Head of Internal Audit who reports directly to the Audit and Risk Committee, but belongs to the management team for Sustainability, Legal & Compliance.

GETINGE'S GOVERNANCE AND ASSURANCE FRAMEWORK



1) The first pillar's control activities include: quality systems audit (at certificate level), management control self-assessment and remediation of audit and investigations findings.
2) The second pillar's control activities include: The Ethics & Compliance function's risk monitoring and risk assessment, internal controls (management testing) and Corporate Quality Audit.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

GETINGE'S PRIMARY RISKS, CONSEQUENCES AND MANAGEMENT

EXTERNAL RISKS	Description	Potential consequences	Management
External shocks, such as geopolitical risks, natural disasters, terrorism, pandemics, etc.	Rapidly emerging situations, which could affect large geographical areas, a single country, a region or a specific facility.	The primary risk of such events is that employees could be injured. In addition, operations can be disrupted, which could have a negative impact on sales and earnings.	Active business intelligence can identify some of these risks at an early stage, which enables the Group to adapt to the changed circumstances. The process of further strengthening the Group's management of continuity risks continued in 2024. This also includes scenarios based on external shocks as part of Getinge's proactive risk management. Getinge conducts operations in Russia in accordance with international sanctions and regulations via a small sales company. The activities in the country are currently limited to fulfilling existing customer commitments. However, the circumstances for conducting operations in the country have gradually deteriorated. Getinge does not conduct any manufacturing operations in either Russia or Ukraine and has no major suppliers in these countries. When Russia invaded Ukraine in 2022, the Group's sales in Russia and Ukraine represented less than 1% of the Group's total net sales and equity. Despite the limited direct impact that the invasion has had on Getinge's operations in Russia and Ukraine, the Russian invasion of Ukraine may nevertheless have a negative impact on the development of the Group's earnings and position. However, it is difficult at the current time to assess the future consequences of the conflict and its impact on the Group. Getinge is actively monitoring the current debate on trade barriers such as tariffs. Getinge has a geographically diversified purchasing and production strategy which partly can help to mitigate any negative consequences.
Interruptions in supply chains / dependence on external suppliers	Critical components manufactured by external suppliers are a vital part of Getinge's production chain. Serious production disruptions may arise if these components are not supplied on schedule.	As a consequence, vital equipment may not be delivered to customers, which may make it difficult or impossible to provide necessary healthcare.	Getinge actively monitors critical suppliers, starting as early as when the partnership is established and continuing with routine evaluations. The Purchasing organization has tools for assessing risk and receives regular training in this area. The Group also works on ensuring that it has adequate levels of critical components in stock, in its own operations or with the relevant supplier. Interruptions of critical deliveries are also managed as an important part of activities related to business continuity risks. See "Business interruptions."
Risks related to healthcare reimbursement systems	Political decisions can change the conditions for healthcare through changed reimbursement models for healthcare providers.	Changes to reimbursement systems could have significant effects on specific markets, with budget cuts or deferred funding potentially impacting the operations.	Although it is difficult to influence this risk directly, since decisions are outside the Group's control, it is mitigated by the presence in a large number of markets, which reduces the overall impact of individual changes.
New competitors and new technologies	Certain markets and product segments have niche players who offer solutions outside customary market behavior.	These competitors could capture market shares from established companies, including Getinge, which could result in lower sales and earnings.	Through continuous innovative development and market analysis, Getinge strives to be at the forefront, identify potential competitors and adapt to technological changes. The industry is also considered to have high barriers to entry since medical devices are subject to extensive regulatory requirements.
Increased expectations and new laws and regulations related to sustainability	The sustainability requirements and expectations placed on Getinge as a company are changing, and the scope is increasing rapidly.	Getinge's failure to meet the ever-more stringent environmental, social and governance requirements could have negative consequences on the company's reputation, operations and financial earnings. It may also impact the company's ability to recruit and retain competent staff, and risk disqualifying the company from participating in tenders with specific requirements.	By engaging with stakeholders and improving its materiality assessment and ERM process, Getinge increases its understanding of the expectations placed on the company. It also helps that the company is adopting the focus areas that are to be prioritized moving forward. In addition, the company has developed its sustainability framework, focusing on the products and solutions placed on the market to ensure quality and corporate responsibility. This also leads to employee engagement. The company reports annually on its performance in sustainability in a transparent manner in accordance with the GRI standards and is making preparations ahead of the forthcoming CSRD regulation.
Increasing competition for public funds	Reduced public budgets for investing in medical devices impacts the total market potential.	Increased competition for limited public funds may lead to reduced funding for medical device investments, which in turn negatively impacts Getinge's sales figures.	Getinge works actively to offer solutions that improve the efficiency of healthcare, which is believed to generate healthy demand even where budgets are constrained.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

OPERATIONAL RISKS	Description	Potential consequences	Management
Quality risks from a regulatory perspective	A large part of Getinge's product range is subject to strict legislation requiring extensive assessments, quality controls and detailed documentation.	It cannot be ruled out that Getinge's operations, financial position and earnings may be negatively impacted in the future if the company is unable to comply with regulatory requirements or if these requirements change.	To limit these risks, Getinge conducts extensive quality and regulatory activities. The Quality Compliance, Regulatory & Medical Affairs function has a representative in the Getinge Executive Team and also on the management teams of each business area, and in all R&D and production units. In addition, Getinge's sales force and service technicians receive quality and regulatory training every other year, and then have their certification renewed, which is a requirement for representing the company. Getinge conducts extensive research and development to ensure that the product portfolio meets all existing and future quality and regulatory requirements. The majority of the production facilities have ISO 13485 and/or ISO 9001 certification. In summary, Getinge invests significant resources in quality and regulatory matters, which is a top priority of the Group's strategy. As previously reported in the first quarter of 2023, the notifying body TÜV SÜD decided to temporarily suspend the CE certificate for Getinge's HLS and PLS sets for ECLS therapy and for Getinge's intra-aortic balloon pumps. As a result, the company initiated corrective actions to regain CE certification for these products. At the end of September 2024, TÜV SÜD reinstated Getinge's CE certificate for HLS and PLS sets, with certain conditions. The temporary suspension of Getinge's Cardiosave intra-aortic balloon pump, effective from March 2024, was extended until July 1, 2025. On May 8, the FDA sent a letter to healthcare providers in the US. The letter does not refer to any new field actions, but healthcare providers are encouraged to move from using Getinge's Cardiosave, Cardiohelp and HLS sets to alternative products and to continue to use Getinge's products only if no other options are available. As a result of the FDA's letter, Getinge has decided to suspend marketing activities for the relevant products in the US until outstanding actions related to quality improvements have been taken and approved. Sales of these products are restricted to customers who do not have any other alternatives. On November 15, 2024, the FDA published a Letter to Health Care Providers on its website, reminding them of the voluntary medical device removal and supply concerns related to all of Getinge's VasoView Hemopro endoscopic vessel harvesting (EVH). Actions are being taken as agreed with the FDA.
Product quality from a customer perspective	In certain cases, Getinge's products do not meet customer expectations.	Product quality shortcomings could lead to customer seeking out alternative suppliers, which in turn could negatively impact sales and profitability over time.	Getinge applies a comprehensive quality process to ensure a high and even level of quality, which is an ongoing process that results in continuous improvements. When quality fails, it is important to rapidly rectify the fault during the first service visit. Getinge closely monitors the "first-time fix" factor of its services operations and works actively to make improvements.
Product liability risks	Healthcare suppliers run a risk, like other players in the healthcare industry, of being subject to product liability and other legal claims.	Such claims can involve large amounts and significant legal expenses. Getinge carries the customary indemnity and product liability insurances, but there is a risk that this insurance coverage may not fully cover product liability and other claims.	The most important way of managing these risks is the extensive quality-related and regulatory activities performed by the Group. Sources of potential future liability claims are monitored through active incident reporting. Corrective and protective action (CAPA) is initiated when necessary to investigate the underlying cause, after which the product design may be corrected to remedy the fault. The settlement process regarding the Multidistrict Litigation (MDL) for surgical mesh implants, which Getinge announced previously, has been completed and payment of the majority of the settlement amount was made in the first quarter of 2023. The settlement is not an admission of liability or wrongdoing by the company. Getinge will continue to defend against any litigation that cannot be resolved under the final agreement. Costs for such processes are not expected to be material.
Information and data security	Leaks of confidential information or hacking into the Group's IT system resulting in restricted availability or interruptions of business-critical systems. In this context, extortion or sabotage cannot be excluded either.	Hacking into IT systems could lead to business interruptions. A loss of sensitive information may adversely affect confidence in the company. Leaks of personal data could lead to high fines.	Getinge's IT structure in production is largely decentralized, which reduces the consequences of any unauthorized access by spreading the risks across different systems. At the same time, a shared infrastructure for central services ensures efficiency and coordination where necessary. During the year the Group improved authentication processes to prevent hacking, and this process will continue in the years ahead. Getinge conducts extensive surveillance and monitoring of the central infrastructure to quickly detect and counteract security threats.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

OPERATIONAL RISKS	Description	Potential consequences	Management
Deficiencies in cybersecurity	Security deficiencies in the Group's digital offering, such as connected machines at customer sites and stricter legal requirements for processing personal data. In this context, extortion or sabotage cannot be excluded either.	Restricted availability of equipment delivered by Getinge to its customers, which could result in interruptions to the hospital operations and it not being possible to offer patients sufficient care in critical situations.	Getinge works diligently and systematically, following a risk-based approach, to ensure the integrity of its connected equipment. By continuously evaluating and prioritizing security risks, we can effectively protect both our systems and customers' data. Comprehensive access testing is carried out before these solutions are offered to the Group's customers so as to identify and rectify potential vulnerabilities.
Business interruptions	Unforeseen events, such as natural disasters or fires, etc. can cause disruptions to production or the supply chain.	Such events may result in costly, delayed or non-delivery of products to Getinge's customers, which may adversely affect the Group's earnings.	There is a risk of temporary business interruptions, for example, due to supply constraints for key components such as semiconductors, as a result of the uncertain global security situation. Getinge takes continuous preventive action to ensure a high level of availability and delivery reliability, including regular inspections of the production facilities with the help of external expertise.
Non-compliance with laws and regulations	Breaches of laws and regulations related to, for example, competition, anti-corruption, AI, cyber security, data protection or trade restrictions.	Breaches of these regulations could lead to fines, sanctions and have a negative impact on the Getinge brand.	Getinge has previously provided information about ongoing investigations and agreements with the authorities regarding anti-competitive procedures in the sale of medical devices in Brazil. The process with the Brazilian federal authority, Comptroller General of the Union (CGU), is still ongoing. During the third quarter of 2024, Getinge made, in line with applicable accounting standards, a provision of SEK 482 M related to anticipated costs related to this process. The provision is the result of an ongoing constructive dialogue to reach a conclusion in the negotiations with the CGU. The final and definitive costs will be determined once the negotiations have been concluded, and such an amount could be lower or higher than the provision that has now been made. No information emerged in the fourth quarter of 2024 that would cause a change in the provision. In addition to the investigations with CGU, Getinge has previously communicated that settlement agreements have been reached with the Brazilian Federal Prosecutor's Office (Ministério Público Federal) in 2018 and the competition authority, Administrative Council for Economic Defense (CADE) in 2019, both related to anti-competitive practices relating to the sale of medical devices. It cannot be ruled out that any further agreements with authorities may have a material impact on the company's financial earnings and position, but cannot currently be estimated neither in terms of amount nor timing. Getinge has a zero tolerance policy when it comes to breaches of these regulations. The Group's Code of Conduct is very clear in this respect. The SVP Sustainability, Legal & Compliance represents the Ethics & Compliance function in the Getinge Executive Team, which highlights the high priority of these issues. A training program in business ethics is provided on an ongoing basis and the aim is for all employees to undergo such training at least once a year. The regulations also apply to external distributors who sell Getinge products.
Dependence on meeting climate targets	Getinge is dependent on meeting the climate targets set to reach net-zero emissions by 2050 that were approved by the SBTi. Getinge's analysis shows that the majority of emissions come from the purchases of goods, logistics and the use of sold products. As a result, the company does not have full control over its emissions and cannot therefore directly control their reduction.	If Getinge does not meet its climate targets, it could have a significant negative impact on the company's reputation and operations, in addition to negative climate impacts.	In 2024, Getinge continued to focus on the actions that will be required to meet its Scope 3 emissions target (25% reduction by 2030) such as reducing air freight, improving energy efficiency for products introduced to market and replacing materials with high emissions. At the same time, the company is preparing for dialog both upstream and downstream in the value chain to increase the use of renewable electricity and energy.
Lack of future skills	Risk of dependency on key people including lack of succession planning and ineffective processes to identify and spread critical know-how within the organization. Also the risk of being unable to attract and retain the right talent and skills.	A lack of future skills could lead to higher staff turnover, operational disruptions and damage the Getinge brand. In the future, it may have a negative impact on Getinge's long-term sustainability and growth, and ultimately affect Getinge's ability to attract and retain talent.	Getinge is continuously improving the succession planning process to ensure the global development of talent. Getinge is focusing on talent mobility and knowledge sharing and strives to create a culture and leadership that attracts both new and existing talent. Getinge's aim is to be a company where everyone can thrive and grow.

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

STRATEGIC RISKS	Description	Potential consequences	Management
Digitalization and innovation	Getinge's future growth depends on successful product development, particularly in digitalization. Innovation is crucial for maintaining and strengthening the company's leading position.	Innovation efforts are costly and it is not possible to guarantee that developed products will be commercially successful, which could result in impairment. In the long term, the Group's market position could be negatively affected if Getinge is unsuccessful in this area.	As means of maximizing the return on investments in research and development, the Group applies a structured selection and planning process that includes careful analyses of the market, technological progress, choice of production method and selection of subcontractors. The actual development work is also conducted in a structured manner and each project undergoes a number of fixed controls. Getinge is particularly concerned with ensuring access to the right skills, retaining key individuals, being an attractive employer to recruit talent externally, and identifying and developing talent within the organization.
Fragmented product portfolio	Getinge's product portfolio consists, to a certain extent, of a large number of acquisitions that were made throughout the years within a variety of product categories.	An offering to our customers that, in certain parts, is too diverse could lead to Getinge lacking the critical mass needed to conduct fully efficient operations in all product categories.	Efforts are being made to enhance the efficiency of the customer offering under the framework of the ongoing strategic activities in each business area. The introduction of the EU Medical Device Regulation means priorities need to be made regarding the certification of products under the new regulatory framework. Products have been selected that, over the long term, will be a part of the customer offering, which will lead to increased concentration as well as streamlining.
Risks related to intellectual property rights	Getinge's leading positions in many product segments are based on patent and trademark rights, which could lead to disputes with competitors.	Costly disputes over intellectual property rights could reduce the return on investment in research and development.	Getinge closely monitors the activities of its competitors and actively defends its intellectual property rights through legal processes if necessary.
Financial risks	Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to currency risks, interest-rate risks, and credit and counterparty risks.	Fluctuations in exchange rates and interest rates and changes in counterparties' credit profiles could adversely affect the Group's income statement and balance sheet.	Risk management is regulated by the finance policy adopted by the Board and a Treasury Directive approved by the Getinge Executive Team based on the finance policy. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the Treasury function. For more detailed information concerning these risks, refer to Note 18 of the Annual Report.
Profitability dependent on certain products and markets	Some products and markets contribute more to overall profitability.	If sales volumes in these markets were to decrease, it could have a negative impact on the Group's profitability.	Getinge works actively to monitor profitability per product and market in order to ensure profitability over time. To reduce the sensitivity of profitability, the Group actively works on ensuring that it has the right cost level in relation to the current price levels in the market. Getinge also works actively to establish itself in new markets.
Transferring the product portfolio	Long lead times in research and development due to comprehensive regulations and long validation processes are hampering rapid development to more sustainable product and packaging solutions. The medical device market is strictly regulated, partly to ensure patient safety, which can affect how quickly Getinge's products can become sustainable.	If it is not possible to transfer Getinge's product and packaging solutions to more sustainable solutions quickly enough, there is a risk that Getinge's reputation and competitiveness could decline.	Getinge will always prioritize patient safety and follow applicable regulations. Without impacting Getinge's fundamental approach, the company has expanded the implementation of eco-design principles in its development process and has begun to carry out life cycle assessments of its product and packaging solutions to ensure that advances can be made when the opportunity arises.

20250623150008

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

Internal control over the financial reporting

At Getinge, internal control over the financial reporting is an integrated part of the corporate governance. It comprises processes and methods to safeguard the accuracy in the financial reporting, and in this manner, is aimed to protect the shareholders' investment in the company.

Control environment

The basis of the internal control over the financial reporting comprises the control environment, including the organization, decision-making channels, authorities and the responsibilities that are documented and communicated in steering documents. The Audit and Risk Committee's responsibilities include monitoring the effectiveness of the company's internal control, financial reporting and risk management. Each business area and the Global Sales and Service organization are responsible for continuous transaction management and accounting. Getinge's Shared Service Center in Krakow, Poland, conducts this management on behalf of the business areas and the Global Sales and Service organization for most of the companies in Europe and North America, primarily regarding customer invoicing, supplier invoices and payment and work duties in the annual accounting process. Each business area and the Global Sales and Service organization has a financial manager, who is responsible for the financial control and for ensuring that the financial statements are accurate, complete and submitted in good time prior to consolidated reporting. In 2024, the finance functions for the larger countries were divided into a financial and a business-oriented function with the aim of streamlining work in accounting and in the business organization. The financial control function is divided into the geographic areas of responsibility of France, the Nordic region, North America, DACH/BNL and East Asia.

Control activities

The most material risks identified relating to financial reporting are handled by the company's control activities. For example, there are automated controls in IT-based systems that manage authority levels and attestation rights, as well as key control elements, such as duality in the day-to-day accounting and closing entries. Detailed financial analyses of results and follow-ups against plan and forecasts supplement the operation-specific controls and provide overall confirmation of the quality of the financial reporting. The Group follows standardized templates and models to document controls.

During the year, an internal framework for general IT controls was defined and implemented in systems and applications that have the greatest impact on the financial reporting. These controls include maintenance, development and authorization management processes. System and application owners have carried out self-assessments of the control environment, which were then evaluated internally and subsequently by the external auditors. The process is similar to the annual assessment of financial controls.

Information and communication

The Group has information and communication procedures to promote completeness and accuracy in the financial reporting. Steering documents and work descriptions are available on the company's internal digital platform. Information regarding the efficiency of the internal controls in the Group is regularly reported to the relevant financial manager for the Global Sales and Service organization and the business areas, as well as to the internal control function, the finance function, the Getinge Executive Team and the Audit and Risk Committee.

Follow-up and monitoring

Each financial manager and the Getinge Executive Team perform monthly analyses of the financial reporting at a detailed level. The Audit and Risk Committee follows up the financial reporting at its meetings and the company's auditors report on their observations and provide recommendations. The Board of Directors receives financial reports on a monthly basis and the company's financial position is discussed at every Board meeting. The efficiency of the internal control activities for the financial reporting is followed up by the internal control function every year using a risk-based random sampling model. This comprises an assessment of the formulation and operative function of key control elements that have been identified and documented. The external auditors perform an annual evaluation of key controls in the internal assurance framework and report the results to the Audit and Risk Committee.

Self-assessment and validation

Getinge has worked for several years with a formalized process for the follow-up and evaluation of the documentation of key control elements. The internal assurance framework is revised every year based on the results of, for example, self-assessments and auditing activities. The validations are performed by each financial manager and the person with the main responsibility for the geographic financial controller function, or the person delegated in the Global Sales and Service organization or the business area, supported by the central internal control function.

The purpose of self-assessment is to proactively identify any weaknesses in the internal control environment, jointly develop improvement measures, but also to ensure the maintenance of the achieved good internal control environment. Another purpose is to enhance the efficiency of the local control activities in Group companies by identifying shared work methods and transferring knowledge between the companies to raise the general quality of the control environment.

In 2024, just over two-thirds of the active companies, jointly totaling just over 90% of the sales in the Group, conducted a self-assessment. In conjunction with the standard Group audit, the auditors conducted an in-depth validation of the internal control environment. The self-assessment includes the following business processes: corporate governance (such as assignment of authority for financial IT systems), financial reporting, production and

Introduction
Strategy
Corporate Governance Report
Corporate governance structure
Board of Directors
President & CEO and Getinge Executive Team
Building blocks in the Getinge corporate governance model
Assurance framework, risks and risk management
Internal control over the financial reporting
Auditor's report on the Corporate Governance Report
Financial statements
Sustainability Report
Other information

inventories, tangible and intangible assets, sourcing of and revenues from products and services, salary and remuneration procedures and tax management. The auditors' assessment includes a sample of these processes.

Outcome 2024
The follow-up of the internal control in 2024 indicated that documentation and control activities over the financial reporting were, in all material respects, established at the validated companies. A couple of areas identified as having the largest potential for improvement are further training for the organization in internal control with a focus on documenting controls and their outcomes, and identifying the automated key controls in the Group's financial system.

Follow-on work
The focus in 2025 will be on continuing to harmonize ways of working in the business processes, thus optimizing the use of the common system environment. Uniform business processes also allow for a higher degree of standardized and automated controls, and enhance efficiency. The outcome from the year's validation and evaluation, and from the various company audits, will be used as a basis for the continuous improvement work on internal control via financial reporting.

Auditor's report on the Corporate Governance Report

To the annual general meeting of the shareholders in Getinge AB (publ), Corporate Identity Number 556408-5032

Engagement and responsibility
It is the Board of Directors who is responsible for the Corporate Governance Report for the year 2024 on pages 32–54 and that it has been prepared in accordance with the Annual Accounts Act.

The scope of the audit
Our examination has been conducted in accordance with FAR's auditing standard RevR 16 The auditor's examination of the corporate governance statement. This means that our examination of the corporate governance statement is different and substantially less in scope than an audit conducted in accordance with International Standards on Auditing and generally accepted auditing standards in Sweden. We believe that the examination has provided us with sufficient basis for our opinions.


Opinions
A Corporate Governance Report has been prepared. Disclosures in accordance with chapter 6 section 6 the second paragraph points 2–6 the Annual Accounts Act and chapter 7 section 31 the second paragraph the same law are consistent with the annual accounts and the consolidated accounts and are in accordance with the Annual Accounts Act.

This is a translation of the Swedish language original. In the event of any differencies between this translation and the Swedish language original, the latter shall prevail.

Gothenburg, March 27, 2025
Öhrlings PricewaterhouseCoopers AB

Cecilia Andrén Dorselius
Auditor in charge
Authorized Public Accountant

Karin Olsson
Authorized Public Accountant



GETINGE

2024 Annual Report

Introduction

Strategy

Corporate Governance Report

Financial statements

- Administration Report
- Guidelines for remuneration
- Remuneration Report 2024
- Proposed appropriation of profit
- Group financial statements
- Group notes
- Parent Company financial statements
- Parent Company notes
- Auditor's report

Sustainability Report

Other information

Financial statements

Contents

56–60 Administration Report

61–63 Guidelines for remuneration

64–67 Remuneration Report 2024

68 Proposed appropriation of profit

69–73 Group financial statements

74–111 Group notes

112–115 Parent Company financial statements

116–122 Parent Company notes

123–126 Auditor's report

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Administration Report

Ownership and Legal form

Getinge AB (publ) with corporate identity no 556408-5032 is a limited liability company and its Class B shares are listed on Nasdaq Stockholm. Getinge AB with registered office at Box 8861, 402 72 Gothenburg, Sweden, is the Parent Company of the Getinge Group and is headquartered in Gothenburg, Sweden. The largest shareholder in Getinge AB (publ) is Carl Bennet AB.

Operation and structure

Getinge is a global provider of products and solutions for operating rooms, intensive-care units and sterilization departments serving 40 countries and with proprietary production in nine countries. Operations are conducted in three business areas – Acute Care Therapies, Life Science and Surgical Workflows.

Sales take place through our own subsidiaries and distributors in more than 135 countries. Approximately 72% of the sales are conducted through the Group's sales companies and the remaining 28% are sold by agents and distributors in markets where Getinge often lacks its own representation. Americas represented the Group's largest market, accounting for 45% (41) of sales, followed by EMEA at 35% (37). APAC accounted for 20% (22) of sales.

Production is conducted at a total of 25 facilities in France, China, the Netherlands, Poland, the UK, Sweden, Türkiye, Germany and the US.

Financial overview

Net sales

Net sales increased 9.2% during the year to SEK 34,759 M (31,827). Organically, sales increased by 4.9%. In Acute Care Therapies, sales amounted to SEK 17,948 M (16,529), corresponding to an organic increase of 8.2%. Life Science's sales decreased organically by 1.9% and amounted to SEK 4,552 M (4,325). Surgical Workflows' sales in 2024 amounted to SEK 12,258 M (10,974). Sales increased organically by 2.6%.

Adjusted EBITA

EBITA adjusted for restructuring and acquisition costs and other items affecting comparability amounted to SEK 4,869 M (3,887).

Operating profit

The Group's operating profit amounted to SEK 2,854 M (3,736). Adjusted for restructuring and acquisition costs and other items affecting comparability, operating profit amounted to SEK 4,549 M (3,653), corresponding to 13.1% (11.5) of net sales. The Group's adjusted EBITDA amounted to SEK 6,546 M (5,574), corresponding to 19.1% (17.5) of net sales.

Net financial items

Net financial items amounted to SEK -571 M (-393), of which net interest items comprised SEK -539 M (-346).

Profit before tax

The Group's profit before tax amounted to SEK 2,282 M (3,343).

Taxes

The Group's tax expense amounted to SEK -628 M (-915), entailing a tax rate of 27.5% (27.4).

Tied-up capital

Inventories amounted to SEK 6,590 M (6,416) and accounts receivable to SEK 6,348 M (5,739). The return on equity was 5.2% (7.8). Goodwill totaled SEK 30,088 M (24,869) at the end of the fiscal year.

Investments

Investments in intangible assets and tangible assets amounted to SEK 1,309 M (1,353). Investments primarily pertained to product development, production facilities, production tools and IT projects. Investments related to acquisitions of businesses amounted to SEK 3,256 M (5,209), primarily relating to the acquisition of Paragonix Technologies, Inc.

Financial position and equity/assets ratio

Consolidated net interest-bearing debt increased to SEK 10,457 M (8,012). The equity/assets ratio amounted to 52.0% (56.7) and the net debt/equity ratio to 0.32 (0.26). The Group's debt ratio (net debt in relation to adjusted EBITDA) amounted to 1.6 (1.4). Equity at year-end amounted to SEK 33,210 M (30,403).

Cash flow

Cash flow from operating activities amounted to SEK 4,577 M (2,957).

Restructuring activities

In 2024, restructuring costs amounted to SEK 848 M (75), which were mainly attributable to impairment of fixed assets and inventory related to the communicated phase-out of the Surgical Perfusion product category and the warranty provisions for planned field actions relating to Cardiosave.

Class of shares and share data

Net profit for 2024 amounted to SEK 1,654 M (2,428). Earnings per share, before and after dilution, amounted to SEK 6.01 (8.86).

For information regarding trading of shares in the company, the number of shares, shareholders, classes of shares and the rights associated with these classes, refer to Getinge as an investment on page 9 and Other information on pages 170–171.

Significant events during the year

Governance of quality

During the year, work continued on the improved global quality management system implemented in 2023. The aim of the system is to enhance focus and establish a well-defined Group-wide quality strategy in order to deliver an even higher level of quality. The quality management system is used to ensure safety, efficiency and compliance for Getinge's products. The system defines the processes, controls and documentation necessary to meet regulatory requirements, manage risks and deliver high- quality products to customers.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Adjustments to EU Medical Device Regulation
Work on meeting the requirements of the new EU Medical Device Regulation (EU MDR) continued during the year. At the end of 2024, 17 of 18 manufacturing sites had received their EU MDR certificates.

CE certificates for HLS and PLS sets and Cardiosave
At the end of September 2024, the notified body, TÜV SÜD, reinstated Getinge's CE certificate for HLS and PLS consumables, used for ECLS therapy, with certain conditions after Getinge developed a new packing solution. Deliveries of the products were resumed during the fourth quarter of 2024. In September 2024, TÜV SÜD announced that the temporary suspension of Getinge's Cardiosave intra-aortic balloon pump had been extended until July 1, 2025. This decision does not affect the previously installed base of Cardiosave, and means that products already on the market can continue to be used. Consumables, service and spare parts for the pumps are not affected.

FDA letter regarding Cardiosave, Cardiohelp and HLS sets
In May 2024, the US Food and Drug Administration (FDA) sent a Letter to Health Care Providers encouraging them to move from using Getinge's Cardiosave, Cardiohelp and HLS sets to alternative products and to continue to use Getinge's products only if no other options are available. As a result of the letter, Getinge decided to immediately suspend marketing activities for Cardiohelp and Cardiosave in the US until outstanding actions related to quality improvements have been addressed and approved, and to limit sales to those customers who have no other options. The installed base for intra-aortic balloon pumps and HLS sets was supplied and serviced. For markets outside the US, Getinge made product improvements and will continue to sell Cardiosave and Cardiohelp and continue to provide intra-aortic balloon pumps and HLS sets in markets where they are permitted and approved for use. At the same time, Getinge accelerated the development of the next generation of Cardiohelp and Cardiosave, and the company expects to submit applications for clearance in the US by the end of H1 to the end of H2 2025, followed by an update and application for clearance of the HLS sets in H2 2026.

FDA letter regarding Getinge's VasoView Hemopro Endoscopic Vessel Harvesting (EVH) system
On November 15, the FDA published a Letter to Health Care Providers on its website, repeating information about the voluntary medical device recall and supply concerns related to all of Getinge's VasoView Hemopro Endoscopic Vessel Harvesting (EVH) Systems. Actions are being taken as agreed with the FDA.

Changes to Getinge Executive Team
Agneta Palmér replaced Lars Sandström as Getinge's CFO on March 31, 2024. Agneta Palmér previously served as Executive Vice President Operational Services and a member of the Executive Team.

Alexandra Holland was appointed as new Executive Vice President Communications, taking up her role on November 11, 2024. She is a member of the Executive Team and based in Wayne, US. Alexandra joins Getinge from Johnson & Johnson where she held the role of Vice President, Business and Culture Communications, MedTech.

Acquisitions of operations

Acquisition of assets from Intact Solutions
In July 2024, Getinge's subsidiary Aseptic Solutions LLC acquired technology and intellectual property rights from Intact Solutions LLC, a company in Connecticut, USA. This technology makes aseptic processing simpler, safer and more efficient, and addresses the entire bioprocessing value chain. The acquisition was consolidated into the Getinge Group on the acquisition date and is included in the business area Life Science.

Getinge paid approximately SEK 128 M (USD 12 M) upon completion of the acquisition. Furthermore, additional earn-out payments may be made between 2027 and 2030 if agreed upon regulatory and financial performance milestones are achieved.

Paragonix Technologies, Inc.
In September 2024, Getinge carried out the acquisition of 100% of the shares in Paragonix Technologies, Inc., a leading US company in organ transport products and services. The company, which was founded in 2010, employs approximately 100 people and is headquartered in Waltham, Massachusetts, USA. The acquisition aligns with Getinge's broader strategy to expand its portfolio into high growth markets that complement and enhance its acute heart and lung support offering already being used in connection with transplantation, positioning the company at the forefront of the fast-growing organ preservation and transportation market. The acquisition was consolidated into the Getinge Group on the acquisition date and is included in the business area Acute Care Therapies. Getinge paid approximately SEK 2,619 M (USD 253 M) in cash upon completion of the acquisition. Furthermore, additional earn-out payments may be made up until 2026 if agreed upon regulatory and financial performance milestones are achieved.

Other
In 2024, additional purchase price of SEK 325 M were paid relating to Talis Clinical LLC.

For further information on this year's acquisitions and contingent considerations, refer to Note 19 Financial instruments and Note 27 Acquisition of operations.

Dispute

Settlement agreements with authorities in Brazil – ongoing
As a consequence of ongoing government investigations regarding anti-competitive practices relating to the sale of medical devices between 2004 and 2017, mainly to public hospitals, Getinge has previously entered into Settlement Agreements with the Brazilian Federal Prosecutor's Office (Ministério Público Federal) and the competition authority, the Administrative Council for Economic Defense (CADE). The negotiations with the federal agency for internal control, public transparency and counter-corruption,

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Comptroller General of the Union (CGU), are still pending and in Q3 2024 Getinge made a provision of SEK 482 M related to these negotiations (refer to Note 15 Other provisions for further information).

Consent Decree with FDA – ongoing

Getinge signed the original Consent Decree with the FDA in 2015 which encompassed four production units in the US and Germany and pertained to certain identified quality concerns. Previous remediation plans have already been implemented and the work at the production units in Hechingen was completed in 2021. In addition, Getinge's production units in Fairfield and Mahwah received warning letters from the FDA in 2018–2019, resulting from observations from inspections in 2018. These observations, which Getinge had also identified, pertain to procedures and processes linked to demands for supplier checks, processes for the approval of design changes and incident reporting. Getinge has subsequently worked to remedy these concerns and submitted an action plan to the FDA and improvements are proceeding according to this plan.

In 2022, the FDA announced that Getinge's subsidiary Datascope would be included in the existing Consent Decree due to observations made at inspections between 2021 and 2022 at the site in Wayne. These observations pertained to Datascope failing to fully comply with the Quality Management System and related processes. Datascope is enforcing the ongoing actions to address the findings and to ensure full compliance with the Quality Management System, including via the new quality organization. A work plan has been submitted to the FDA and dialogue and improvements are continuing.

Getinge's financial targets 2024–2028 and dividend policy

Getinge updated its financial targets in May 2024 as follows:

- Average adjusted earnings per share growth: >12%
- Getinge's dividend policy is to pay dividends of 30–50% of net profit to shareholders

Innovation and product development

Innovation and product development are a cornerstone of the Group's strategy to strengthen the customer offering and ensure future organic growth. The Group uses innovation and product renewal to manufacture products, systems and solutions with a documented ability to deliver high-quality clinical results and economic benefits. The Group's research and development costs amounted to SEK 2,091 M (1,821) in 2024. Of this amount, SEK 660 M (629) was capitalized as intangible assets.

New products during the year

Surgical Workflows

- Maquet Ezea – a versatile and robust surgical light
- Aquadis Index – a multi-chamber washer-disinfector that combines high capacity with low utility consumption
- FleetView – a web application with data-driven device lifecycle management, offering healthcare providers and life science companies a tool to navigate large amounts of service data and statistical insights
- Poladus 150 – a low-temperature sterilizer, designed for heat-sensitive surgical instruments

Acute Care Therapies

- Servo TwinView – a virtual twin of the Servo ventilators that enables clinics to analyze near real-time data from the ventilators, without having to step inside the intensive care unit
- Pulsiocare – an advanced hemodynamic monitoring platform that recently received its CE certificate

Life Science

- LiviT ACE – a continuous cell processing platform developed together with bioprocessing company CellRev
- SUPR – an extension of the bioreactor portfolio by introducing the Single-Use Production Reactor (SUPR) system, which initially is available in 50-liter and 250-liter sizes that helps operators to bring life-saving medicines to market faster
- GEW 888 neo – cGMP washer designed to develop cleanroom efficiency and meet the strictest demands of the biopharmaceutical industry
- DPTE-BetaBag® – a new version with material from renewable sources
- Lancer LSS – an innovative lab sterilizer where cutting-edge technology meets refined design

Approval and certifications

In the first quarter, Getinge took a giant leap forward in cardiovascular surgery with 510(k) clearance for Vasoview Hemopro 3. In the same quarter, the notified body, TÜV SÜD, temporarily suspended the CE certificate for Getinge's intra-aortic balloon pump, Cardiosave, and this suspension was extended later in the year until 2025. Early in the second quarter, Getinge's covered stent system Advanta V12 received EU MDR approval for use for patients with renal artery stenosis and/or aortoiliac occlusive disease (AIOD). Getinge was also granted FDA 510(k) clearance for its innovative clinical decision support software Talis +ACG (+Advanced Clinical Guidance). After having been suspended since March 2023, Getinge's CE certificate for HLS and PLS consumables, used for ECLS therapy, was reinstated by TÜV SÜD in September with certain conditions. In October, Paragonix Technologies, Getinge's most recent acquisition, received FDA clearance for KidneyVault, an innovative device to optimize the protection of donor kidneys during transport.

Personnel

At December 31, 2024, there were 11,791 (11,739) employees, of whom 1,296 (1,263) were employed in Sweden. The number of employees increased by 121 in connection with the acquisitions of Paragonix Technologies and Aseptic Solutions. In 2024, Getinge continued its extensive efforts to strengthen the Group's personnel and management development. The Group also carried out activities intended to further strengthen the commitment of its employees and implemented digital tools for personnel development. Since early 2023, all Getinge units offer at least 16 weeks paid parental leave applicable to birth, adoption and surrogacy, and four weeks

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

paid caregiver leave to care for a close family member. In 2024, the Group also continued its long-term endeavors to increase diversity and collaboration. Getinge has a previously implemented policy to ensure that all employees are given equal opportunity to develop and receive equal pay for equal work, regardless of such factors as gender, ethnicity or religion.

Annual General Meeting's guidelines for remuneration to Senior Executives

The guidelines for remuneration to senior executives adopted at the 2023 AGM are presented on pages 61–63. During 2024, the company complied with these guidelines. No deviations from the guidelines nor any derogations from the procedure for resolution on remuneration, established by the remuneration guidelines, have been made. Total remuneration to senior executives amounted to SEK 144 M (106) in 2024, see Note 22 for more information. The total cost for remuneration and benefits to the Getinge Executive Team amounted to SEK 165 M (170) and pertains to base salaries, variable short-term and long-term remuneration, other benefits and pensions. It also includes social security expenses on salaries and benefits and special payroll tax on pensions.

Sustainability Report

In accordance with Chapter 6, Section 11 of the Annual Accounts Act, Getinge has chosen to prepare the Sustainability Report as a part of the Annual Report. The statutory Sustainability Report is defined on page 128. A description of diversity on the Board can be found on page 36. Refer to page 153–154 for a more detailed description of the work with diversity.

Environmental accounting

Getinge's environmental activities are based on the Group's sustainability policy, environmental policy and the international ISO 14001 environmental management standard. The 2019–2025 sustainability program has been based on a materiality assessment which anchors KPIs within the entire organization. All manufacturing units have or will implement and certify environmental management systems that meet the standard. For acquisitions, the management system is to be introduced and certified within 24 months.

The management system ensures structured environmental work and provides a basis for the reporting of environmental performance that Getinge's manufacturing units submit every quarter. Through the targeted activities related to environmentally compatible product development, EcoDesign, the aim is to reduce the environmental impact from manufacturing and product usage, and offer customers sustainable market offerings.

One facility in Sweden conducts operations requiring permits or declaration under the Swedish Environmental Code. This facility holds the necessary permits. The operations were conducted in accordance with applicable permits and conditions during the year.

Getinge's climate target of reaching net-zero greenhouse gas emissions across the value chain by 2050 was validated by the SBTi. Further information concerning Getinge's environmental work and its sustainability targets is presented in the section Strategy and in the Sustainability Report.

Risks and uncertainties

Getinge actively and systematically manages the risks that the Group is exposed to. In accordance with this, the Getinge Executive Team conducts an annual evaluation of material risks and effects, and decides and acts on measures to reduce risks and their potential effects. The risk evaluation is reported to the Board of Directors and serves as a key starting point in determining the focus areas for Corporate Internal Audit. At the end of September 2024, the notified body, TÜV SÜD, reinstated Getinge's CE certificate for HLS and PLS consumables, used for ECLS therapy, with certain conditions after Getinge developed a new packing solution. Deliveries of the products were resumed during the fourth quarter of 2024. In September 2024, TÜV SÜD announced that the temporary suspension of Getinge's Cardiosave intra-aortic balloon pump had been extended until July 1, 2025. This decision does not affect the previously installed base of Cardiosave, and means that products already on the market can continue to be used. Consumables, service and spare parts for the pumps are not affected.

In addition, Getinge is exposed to risk related to other external events, such as geopolitical risks, natural disasters, terrorism, pandemics, etc. Active business intelligence can detect some of these risks at an early stage and the Group will then have the chance to adapt to the new situation. The process of further enhancing the Group's work on continuity risks continued in 2024.

External factors such as geopolitical tensions and possible associated sanctions are risks that could affect Getinge's ability to expand in markets that have significant needs for the Group's products and solutions. It can also not be ruled out that Getinge could be exposed to conflicting trade sanctions as a result of the geopolitical situation. Getinge actively follows the ongoing debate on increased trade barriers such as tariffs. Getinge has a geographically diversified purchasing and manufacturing strategy, which can partially limit any potential negative consequences.
Technological advances are currently being made at a very fast pace, which is affecting the competitive situation in the market. The Group assigns considerable resources to developing its customer offering, such as in the form of a higher degree of connected products. In this way, information about how the products are used clinically can be transferred from the customers back to Getinge, and this information will then form the basis of the next stage of product development. There is a certain risk that new, or existing, players could develop transformative technology more successfully than Getinge and thus gain an advantage in the market.

Cyber-related risks are a focal point for the Group in terms of both IT infrastructure and connected equipment with customers. In both of these areas, Getinge carries out active and extensive measures to manage these risks. A circumstance that reduces exposure related to infrastructure is that this can be considered to be decentralized. In addition, the Group also closely monitors critical systems to prevent these risks. In relation to the cyber security of the Group's customer offering, the company works diligently to ensure the integrity of its equipment that is connected to the Internet. Comprehensive access testing and other measures are also carried out before these solutions are offered to the Group's customers.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Furthermore, Getinge is also exposed to risks related to non-compliance with laws and regulations, mainly pertaining to business ethics. Corruption in particular remains a risk in many markets in which Getinge operates and has ambitions to grow. The Group has a zero tolerance policy when it comes to deviations in this area and takes extensive action in business ethics such as the responsible leadership training program and other training courses. The aim is for all employees to undergo training in business ethics every year. Business ethics regulations also apply to external distributors who sell the Group's products in markets in which it does not have its own presence. Further information about the Group's financial risk management can be found on pages 47–52.

Financial risk management

Getinge is exposed to a number of financial risks in its operations. Financial risks principally pertain to risks related to currency risks, interest-rate risks, financing and liquidity risks and credit and counterparty risks. Risk management is regulated by the finance policy adopted by the Board and a Treasury directive decided by the Getinge Executive Team that supplements the finance policy. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the finance function. For more detailed information concerning these risks, refer to Note 18 Financial risk management.

Sensitivity analysis

Getinge's earnings are affected by a series of external factors. The following table shows how changes to some of the key factors that are important to Getinge could have affected the Group's profit before tax in 2024.

Change in profit before tax		SEK M
Price change	+/-1%	+/-348
Cost of goods sold	+/-1%	+/-186
Salary costs	+/-1%	+/-132

Outlook

Organic sales growth is expected to be in the range of 2–5% for the full-year 2025.

Significant events after the end of the reporting period

Getinge has announced its intention to phase out the Surgical Perfusion product portfolio, which is part of the Cardiopulmonary product segment in Acute Care Therapies, in 2025. The intention is to reallocate resources to areas of more profitable growth, mainly in ECLS and Transplant Care. The Surgical Perfusion market has experienced low growth and Getinge has continuously lost market share to the current level of 7% outside the US, which is the largest market globally.

The products intended to be phased out are the HL40 heart-lung machine and the HCU40 heater-cooler unit, as well as consumables used in Surgical Perfusion. The production facilities concerned are located in Hechingen and Rastatt in Germany and in Antalya, Türkiye.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Current guidelines for remuneration to senior executives

Adopted at the 2023 Annual General Meeting

1. Scope of the guidelines, etc.

These guidelines cover the individuals who, during the validity period of the guidelines, are included in the group management of Getinge AB (publ), below referred to as "Senior Executives". The guidelines shall apply for remuneration agreed and amendments in any remunerations already agreed, as of the adoption of the guidelines by the 2023 Annual General Meeting. The guidelines are not applicable on any remuneration resolved by the General Meeting.

2. Promotion of Getinge's business strategy, long-term interests and sustainability, etc.

A prerequisite for successful implementation of the company's business strategy and safeguarding of the company's long-term interests is that the company is able to recruit and retain qualified personnel. The main principle is that remuneration and other employment conditions for Senior Executives, shall be in line with market terms and competitive on every market where Getinge operates, to ensure that competent and skilled personnel can be attracted, motivated and retained. Individual levels of remuneration shall be based on experience, competence, level of responsibility and performance, and also the country were the Senior Executive is employed. These guidelines promote the company's business strategy, long-term interests and sustainability as described in the below section regarding criteria for variable remuneration, and contribute to the company's ability to, on a long-term basis, retain qualified personnel.

For information regarding Getinge's business strategy, please see the company's annual reports and the website (https://www.getinge.com).

3. Principles for various types of remuneration, etc.

The total remuneration to Senior Executives shall be in line with market terms and consist of base salary (fixed cash remuneration), variable cash remuneration, any other variable remuneration, pension benefits and other benefits. In addition, the General Meeting may – irrespective of these guidelines – resolve on, for instance, share- or share price-related remunerations.

Fixed remuneration

The fixed remuneration, meaning the base salary, shall be based on the individual employee's area of responsibility, authority, competence, experience and performance.

Variable remuneration

The allocation between base salary and variable remuneration shall be in proportion with the area of responsibility and authority of the executive. The variable remuneration shall always be pre-limited to a maximum amount and related to predetermined and measurable criteria, designed to contribute to the business strategy and long-term added value of the company.

The annual variable remuneration is designed to promote the company's strategy to produce and offer products that can support in making health care more efficient in the long-term and to provide better health care for the people who need Getinge's products. If the above-mentioned activities are performed in an efficient and sustainable way, one outcome is improved financial results and increased capital efficiency, which constitutes the foundation of the variable remuneration. The sustainability work is integrated in the company's day-to-day operations. If the company's principles for sustainability or ethical guidelines are not complied with, the company has the possibility to withhold any variable remuneration or reclaim already awarded remuneration.

Annual variable remuneration

For Senior Executives, the annual variable remuneration (annual bonus) shall be capped at 70% and, in specific cases, were the nature of the position, the competitive situation and the country of employment so require, capped at 90% of the fixed annual base salary. The variable remuneration shall be based on objectives set by the Board of Directors. These objectives are related to (i) earnings, (ii) organic growth, (iii) working capital and cash flow, and (iv) sustainability. In order to promote the interest of the shareholders', the company's values and collectively strive to achieve the business strategy, long-term interests and sustainable development of the company, all members of the group management have the same targets for annual variable remuneration.

Variable long-term cash bonus (LTI-bonus)

In addition to base salary and annual variable remuneration as described above, Senior Executives can obtain a variable long-term bonus (LTI-bonus). The target that forms the basis for the LTI-bonus is adjusted earnings per share for a three year period, adjusted for the category of adjustment items decided at implementation of the program by the Board of Directors at the recommendation by the Remuneration Committee. By connecting the performance target to the shareholders' objective, a common interest to promote Getinge's business strategy, long-term interests and value creation is created. Payment is subject to continued employment at the end of the vesting period for the LTI-bonus (with some customary exceptions).

The vesting period for the LTI-bonus shall be not less than three financial years. The payment of LTI-bonus per each three-year program shall be capped to 33% of one year's base salary. A new LTI-bonus program can be set up every year with a duration period of three years. Senior Executives of the group management shall invest not less than 50% of the received LTI-bonus (net, after taxes paid) in Getinge shares, until the Senior Executive's own total holdings of shares correspond to one year's salary (gross). The Senior Executive shall keep these shares for at least three years.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Limitation of total variable remuneration for the CEO
For the CEO, the total payment of variable remuneration (annual variable remuneration and LTI-bonus), in addition to what is previously mentioned, annually be limited so that the total variable remuneration does not exceed 100% of the fixed salary. This applies to variable remuneration that is paid 2022 or later.

Determination of result for variable remuneration, etc.
When the measuring period for achievement of the criteria for payment of the variable remuneration has expired, the Board of Directors shall, based on proposal by the Remuneration Committee, establish to which extent the criteria are achieved. In their assessment on whether the criteria are achieved or not, the Board of Directors may, in accordance with proposal by the Remuneration Committee, allow exception from the established targets on the conditions set out in the below item 5. The assessment of achievement of the financial targets shall be based on the company's most recent published financial information, with any adjustments predetermined by the Board of Directors when implementing the program. Variable cash payment can be awarded after the expiration of the measuring period (annual variable remuneration) or be subject to postponed payment (LTI-bonus).

Getinge is actively working to ensure that the company is managed in the most sustainable, responsible and efficient way possible, and that applicable legislations and regulations are complied with. Getinge also apply internal rules, including a code of conduct and different group-wide steering documents (policies, instructions and guidelines) within a range of different areas. Variable remuneration shall not be awarded, and can be reclaimed, if the Senior Executive has acted contrary to these rules, principles or the company's code of conduct. Variable remuneration shall not be awarded if the earnings before tax is negative. The Board of Directors shall also have the possibility to, in accordance with legislation or agreement, in whole or partly, reclaim any variable wrongly awarded remuneration.

Other variable remuneration
Additional variable cash remuneration can be awarded in case of extraordinary circumstances, provided such extraordinary arrangements are only conducted for the purpose of recruiting or retaining executives. Such remuneration may not exceed an amount corresponding to 100% of the base salary and only be awarded once a year per individual. Resolution on such remuneration shall be made by the Board of Directors and based on a proposal by the Remuneration Committee. In addition to variable remuneration, resolutions on share- or share price related incentive programs, in accordance with the above, can from time to time be made.

Pension and insurance
The CEO has right to retire from the age of 62 and other Senior Executives has right to retire in accordance with applicable local regulations.

Pension contributions for the CEO shall amount to no more than 40% of the fixed base salary on a defined contribution basis. Variable cash remuneration shall not qualify for pension benefits.

Pension contributions for other Senior Executives shall amount to a maximum of 40%[1] of the pensionable salary and shall be on a defined contribution basis. Variable cash remuneration shall not qualify for pension benefits in general, except where mandatory by collective bargaining agreement provisions applicable for the executive. In such case, this shall be considered when creating the total benefits package. In addition to the above, Senior Executives may be covered by an additional health income insurance (sw. *sjukinkomstförsäkring*).

For employments governed by other than Swedish regulations, pension benefits and other insurances may be duly amended to comply with mandatory rules or established local regulations, taking into consideration, to the extent possible, the overall purpose of these guidelines.

Other benefits
Other benefits such as company car, additional medical insurance (sw. *sjukvårdsförsäkring*) and company health care (sw. *företagshälsovård*), may be provided to the extent this is considered to be in line with market terms for Senior Executives on similar positions on that local market. The total value of such benefits may not exceed 10% of the fixed base salary.

Conditions for termination
Senior Executives shall have a permanent employment. If the company terminates the employment, the notice period shall not exceed twelve months. Upon termination of employment, the total of the fixed salary during the notice period together with severance pay may not exceed an amount equivalent to two years fixed base salary for the CEO, and one year for other executives. If the executive terminates the employment, the notice period shall not exceed six months and be without any right to severance pay.

Senior Executives may be entitled to compensation for any competition restrictions after the termination of employment, however, only to the extent severance pay for the corresponding period is not awarded. The purpose of such compensation is to compensate the executive for any gap between the monthly base salary at the notice of termination and (lower) monthly income received, or that could be received, by a new employment, assignment or own business. The compensation can be awarded during the period of the competition restriction, however, not more than for 12 months after the termination of employment.

Salary and employment conditions for employees
When preparing the Board of Director's proposal for these remuneration guidelines, salary and employment conditions for the company's employees have been considered. This have been made by including information of the total income of the employees, the components of the remuneration and the increase and growth rate over time, as part of the Remuneration Committee's and the Board of Directors' basis for decision when evaluating whether the guidelines and the limitations set out herein are reasonable.

1) Pension contributions may, exceptionally, exceed this limit if required to comply with mandatory law, collective bargaining agreements or other applicable rules or established local practice, taking into consideration, to the extent possible, the overall purpose of these guidelines.

Introduction

Strategy

Corporate Governance Report

Financial statements

Administration Report

Guidelines for remuneration

Remuneration Report 2024

Proposed appropriation of profit

Group financial statements

Group notes

Parent Company financial statements

Parent Company notes

Auditor's report

Sustainability Report

Other information

The development of the gap between the remuneration to Senior Executives and remuneration to other employees will be disclosed in the remuneration report.

4. The resolution process to determine, review and implement the guidelines

The Board of Directors has established a Remuneration Committee. The Committee's tasks include preparing the Board of Directors' decision to propose guidelines for Senior Executive remuneration. These are reviewed annually and new proposals for guidelines shall be drafted by the Board at least every fourth year and presented to the Annual General Meeting for resolution. The guidelines shall be in force until new guidelines are adopted by the Annual General Meeting.

The Remuneration Committee shall also monitor and evaluate programs for variable remuneration to Senior Executives, the guidelines for remuneration to Senior Executives, as well as the current remuneration structures and compensation levels in the company, and provide recommendations to the Board of Directors in relation to remuneration to the CEO. Regarding resolution on remuneration to other Senior Executives in accordance with the guidelines (other than the specifically regulated above) the CEO shall consult with the Remuneration Committee.

The CEO and other members of the group management do not participate in the Board of Directors' processing of, and resolutions on, remuneration-related matters when such matters concern them.

The Board of Directors shall annually draw up a remuneration report that shall be presented to the Annual General Meeting for approval.

5. Deviations from the guidelines

The Board of Directors may temporarily resolve to deviate from the guidelines, entirely or partly, if in a specific case there is special cause for the deviation and a deviation is necessary to serve the company's long-term interests, a sustainable development of the company or to ensure the company's financial viability. As set out above, the Remuneration Committee's tasks include preparing the Board of Directors' resolutions in remuneration-related matters. This includes any resolutions to deviate from the guidelines.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Remuneration Report 2024

Introduction

This report reflects how the guidelines for remuneration to Senior Executives, adopted at the 2023 Annual General Meeting ("AGM"), have been implemented and applied during 2024. The report also provide details on the remuneration to the President & CEO, how the performance targets for variable remuneration have been applied, and information that the company has not implemented any share- or share price-related incentive programs. This report has been prepared in compliance with the Swedish Companies Act and the *Rules on remuneration of the Board and Executive Management and Incentive programs* issued by the Stock Market Self-Regulation Committee (the Remuneration Rules).

Further information on remuneration to Senior Executives is available in Note 22 on pages 105–106 of the 2024 Annual Report. Information on the work by the Remuneration Committee in 2024 is set out in the Corporate Governance Report, which can be found on pages 32–54 of the 2024 Annual Report.

Remuneration of the Board of Directors is not covered by this report, but is resolved annually by the AGM. Information about remuneration to the Board of Directors is disclosed in Note 22 on page 105 and the Corporate Governance Report on pages 32–54 of the 2024 Annual Report.

The company has not received any comments on the 2023 Remuneration Report.

The group's overall performance 2024

The President & CEO summarizes the Group's result and overall performance in his statement, which is included on pages 6–7 of the 2024 Annual Report.

The company's remuneration guidelines

A prerequisite for successful implementation of the company's business strategy and safeguarding of its long-term interests and sustainability is that the company is able to recruit, motivate and retain qualified personnel. By offering Senior Executives a competitive total compensation, the remuneration guidelines enable the company, on a long-term basis, to attract qualified personnel to the business.

The total remuneration to Senior Executives shall be in line with market terms and consist of base salary (fixed cash remuneration), variable cash remuneration, any other variable remuneration, pension benefits and other benefits. The remuneration, and other employment conditions, shall be on market terms and competitive on every market where Getinge operates. In addition, the General Meeting can decide on share- or share price-related remunerations.

The current guidelines for remuneration, adopted at the 2023 AGM, are presented on pages 61–63 of the 2024 Annual Report.

Application and deviations from the remuneration guidelines

In 2024, the company has complied with the guidelines adopted at the 2023 AGM. No deviations have been made from the guidelines nor any derogations from the procedure for resolution on remuneration, established by the remuneration guidelines.

The auditors' statement regarding the company's compliance with the guidelines is available on www.getinge.com/int/company/corporate-governance/general-meetings/ under the tab 2025 Annual General Meeting. No paid remuneration has been reclaimed during 2024.

Share based remuneration

The General Meeting has not resolved on implementation of any share- or share price-related incentive programs.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information


Total remuneration to the President & CEO during 2024

SEK 000s


	Fixed remuneration		Variable remuneration				
Executive	Fixed salary[1]	Other benefits[2]	Short-term variable remuneration[3]	Long-term variable remuneration[4]	Pension expenses[5]	Total	Share of fixed and variable remuneration (%)[6]
Mattias Perjos, President & CEO	27,141	790	21,088	-	10,826	59,845	65/35

1) Fixed salary refer to base salary, including holiday pay.
2) Other benefits refer to benefits such as company car, medical insurance (sw: *sjukvårdsförsäkring*), health income insurance (sw: *sjukinkomstförsäkring*) etc.
3) Short-term variable remuneration refers to bonus accrued during the 2024 fiscal year and to be paid during 2025.
4) Long-term variable remuneration refers to bonus accrued for expired long-term incentive program. During 2024, the program for 2022–2024 expired without reaching the performance target, why no long-term bonus has been accrued.
5) Pension expense for the President & CEO is based on a defined contribution basis and amounts to 40% of the base salary.
6) The pension expense for the President & CEO is based on the fixed base salary and is included in its entirety in the fixed remuneration.

Total remuneration to the President & CEO in 2024



Percentage of fixed and variable remuneration in 2024



Principles for the application of performance targets for variable remuneration

Selection of performance targets and resolution to determine the variable remuneration has been prepared by the Remuneration Committee and resolved by the Board of Directors. The variable remuneration is pre-limited to a maximum amount and related to predetermined and measurable criteria, designed to contribute to the interests of shareholders and the company's core values and creates an incentive for joint efforts to achieve the company's business strategy, long-term added value and the sustainable development of the company. The sustainability work is integrated in the company's day-to-day operations. If the company's principles for sustainability or ethical guidelines are not complied with, the company has the possibility to withhold any variable remuneration or reclaim already awarded remuneration.

After the end of the fiscal year and based on a proposal by the Remuneration Committee, the Board of Directors has resolved to which extent the criteria for payment of the short- and long-term variable remuneration have been fulfilled. The assessment if the financial targets have been reached has been based on the company's most recent published financial information, with any adjustments approved by the Board of Directors at the proposal of the Remuneration Committee.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Application of the performance targets for short-term variable remuneration

The variable short-term remuneration to the President & CEO is limited to 80% of the fixed annual base salary. The targets for the 2024 fiscal year were related to earnings, organic growth, tied-up working capital and sustainability. All five performance targets were fully or partly achieved in 2024, resulting in a degree of target fulfillment of 98.7% and a corresponding bonus payout.

The performance by the President & CEO during the reported fiscal year: short-term variable cash remuneration

Criteria for determination of short-term variable remuneration for the President & CEO and outcome


Executive	Performance target	Weighting of performance target	Outcome of performance target	Variable remuneration per performance target (SEK 000s)
Mattias Perjos, President & CEO				
	Adjusted EBITA (SEK M)[1]	50%	SEK 4,874 M	10,686
	Net sales – organic growth (%)[2]	20%	4.9%	- 4,224
	Tied-up working capital – no. of days	20%	89 days	4,275
	Sustainability – reduction of CO_2 emissions in Scope 1 and Scope 2[3]	5%	-13.4%	834
	Sustainability – implementation of process for supplier ESG qualification	5%	Achieved	1,069
				21,088

1) Adjusted EBITA refers to the operating profit adjusted for exchange rate changes, acquisitions, divestments, restructuring costs and other material items affecting comparability.
2) Refers to the Group's organic net sales growth.
3) Scope 1 includes emissions from the consumption of oil and gas, and Scope 2 includes emissions from the consumption of electricity, heating and cooling.

Set performance target



Distribution of outcome of short-term variable remuneration per performance target 2024



Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Applying the performance targets for the variable long-term remuneration

The long-term variable remuneration ("LTI-bonus") for the President & CEO is capped for a three-year period at an amount corresponding to one-year base salary and is subject to continued employment at the end of the vesting period (with some customary exceptions). The vesting period for the LTI-bonus is three fiscal years.

The performance target for LTI 2022–2024, LTI 2023–2025 and LTI 2024–2026 is development of earnings per share over a three-year period adjusted for the categories of adjustment items that the Board of Directors determines at the recommendation of the Remuneration Committee at the implementation of each program.

The incentive program LTI 2022–2024 expired at the end of the 2024 fiscal year and the performance targets was not achieved, which resulted in that there is no bonus payout.

The performance by the President & CEO during the reported fiscal year – long-term variable remuneration

Criteria for determination of long-term variable remuneration for the President & CEO and outcome, SEK 000s

Executive	Long-term incentive program (LTI)	Performance target[1]	Outcome of performance target	Variable remuneration per performance target[2]
Mattias Perjos, President & CEO				
	LTI 2022–2024	Development of adjusted earnings per share 2022–2024	SEK 11.73 (adjusted earnings per share 2024)	-
				-
	LTI 2023–2025	Development of adjusted earnings per share 2023–2025	-	-[3]
	LTI 2024–2026	Development of adjusted earnings per share 2024–2026	-	-[4]

1) The performance targets in the group's long-term variable remuneration schemes are earnings per share, adjusted for acquisitions, divestments, restructuring costs and other material non-recurrent costs.
2) At the end of the year, there was no provision for earned LTI-bonus to the President & CEO as LTI 2022–2024 has expired and the performance target was not met. The vesting period for the group's long-term incentive scheme is three years and the remuneration is conditioned by the President & CEO remaining an employee at the end of the vesting period.
3) Since the three-year performance period for the performance target for the incentive program LTI 2023–2025 has not ended, there is no earned compensation for the incentive program and therefore no outcome for the performance target is reported.
4) Since the three-year performance period for the performance target for the incentive program LTI 2024–2026 has not ended, there is no earned compensation for the incentive program and therefore no outcome for the performance target is reported.


Comparative information regarding the company's result and changes in remuneration

Changes in remuneration and company performance over the last five reported fiscal years[1]

	2020 compared with 2019	2021 compared with 2020	2022 compared with 2021	2023 compared with 2022	2024 compared with 2023	2024[4]
Changes in remuneration to the President & CEO, SEK 000s[2]	20,663 (44.9%)	-7,082 (-10.6%)	-16,378 (-27.5%)	3,143 (7.3%)	13,457 (29.0%)	59,845
Changes in average remuneration to employees of Getinge AB, SEK 000s[3]	-34 (-2.1%)	-340 (-21.1%)	-244 (-19.2%)	356 (34.6%)	-34 (-2.4%)	1,352
Changes in operating profit for the group, SEK M	2,412 (101.7%)	-413 (-8.6%)	-745 (-17.0%)	110 (3.0%)	-882 (-23.6%)	2,854

1) In the above table, changes in remuneration and result between the years are presented. The changes are presented in both absolute terms and as a percentage.
2) Remuneration to the President & CEO relates to the total remuneration including fixed salary, short- and long-term variable remuneration, pension expenses and other benefits.
3) Remuneration to the Senior Executives excluded.
4) Refers to the outcome for year 2024.

Relative changes in remuneration and profit



Gothenburg in March 2025

The Board of Directors of Getinge AB (publ)

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Proposed appropriation of profit

Getinge AB (publ), Corp. ID No. 556408-5032

The following non-restricted equity in the Parent Company is at the disposal of the Annual General Meeting, SEK M:

Share premium reserve	4,264
Retained earnings	17,117
Net profit for the year	1,627
Total	**23,008**

The Board and CEO propose that a dividend of SEK 4.60 per share shall be distributed to shareholders	1,253
to be carried forward	21,755
Total	**23,008**

The Board of Directors deems the proposed dividend to be justified in relation to requirements that the nature of the business, scope and risks impose on consolidated equity and the group's consolidation requirements, liquidity and financial position.

The Board of Directors and CEO affirm that the consolidated financial statements have been prepared in accordance with international financial reporting standards IFRS, as adopted by the EU, and provide a true and fair view of the group's financial position and profit. This Financial statements was prepared in accordance with generally accepted accounting policies and provides a true and fair view of the Parent Company's financial position and profit.

The Administration Report for the group and Parent Company provides a fair and accurate overview of the performance of the Parent Company and the group's operations, financial position and earnings and describes the material risks and uncertainties faced by the Parent Company and companies belonging to the group.

Gothenburg, March 26, 2025

Johan Malmquist
Chairman
AGM-elected Board member

Carl Bennet
Vice Chairman
AGM-elected Board member

Johan Bygge
AGM-elected Board member

Cecilia Daun Wennborg
AGM-elected Board member

Dan Frohm
AGM-elected Board member

Mattias Perjos
President & CEO,
AGM-elected Board member

Malin Persson
AGM-elected Board member

Kristian Samuelsson
AGM-elected Board member

Fredrik Brattborn
Board member
Representative of the Swedish Metalworkers' Union

Åke Larsson
Board member
Representative of the Swedish Association of Graduate Engineers

Our auditor's report was submitted on March 27, 2025
Öhrlings PricewaterhouseCoopers AB

Cecilia Andrén Dorselius
Authorized Public Accountant
Auditor in Charge

Karin Olsson
Authorized Public Accountant

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Consolidated income statement

SEK M	Note	2024	2023
Net sales	2,3	34,759	31,827
Cost of goods sold	4	-18,606	-17,332
Gross profit		**16,153**	**14,495**
Selling expenses	4	-5,979	-5,366
Administrative expenses	4	-4,654	-4,315
Research and development costs	4,9	-1,431	-1,192
Acquisition expenses	4	-50	-167
Restructuring costs	4	-848	-75
Other operating income	4	672	1,030
Other operating expenses	4	-1,008	-673
Operating profit (EBIT)	3,4,5,6	**2,854**	**3,736**
Interest income and other similar income	6,7	107	167
Interest expenses and other similar expenses	6,7	-678	-560
Profit after financial items		**2,282**	**3,343**
Taxes	8	-628	-915
Net profit for the year		**1,654**	**2,428**
Net profit for the year attributable to:			
Parent Company's shareholders		1,638	2,412
Non-controlling interests		16	16
Earnings per share, SEK[1)]	17	**6.01**	**8.86**
Weighted average number of outstanding shares for calculation of earnings per share (000s)	17	272,370	272,370

1) Before and after dilution.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Consolidated statement of comprehensive income

SEK M	Note	2024	2023
Net profit for the year		1,654	2,428
Other comprehensive income			
Items that cannot be restated in profit			
Actuarial gains/losses pertaining to defined-benefit pension plans		31	-258
Tax attributable to items that cannot be restated in profit		-3	68
Items that can later be restated in profit			
Translation differences		2,063	-743
Hedging of net investments		393	-276
Cash flow hedges	19	12	30
Tax attributable to items that can be restated in profit		-83	50
Other comprehensive income for the year, net after tax		**2,412**	**-1,128**
Comprehensive income for the year		**4,066**	**1,301**
Comprehensive income for the year attributable to:			
Parent Company's shareholders		4,038	1,285
Non-controlling interests		28	15

20250623150017

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Consolidated balance sheet

SEK M	Note	2024	2023
ASSETS			
Non-current assets			
Intangible assets	3, 9	39,242	30,670
Tangible assets	3, 10	3,902	3,723
Right-of-use assets	11	1,795	1,486
Financial instruments, long-term	19	15	–
Financial receivables, long-term	19	33	61
Deferred tax assets	8	770	1,000
Total non-current assets		**45,757**	**36,939**
Current assets			
Inventories	12	6,590	6,416
Accounts receivable	13, 19	6,348	5,739
Contract assets	14	926	625
Current tax assets		73	135
Financial instruments, current	19	3	36
Other receivables	19	806	581
Prepaid expenses and accrued income	16	455	386
Cash and cash equivalents	19, 20, 26	2,961	2,728
Total current assets		**18,162**	**16,647**
TOTAL ASSETS		**63,918**	**53,586**

SEK M	Note	2024	2023
EQUITY AND LIABILITIES			
Equity			
Share capital	17	136	136
Other capital provided		6,789	6,789
Other reserves		5,752	3,380
Retained earnings		20,328	19,861
Equity attributable to the Parent Company's shareholders		**33,005**	**30,166**
Non-controlling interests		205	237
Total equity		**33,210**	**30,403**
Long-term liabilities			
Interest-bearing long-term liabilities	19, 20	6,971	3,903
Other long-term liabilities	19	1,892	185
Provisions for pensions and similar obligations, interest-bearing	20, 21	2,700	2,664
Provisions for pensions and similar obligations, non-interest-bearing	21	86	120
Leasing liabilities, long-term	11, 19, 20	1,309	1,057
Deferred tax liabilities	8	2,172	1,681
Restructuring reserves, long-term	15	19	6
Other provisions, long-term	15	510	381
Total long-term liabilities		**15,660**	**9,998**
Current liabilities			
Restructuring reserves, current	15	177	96
Other provisions, current	15	1,537	960
Interest-bearing current liabilities	19, 20	1,956	2,694
Leasing liabilities, current	11, 19, 20	491	422
Accounts payable	19	2,398	2,355
Contract liabilities	14	2,464	2,453
Current tax liabilities		444	387
Financial instruments, current	19	13	60
Other liabilities	19	2,046	840
Accrued expenses and deferred income	16	3,522	2,919
Total current liabilities		**15,047**	**13,185**
TOTAL EQUITY AND LIABILITIES		**63,918**	**53,586**

Refer to Note 25 Pledge assets and contingent liabilities for information concerning Getinge Group's pledged assets and contingent liabilities.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Changes in equity for the group

SEK M	Share capital	Other capital provided	Reserves[1]	Retained earnings	Total	Non-controlling interests	Total equity
Opening balance 2024	136	6,789	3,380	19,861	30,166	237	30,403
Comprehensive income for the year	–	–	2,372	1,665	4,038	28	4,066
Dividend	–	–	–	-1,198	-1,198	-29	-1,228
Transactions with non-controlling interests	–	–	–	–	–	-31	-31
Closing balance 2024	136	6,789	5,752	20,328	33,005	205	33,210
Opening balance 2023	136	6,789	4,317	18,796	30,038	415	30,453
Comprehensive income for the year	–	–	-937	2,223	1,285	15	1,301
Dividend	–	–	–	-1,158	-1,158	-23	-1,181
Transactions with non-controlling interests	–	–	–	–	–	-170	-170
Closing balance 2023	136	6,789	3,380	19,861	30,166	237	30,403

1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.

20250623150 18

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Consolidated cash flow statement

SEK M	Note	2024	2023
Operating activities			
Operating profit (EBIT)		2,854	3,736
Add-back of amortization, depreciation and write-down		2,421	2,093
Other non-cash items[1]	26	808	35
Add-back of restructuring costs[2]		523	49
Paid restructuring costs		-288	-176
Interest paid and received	26	-560	-300
Other financial items		-24	-24
Taxes paid		-742	-815
Cash flow before changes in working capital		**4,993**	**4,598**
Changes in working capital			
Inventories		-46	-202
Operating receivables		-712	-305
Operating liabilities[3]		250	-1,133
Cash flow from operating activities		**4,577**	**2,957**
Investing activities			
Acquisition of operations	27	-3,256	-5,209
Investments in intangible assets and tangible assets	9, 10	-1,309	-1,353
Divestment of non-current assets		15	19
Cash flow from investing activities		**-4,549**	**-6,543**

SEK M	Note	2024	2023
Financing activities			
Raising of loans		7,736	3,133
Repayment of loans		-5,529	-936
Lease payments		-506	-476
Change in long-term receivables		31	-30
Dividend paid		-1,227	-1,181
Cash flow from financing activities		**504**	**511**
Cash flow for the year		**532**	**-3,075**
Cash and cash equivalents at the beginning of the year		2,728	5,676
Cash flow for the year		532	-3,075
Translation differences		-299	127
Cash and cash equivalents at year-end	26	**2,961**	**2,728**

1) Provision for field actions for Cardiosave had an impact of SEK 297 M and negotiations with CGU in Brazil had an impact of SEK 482 M in 2024.
2) Excluding write-downs on fixed assets.
3) 2023 figures have been affected by payments related to the settlement regarding surgical mesh products.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 1 Accounting policies

General information

Getinge AB (publ), which is the Parent Company of Getinge Group, is a limited liability company with its registered offices in Gothenburg, Sweden. A description of the company's operations is included in the Administration Report on page 56–60. The consolidated financial statements for the fiscal year ending December 31, 2024 were approved by the Board on March 26, 2025 and will be presented to the AGM on April 22, 2025 for adoption.

Accounting policies

Consolidation

The consolidated financial statements for Getinge AB (publ) and its subsidiaries have been prepared in accordance with the International Financial Reporting Standards (IFRS), issued by the International Accounting Standards Board (IASB), as endorsed by the EU. This Annual Report has been prepared in accordance with IAS 1 Presentation of Financial Statements and the Swedish Annual Accounts Act. In addition, the Swedish Corporate Reporting Board's recommendation RFR 1 Supplementary Accounting Rules for Groups has been applied. Getinge presents the most material accounting policies in each note to provide a deeper understanding of each accounting area.

The consolidated financial statements include Getinge AB (publ) and its subsidiaries which are the companies (including structured entities) over which the Group exercises a controlling influence. The controlling influence is usually transferred at the acquisition date. The consolidated financial statements were prepared in accordance with the cost method.

The Parent Company applies the same accounting policies as the Group, except in the instances stated in the section Parent company Financial statements Note 1 Parent Company's accounting policies. The differences that arise between the Parent Company and Group accounting policies are attributable to the limited opportunities for the application of IFRS in the Parent Company, as a result of the Swedish Annual Accounts Act and the Swedish Pension Obligations Vesting Act.

Intra-Group transactions

Intra-Group transactions and unrealized intercompany profits are eliminated in the consolidated financial statements, without respect of shares in non-controlling interests. In profit or loss, net profit is recognized without deductions for non-controlling interests in net profit for the year. Non-controlling interests are recognized as a separate item in consolidated equity in the balance sheet.

Translation to SEK on consolidated of subsidiaries that have a different functional currency to the Group

The Parent Company's functional currency is Swedish kronor (SEK), which is also the Parent Company's and Group's presentation currency. This means that the financial statements are presented in Swedish kronor (SEK). Getinge applies the current rate method, which means that when the consolidated financial statements are prepared, items in the income statements of foreign subsidiaries are translated to SEK at the average exchange rates for the fiscal year. Items in the balance sheet are translated to SEK using the exchange rates at the end of the reporting period (closing day rate). The exchange-rate fluctuations that arise are recognized as a separate component in other comprehensive income and are accumulated in equity. Getinge applies hedge accounting to external loans raised in order to reduce translation effects in exposed currencies. Exchange rate differences for these external loans are recognized directly in other comprehensive income for the Group.

Accumulated exchange-rate fluctuations attributable to a certain subsidiary are reversed to profit or loss as part of the gain or loss that arises on the divestment of this subsidiary.

Receivables and liabilities in foreign currencies

Each group company's functional currency is determined based on the primary economic environment in which the company operates. Transactions in foreign currencies are translated to the functional currency of the financial statements according to the exchange rate on the date of the transaction. Receivables and liabilities in currencies other than the functional currency of the reporting company (foreign currencies) are translated to the functional currency using the closing day rate, and unrealized currency gains and losses are included in profit or loss. Exchange-rate fluctuations on operating assets and liabilities are attributed to operating profit, while exchange-rate fluctuations on financial assets and liabilities are attributed to the Group's net financial items.

Unless otherwise stated, all amounts are given in millions of Swedish kronor (SEK M). For practical reasons, the figures in this Annual Report have not been rounded off, which is why notes and tables may not total correct amounts.

Significant estimates and assessments

To prepare the financial statements in accordance with IFRS Accounting Standards, the company management is required to make assessments and assumptions that affect the recognized amounts of assets and liabilities and other information in the financial statements as well as the revenues and expenses recognized during the period. Assumptions, assessments and estimates are reviewed on a regular basis. The actual outcome may diverge from these assumptions, assessments and estimates.

20250623150019

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Getinge presents the most significant estimates and assessments made in each note to provide a deeper understanding.

The Board of Directors and Getinge Executive Team have deemed that the following areas may have a significant impact on Getinge's earnings and financial position in the year ahead:

- Measurement of identifiable assets, liabilities and additional purchase prices on acquisitions (Note 27 Acquisition of operations and Note 19 Financial instruments).
- Goodwill and intangible assets with an indefinite useful life and capitalized product development costs (Note 9 Intangible assets).
- Provisions for pensions and similar obligations (Note 21 Provisions for pensions and similar obligations).
- Write-down of inventories (Note 12 Inventories).
- Deferred tax (Note 8 Income taxes).
- Disputes and claims for damages (Note 15 Other provisions and Note 26 Pledged assets and contingent liabilities).

New accounting policies applied by the Group in 2024

No standards, amendments or interpretations effective from January 1, 2024 had a material impact on the consolidated financial statements.

New and amended standards and interpretations that have not yet come into effect

In 2024, the IASB presented the new standard IFRS 18 Presentation and Disclosure in Financial Statements. This standard includes requirements for changes to the structure of the financial statements and new requirements for the disclosure of information. Getinge has evaluated the impact on the Group's reporting and predicts minor changes to the presentation of the income statement and cash flow when IFRS 18 is implemented. The standard is effective from January 1, 2027 but has not yet been endorsed by the EU.

No other new or changed accounting standards and interpretations that have been published and take effect in 2025 or later are expected to have a material impact on Getinge's consolidated financial statements.

Alternative performance measures and definitions

In the Annual Report, alternative performance measures are used to facilitate analyses of the Group's operations, and the primary alternative performance measures that are presented are net debt/equity ratio, adjusted earnings per share, gross profit, EBIT, EBITA, EBITDA with add-back of acquisition and restructuring costs as well as other items affecting comparability. For reconciliations of the alternative performance measures and definitions, see pages 176–178 and 182–183.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 2 Net sales per revenue classification

Accounting policies

Sales are recognized according to IFRS 15 and include products, services and rental, net after discounts, excluding indirect sales tax. Getinge's overall performance obligations can be divided into products and services, with services primarily comprising service/maintenance, installation and licenses/software but also including, to a certain extent, extended guarantees, training and revenue from the rental operations. Getinge's products comprise medical devices, spare parts and consumer goods, such as disposables and detergents. Getinge's customers generally conduct their operations in the healthcare sector and laboratory industry.

Revenue is mainly recognized when control of the sold product or service is passed to the buyer and the buyer is able to use or benefit from the product or service. Revenue recognition of a standardized product or equipment usually takes place at a point in time when the goods are delivered or installed and when collection of the receivable is reasonably assured. When delivered, the customer takes physical possession of the standardized product or equipment and Getinge, as a result, has a right to payment.

Revenue recognition from service agreements is adapted to the structure of the underlying customer contract. Getinge has ongoing service agreements with an unspecified number of service matters that take place at several undefined times during the year, and therefore revenue is recognized on a straight-line basis over the agreed contract period. Getinge also has more specific service agreements and revenue is then recognized at a point in time in the period when the specified service is provided.

For software licenses, revenue is recognized when the licenses are made available to the customer, which is usually at the time that the software is accepted and any training is given. Revenue from rental is allocated to a particular period over the term of the rental agreement.

For larger assignments that meet Getinge's and the regulatory criteria for revenue recognition over time, revenue and expenses are recognized in relation to the degree of completion of the assignment on the closing date. Getinge applies stricter criteria for the possibility of recognizing projects on a percentage of completion basis than those criteria prescribed by the regulations. For example, Getinge requires that a specific stage of the project must have been reached, that the contract price of the performance obligation must be above a specific amount and that the project must have been completely customized and cover a period of at least three months.

The Group primarily recognizes revenue at one point in time. Revenues distributed over time are mainly referring to service agreements, which usually generate revenue over several years. Other revenue recognized over time refers to projects where revenue is recorded according to percentage of completion, revenues from rental of products and from sales of software and licenses.

Expected future revenue from existing customer contracts where the revenue is recognized over time amounts to SEK 1,610 M for 2025 and SEK 654 M for 2026, and primarily derives from multi-year service contracts in Surgical Workflows. Expected revenue for 2027 and beyond for existing customer contracts is not of a material value for the Group.

For information about Getinge's accounting policies for performance obligations that have not yet been invoiced or delivered, see Note 14 Contract assets and liabilities.

Significant estimates and assessments

The classification of contracts in performance obligations and determining when revenue for a performance obligation is recognized depends on a number of underlying factors in the contract, with Getinge considering, for example, time of delivery, the complexity and customization in the installation phase, delivery terms, how customized the entire product or service is, and how the terms for customer acceptance and option for the customer to terminate the contract are designed.

The degree of completion of an assignment to which percentage of completion is applied is established in a ratio between accrued assignment costs for work completed on the closing date and the calculated total assignment costs, except in those instances this does not correspond to the degree of completion. When the outcome of an assignment cannot be calculated in a reliable manner, only the amount corresponding to the accrued assignment costs that will probably be paid by the client is recognized as revenue. Other accrued assignment costs are recognized as costs in the period in which they occur. If it is probable that the total amount of accrued assignment costs will exceed total revenue from the assignment, the expected loss is promptly recognized as a cost in its entirety.

Net sales, SEK M	2024	2023
Capital goods	12,421	12,474
Recurring revenue		
Product sales	15,588	12,962
Service assignments incl. spare parts	6,750	6,391
Total recurring revenue	**22,338**	**19,353**
Total	**34,759**	**31,827**

Net sales, SEK M	2024	2023
Revenue recognized at one point in time	30,791	28,000
Revenue recognized over time		
Service	3,025	2,716
Percentage of completion	676	776
Other revenue recognized over time	267	335
Total revenue recognized over time	**3,968**	**3,828**
Total	**34,759**	**31,827**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 3 Segment reporting

Accounting policies

Getinge's reporting of operating segments is in line with the internal reporting to the CEO, the chief operating decision maker. The group's operations are controlled and reported primarily by business area. Each segment is consolidated according to the same policies as for the group in its entirety and the earnings of the segments represent their contribution to the group's earnings. Assets in a segment include all operating assets used by the segment and primarily comprise intangible assets, tangible assets, inventories, external accounts receivable, other receivables and prepaid expenses and accrued income. Liabilities in a segment include all operating liabilities utilized by the segment and primarily comprise provisions excluding interest-bearing pension provisions and similar obligations, deferred tax liabilities, external accounts payable, other current liabilities and accrued expenses and deferred income. Non-distributed assets and liabilities include all tax items and all items of a financial interest-bearing nature.

The segment reporting has been prepared in accordance with the same policies as for the group in its entirety. Getinge's operations throughout the world are organized into three business areas – Acute Care Therapies, Life Science and Surgical Workflows. These business areas form the basis for the group's segment information. Business terms and conditions as well as market-regulated pricing apply for delivery of products and services between group companies. No sales are made between the different business areas. The group has no single customer that accounts for 10% or more of the group's sales.

The reporting segments are active in the following operations

Acute Care Therapies offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures, efficient handling of organs for transplantation and a broad selection of products and therapies for intensive care.

Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.

Surgical Workflows offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.

	Net sales		Adjusted EBITA		Operating profit (EBIT)		Amortization, depreciation and write-downs	
SEK M	2024	2023	2024	2023	2024	2023	2024	2023
Acute Care Therapies	17,948	16,529	3,554	3,117	2,065	3,215	-1,415	-1,214
Life Science	4,552	4,325	608	430	526	395	-257	-222
Surgical Workflows	12,258	10,974	1,090	721	703	675	-742	-649
Group functions	–	–	-383	-381	-440	-549	-8	-9
Total	**34,758**	**31,827**	**4,869**	**3,887**	**2,854**	**3,736**	**-2,421**	**-2,093**
Interest income and other similar income					107	167		
Interest expenses and other similar expenses					-678	-560		
Tax on profit for the year					-628	-915		
Net profit					**1,654**	**2,428**		

	Assets		Liabilities		Investments	
SEK M	2024	2023	2024	2023	2024	2023
Acute Care Therapies	39,769	32,919	9,762	6,666	894	914
Life Science	5,201	4,159	1,636	1,057	105	105
Surgical Workflows	15,169	12,719	3,696	2,979	309	333
Total business areas	**60,139**	**49,797**	**15,094**	**10,702**	**1,308**	**1,353**
Undistributed	3,779	3,789	15,614	12,481	1	–
Total	**63,918**	**53,586**	**30,708**	**23,183**	**1,309**	**1,353**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

	Net sales		Intangible assets, tangible assets and right-of-use assets	
SEK M	2024	2023	2024	2023
EMEA	12,182	11,739	11,814	11,903
of which, Sweden	617	632	2,308	2,345
Americas	15,516	13,146	32,334	23,214
of which, USA	13,929	11,697	32,234	23,107
APAC	7,061	6,943	791	761
Total	**34,759**	**31,827**	**44,939**	**35,879**

Secondary reporting segment

Getinge's operations are secondarily reported by geographic area. The US accounted for 40% (37) of the group's sales and was the only country that accounted for more than 10% of total sales.

Refer also to page 173 for a list of the group's 20 largest markets. The geographic areas' consolidation is conducted in accordance with the same policies as for the group in its entirety.

Net sales per business area and region, 2024

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
EMEA	4,742	2,057	5,383	12,182
Americas	9,223	1,937	4,356	15,516
APAC	3,983	559	2,519	7,061
Total	**17,948**	**4,552**	**12,258**	**34,759**

Net sales per business area and region, 2023

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
EMEA	4,497	1,977	5,265	11,739
Americas	8,288	1,607	3,251	13,146
APAC	3,744	741	2,458	6,943
Total	16,529	4,325	10,974	31,827

Net sales per business area and revenue type, 2024

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
Capital goods	4,318	1,970	6,133	12,421
Recurring revenue	13,631	2,582	6,125	22,338
Total	17,948	4,552	12,258	34,759

Net sales per business area and revenue type, 2023

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
Capital goods	4,011	2,230	6,233	12,474
Recurring revenue	12,517	2,095	4,741	19,353
Total	16,529	4,325	10,974	31,827

Net sales per business area and revenue stream, 2024

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
Revenue recognized at one point in time	16,808	3,579	10,403	30,791
Revenue recognized over time	1,140	973	1,855	3,968
Total	17,948	4,552	12,258	34,759

Net sales per business area and revenue stream, 2023

SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Total
Revenue recognized at one point in time	15,520	3,338	9,142	28,000
Revenue recognized over time	1,008	987	1,832	3,828
Total	16,529	4,325	10,974	31,827

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 4 Costs by cost category

Costs by cost category, SEK M	2024	2023
Goods and services	-15,918	-14,557
Salaries and remuneration	-11,113	-9,831
Social security expenses	-1,622	-1,511
Pension expenses	-495	-455
Amortization and write-downs of intangible assets[1]	-1,249	-981
Depreciation and write-downs of tangible assets[2]	-639	-600
Depreciation and write-downs of right-of-use assets	-534	-512
Other operating income	672	1,030
Other operating expenses	-1,008	-673
Total	**-31,905**	**-28,091**

1) 2024 figure includes SEK -278 M phasing out of Surgical Perfusion product portfolio reported as restructuring costs in income statement.
2) 2024 figure includes SEK -46 M phasing out of Surgical Perfusion product portfolio reported as restructuring costs in income statement.

Amortization, depreciation and write-downs, SEK M	2024	2023
Cost of goods sold	-960	-1,029
Selling expenses	-625	-520
Administrative expenses	-414	-457
Research and development costs	-99	-61
Restructuring costs	-325	-26
Total	**-2,421**	**-2,093**

Other operating income, SEK M	2024	2023
Currency gains	518	445
Capital gains	1	2
Other[1]	154	583
Total	**672**	**1,030**

1) Other operating income in 2023 includes insurance compensation amounting to SEK 450 M.

Other operating expenses, SEK M	2024	2023
Currency losses	-461	-610
Capital losses	-10	-7
Other[1]	-538	-56
Total	**-1,008**	**-673**

1) Other operating expenses in 2024 includes provisions related to negociations with CGU inBrazil amounting to SEK 492 M.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 5 Auditing

Fee to PwC, SEK M	2024	2023
Auditing assignment	-41	-39
Auditing activities other than auditing assignments	-1	-1
Tax consultancy services	-6	-3
Other services	-2	-11
Total	**-50**	**-54**

Total fees to PwC and its international network amounted to SEK 50 M (54) for the 2024 fiscal year. Fee to the Swedish auditing firm Öhrlings PricewaterhouseCoopers AB amounted to SEK 17 M (12), of which SEK 15 M (11) refers to the auditing assignment, SEK 1 M (1) to other statutory assignments and other auditing assignments and SEK 1 M (0) to tax consultancy and other services.

PwC has the auditing assignment for the entire group. Auditing assignments refer to auditing of the financial statements and statutory accounts and other required legal audit.

Auditing activities other than auditing assignments include review of sustainability report, review of interim reports as well as services in conjunction with the issuance of certificates and audit certificates. Tax consultancy services primarily pertain to general tax matters concerning corporate tax and internal pricing. Other services mainly pertain to services in connection with acquisitions.

NOTE 6 Exchange-rate differences in income statement

Recognized in income statement within, SEK M	2024	2023
Other operating income and expenses	57	-166
Financial items	-8	-23
Total	**49**	**-188**

NOTE 7 Financial items

Accounting policies

Financial income and expenses include interest income on bank deposits and receivables, interest expenses on loans, income from dividends, unrealized and realized profits and losses on financial investments, exchange rate differences and the change in value of derivative instruments used in financial activities. Borrowing costs in conjunction with the raising of loans are recognized as part of the loan to which they pertain and are charged to profit or loss during the term of the loan.

Interest income and other similar income, SEK M	2024	2023
Interest income	68	123
Exchange rate gains	39	44
Other	–	0
Total	**107**	**167**

Interest expense and other similar expenses, SEK M	2024	2023
Interest expenses	-410	-299
Interest expenses on lease liabilities[1]	-56	-45
Interest expenses on pension liabilities[2]	-98	-107
Discounting of contingent considerations[3]	-32	-18
Exchange rate losses	-47	-67
Other	-24	-24
Total	**-678**	**-560**

1) See Note 11 Leases
2) See Note 21 Provisions for pensions and other obligations
3) See Note 19 Financial instruments

20250623150022

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 8 Income taxes

Accounting policies

Getinge's income taxes include taxes on group companies' profits recognized during the accounting period and tax adjustments attributable to earlier periods and changes in deferred taxes. Measurement of all tax liabilities/receivables is conducted at nominal amounts and in accordance with enacted tax regulations and tax rates or those that have been announced and will almost certainly be adopted in the countries where the group companies operate. Tax is recognized directly in equity if the tax is attributable to items that are recognized directly in equity. Deferred tax is calculated to correspond to the tax effect arising when final tax is determined and corresponds to the net effect of tax on all existing differences between fiscal and carrying amounts of assets and liabilities by applying applicable tax rates. Tax loss carryforwards is recognized as an asset only to the extent that it is probable that these loss carryforwards will be matched by future taxable profits. Deferred tax liabilities pertaining to temporary differences that are attributable to investments in subsidiaries and affiliates are not recognized, since the Parent Company, in each instance, can control the point in time of reversal of the temporary differences and a reversal in the foreseeable future has been deemed improbable.

Significant estimates and assessments

Deferred tax

Getinge reports deferred tax assets related to loss carryforwards. The reporting of deferred tax assets is based on assessments of future taxable income in various tax jurisdictions, which includes assumptions about whether costs that have not yet been subject to taxation are deductible. The purpose of these assessments is to ensure that it is likely that the company's future taxable results will enable the utilization of reported loss carryforwards. Additionally, the offsetting possibilities of tax assets and tax liabilities are considered, as well as the fact that a significant portion of the loss carryforwards are attributable to countries with long or unlimited utilization periods.

The group's tax expense amounted to SEK -628 M (-915), entailing a tax rate of 27.5% (27.4).

Taxes, SEK M	2024	2023
Current tax	-848	-678
Deferred tax	219	-236
Total	**-628**	**-915**

The relationship between the year's tax expense and the recognized profit before tax, SEK M	2024	2023
Recognized profit before tax	**2,282**	**3,343**
Tax according to current tax rate in Sweden	-470	-689
Adjustment for tax rates in foreign subsidiaries	-140	-120
Adjustment of tax expenses from earlier years	18	-24
Other tax effects[1]	-36	-82
Recognized tax expense	**-628**	**-915**

1) Mainly refers to foreign withholding tax and tax effects of non-deductible costs/non-taxable income.

Deferred tax assets relate to the following temporary differences and loss carryforwards, SEK M	2024	2023
Non-current assets	391	160
Leasing liabilities	452	369
Current assets	567	545
Provisions	467	384
Loss carryforwards	442	686
Other	408	369
Offset	-1,957	-1,513
Deferred tax assets	**770**	**1,000**

Deferred tax liabilities relate to the following temporary differences, SEK M	2024	2023
Non-current assets	3,219	2,289
Right-of use assets	450	371
Current assets	72	73
Other	388	461
Offset	-1,957	-1,513
Deferred tax liabilities	**2,172**	**1,681**

Maturity structure for loss carryforwards, SEK M	2024	2023
Due within 1 year	–	–
Due within 2 years	–	–
Due within 3 years	–	–
Due within 4 years	4	4
Due within 5 years	–	–
Due after 5 years	17	16
No due date	1,305	2,441
Total	**1,327**	**2,461**

At year-end 2024, there were unrecognized deferred tax assets pertaining to loss carryforwards and unutilized interest deductions amounting to SEK 74 M (70).

OECD global minimum tax model rules

The group is subject to the Global Anti-Base Erosion (GloBE) rules. Legislation on global minimum tax has been adopted in Sweden, where Getinge AB (publ) has its registered offices, and came into effect on January 1, 2024. The group applies the exception to recognizing and disclosing information about deferred tax assets and liabilities related to OECD pillar two income taxes, as stipulated in IAS 12. As of the balance sheet date, the group has no significant tax exposure regarding Global Anti-Base Erosion rules.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 9 Intangible assets

Accounting policies

Goodwill

Goodwill comprises the portion of a purchase price for an acquisition that exceeds the market value of the identifiable assets, with deductions for liabilities and contingent liabilities, calculated on the acquisition date, on the share of the acquired company's assets acquired by the group. In a business acquisition whereby the acquisition costs are less than the net value of acquired assets, assumed liabilities and contingent liabilities, the difference is recognized directly in profit or loss. Goodwill arising in conjunction with the acquisition of a foreign entity is treated as an asset in the foreign entity and translated at the exchange rate on the closing date. Goodwill is recognised as an intangible asset with an indefinite useful life. For assets with an indefinite useful life such as goodwill, in addition to indications of impairment, an annual assessment of impairment needs is carried out. Goodwill is allocated and tested at the level of cash-generating units, which are identified as the Getinge Group's business areas. If the carrying amount of the tested cash-generating unit exceeds the estimated recoverable value, the difference is recognised as an impairment in the income statement. In 2024, the recoverable value of the Group's operations exceeded the carrying amount of all cash-generating units, thus no impairment has been recognized.

Other intangible assets

Other intangible assets comprise capitalized development costs, customer relations, technical know-how, trademarks, agreements and other assets. Intangible assets are recognized at cost with deductions for accumulated amortization and any impairment losses. Amortization is applied proportionally over the asset's anticipated useful life, which usually varies between three and 15 years. Acquired intangible assets are recognized separately from goodwill if they fulfill the criteria for qualifying as an asset, implying they can be separated or they are based on contractual or other legal rights and that their market value can be established in a reliable manner. Intangible assets that are recognized separately from goodwill in acquisitions of operations include customer relations, technical know-how, trademarks, agreements, etc.

Acquired intangible assets are measured at market value and amortized on a straight-line basis over their anticipated useful life. The useful life can, in certain cases, be indefinite. These intangible assets are not amortized; instead they are tested for impairment every year or more often if there is an indication that there could have been a decrease in value. Costs for development, whereby research results or other knowledge is applied to produce new products, are recognized as an asset in the balance sheet to the extent that these products are expected to generate future financial benefits. These costs are capitalized when management deems that the product is technically and financially viable, which is usually when a product development project has reached a defined milestone in accordance with an established project model. The capitalized value includes expenses for material, direct expenses for salaries and indirect expenses that can be assigned to the asset in a reasonable and consistent manner. In other cases, development costs are expensed as they arise. Research costs are charged to earnings as they arise. Capitalized expenses are amortized on a straight-line basis from the point in time at which the asset is put into commercial operation and during the asset's estimated useful life. The amortization period is determined based on historical data and taking into consideration future changes in technology. For capitalized development costs, the amortization period is five to 15 years and for software three years.

Depreciation and impairment of intangible assets with determinable useful life

At the end of each accounting period, the carrying amount of the assets is assessed to determine whether there is any indication that impairment is required. If there is such an indication, the asset's recoverable amount is established. The recoverable amount is deemed to be the higher of the asset's net realizable value and its value in use, for which the impairment loss is recognized as soon as the carrying amount exceeds the recoverable amount. Earlier recognized impairment losses on intangible assets and tangible assets are reversed if the recoverable amount is deemed to have increased, although the impairment losses are not reversed to an amount greater than what the carrying amount would have been if no impairment losses had been recognized in earlier years. Recognized impairments of goodwill are not reversed.

Significant estimates and assessments

Goodwill and intangible assets with an indefinite useful life

Each year Getinge evaluates whether there is an impairment of goodwill and other intangible assets with an indefinite useful life. In the impairment testing of goodwill and other intangible assets, estimates are made to determine the recoverable value of cash-generating units. The recoverable value for cash-generating units has been determined by calculating the value in use, which is based on management's estimate of future cash flows and is to varying degrees sensitive to changes in assumptions and external factors. Although management considers estimated future cash flows and other assumptions to be reasonable, there are uncertainties, which can significantly affect valuations.

Capitalized product development costs

Costs for product development projects are capitalized to the extent that the costs can be expected to generate financial benefits for the company. Capitalization starts when management assess the product to be technically or financially viable. This means that established criteria must be met before a development project is capitalized as an intangible asset. Capitalization ends and amortization of the capitalized development costs starts when the asset is ready for use. Capitalized development costs are tested for impairment when there are indications of a decline in value. Determining the amortization period and testing for impairment require management to make assessments.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

20250623150023

Note 9 Intangible assets cont.

Intangible assets, SEK M	Goodwill	Trademarks	Capitalized development costs[1)]	Patents & Agreements	Customer relations	Technical know-how	Intangible assets, other	Total
Acquisition cost, Jan 1, 2024	25,579	1,130	9,131	1,146	4,493	1,623	5,886	48,988
Investments	–	–	660	–	–	–	196	856
Acquisitions	3,104	226	–	–	–	–	–	3,330
Sales/disposals	–	–	-217	-79	325	2,690	–	6,345
Reclassifications	–	105	0	–	–	–	-643	-939
Translation differences	2,148	–	305	88	–	–	0	0
Accumulated cost, Dec 31, 2024	30,831	1,461	9,879	1,154	5,226	4,615	5,809	58,975
Amortization and write-downs, Jan 1, 2024	-710	-627	-6,176	-1,126	-3,146	-1,427	-5,106	-18,318
Amortization for the year	0	-4	-398	-7	-134	-121	-275	-939
Write-downs	–	–	-309	–	–	–	0	-309
Acquisitions	–	–	–	0	–	0	–	0
Sales/disposals	–	–	217	79	–	–	639	935
Reclassifications	-33	-55	0	–	–	–	–	0
Translation differences	–	–	-186	-87	-272	-133	-337	-1,102
Accumulated amortization and write-downs, Dec 31, 2024	-743	-687	-6,852	-1,140	-3,551	-1,682	-5,078	-19,734
Closing carrying amount, Dec 31, 2024	30,088	774	3,027	14	1,675	2,932	731	39,242

1) Research and Development cost, gross amounted to SEK 2,091 M (1,827) whereof SEK 660 M (629) were capitalized.
2) Write-downs of capitalized development costs amounted to SEK -309 M (-133), whereof SEK -278 M (-133) within Acute Care Therapies mainly attributable to the phase out of Surgical Perfusion, SEK -31 M (-) within Life Science and SEK - M (-0) within Surgical Workflows.

Intangible assets, SEK M	Goodwill	Trademarks	Capitalized development costs[1)]	Patents & Agreements	Customer relations	Technical know-how	Intangible assets, other	Total
Acquisition cost, Jan 1, 2023	23,232	848	8,683	1,182	3,412	1,638	5,841	44,836
Investments	–	–	629	–	–	–	166	795
Acquisitions	3,260	331	–	–	1,284	43	12	4,930
Sales/disposals	–	–	-93	–	–	–	-18	-111
Reclassifications	–	–	-2	0	–	–	2	0
Translation differences	–	–	-86	-36	-203	-57	-117	-1,462
Accumulated cost, Dec 31, 2023	25,579	1,130	9,131	1,146	4,493	1,623	5,886	48,988
Amortization and write-downs, Jan 1, 2023	-718	-641	-5,832	-1,142	-3,174	-1,406	-4,912	-17,825
Amortization for the year	–	-7	-357	-20	-77	-75	-306	-843
Write-downs	–	–	-133	–	–	–	-5	-139
Acquisitions	–	–	–	–	–	–	-9	-9
Sales/disposals	–	–	93	–	–	–	18	111
Reclassifications	8	22	1	0	–	–	-1	–
Translation differences	–	–	52	36	105	54	110	386
Accumulated amortization and write-downs, Dec 31, 2023	-710	-627	-6,176	-1,126	-3,146	-1,427	-5,106	-18,318
Closing carrying amount, Dec 31, 2023	24,869	503	2,956	19	1,347	196	780	30,670

1) Research and Development cost, gross amounted to SEK 1,827 M (1,658) whereof SEK 629 M (473) were capitalized.
2) Write-downs of capitalized development costs amounted to SEK -133 M (-230), whereof SEK -133 M (-228) within Acute Care Therapies, SEK - M (-) within Life Science and SEK -0 M (-2) within Surgical Workflows.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Impairment testing

Goodwill, SEK M	2024	2023
Acute Care Therapies	21,882	17,391
Surgical Workflows	6,161	5,780
Life Science	2,046	1,697
Total	**30,088**	**24,869**

Goodwill is distributed among the group's cash generating units (CGUs), which are identified per business area.

Goodwill and other net assets are tested for impairment annually and whenever conditions indicate that impairment may be necessary. The recoverable amount for CGUs is determined based on the calculated value in use. For impairment testing purposes, this has been done at the lowest level where separable cash flows have been identified, which for Getinge is the same as its business areas.

Assumptions

The value in use of goodwill and other net assets attributable to Acute Care Therapies, Surgical Workflows and Life Science was calculated based on discounted cash flows, which are based on assumptions regarding sales growth and the cost trend. Cash flows for the first three years are based on a financial plan approved by the Board. Cash flows after this three-year period have been determined using a growth rate corresponding to 2%. This growth is based on reasonable prudence and does not exceed long-term growth for the industry as a whole. A discount rate before tax for Acute Care Therapies of 9.5% (10.1) and for Surgical Workflows and Life Science of 10.2% (11.0), was applied when calculating the value in use of all business areas. Right-of-use assets are included in the net assets tested for impairment for each business area and future cash flows referring to lease contracts are taken into account when determining the value in use. With the assumptions described above, value in use exceeds the carrying amount for all CGUs.

Sensitivity analysis

In connection with the impairment test, sensitivity analyses have been performed regarding changes in growth rate and discount rate, which have a significant impact on the calculation of the discounted cash flows. The sensitivity analyses showed that the negative changes below would not individually generate a need for impairment in any business area:

- Growth rate after year three decreases to 1%
- Discount rate before tax increases 1 percentage point to 10.5% and 11.2%

Intangible assets

Except goodwill, there are within intangible assets also trademarks amounting to SEK 739 M (463) whose useful life has been assessed as indefinite. For these trademarks, no forseeable time limit have been applied for Getinge's expected future cash flows. The useful life for other intangible assets is three to 15 years. For strategic acquisitions, the useful life exceeds five years.

20250623150240

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 10 Tangible assets

Tangible assets, SEK M	Buildings and land[1)]	Plant and machinery	Equipment, tools, fixtures, fittings	Rental equipment	Construction in progress	Total
Acquisition cost, Jan 1, 2024	**3,689**	**2,095**	**3,212**	**560**	**654**	**10,210**
Investments	113	56	84	3	196	453
Acquisitions	1	17	19	–	–	38
Sales/disposals	-22	-61	-254	-65	-10	-411
Reclassifications	139	161	139	101	-391	150
Translation differences	221	119	129	24	38	532
Accumulated cost, Dec 31, 2024	**4,141**	**2,388**	**3,330**	**624**	**488**	**10,971**
Depreciation and write-downs, Jan 1, 2024	**-2,033**	**-1,700**	**-2,381**	**-372**	**–**	**-6,488**
Depreciation for the year	-174	-97	-263	-58	–	-591
Write-downs	0	–	-48	–	–	-48
Acquisitions	0	-3	-12	–	–	-15
Sales/disposals	18	59	244	55	–	376
Reclassifications	0	0	54	-52	–	2
Translation differences	-105	-91	-92	-17	–	-305
Accumulated depreciation and write-downs, Dec 31, 2024	**-2,295**	**-1,832**	**-2,498**	**-444**	**–**	**-7,069**
Closing carrying amount, Dec 31, 2024	**1,846**	**556**	**832**	**180**	**488**	**3,902**

1) Closing carrying amount for land amounted to SEK 180 M (170).

Tangible assets, SEK M	Buildings and land[1)]	Plant and machinery	Equipment, tools, fixtures, fittings	Rental equipment	Construction in progress	Total
Acquisition cost, Jan 1, 2023	**3,445**	**2,011**	**2,951**	**815**	**502**	**9,724**
Investments	40	37	149	1	331	558
Acquisitions	256	50	89	3	15	414
Sales/disposals	-13	-20	-200	-146	-12	-392
Reclassifications	48	53	299	-118	-162	119
Translation differences	-86	-36	-74	4	-19	-212
Accumulated cost, Dec 31, 2023	**3,689**	**2,095**	**3,212**	**560**	**654**	**10,210**
Depreciation and write-downs, Jan 1, 2023	**-1,883**	**-1,615**	**-2,203**	**-492**	**–**	**-6,192**
Depreciation for the year	-133	-91	-269	-64	–	-557
Write-downs	-26	-16	0	-1	–	-43
Acquisitions	-36	-19	-51	–	–	-105
Sales/disposals	10	19	187	79	–	295
Reclassifications	–	-8	-100	107	–	-1
Translation differences	35	28	54	-1	–	116
Accumulated depreciation and write-downs, Dec 31, 2023	**-2,033**	**-1,700**	**-2,381**	**-372**	**–**	**-6,488**
Closing carrying amount, Dec 31, 2023	**1,655**	**394**	**831**	**188**	**654**	**3,723**

1) Closing carrying amount for land amounted to SEK 170 M (174).

Accounting policies

Properties, machinery, equipment and other tangible assets are recognized at acquisition cost, with deductions for accumulated depreciation and any impairment losses. The acquisition cost includes the purchase price and expenses directly attributable to the asset to bring the asset to the site and in the working condition for its intended use. Examples of directly attributable expenses included in the acquisition cost are delivery and handling costs, installation, legal services and consultancy services. Assets provided to the company in conjunction with the acquisition of new subsidiaries are recognized at market value on the acquisition date. Depreciation is conducted straight line. The value in the balance sheet represents acquisition costs with deduction for accumulated depreciation and any impairment losses. Land is not depreciated since it is deemed to have an infinite economic life, however, the depreciation of other assets is based on the following anticipated useful lives:

Class of assets	Depreciation, number of years
Land improvements	40–50
Buildings	10–50
Machinery	5–25
Equipment	10
Production tools	5
Rental equipment	5
Cars	4
Computer equipment	3

Tangible assets comprising parts with different useful lives are treated as separate components of tangible assets. Standard maintenance and repair costs are expensed during the periods in which they arise. More extensive repair and upgrading costs are capitalized and depreciated over the item's remaining anticipated useful life. Capital gains/losses are recognized under other operating income/expenses.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 11 Leases

Accounting policies

Getinge as a lessee

The group's leases mainly comprise right-of-use assets for premises and vehicles. The leases are recognized as a right-of-use asset with a corresponding lease liability when the leased asset is available for use by the group. Short-term leases and leases for which the underlying asset is of low value are exempted. Each lease payment should be divided between amortization of the lease liability and a financial cost. The financial cost should be allocated over the lease term, so that each reporting period is charged with an amount corresponding to a fixed interest rate for the liability recognized under each period.

The groups lease liabilities are recognized at the present value of the group's fixed lease payments. Purchase options are included if it is reasonably certain that Getinge will exercise the option to acquire the underlying asset. Penalties for terminating the lease are included if the lease term reflects that the lessee will exercise an option to cancel the lease.

The group's right-of-use assets are recognized at acquisition cost, and include initial present value of the lease liability, adjusted for lease payments made at or before the commencement date and any initial direct expenses. Restoration costs are included in the asset if a corresponding provision for restoration costs exists. The right-of-use asset is depreciated on a straight-line basis over the assets useful life and the lease term, whichever is the shortest.

For leases of premises and vehicles, service components are normally a considerable portion of the contracts and are therefore separated. The service components, if these are distinguishable, are recognized as operating expenses and not included in the right of use asset and the lease liability. If a lease contract includes variable lease payments not dependent on an index or rate, or include a low value asset or has a lease term that is twelve months or less, the lease payments are recognized as operating expenses as they occur.

Getinge as a lessor

Leases in which Getinge is the lessor are defined in two categories, operating and finance, depending on the financial significance of the agreement. Operating leases are recognized as tangible assets in the category rental equipment. Revenue from operating leases is recognized evenly over the lease term.

Straight-line depreciation is applied to these assets in accordance with the undertakings and the depreciation amount is adjusted to correspond with the estimated realizable value when the undertaking expires. The estimated impairment requirement is immediately charged to profit or loss. The products estimated realizable value at the expiration of the undertaking is continuously followed up on an individual basis. Finance leases are recognized as long-term or current receivables. Payments received from finance leases are divided between interest income and depreciation of receivables.

Significant estimates and assessments

Getinge as a lessee

Measurement of lease liabilities and right-of-use assets

When entering a lease contract, judgments related to contract scope, lease term and interest rate to be used when discounting future lease payments are made which affect the measurement of the lease liability and the right-of-use asset. Assessment of contract scope includes judgments whether a leased asset is identified in the contract. When determining the lease term of a contract, judgments are also required. Getinge evaluates all agreements with the exception of vehicles, which are evaluated as a portfolio. The lease term includes the non-cancellable period. If Getinge is reasonably certain to use an option to extend the lease, or not to use an option to terminate the lease in advance, this is also considered. The contracts contain a range of different conditions. Extension and termination options are mainly related to real estate leases. Thus, all relevant facts and circumstances that create an economic incentive to include optional periods are evaluated.

The importance of the underlying asset in the operations and its location, significant leasehold improvements and level of rentals in optional periods compared to market rates are examples of factors included in the assessment. Lease terms are negotiated on an individual basis and are reassessed if an option is exercised. Judgments are also required to determine the interest rate when discounting future lease payments and whether the interest rate implicit in the lease can be readily determined and thereby used, or if Getinge's incremental borrowing rate should be used.

Getinge as a lessor

Measurement of lease liabilities and right-of-use assets

Income from equipment for rental primarily refers to capital goods utilized within the healthcare sector. The typical contract duration ranges from six months to five years. In the period, there have been no material gains or losses recognized from the sale of assets related to the rental operations. The estimated resale value of the rented products at the conclusion of the commitments is continuously monitored on an individual basis. No significant impairments have been recorded against the reported net value of rented products during the year. For further details regarding rental equipment, please refer to Note 10 Tangible assets. Interest income related to lease agreements classified as financial leases is reported within financial items.

202506231502S

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Right-of-use assets, SEK M	Building	Cars & other vehicles	Machinery & equipment	Total
Acquisition cost, Jan 1, 2024	**1,930**	**710**	**23**	**2,663**
Entered into new leasing contracts	369	359	3	731
End of lease contracts	-213	-206	-4	-423
Reassessment/modifications	77	–	1	78
Translation differences	91	40	1	131
Accumulated cost, Dec 31, 2024	**2,253**	**903**	**24**	**3,181**
Depreciation and write-downs, Jan 1, 2024	**-816**	**-347**	**-15**	**-1,177**
Depreciation for the year	-303	-227	-4	-534
End of lease contracts	165	206	4	375
Translation differences	-30	-19	-0	-49
Accumulated depreciation and write-downs, Dec 31, 2024	**-984**	**-386**	**-15**	**-1,385**
Closing carrying amount, Dec 31, 2024	**1,270**	**517**	**9**	**1,795**

Right-of-use assets, SEK M	Building	Cars & other vehicles	Machinery & equipment	Total
Acquisition cost, Jan 1, 2023	**1,677**	**653**	**25**	**2,355**
Entered into new leasing contracts	449	246	2	697
End of lease contracts	-182	-168	-4	-354
Reassessment/modifications	41	–	1	41
Translation differences	-54	-21	0	-75
Accumulated cost, Dec 31, 2023	**1,930**	**710**	**23**	**2,663**
Depreciation and write-downs, Jan 1, 2023	**-670**	**-335**	**-14**	**-1,019**
Depreciation for the year	-316	-190	-5	-512
End of lease contracts	148	168	4	320
Translation differences	23	11	-0	33
Accumulated depreciation and write-downs, Dec 31, 2023	**-816**	**-347**	**-15**	**-1,177**
Closing carrying amount, Dec 31, 2023	**1,114**	**363**	**9**	**1,486**

The leasing period for buildings usually amounts to between 3 to 5 years, while for cars and other vehicles it is between 3 to 4 years. Leasing payments are discounted with the group's marginal borrowing rate. The group's weighted average marginal borrowing rate was 3.9% (4.1).

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Recognized cost for lease contracts, SEK M	2024	2023
Depreciation on right-of-use assets	-534	-512
Interest expenses on lease liabilities	-66	-45
Cost related to short-term leases	-2	-1
Cost related to low-value leases	-19	-17
Total	**-621**	**-575**

Payments for short-term leasing agreements regarding equipment and vehicles and all leasing agreements of low-value are expensed in the income statement.

Short-term leasing agreements are agreements with a leasing period of less than 12 months. Low-value contracts include IT equipment and office equipment.

Leasing liabilities, SEK M	2024	2023
Short-term	491	422
Long-term	1,309	1,057
Total	**1,800**	**1,479**

The total cash-outflow for leasing contracts amounted to SEK -607 M (-573).
Information about Getinge's leasing liabilities undiscounted cash out-flows, see Note 19 Financial instruments.

Getinge as a lessor

Operating leases, SEK M	2024	2023
Leasing income recognized during the year	64	62
Due within 1 year	49	41
Due within 2 to 5 years	68	57
Due in more than 5 years	31	22
Total	**212**	**183**

Financial leases, SEK M	2024	2023
Leasing income recognized during the year	9	9
Due within 1 year	8	10
Due within 2 to 5 years	21	33
Due in more than 5 years	9	19
Total	**48**	**71**

NOTE 12 Inventories

Accounting policies
Inventories are measured at the lower of cost and production value, according to the first in/first out (FIFO) principle, and net realizable value. The carrying amount of finished products includes raw materials, direct labor, other direct costs and production-related expenses including depreciation.

Significant estimates and assessments
Assessment of obsolescence in inventories is conducted on an ongoing basis during the year. The value of inventories is adjusted for the estimated decrease in value for products no longer sold, surplus inventories, items under shipping restrictions, physical damage, lead times for inventories, and handling and sales overheads.

Inventories, SEK M	2024	2023
Raw materials	2,585	2,626
Work in progress	879	981
Finished products	3,126	2,809
Total	**6,590**	**6,416**

Of the group's inventories, SEK 6,382 M (6,243) is measured at cost and SEK 208 M (174) at net realizable value. The write-down during the year amounted to SEK 913 M (428) and reversed amounts from prior years amounted to SEK 221 M (198) for the group. The amounts are included in cost of goods sold in the income statement, with the exception of a write-down amounting to SEK 150 M, which is included in restructuring cost.

20250623150026

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 13 Accounts receivable

Accounting policies

Accounts receivable belong to the category of financial assets that are measured at amortized cost since the purpose of the holding is to collect contractual cash flows. They are included in current assets with the exception of items that fall due more than 12 months after the end of the reporting period, which are classified as non-current assets. After the acquisition date, they are recognized at amortized cost using the effective interest method. The Group assesses the future expected credit losses related to assets measured at amortized cost and recognizes a reserve for such credit losses ("loss allowance") on each reporting date. For accounts receivable, the Group applies the simplified approach for loss allowance, meaning that the reserve will correspond to the expected loss for the full lifetime of the receivable. Expected credit losses on accounts receivable are recognized under the item selling expenses in profit or loss. More information on the measurement of accounts receivable and credit losses can be found in Note 13 Financial instruments.

SEK M	2024	2023
Accounts receivable before provisions	6,556	5,957
Provision for doubtful receivables	-209	-218
Total	**6,348**	**5,739**

Accounts receivable net, after provision for doubtful receivables, theoretically constitutes maximum exposure for the calculated risk of losses. Accordingly, the carrying amount of accounts receivable represents the fair value. It is the group's opinion that there is no significant concentration of accounts receivable to any single client. Letters of credit or the equivalent normally cover sales to countries outside the OECD. Confirmed credit losses in relation to net sales amounted to 0.1% (0.0) for the fiscal year 2024.

The provision for doubtful receivables is based on historical credit losses and taking into consideration current and forward-looking information about customers' payment capacity.

Maturity analysis of accounts receivable before provision for doubtful receivables, SEK M	2024	2023
Not fallen due	4,961	4,446
Fallen due 1–5 days	232	263
Fallen due 6–30 days	415	413
Fallen due 31–60 days	346	281
Fallen due 61–90 days	119	128
Fallen due, more than 90 days	483	427
Total	**6,556**	**5,957**

At December 31, 2024, the group's provisions for doubtful receivables totaled SEK 209 M (218).

Maturity analysis of provision for doubtful receivables, SEK M	2024	2023
Not fallen due	-31	-24
Fallen due 1–5 days	-1	-1
Fallen due 6–30 days	-1	-2
Fallen due 31–60 days	-1	-12
Fallen due 61–90 days	-2	-9
Fallen due, more than 90 days	-172	-171
Total	**-209**	**-218**

Recognized amounts, by currency, for the group's accounts receivables, SEK M	2024	2023
USD	2,523	2,178
EUR	1,845	1,753
JPY	384	357
GBP	227	199
CNY	147	192
INR	136	127
CAD	133	122
SEK	125	111
AUD	97	93
HKD	85	89
Other currencies	854	736
Total	**6,556**	**5,957**

Changes in provision for doubtful receivables, SEK M	2024	2023
Opening balance	**-218**	**-256**
Acquisitions	-2	-5
Provision for expected losses	-33	-9
Receivables written off during the year that cannot be recovered	24	15
Recovered doubtful receivables	29	30
Translation differences	-9	7
Closing balance	**-209**	**-218**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 14 Contract assets and liabilities

Contract assets

A contract asset represents accrued income in projects where performance conditions are met over time. Performance conditions fulfilled over time may occur in the case of sale of service and installation as well as longer projects. Contract assets are reclassified as accounts receivable when invoicing. If, in a specific project, advance payments have been received from the customer, the payment reduces the value of the contract asset in accordance with IFRS 15. A contractual asset can also represent the right to compensation for goods and services supplied that have not yet been invoiced.

Contract liabilities

A contractual liability is recognized where the group has received compensation from the customer but has not fulfilled its contractual obligations regarding the delivery of goods and services. At Getinge, contractual liabilities typically refer to prepaid revenues for service contracts and advances related to projects. If advances have been obtained for a specific project, this has reduced the value of the contract liability in accordance with IFRS15. Contract liabilities in the form of deferred income and advances from customers in the beginning of the year are essentially recognized in income during the financial year.

Contract assets, SEK M	2024	2023
Service	138	112
Projects	741	442
Other	48	72
Total	**926**	**625**

Contract liabilities, SEK M	2024	2023
Advances from customers	1,243	1,380
Service	810	810
Other	410	262
Total	**2,464**	**2,453**

NOTE 15 Other provisions

Accounting policies

Provisions are recognized when the group has a legal or informal obligation as a result of past events and it is probable that payment will be required to fulfill the commitment and if a reliable estimation can be made of the amount to be paid. Restructuring measures, guarantee commitments and similar items are recognized as provisions in the balance sheet. Provisions are reviewed at the end of each accounting period.

Significant estimates and assessments

Disputes and claims for damages

Provisions for disputes and claims for damages represent management's best estimate of the future cash flow required to settle the obligations. The disputes primarily relate to contractual commitments in contracts with customers and suppliers and damages related to product liability. Management's assessment is that the need for a provision or contingent liability depends on the legal processes in the country in question and the course of the proceedings. Comments from external and internal advisors are taken into consideration, as is experience from similar cases. The results of complicated disputes and claims for damages may nevertheless be difficult to predict and disputes could be both time-consuming and costly (see Note 25 Pledge assets and contingent liabilities). Provision for disputes and claims for damages are included under the item other.

	2024	2023
Provision at beginning of year	1,000	1,000
Provisions made during the year	482	0
Provisions used during the year	-1,000	0
Provisions reversed during the year	0	0
Translation differences	0	0
Provision at end of year	**482**	**1,000**
Of which, current	482	1,000
Of which, non-current	0	0

Provision under the item other in 2024 refer to ongoing government investigations regarding anti-competitive practices relating to the sale of medical devices between 2004 and 2017, mainly to public hospitals. Getinge has previously entered into Settlement Agreements with the Brazilian Federal Prosecutor's Office (Ministério Público Federal) and the competition authority, the Administrative Council for Economic Defense (CADE). The negotiations with the federal agency for internal control, public transparency and counter-corruption, Comptroller General of the Union (CGU), are still pending and in Q3 2024, Getinge made a provision of SEK 482 M related to these negotiations.

In addition to the investigations with CGU, Getinge has previously communicated that settlement agreements have been reached with the Brazilian Federal Prosecutor's Office (Ministério Público Federal) in 2018 and the competition authority, Administrative Council for Economic Defense (CADE) in 2019, both related to anti-competitive practices relating to the sale of medical devices. It cannot be ruled out that any further agreements with authorities may have a material impact on the company's financial earnings and position, but it is not currently possible to estimate the amount or date. Getinge has a zero tolerance policy when it comes to contraventions of these regulations.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Note 15 Other provisions cont.

	Other provision				
2024, SEK M	Guarantee reserve	Personnel	Other	Total Other provisions	Restructuring reserves
Opening balance	**368**	**204**	**769**	**1,341**	**103**
Provisions	536[1]	50	569	1,155	300
Used amount	-211	-55	-132	-399	-186
Unutilized funds restored	-32	-5	-36	-73	-29
Translation differences	25	7	-9	23	8
Closing balance	**686**	**201**	**1,161**	**2,048**	**196**
Of which:					
Short-term				1,537	177
Long-term				510	19
Closing balance				**2,048**	**196**

1) Includes provision for field actions for Cardiosave amounting to SEK 297 M, for more information se page 50, risk section.

Expected timing of outflow 2024, SEK M		
Within 1 year	1,537	177
Within 3 years	465	19
Within 5 years	14	–
> 5 years	31	–
Closing balance	**2,048**	**196**

2023, SEK M	Guarantee reserve	Personnel	Other	Total Other provisions	Restructuring reserves
Opening balance	**395**	**184**	**2,436**	**3,016**	**229**
Acquisitions	–	–	0	0	–
Provisions	179	87	251	517	37
Used amount	-179	-65	-1,894	-2,138	-137
Unutilized funds restored	-19	-4	-32	-55	-28
Reclassification	–	5	-5	–	–
Translation differences	-8	-3	13	2	1
Closing balance	**368**	**204**	**769**	**1,341**	**103**
Of which:					
Short-term				960	96
Long-term				381	6
Closing balance				**1,341**	**103**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 16 Prepaid and accrued items

Prepaid expenses and accrued income, SEK M	2024	2023
Insurance expenses	50	59
Commissions	43	57
IT expenses	191	148
Other	171	121
Total	**455**	**386**

Accrued expenses and deferred income,SEK M	2024	2023
Salaries	1,965	1,594
Social security expenses	476	418
Commissions	180	142
Interest expenses	49	70
Consultancy fees	69	69
Office related expenses	15	13
Logistics, warehousing and freight expenses	72	71
Other	696	542
Total	**3,522**	**2,919**

NOTE 17 Supplementary disclosure to equity

Accounting policies

Dividend

Decision on dividends are made at the Annual General Meeting, or, when applicable, during an Extraordinary General Meeting. After the decision is made, equity is reduced and the dividend is reported as a liability to shareholders in the balance sheet until payment.

Share capital

Class of shares	A	B	Total
Quotient value per share, SEK	0.50	0.50	
Number of shares outstanding:			
December 31, 2023	18,217,200	254,152,373	**272,369,573**
December 31, 2024	18,217,200	254,152,373	**272,369,573**
Shares' voting rights in %	**41.8**	**58.2**	**100.0**

In accordance with the Articles of Association, the company's share capital amounts to not less than SEK 75 M and not more than SEK 300 M. Within these limits, the share capital can be raised or lowered without requiring an amendment to the Articles of Association. The maximum number of shares is 600 million. One Class A share carries ten votes and one Class B share carries one vote. Both classes of shares have the same quotient value, which is SEK 0.50. At December 31, 2024, the company's share capital totaled SEK 136 M (136).

Dividend

On April 29, 2024, shareholders were paid a dividend of SEK 4.40 per share (SEK 1,198 M in total) relating to 2023.

The Board and the CEO propose to the Annual General Meeting that a dividend of SEK 4.60 per share, relating to 2024 (SEK 1,243 M in total), to be paid to shareholders. The proposed record date is April 24, 2025. Euroclear is expected to distribute the dividend to shareholders on April 29, 2025.

Getinge's dividend policy is to pay dividends of 30–50% of net profit to shareholders. The Board's dividend proposal for 2024 is a deviation from the policy of paying dividends of 30–50% of net profit. The proposal is based on the favorable cash flow generated by the operations.

Earnings per share

Earnings per share, before and after dilution, amounted to SEK 6.01 (8.86). The calculation of earnings per share relating to the Parent Company's shareholders is based on the following information:

Earnings (numerator), SEK M	2024	2023
Earnings relating to the Parent Company's shareholders, which form the basis for calculation of earnings per share	1,638	2,412

Number of shares (denominator)	2024	2023
Weighted average number of outstanding ordinary shares for calculation of earnings per share	272,369,573	272,369,573

202506231502S

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 18 Financial risk management

Financial risks

Through its global operations, Getinge is exposed to a number of financial risks in the form of currency risks, interest-rate risks, financing risks, and credit and counterparty risks. Risk management is regulated by the finance policy adopted by the Board with an associated Treasury directive decided by the Getinge Executive Team and revised yearly. The ultimate responsibility for managing the Group's financial risks and developing methods and principles of financial risk management lies with the Getinge Executive Team and the finance function. Getinge's financial activities are centralized to benefit from economies of scale, to ensure good internal control and to facilitate monitoring of risk.

Currency risks


Currency risks comprise exchange-rate fluctuations, which have an impact on the Group's earnings and equity. Currency exposure occurs in connection with payments in foreign currency (transaction exposure) and when translating foreign subsidiaries' balance sheets and income statements to the presentation currency Swedish kronor (translation exposure).

Transaction exposure

Policy
The Group's policy states that in the first instance currency exposure is to be reduced by matching inflows and outflows in foreign currency to endeavor to achieve a "natural hedge" as far as possible. In addition, Getinge's Treasury Directive stipulates that the President and CEO has the mandate to decide to hedge all of the annual forecasted net flow in a foreign currency and half of the flow for the next 13–24 months. Hedging may take place using currency forwards, currency swaps and currency options.

The Group's payment flows in foreign currencies are mainly generated by export sales, with the largest flows in USD, EUR, CNY and JPY. The market value of financial currency derivative instruments that meet the cash flow hedging requirements amounted to SEK 0 M (3) on December 31, 2024.

Transaction exposure in selected foreign currencies, 2024[1]



1) In values: 1,236 SEK M in currency CNY; -4,057 SEK M in currency EUR; 537 SEK M in currency JPY; 2,754 SEK M in currency USD

Translation exposure

Policy
When translating net assets of foreign subsidiaries into Swedish kronor, a translation difference occurs, which can affect consolidated other comprehensive income.
When translating the results of foreign subsidiaries into Swedish kronor, a translation difference also arises, which affects the Group's earnings when exchange rates fluctuate. Getinge's policy is not to hedge this risk.

Although Getinge does not have the specifically stated goal of hedging translation exposure, the Group's borrowing in foreign currency takes place in currencies that limit translation exposure through what is known as "natural hedging".


Sensitivity analysis of currency exposure

At a 5% rate movement in all exposure currencies, the impact of revaluation effects on equity is approximately SEK 1,513 M (1,355). The extent to which operating profit is impacted by exchange-rate fluctuations is detailed in the following table, based on the exchange rates specified. The effect of exchange-rate movements on operating profit below is calculated using volumes and operating profit in foreign currency for 2024.

Currency:	Net volume in 2024, millions (local currency)	Impact in SEK M of 5% rate movement
CNY: 1.50	1,042	+/-78
EUR: 11.47	222	+/-127
JPY: 0.07	9,166	+/-32
USD: 11.00	272	+/-149


Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Transaction exposure in selected foreign currencies[1]



1) In values: 1,260 SEK M (1,074) in currency CNY; 9,012 SEK M (9,058) in currency EUR; 709 SEK M (699) in currency GBP; -7,621 SEK M (-6,553) in currency SEK; 26,781 SEK M (23,414) in currency USD; 3,069 SEK M (3,210) in other currencies.

Interest-bearing debt per currency[1,2]




1) Excludes pension provisions and lease liabilities.
2) In values: -143 SEK M (-277) in currency EUR; -5,253 SEK M (-4,462) in currency SEK; -3,483 SEK M (-1,737) in currency USD; -48 SEK M (-101) in other currencies.

Capital structure

Policy:
Getinge monitors its leverage ratio (net debt in relation to adjusted EBITDA). The finance policy stipulates that the leverage ratio is to be kept within a multiple of 2.5x. However, Getinge's leverage ratio may temporarily exceed this level from time to time in order to finance acquisitions or on the basis of short-term effects. Getinge's ambition is to meet credit ratios equivalent to an "investment grade rating".

Net debt/adjusted EBITDA[1]



1) In values: Year 2020, 1.0; Year 2021, 0.5; Year 2022, 0.4; Year 2023, 1.4; Year 2024, 1.6

Interest-rate risk

Interest-rate risks are the changes in market interest rates that affect the Group's net interest.

Policy
How quickly interest-rate changes impact net interest depends primarily on the fixed-interest term of the debt portfolio. To mitigate the effect of potential increases in market rates, the Group's finance policy stipulates defined frameworks for decisions on the distribution of debt at fixed and variable interest rates.

Of the total loan portfolio of SEK 8,927 M, SEK 3,133 M was raised with fixed interest or hedged using interest-rate derivative instruments, and all other loans with variable interest. The market value of financial interest-rate derivative instruments that meet the cash flow hedging requirements amounted to SEK 15 M (0) on December 31, 2024. The average interest expense for the Group's liabilities to credit institutions amounted to approximately 5.4% (5.2). If the average interest rate for currencies represented in the Group's loan portfolio at the end of the year changed by 1 percentage point, this would affect profits by SEK +/-58 M on an annual basis.

The financial position remains solid, although the share of net interest-bearing debt in relation to EBITDA has increased after the acquisition of Paragonix Technologies, Inc. The Group's leverage ratio (net debt in relation to adjusted EBITDA) was 1.6 (1.4) on December 31, 2024.

According to the terms of the Group's main credit facilities, the net debt/equity ratio (net debt in relation to equity) must be below a certain level. The terms also state that the net debt/equity ratio is to be reported to the counterparty every quarter. At year-end, the net debt/equity ratio was well below this level.

20250623150029


Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Financing and liquidity risk

Financing and liquidity risk is defined as the risk of the cost being higher and financing opportunities limited as the loan is renegotiated. This also includes not being able to fulfill payment commitments as a result of insufficient liquidity or difficulties in securing funding. Financing risk can arise through disruptions in the financial markets, for example, decisions on new regulations or the implementation of recently enacted laws.

Policy
To reduce financing risks, the Group strives to diversify its sources of financing and maturities according to the Group's finance policy.
Group Treasury is responsible for proactively managing and controlling the liquidity risk and for ensuring sufficient liquidity reserves and that committed back-up facilities are available.

Maturity profile, interest-bearing debt, SEK M[1,2]



1) Excludes pension provisions and lease liabilities.
2) In values: Year 2025, -1,956 SEK M; Year 2026, -1,619 SEK M; Year 2027, -2,415 SEK M; Year 2028, -1,621 SEK M; Year 2029, -1,316 SEK M

The Group's sources of financing primarily comprise equity, cash flow from operating activities and borrowing. Getinge has several borrowing programs, including both confirmed bank overdraft facilities and capital market financing programs. These provide a high level of contingency for temporary fluctuations in the Group's short-term liquidity requirements, at the same time as they ensure long-term financing. In addition to the capital market programs, Getinge also has a back-up revolving credit facility of EUR 470 M with a syndicate of seven banks. This loan agreement falls due in 2029 with an extension option of one year. In 2024, the Group renewed the existing MTN program from 2012 to issue bonds in the Swedish capital market. At year-end 2024, SEK 4,974 M was outstanding under this program. For short-term financing requirements, a Swedish program for commercial paper is available. In addition to these credit facilities, the Group has short-term uncommitted credit lines.

At December 31, 2024, the total granted, unutilized overdraft facilities were SEK 468 M (422). In addition, there were unutilized short-term credit facilities of SEK 441 M (476) and committed, unutilized facilities for medium and long-term credit of SEK 5,389 M (5,215), which may be utilized without qualification.

The Group's existing credit facilities are currently deemed to be sufficient. As of December 31, 2024, the Group's borrowings were in line with the requirements under the finance policy pertaining to diversification of lenders.

Credit and counterparty risks

The Group's financial transactions cause credit risks with regard to financial counterparties. Financial credit risks or counterparty risks constitute the risk of losses if the counterparties do not fully meet their commitments.

Policy
The management of the Group's financial credit risk is regulated in the finance policy through accepting only credit-worthy counterparties and fixed limits, which are monitored continuously.

As of December 31, 2024, the total counterparty exposure in derivative instruments was SEK 15 M (8). The Group has signed standard netting agreements (ISDA) with counterparties for currency transactions and interest-rate swaps. These agreements permit relevant financial assets and liabilities to be offset. Transactions take place within established limits and exposures are continuously monitored.

Commercial credit risks are limited by a diversified customer base with a high credit rating. The Group's customers are found primarily in the public sector, which means that its credit risk is generally very low. The credit risk for Getinge's customers in the private sector is also deemed to be low. When deemed necessary, credit risk is managed using letters of credit or export credit-related guarantees. The provision for doubtful receivables at year-end totaled SEK 209 M (218).

The Group's accounts receivable are presented in Note 13, which shows that the share of past due accounts receivable on December 31, 2024 amounted to SEK 1,595 M in relation to the total volume of accounts receivable, which amounted to SEK 6,556 M. For 41% of past due accounts receivable, payment is past due by a maximum of one month.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 19 Financial instruments

Accounting policies

Financial instruments – initial recognition

Financial assets and financial liabilities are recognized when the Group becomes party to the contractual terms of the instrument. Purchases and sales of financial assets are recognized on the transaction date, which is the date on which the Group undertakes to buy or sell the asset. A financial asset is derecognized from the balance sheet when the contractual rights to the asset are realized, extinguished or the company loses control over them. A financial liability is derecognized from the balance sheet when the contractual obligation has been fulfilled or in some other manner extinguished. Financial instruments are initially measured at fair value plus transaction costs that are directly attributable to the acquisition or issue of a financial asset or financial liability. The Group classifies its financial assets and liabilities depending on the purpose for which the financial asset or liability was acquired.

Financial assets measured at amortized cost

Assets held for the purpose of collecting the contractual cash flows that are solely payments of principal and interest on the principal amount are measured at amortized cost. Assets in this category are initially measured at fair value, including transaction costs. After the acquisition date, they are recognized at amortized cost using the effective interest method. The carrying amount of the assets is adjusted for any impairment for expected credit losses. Interest income from these financial assets is recognized using the effective interest method and is included in financial income. Assets in this category comprise long-term financial receivables, accounts receivable and other current receivables. They are included in current assets with the exception of items that fall due more than 12 months after the end of the reporting period, which are classified as non-current assets.

Impairment of financial assets measured at amortized cost

The Group assesses the future expected credit losses related to assets measured at amortized cost and recognizes a reserve for such credit losses ("loss allowance") on each reporting date. For accounts receivable, the Group applies the simplified approach for loss allowance, meaning that the reserve will correspond to the expected loss for the full lifetime of the receivable. Expected credit losses on accounts receivable are recognized under the item selling expenses in profit or loss.

Financial liabilities measured at amortized cost

The Groups other financial liabilities are initially measured at fair value, net after transaction costs. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Long-term liabilities have an expected term longer than one year while current liabilities have a term of less than 12 months. This category includes liabilities to credit institutions, issued bonds, accounts payable and other current liabilities.

Cash and cash equivalents

The major portion of cash and cash equivalents comprises cash funds held at financial institutions, and only a minor portion comprises current liquid investments with a term from the acquisition date of less than three months, which are exposed to only an insignificant risk of value fluctuations. Cash and cash equivalents are recognized at nominal amounts, which are equivalent to fair value.

Financial assets measured at fair value

Financial assets in this category comprise derivatives. They are included in current assets if they are expected to be settled within 12 months of the end of the reporting period, otherwise, they are classified as non-current assets. All derivatives are measured at fair value in the balance sheet. Changes in fair value are recognized as a component of other comprehensive income insofar as they are part of a hedging relationship that qualifies as hedge accounting. They are reversed to profit or loss when the hedged transaction occurs. Derivatives that do not meet the requirements for hedge accounting are measured at fair value through profit or loss.

Hedge accounting

For derivative instruments or other financial instruments that meet hedge accounting requirements under the cash flow hedging method or hedging of net investments in foreign operations method, the effective component of the value change is recognized in other comprehensive income. Accumulated value changes from cash flow hedges are reversed from equity to profit or loss at the same time as the hedged item impacts profit or loss. Interest-bearing liabilities in foreign currencies are defined as hedges to handle translation exposure related to net investments in foreign operations. Accumulated value changes from the hedging of net investments in foreign operations are reversed from equity to profit or loss when the foreign operation is divested in full or in part.

Fair value

Derivative instruments

The fair value of derivative instruments was calculated using the most reliable market prices available. This requires all instruments that are traded in an effective market, such as currency forward contracts, to be measured at market-to-market at current prices. In terms of instruments for which no reliable prices were available, such as interest-rate swaps, cash flows were discounted using deposit and interest-rate swaps for the currency in question. Translation to Swedish kronor is conducted at the closing day rate.

Borrowing and other financial instruments

Loans raised are measured at amortized cost using the effective interest method. Contingent considerations are measured at fair value at Level 3 of the fair value hierarchy. For other financial assets and liabilities, fair value is assessed as corresponding to the carrying amount due to the short expected maturity in time.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Financial derivatives

Getinge uses financial derivatives to manage interest and currency exposure arising in its business. The effectiveness of a hedge is assessed when the hedging relationship is entered into. The hedged item and the hedging instrument are continuously assessed to ensure that the relationship meets the hedge accounting requirements. When the Group hedges purchases and sales in foreign currency, a hedging relationship is entered into whereby the critical terms of the hedging instrument match the terms of the hedged item. In this way, a qualitative assessment of the effectiveness of the hedging relationship is performed and the relationship is expected to be effective for the period for which it is valid.

The Group also enters into interest-rate swap agreements that have the same critical terms as the hedged item. Critical terms may be benchmark interest rates, reset dates, currency, maturities and nominal amount. The Group does not hedge 100% of the principal and thus identifies only a portion of the principal outstanding that corresponds to the nominal amount of the swap. The Group applies hedge accounting.

All derivatives are classified under level 2 of the value hierarchy. Fair value measurements for currency forwards are based on published forward rates in an active market. The measurement of interest-rate swaps is based on forward rates as expressed in market yield curves.

Contingent considerations

Getinge signed agreements on contingent considerations in connection with acquisitions of business and subsidiaries. The liabilities for these additional purchase prices are measured at fair value through profit or loss. In most cases, the additional purchase prices are contingent on securing government approval for the acquired product development projects and contingent on the earnings performance of the acquired businesses.

The future cash flows are discounted if the planned disbursement date exceeds 12 months. Assessments about future cash flows linked to the contingent considerations are regularly reviewed by company management and are reported at fair value. The discount effect is recognized on an ongoing basis in profit or loss under financial items.

Contingent consideration, SEK M	2024	2023
Opening balance	**498**	**571**
Business combinations	3,112	14
Dissolution of provision	-13	-49
Fair value adjustments recognized in profit or loss	11	–
Payments	-512	-40
Discount effect	32	18
Translation differences	152	-17
Closing balance	**3,280**	**498**
Of which:		
Short-term	1,523	445
Long-term	1,756	53
Closing balance	**3,280**	**498**

Contingent considerations are included in other liabilities in the balance sheet.

Regarding the acquisition of Aseptic Solutions LLC, a maximum of approximately SEK 1,507 M (USD 137 M) may be paid in 2025–2030 if contracted results-based milestones are achieved in 2025–2029, and in relation to this, a liability of SEK 396 M (USD 36 M) was recognized in the balance sheet.

Regarding the acquisition of Paragonix Technologies, Inc, approximately SEK 118 M (USD 11 M) may be paid in 2025–2026 if certain regulatory clearance is obtained in 2025. A liability of SEK 100 M (USD 9 M) was recognized in relation to this. In addition, certain results-based milestones have been agreed for which payments may be made in 2025–2026, and for which a liability of SEK 2,571 M (USD 234 M) was recognized.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Cash flow for financial liabilities

The table below shows the Group's financial liabilities and derivative instruments that comprise financial liabilities, subdivided into the periods remaining on the closing date until the agreed date of maturity. The amounts stated in the table comprise contractual, undiscounted cash flows.

At December 31, 2024, SEK M	< 1 year	1–2 Years	2–5 Years	> 5 years
Bank loans and bond loans (including interest)	-2,321	-1,941	-5,709	–
Leasing liabilities	-546	-433	-597	-476
Accounts payable	-2,398	–	–	–
Total	**-5,265**	**-2,374**	**-6,306**	**-476**

Outstanding derivative instruments

	2024		2023	
SEK M	Nominal amount	Fair value	Nominal amount	Fair value
Interest-rate derivatives	750	15	–	–
Currency derivatives	2,408	-11	2,647	-24
Total	**3,158**	**4**	**2,647**	**-24**

	2024		2023	
SEK M	Asset	Liability	Asset	Liability
Interest-rate derivatives	15	–	–	–
Currency derivatives	3	13	36	60
Total	**17**	**13**	**36**	**60**
Of which:				
Short-term	3	13	36	60
Long-term	15	–	–	–

Paid and accrued interest on interest-rate derivatives is continuously recognized in profit or loss. The fair value of derivative instruments is established using valuation techniques based on observable market information.

Financial instruments by category

	Assets at amortized cost		Assets at fair value through profit or loss		Derivatives used for hedging purposes		Total	
Financial assets, SEK M	2024	2023	2024	2023	2024	2023	2024	2023
Derivative instruments	–	–	3	33	15	3	17	36
Accounts receivable, financial receivables and other receivables	7,186	6,381	–	–	–	–	7,186	6,381
Cash and cash equivalents	2,961	2,728	–	–	–	–	2,961	2,728
Total	**10,147**	**9,109**	**3**	**33**	**15**	**3**	**10,165**	**9,145**

	Liabilities at amortized cost		Liabilities at fair value through profit or loss		Derivatives used for hedging purposes		Total	
Financial liabilities, SEK M	2024	2023	2024	2023	2024	2023	2024	2023
Borrowing	8,927	6,597	–	–	–	–	8,927	6,597
Derivative instruments	–	–	13	60	–	–	13	60
Leasing liabilities	1,800	1,479	–	–	–	–	1,800	1,479
Contingent considerations	–	–	3,280	498	–	–	3,280	498
Accounts payable and other financial liabilities	3,055	2,882	–	–	–	–	3,055	2,882
Total	**13,783**	**10,958**	**3,293**	**558**	**–**	**–**	**17,076**	**11,516**

20250623150031

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Distribution of currency for outstanding derivative instruments in nominal amounts, SEK M

The table below shows the Group's financial liabilities distributed over the remaining maturity. The amounts shown in the table are the contractual, undiscounted cash flows.

	2024	2023
AUD	–	17
CHF	–	3
CNY	301	603
CZK	–	15
DKK	58	2
EUR	1,190	1,181
GBP	69	32
HKD	–	230
JPY	0	57
NOK	20	10
PLN	–	56
SEK	750	–
SGD	41	–
TRY	0	–
USD	728	427
ZAR	–	14
Total	**3,158**	**2,647**

Maturity structure for outstanding derivative instruments in 2024, SEK M

	2025	2026	2027	2028	2029	Total
Interest-rate derivatives	–	–	–	–	750	750
Currency derivatives	2,408	–	–	–	–	2,408
Total	**2,408**	**–**	**–**	**–**	**750**	**3,158**

Maturity structure for outstanding derivative instruments in 2023, SEK M

	2024	2025	2026	2027	2028	Total
Interest-rate derivatives	–	–	–	–	–	–
Currency derivatives	2,647	–	–	–	–	2,647
Total	**2,647**	**–**	**–**	**–**	**–**	**2,647**

Reserve of cash flow hedges

The table below shows the composition of the Group's reserve of cash flow hedges and the change in each component during the year.

	Currency derivatives	Interest-rate derivatives	Total
Opening balance 2023	**-21**	**–**	**-21**
Change in fair value of hedging instruments recognized in other comprehensive income	3	–	3
Reclassification to profit or loss	27	–	27
Deferred tax	-6	–	-6
Closing balance 2023	**3**	**–**	**3**
Opening balance 2024	**3**	**–**	**3**
Change in fair value of hedging instruments recognized in other comprehensive income	–	15	15
Reclassification to profit or loss	-3	0	-3
Deferred tax	1	-3	-2
Closing balance 2024	**0**	**12**	**12**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Derivative instruments – currency derivatives

Currency derivatives, in the three largest currency pairs, impact the Group's financial position and earnings as follows:

Derivative instruments – currency derivatives CNY/SEK, SEK M	2024	2023
Recognized amount (asset/liability(-))	1	-15
Nominal amount CNY M	200	427
Maturity	Jan 2025	Jan 2024–Mar 2024
Hedge ratio	1:1	1:1
Change in discounted forward rates for outstanding hedging instruments since January 1	1	-15
Change in value of hedged item to determine effectiveness	-1	15
Weighted average of forward rates at year-end (including forward points)	1.50	1.45

Derivative instruments – currency derivatives EUR/SEK, SEK M	2024	2023
Recognized amount (asset/liability(-))	-1	-15
Nominal amount EUR M	104	106
Maturity	Jan 2025–Apr 2025	Jan 2024–Jun 2024
Hedge ratio	1:1	1:1
Change in discounted forward rates for outstanding hedging instruments since January 1	-1	-12
Change in value of hedged item to determine effectiveness	1	12
Weighted average of forward rates at year-end (including forward points)	11.46	11.23

Derivative instruments – currency derivatives USD/SEK, SEK M	2024	2022
Recognized amount (asset/liability(-))	-9	10
Nominal amount USD M	66	43
Maturity	Jan 2025–Apr 2025	Jan 2024–Jun 2024
Hedge ratio	1:1	1:1
Change in discounted forward rates for outstanding hedging instruments since January 1	-9	9
Change in value of hedged item to determine effectiveness	9	-9
Weighted average of forward rates at year-end (including forward points)	10.81	10.24

Derivative instruments – interest-rate derivatives

Interest-rate derivatives impact the Group's financial position and earnings as follows:

SEK M	2024	2023
Recognized amount (asset/liability(-))	15	-
Nominal amount	750	-
Maturity	Sep 2029	-
Hedge ratio	1:1	-
Change in value of outstanding derivative instruments since January 1	15	-
Change in value of hedged item to determine effectiveness	-15	-
Weighted average of forward rates at year-end (including forward points)	2.00%	-

20250623150032

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 20 Net interest-bearing debt

SEK M	2024	Change	2023
Interest-bearing current liabilities	1,956	-738	2,694
Interest-bearing long-term liabilities	6,971	3,068	3,903
Provision for pension and similar obligations, interest-bearing	2,700	36	2,664
Leasing liabilities	1,800	321	1,479
Less cash and cash equivalents	-2,961	-233	-2,728
Total	**10,467**	**2,455**	**8,012**

Net interest-bearing debt 2024, SEK M	Cash and cash equivalents	Leasing liabilities	Interest-bearing liabilities	Pension provision, interest-bearing	Total
Opening balance	**-2,728**	**1,479**	**6,597**	**2,664**	**8,012**
Cash flow affecting net debt					
- *Raising of loans*	–	–	7,736	–	7,736
- *Amortization*	–	-506	-5,513	-16	-6,035
- *Changes in cash*	-532	–	–	–	-532
Non cash flow changes					
- *Changes in lease agreements*	–	745	–	–	745
- *Actuarial gains/losses pension plans*	–	–	–	-31	-31
- *Translation differences*	-299	83	-107	-83	-572
Closing balance	**-2,961**	**1,800**	**8,927**	**2,700**	**10,467**

Net interest-bearing debt 2023, SEK M	Cash and cash equivalents	Leasing liabilities	Interest-bearing liabilities	Pension provision, interest-bearing	Total
Opening balance	**-5,676**	**1,314**	**4,510**	**2,454**	**2,602**
Cash flow affecting net debt					
- *Raising of loans*	–	–	3,133	–	3,133
- *Amortization*	–	-476	-909	-28	-1,413
- *Changes in cash*	2,919	–	–	–	2,919
Non cash flow changes					
- *Changes in lease agreements*	–	682	–	–	682
- *Actuarial gains/losses pension plans*	–	–	–	258	258
- *Translation differences*	28	-41	-138	-19	-170
Closing balance	**-2,728**	**1,479**	**6,597**	**2,664**	**8,012**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 21 Provisions for pensions and similar obligations

Accounting policies

Getinge has both defined-contribution and defined-benefit pension plans, of which some have assets in special funds or similar securities. The plans are usually financed by payments from the respective group companies and the employees. The Group's Swedish companies are generally covered by the ITP plan, which does not require any payments from employees.

Defined-contribution plans

Defined-contribution plans are plans in which Getinge pays fixed fees to an independent legal entity and does not have any legal or informal obligation to pay additional fees. The Group's payments for defined-contribution plans are recognized as expenses during the period in which the employees perform the services that the fee covers.

Defined-benefit plans

Some post-employment benefits are fulfilled through so-called define- benefit plans where the obligations remain within Getinge and are primarily secured by own foundations or similar. Getinge's largest defined benefit plans are found in subsidiaries in Sweden, Germany, and the US. Pension expenses for defined-benefit plans is calculated annually by independent actuaries using the so-called Projected Unit Credit Method, which allocates the expenses over the employees working life. These commitments are measured at the present value of expected future payments, with consideration given to calculated future salary increases, and utilizing a discount rate corresponding to the interest rate of first-class company or government bonds with a remaining term that is almost equivalent to the actual commitments. For the significant pension plans, an assessment is also made quarterly, and if significant assumptions have changed, a revaluation is carried out. The Group's net liabilities for each defined-benefit plan are recognized in the balance sheet and comprises the present value of the obligation less the fair value of the plan assets. If the value of the plan assets exceeds the value of the obligation, a surplus arises, which is recognized as an asset. The recognized asset value is limited to the present value of future repayments from the plan, or reductions in future contributions to the plan. Actuarial gains and losses are recognized in other comprehensive income for the period in which they are incurred.

Costs for defined-benefit pension plans in profit or loss comprise the total costs for service during the current and earlier years and interest on commitments. Costs for service during the current period and previous periods are recognized as employee costs. The interest component of pension expenses is recognized under financial expenses.

Significant estimates and assessments

Pension commitments

Recognition of the costs of defined-benefit pensions and other applicable retirement benefits is based on actuarial valuations, relying on key assumptions for discount rates, future salary increases and expected inflation. The actuarial assumptions constitute the company's best assessment of the different variables that determine the costs of providing the benefits. Special assumptions and actuarial calculations are made for each defined-benefit plan. In turn, the discount rate assumptions are based on rates for high-quality fixed-interest investments with durations similar to the pension plans. In Sweden the pension commitments were calculated at a discount rate based on the return on the market rate of Swedish mortgage bonds. These bonds are deemed to be of high quality since they are guaranteed by assets and the mortgage bond market in Sweden is considered to be deep and liquid. In Germany and the US the discount rate is based on high-quality corporate bonds with a term corresponding to the average remaining term of the commitment.

Defined-contribution plans

In several countries, the group's employees are covered by defined-contribution pension plans. The pension plans are primarily retirement pensions. The premiums are paid continuously throughout the year by each group company to independent legal entities, such as insurance companies. The size of the premium paid by the employees and group companies is normally based on a set proportion of the employee's salary and in certain cases the employees pay for a portion of the premiums themselves. The expense for defined-contribution plans amounted to SEK 455 M (425) during 2024.

Defined-benefit plans

Getinge has large defined-benefit pension plans mainly in Sweden, Germany and the US. The pension plans primarily comprise retirement pensions. Each employer normally has an obligation to pay a lifelong pension. The pension is earned according to the number of employment years and the employee must be affiliated with the plan for a certain number of years to achieve full retirement pension entitlement.

Sweden

Most of the Group's defined-benefit pension commitments in Sweden are so called PRI liabilities. These plans are closed for new employees but remain open for the employees encompassed by the plans. The commitments pertain to lifelong retirement pensions and the benefits are primarily based on the employees' final salary. The term of the commitments is 20 years.

At year-end, the amount of the group's defined-benefit pension commitments in Sweden totaled SEK 511 M (555). The Swedish pension commitments decreased year-on-year mainly due to a higher discount rate. Plan assets exist only to a minor extent and are attributable to a small plan that is not credit insured.

The commitment for retirement pensions and family pensions for salaried employees in Sweden is safeguarded through insurance with Alecta. According to a statement from the Swedish Corporate Reporting Board, UFR 10, this is a multi-employer defined-benefit plan. For the 2024 fiscal year, the company did not have access to such information that makes it possible to recognize this plan as a defined-benefit plan. The pension scheme

20250623150333

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

in accordance with ITP, which is safeguarded through insurance with Alecta, is thus recognized as a defined-contribution scheme. During the year, fees for pension insurance covered by Alecta amounted to SEK 39 M (37). Alecta's surplus can be distributed to the insurers and/or the insured. At year-end 2024, Alecta's surplus in the form of the collective consolidation level was approximately 162% (158). The collective consolidation level comprises the market value of Alecta's assets as a percentage of the insurance commitment calculated in accordance with Alecta's actuarial calculation assumption, which does not correspond with IAS 19.

Germany

Some employees in Germany are part of defined-benefit pension plans. These plans are closed for new employees but remain open for the employees encompassed by the plan. The benefits are based on the employees' final salary and the remaining weighted average term of the total commitment is 13 years. The pension plans are insured in accordance with statutory requirements.

Total defined-benefit pension commitments increased to SEK 2,011 M (1,925) during the year. The increase was mainly due to lower discount rate assumptions.

USA

The Group's defined-benefit pension commitment in the US is closed for new employees and also to the employees encompassed by the plan, meaning that no new pension rights are vested. The commitment's remaining average term is 10 years.

The total defined-benefit commitment increased to SEK 1,081 M (1,053), mainly due to currency rate fluctuation.

The value of the plan assets increased from SEK 833 M to SEK 915 M, mainly due to currency rate change.

Pension and similar commitments, SEK M	2024			2023		
	Present value of commitments	Fair value of plan assets	Net provision in the balance sheet	Present value of commitments	Fair value of plan assets	Net provision in the balance sheet
Opening balance	**-3,663**	**879**	**-2,784**	**-3,451**	**854**	**-2,597**
Costs for service in the current year [1]	-37	–	-37	-30	–	-30
(Interest expenses)/interest income [2]	-142	43	-98	-148	42	-107
Past service cost [1]	-3	–	-3	0	–	0
Remeasurements [3]:						
– Return on plan assets	–	-29	-29	–	31	31
– Gains/(losses) attributable to changed demographic assumptions	0	–	0	-4	–	-4
– Gains/(losses) attributable to changed financial assumptions	89	–	89	-221	–	-221
– Experience-based gains/(losses)	-42	–	-42	-53	–	-53
– Special employer's contribution on actuarial assumptions	15	–	15	-12	–	-12
– Restriction in plan surpluses with regard to asset ceilings	–	-1	-1	–	1	1
Translation differences	-162	80	-81	52	-34	18
Contributions paid by employer	-1	60	59	–	58	58
Paid benefits	204	-70	134	204	-72	132
Other changes	-7	–	-7	–	–	–
Closing balance	**-3,749**	**962**	**-2,787**	**-3,663**	**879**	**-2,784**
Of which:						
Interest-bearing pension commitments	-3,663	962	-2,700	-3,543	879	-2,664
Non-interest-bearing pension commitments	-86	–	-86	-120	–	-120
Of which:						
Funded pension plans	-1,089	962	-127	-1,068	879	-189
Unfunded pension plans	-2,660	–	-2,660	-2,596	–	-2,596

1) Costs for service during the current period and previous periods are recognized as employee costs. 2) The interest component of pension expenses is recognized under financial expenses.
3) Actuarial gains and losses are recognized in other comprehensive income for the period in which they are incurred.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

The defined-benefit pension commitment and composition of plan assets 2024, SEK M	Present value of commitments	Fair value of plan assets	Net provision in the balance sheet
Sweden	-511	26	-485
Germany	-2,011	15	-1,996
USA	-1,081	915	-166
Other countries	-146	6	-140
Total	**-3,749**	**962**	**-2,787**

The defined-benefit pension commitment and composition of plan assets 2023, SEK M	Present value of commitments	Fair value of plan assets	Net provision in the balance sheet
Sweden	-555	26	-529
Germany	-1,925	12	-1,913
USA	-1,053	833	-221
Other countries	-130	9	-121
Total	**-3,663**	**879**	**-2,784**

Significant actuarial assumptions 2024, %	Sweden	Germany	USA
Weighted average, %			
Discount rate	3.8	3.5	5.4
Expected salary increase rate	2.0	2.5	-
Expected inflation	2.0	2.2	-

Significant actuarial assumptions 2023, %	Sweden	Germany	USA
Weighted average, %			
Discount rate	3.3	3.6	4.8
Expected salary increase rate	2.0	2.5	-
Expected inflation	2.0	2.2	-

Sensitivity of defined-benefit commitments to changes in the significant assumptions 2024, SEK M	Change in assumption	Effect on commitment
Discount rate	+1 percentage point	399
	-1 percentage point	-490
Inflation	+1 percentage point	-322
	-1 percentage point	267
Salary increases	+1 percentage point	-39
	-1 percentage point	32

The sensitivity analyses above covers the significant pension plans in Sweden, Germany, and the US and are based on a change in an assumption, while all other assumptions remain constant. It is unlikely that this will happen in practice, and changes in some of the assumptions may correlate. The calculation of sensitivity in the defined-benefit commitments for material actuarial assumptions uses the same method as that used in the calculation of pension liabilities.

Composition of plan assets, SEK M	2024	2023
Equities	157	137
Debt instruments	734	652
Properties	13	22
Cash and cash equivalents and similar assets	14	16
Other	44	53
Total	**962**	**879**

The weighted average term of the significant plans' pension commitments amounts to 13 years (13).
For the 2025 fiscal year, the expenses for defined-benefit plans are expected to amount to SEK 133 M.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 22 Employee costs

	2024[1]			2023		
SEK M	Board and CEO[1]	Other	Total	Board and CEO[1]	Other	Total
Salaries and remuneration	-253	-10,861	-11,113	-228	-9,603	-9,831
Social security expenses	-40	-1,582	-1,622	-39	-1,472	-1,511
Pension expenses	-20	-474	-495	-19	-436	-455
Total	**-313**	**-12,917**	**-13,230**	**-286**	**-11,511**	**-11,797**

1) Refers to the entire Getinge Group.

Remuneration and other benefits to Senior Executives in 2024

		Fixed remuneration		Variable remuneration			
SEK 000s	Board fee[1]	Fixed salary	Other benefits	Short-term variable remuneration	Long-term variable remuneration	Pension expenses	Total
Chairman of the Board	-1,806	–	–	–	–	–	-1,806
Board members	-5,604	–	–	–	–	–	-5,604
Mattias Perjos, President & CEO	–	-27,141	-790	-21,088	–	-10,826	-59,845
Other Senior Executives (9 people)	–	-38,328	-3,026	-36,902	–	-5,655	-83,911
Total	**-7,410**	**-65,469**	**-3,816**	**-57,990**	**–**	**-16,481**	**-151,166**

1) Also includes fees for work on Board Committees.

Remuneration and other benefits to Senior Executives in 2023

		Fixed remuneration		Variable remuneration			
SEK 000s	Board fee[1]	Fixed salary	Other benefits	Short-term variable remuneration	Long-term variable remuneration	Pension expenses	Total
Chairman of the Board	-1,728	–	–	–	–	–	-1,728
Board members	-6,035	–	–	–	–	–	-6,035
Mattias Perjos, President & CEO	–	-25,915	-498	-5,944	-3,847	-10,184	-46,388
Other Senior Executives (10 people)	–	-38,283	-2,655	-8,431	-3,377	-6,968	-59,714
Total	**-7,763**	**-64,198**	**-3,153**	**-14,375**	**-7,224**	**-17,152**	**-113,865**

1) Also includes fees for work on Board Committees.

Comments on the table remuneration and other benefits

- Other Senior Executives refers to members in the Getinge Executive Team, other than the CEO. Excluding the CEO, the Getinge Executive Team comprised 9 individuals at year-end. Only remuneration that has been received as a member of the Getinge Executive Team is included in the amounts recognized, which includes individuals that joined and left the Getinge Executive Team during the year.
- For information on Board fees for each member, refer to pages 39–41.
- Fixed salary pertains base salary including vacation payment.
- Other benefits refer to benefits such as company car, medical insurance (sw: sjukvårdsförsäkring), etc.
- Short-term variable remuneration refers to bonuses for the 2024 fiscal year, which will be paid in 2025.
- Short-term variable remuneration also includes other extraordinary variable remuneration, decided with the support of the guidelines for remunerations to senior executives, which were recognized and paid during 2024.
- Long-term variable remuneration refers to amounts earned in a long-term bonus program for 2022–2024, which will be paid in 2025.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Annual General Meeting's guidelines for remuneration to Senior Executives

The 2024 Annual General Meeting resolved on guidelines for remuneration to Senior Executives, which are described in pages 61–63. Getinge applied the guidelines adopted by the AGM as follows:

Principles: The Annual General Meeting decides on remuneration to the Chairman of the Board and Board members. Employee representatives do not receive Board remuneration. Remuneration to the CEO and other Senior Executives comprises base salary, variable remuneration, other benefits as well as pensions. Other Senior Executives comprise the individuals, who together with the CEO, comprise the Getinge Executive Team. For the Getinge Executive Team structure, see pages 43–44. The allocation between base salary and variable remuneration should be proportionate to the Senior Executive's responsibility and authority. The CEO's variable remuneration is maximized to 80% of base salary. For other Senior Executives, the variable remuneration is maximized to between 60 and 90% of the base salary.

Annual variable remuneration: The variable remuneration for Senior Executives is based on performance targets set by the Board and in order to promote the company's development, all members of the Getinge Executive Team have identical targets. For the 2024 fiscal year, the goals were related to earnings, organic sales growth, working capital, cash flow and sustainability.

Variable long-term remuneration: In addition to base salary and the above annual variable remuneration, Senior Executives may also receive a variable long-term bonus that rewards and promotes the company's long term value creation. The earning period for this bonus must be at least three fiscal years and the bonus may amount to a maximum of 100% of base salary. In addition, a limitation rule applies to the CEO regarding the payment of variable long-term remuneration that payment of the annual variable remuneration and variable long-term remuneration together may not exceed 100% of basic salary. The part of long-term variable remuneration that cannot be paid due to the limitation rule will be payable in coming years or later to the extent that the limitation rule is not exceeded for the current year.

Pensions: The CEO is entitled to a pension from the age of 62. The pension is premium based and pension expenses amount to 40% of base salary. Variable cash remunerations do not qualify for pension benefits. For other Senior Executives, the retirement age is 65 years, except for one Senior Executive whose retirement age is 62 years in accordance with local regulations in the country of residence. All pension benefits are transferable, i.e. not conditional on future employment.

Severance pay: The period of notice for the CEO is a minimum of six months. If termination of employment is initiated by the company then termination pay of 12 months' pay will be awarded. Termination pay is not offset against any other income. After the end of the period of notice, severance pay corresponding to one annual salary is paid. The company is entitled to deduct any income the CEO may receive from other employment or business activities from the severance pay. Upon termination of employment of any other Senior Executives, they have the right to termination pay of six months and a maximum of one year.

Getinge's total cost for remunerations to the Getinge Executive Team: The total cost for remunerations to the Getinge Executive Team amounted to SEK 165 M (170) and pertain base salaries, variable short-term and long-term remuneration, other benefits and pensions. It also includes social security expenses on salaries and benefits and special payroll tax on pensions.

Drafting and decision-making process: During the year, the Remuneration Committee gave the Board its recommendations concerning policies for the remuneration to Senior Executives. The Board discussed the Remuneration Committee's proposals and decided in line with the Remuneration Committee's recommendations. Remuneration to the CEO for the 2024 fiscal year was decided by the Board taking into account the Remuneration Committee's recommendations. Remuneration to other Senior Executives was decided by the Remuneration Committee following a recommendation by the CEO and in consultation with the Chairman of the Board.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 23 Average number of employees

	2024				2023			
By region	Men	Women	Unknown	Total	Men	Women	Unknown	Total
EMEA	4,213	2,669	7	6,889	4,182	2,540	6	6,728
of which, Sweden	*900*	*388*	*2*	*1,290*	*893*	*360*	*2*	*1,255*
Americas	1,859	1,225	215	3,299	1,739	1,140	2	2,881
of which, USA	*1,679*	*1,120*	*214*	*3,013*	*1,559*	*1,030*	*1*	*2,589*
APAC	1,098	498	1	1,597	1,106	510	1	1,617
Total	**7,170**	**4,392**	**223**	**11,785**	**7,027**	**4,190**	**9**	**11,226**

1) The large increase in the Other category relates mainly to acquisitions, where all employees have not yet been fully registered.
For more information, please refer to pages 155–156 Employee metrics.

Distribution of Senior Executives and Board members at the closing date, %	2024	2023
Women:		
Board members[2] of the Parent Company	20%	27%
Other members of the company's management, incl. CEO	50%	45%
Men:		
Board members[2] of the Parent Company	80%	73%
Other members of the company's management, incl. CEO	50%	55%

2) Includes board members elected by the Annual General Meeting and members appointed by employee organizations.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 24 Government grants

Accounting policies

Government grants are measured at fair value when it is probable that the terms associated with the grants will be met and that the grants will be received. Government grants that apply to costs are recognized in profit or loss as a reduction in costs in the same period as the costs that the grants are intended to cover. If the grants received do not pertain to a specific cost, the grants are recognized as revenue under the item other operating income. Government grants relating to the acquisition of assets reduce the assets' carrying amounts. Such grants affect recognized earnings over the asset's useful life by reducing depreciation.

Government grants received, SEK M	2024	2023
Received	60	66
Repaid	–	–
Total	**60**	**66**

Government grants reported in the income statement, SEK M	2024	2023
Other operating income	24	27
Other operating expenses	–	–
Reduction of costs related to the grant	17	17
Total	**41**	**44**

Grants received, which have reduced the carrying amount of the assets to which the grants were related amounted to SEK 19 M (22).

NOTE 25 Pledged assets and contingent liabilities

Accounting policies

Contingent liabilities are commitments and other claims for damages not recognized as liabilities/provisions either because it is not certain that an outflow of resources will be required to settle the commitment or because it is not possible to make a reliable estimate of the amount.

Significant estimates and assessments

For significant estimates and assessments regarding disputes and claims for damages, see Note 15 Other provisions.

Pledged assets, SEK M
The group had no pledged assets

Contingent liabilities, SEK M	2024	2023
Guarantees	612	428
Other	90	96
Total	**702**	**524**

NOTE 26 Supplementary disclosure to cash flow statement

Accounting policies

The cash flow statement is prepared in accordance with IAS 7, the indirect method. The cash flows of foreign group companies are translated at average rates. Changes in group structure, acquisitions and divestments are recognized net excluding cash and cash equivalents and are included in cash flow from investing activities, in the items acquisition of operations and divestment of operations.

Cash and cash equivalents, SEK M	2024	2023
Investments	26	60
Cash and bank balances	2,935	2,669
Total	**2,961**	**2,728**

Adjustments for items not included in cash flow, SEK M	2024	2023
Gain(-)/loss(+) from divestment/ disposal of non-current assets	21	19
Change in provisions, reversed (-)/added (+)	782	–
Other	5	16
Total	**808**	**35**

Interest paid and received, SEK M	2024	2023
Interest received	68	125
Interest paid	-627	-425
Total	**-560**	**-300**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 27 Acquisition of operations

Accounting policies

Acquired companies are included in the consolidated accounts from the date of acquisition, which is when Getinge Group can exercise control over the operations in the subsidiary. Acquired companies are consolidated in the financial statements in accordance with the purchase method, which means that the cost of the shares in subsidiaries is eliminated against their equity at the acquisition date. Accordingly, only the portion of the subsidiary's equity that has arisen after the acquisition is included in consolidated equity. Equity in the subsidiaries is thus determined on a market-based value of identifiable assets, liabilities, provisions, and contingent liabilities on the date of the acquisition. If the cost of the shares in the subsidiaries exceeds the value of the acquired net assets, the difference is assigned to goodwill. If the acquisition cost falls below the fair value of the acquired subsidiary's net assets (a bargain purchase), the difference is recognized directly in profit or loss as other operating income. Deferred tax is calculated on the difference between the calculated market values of assets and liabilities and the fiscal residual values. If assets are included in the subsidiary at the time of acquisition – for example, property, participations, or other operations – that will not be retained but sold in the near future, these assets are recognized in the acquisition analysis at the amount expected to be received. Transaction costs in connection with business combinations are expensed in profit or loss when they arise.

Significant estimates and assessments

In conjunction with acquisitions, all identifiable assets and liabilities in the acquired company are measured at fair value, including the value of assets and liabilities previously owned as well as the shares attributable to non-controlling interests.

Contingent considerations

Getinge signed agreements on contingent considerations in connection with acquisitions of business and subsidiaries. The liabilities for these additional purchase prices are measured at fair value through profit or loss. In most cases, the additional purchase prices are contingent on securing government approval for the acquired product development projects and the earnings performance of the acquired businesses. The future cash flows are discounted if the planned disbursement date exceeds 12 months. Assessments about future cash flows linked to the contingent considerations are regularly reviewed by company management and are reported at fair value. The discount effect is recognized on an ongoing basis in profit or loss under financial items. Contingent considerations are included in other non-interest bearing liabilities in the balance sheet, of which SEK 1,756 M is classified as non-current and SEK 1,523 M is classified as current.

Acquisition of assets in Getinge Aseptic Solutions LLC

In July 2024, Getinge's subsidiary Aseptic Solutions LLC acquired technology and intellectual property rights from Intact Solutions LLC, a company in Connecticut, USA. This technology makes aseptic processing simpler, safer and more efficient, and addresses the entire bioprocessing value chain. The acquisition was consolidated into the Getinge Group on the acquisition date and is included in the business area Life Science.

Getinge paid approximately SEK 128 M (USD 12 M) upon completion of the acquisition. Furthermore, additional earn-out payments may be made between 2027 and 2030 if agreed upon regulatory and financial performance milestones are achieved, and a non-interest-bearing liability of SEK 383 M was recognized in relation to these payments. For more information regarding contingent considerations, see Note 19 Financial instruments. Acquired goodwill amounted to SEK 260 M, which is mainly attributable to growth opportunities and synergies within Life Science. The costs of the acquisition amounted to SEK 14 M and were charged to earnings. The acquisition did not have any material impact on Getinge's sales or earnings in the period. The acquisition analysis was not yet completed during the period.

Paragonix Technologies, Inc

In September 2024, Getinge carried out the acquisition of 100% of the shares in Paragonix Technologies, Inc., a leading US company in organ transport products and services. The company, which was founded in 2010, employs approximately 100 people and is headquartered in Waltham, Massachusetts, USA. The acquisition was consolidated into the Getinge Group on the acquisition date and is included in the business area Acute Care Therapies.

Getinge paid approximately SEK 2,619 M (USD 253 M) in cash upon completion of the acquisition. Furthermore, additional earn-out payments may be made until 2026 if agreed upon regulatory and financial performance milestones are achieved. Linked to these, an additional purchase price of SEK 2,660 M was, at acquisition, recognized as a liability and is included in other non-interest-bearing liabilities in the balance sheet. For more information regarding contingent considerations, see Note 19 Financial instruments.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

The goodwill that arose on acquisition amounted to SEK 2,843 M and was primarily attributable to the value of new technology and a new future customer base. Since the acquisition, the company has contributed SEK 293 M to the Group's net sales and net earnings of SEK -44 M. If the acquisition had been carried out on January 1, 2024, the contribution to the Group's net sales would have been SEK 826 M and to net earnings SEK -115 M. The costs of the acquisition amounted to SEK 43 M and were charged to earnings. The acquisition analysis was not yet completed during the period.

During the fourth quarter of 2024, Paragonix achieved one performance-related target, whereby a payout of SEK 166 M (USD 15 M) took place in December.

Other acquisitions

In 2024, additional earn-out payments of SEK 325 M were made relating to Talis Clinical LLC. The acquisition analyses for Healthmark Industries and High Purity New England were completed during the year, whereby Getinge received SEK 34 M in reduced purchase price for these acquisitions. Shares were also acquired from non-controlling interests in the subsidiary Pulsion Medical Systems SE for SEK 31 M.

Net assets acquired, SEK M	Aseptic Solutions	Paragonix Technologies	Other acquisitions	2024	2023
Intangible assets	251	2,990	–	3,241	1,661
Tangible assets	–	23	–	23	309
Deferred tax assets	–	25	–	25	–
Financial assets	–	–	–	–	2
Inventories	–	93	–	93	247
Accounts receivables	–	142	–	142	178
Other current receivables	–	8	–	8	15
Cash and cash equivalents	–	115	–	115	98
Deferred tax liabilities	–	-755	–	-755	-464
Accounts payables	–	-32	–	-32	-102
Other short-term liabilities	–	-57	–	-57	-94
Identifiable net assets	**251**	**2,551**	**–**	**2,802**	**1,851**
Goodwill	260	2,843	–	3,103	3,260
Total purchase prices	**511**	**5,394**	**–**	**5,905**	**5,111**
Add/Less:					
Additional purchase prices and other adjustments	–	–	290	290	41
Acquisition of shares from non-controlling interests	–	–	31	31	170
Unpaid purchase prices	383	2,472	–	2,855	14
Cash and cash equivalents in the acquired operations	0	-115	–	-115	-98
Impact on the group's cash and cash equivalents	**128**	**2,807**	**321**	**3,256**	**5,209**

20250623150037

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 28 Transactions with related parties

Transactions between Getinge AB (publ) and its subsidiaries, which are related companies to Getinge AB (publ), were eliminated in the consolidated financial statements. Business terms and conditions as well as market-regulated pricing apply for delivery of products and services between group companies. No Board member or Senior Executive has, or has had, any direct or indirect participation in any business transactions, between themselves and the company, that are or were non-transparent in nature, regarding the applicable terms or conditions. In addition to the above, there were no significant transactions with related parties. For remuneration and benefits to Senior Executives and Board members, see Note 22 Employee costs.

NOTE 29 Events after the end of the reporting period

Except what is described below, no significant events have occurred after the end of the reporting period.

Intention to phase-out Surgical Perfusion

Getinge has announced its intention to phase out the Surgical Perfusion product portfolio, which is part of the product area Cardiopulmonary in Acute Care Therapies, in 2025. The intention is to reallocate resources to areas of more profitable growth, mainly in ECLS and Transplant Care. The Surgical Perfusion market has experienced low growth and Getinge has continuously lost market share to the current level of 7% outside the US, which is the largest market globally.

The products intended to be phased out are the HL40 heart-lung machine and the HCU40 heater-cooler unit, as well as consumables used in Surgical Perfusion. The assumption is that competitors will be able to meet demand. Getinge is aware of the potential impact of this intention and is committed to working closely with customers during a potential transition. The production facilities concerned are located in Hechingen and Rastatt in Germany and in Antalya, Türkiye. The intention is to maintain all three production facilities with a continued focus on producing ECLS solutions.

The intention has been shared with relevant employee representation bodies and employees, in line with local labour regulations, and necessary steps have been initiated. The final decision on the restructuring is dependent on the outcome of negotiations with the employee representation bodies.

In 2024, Surgical Perfusion had net sales of approximately SEK 450 M. The preliminary assessment is that approximately 385 positions are in scope of the intended phase-out and the expected restructuring costs amount to a total of approximately SEK 800 M, of which SEK 522 M is recognized in the fourth quarter of 2024 as an item affecting comparability, primarily consisting of write downs of capitalized R&D and inventory. This means limited impact on cashflow. In total, the restructuring process is expected to have a marginally positive impact on adjusted EBITA in 2025 and beyond.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Parent Company's income statement

SEK M	Note	2024	2023
Net sales		293	246
Administrative expenses	2, 15, 16	-328	-373
Operating result		-35	-127
Result from participations in group companies	5	1,743	2,549
Interest income and other similar income	6	37	38
Interest expenses and other similar expenses	6	-218	-260
Profit after financial items		1,527	2,200
Appropriations	7	139	141
Taxes	8	-39	-21
Net profit for the year		1,627	2,320

Parent Company's statement of comprehensive income

SEK M	Note	2024	2023
Net profit for the year		1,627	2,320
Other comprehensive income		-	-
Comprehensive income for the year		1,627	2,320

20250623150338

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Parent Company's balance sheet

SEK M	Note	2024	2023
ASSETS			
Non-current assets			
Intangible assets	3	–	1
Tangible assets	4	2	2
Participations in group companies	9	29,582	28,336
Deferred tax assets		99	97
Total non-current assets		**29,683**	**28,436**
Current assets			
Accounts receivable		1,244	1,102
Current tax assets		–	7
Other receivables		2	14
Prepaid expenses and accrued income		16	16
Cash and cash equivalents	11	0	1
Total current assets		**1,262**	**1,140**
TOTAL ASSETS		**30,945**	**29,576**

SEK M	Note	2024	2023
EQUITY AND LIABILITIES			
Equity	17		
Restricted equity			
Share capital		136	136
Statutory reserve		2,525	2,525
Non-restricted equity			
Share premium reserve		4,264	4,264
Retained earnings		17,117	15,994
Net profit for the year		1,627	2,320
Total equity		**25,668**	**25,239**
Long-term liabilities			
Interest-bearing long-term liabilities	10, 11	3,595	3,470
Other provisions, long-term		16	17
Total long-term liabilities		**3,611**	**3,487**
Current liabilities			
Interest-bearing short-term liabilities	10	1,374	570
Accounts payable		17	37
Liabilities to group companies		7	5
Current tax liabilities		15	–
Other liabilities		6	7
Accrued expenses and deferred income	12	247	231
Total current liabilities		**1,666**	**850**
TOTAL EQUITY AND LIABILITIES		**30,945**	**29,576**

Refer to Note 13 Pledge assets and contingent liabilities for information concerning pledged assets and contingent liabilities.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Changes in Parent Company equity

	Restricted equity	Non-restricted equity			
SEK M	Share capital[1)]	Statutory reserve	Share premium reserve	Retained earnings and net profit for the year	Total equity
Opening balance, 2024	136	2,525	4,264	18,314	25,239
Comprehensive income for the year	–	–	–	1,627	1,627
Dividend	–	–	–	-1,198	-1,198
Closing balance, 2024	**136**	**2,525**	**4,264**	**18,743**	**25,668**
Opening balance, 2023	**136**	**2,525**	**4,264**	**17,152**	**24,077**
Comprehensive income for the year	–	–	–	2,320	2,320
Dividend	–	–	–	-1,158	-1,158
Closing balance, 2023	**136**	**2,525**	**4,264**	**18,314**	**25,239**

1) The share capital consists of 18,217,200 Class A shares and 254,152,373 Class B shares. Each share's quotient value is SEK 0.50 and all shares carry equal rights to dividends. One Class A share carries ten votes and one Class B share carries one vote.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Parent Company's cash flow statement

SEK M	Note	2024	2023
Operating activities			
Operating result		-35	-127
Adjustments for items not included in cash flow		-	4
Interest received and similar items		5	38
Dividend received		1,743	2,622
Interest paid and similar items		-191	-239
Taxes paid		-22	-22
Cash flow before changes in working capital		**1,500**	**2,276**
Changes in working capital			
Current receivables		-133	-749
Current liabilities		4	-3,867
Cash flow from operating activities		**1,371**	**-2,340**
Investing activities			
Investments in subsidiaries		-1,246	-
Divestment of shares in subsidiaries		-	5
Repayment of shareholders' contribution		-	-
Cash flow from investing activities		**-1,246**	**5**
Financing activities			
Raising of loans	11	2,439	1,500
Repayment of loans	11	-1,510	-4
Change in long-term receivables		-	191
Dividend paid		-1,198	-1,158
Group contributions received		143	135
Cash flow from financing activities		**-126**	**665**
Cash flow for the year		**-1**	**-1,670**
Cash and cash equivalents at the beginning of the year		1	1,671
Cash flow for the year		-1	-1,670
Cash and cash equivalents at year-end		**0**	**1**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 1 Parent Company's accounting policies

The Parent Company has prepared its annual report in accordance with the Annual Accounts Act and the Council for Sustainable and Financial Reporting's recommendation RFR 2, Accounting for Legal Entities. The rules in RFR 2 stipulate that the Parent Company, in its annual report for the legal entity, shall apply all EU-approved IFRS Accounting Standards to the extent possible within the framework of the Annual Accounts Act and considering the relationship between accounting and taxation. The recommendation specifies the exceptions to be made from IFRS Accounting Standards. For further information regarding IFRS Accounting Standards, see Note 1 Accounting Principles in the group's financial reports. The Parent Company applies the accounting policies detailed for the group with the exception of the following:

Revenue recognition
The recognized net sales in the parent company pertain revenues from sale of services to group companies. Revenue is recognized when the control of the service has been transferred to the group company, which is when the parent company incurs the associated cost to deliver the service and the receiver can benefit from the use of the delivered services.

Remuneration to employees
The Parent Company complies with the Swedish Pension Obligations Vesting Act and directives from the Swedish Financial Supervisory Authority when calculating defined-benefit pension plans.

Financial derivatives
For derivatives, the exception in RFR 2 regarding IFRS 9 is applied, i.e., financial instruments are valued and reported based on acquisition values according to the Annual Accounts Act.

The parent company applies hedge accounting for its derivatives (interest rate swaps), which means that the derivatives are not continuously reported at fair value. Any interest difference to be received or paid due to an interest rate swap is continuously reported in the income statement.

Shares and participations
Subsidiaries are recognized in accordance with the acquisition method, implying that holdings are recognized at cost in the balance sheet less any impairment and with the addition of acquisition costs. Dividends from subsidiaries are recognized as dividend income.

Group contributions
Group contributions received and paid are recognized as appropriations according to the alternative rule in RFR 2.

Operational leases
All leasing agreements in the Parent Company are recognized as operational leases.

NOTE 2 Depreciation/amortization according to plan

SEK M	2024	2023
Equipment, tools, fixtures and fittings	-1	-1
Intangible assets	-1	-2
Total	**-2**	**-3**

NOTE 3 Intangible assets

Intangible assets, SEK M	2024	2023
Opening acquisition cost	19	19
Closing accumulated acquisition cost	**19**	**19**
Opening amortization	-18	-16
Amortization for the year	-1	-2
Closing accumulated amortization	**-19**	**-18**
Closing carrying amount	**0**	**1**

NOTE 4 Tangible assets

Equipment, tools, fixtures and fittings, SEK M	2024	2023
Opening acquisition cost	9	9
Closing accumulated acquisition cost	**9**	**9**
Opening depreciation	-7	-6
Depreciation for the year	-1	-1
Reclassifications	1	–
Closing accumulated depreciation	**-7**	**-7**
Closing carrying amount	**2**	**2**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 5 Result from participations in group companies

SEK M	2024	2023
Dividends from Group companies	1,743	2,621
Impairment of shares in subsidiaries	–	-72
Total	**1,743**	**2,549**

NOTE 6 Financial items

Interest income and other similar income, SEK M	2024	2023
Interest income from group companies	37	10
Interest income	–	28
Total	**37**	**38**

Interest expenses and other similar expenses, SEK M	2024	2023
Interest expenses to group companies	–	-102
Interest expenses	-215	-152
Exchange rate losses	-1	-5
Other	-2	-1
Total	**-218**	**-260**

NOTE 8 Income taxes

Taxes, SEK M	2024	2023
Current tax	-41	-22
Deferred tax	2	1
Total	**-39**	**-21**

The relationship between the year's tax expense and the recognized profit before tax, SEK M	2024	2023
Recognized profit before tax	**1,666**	**2,341**
Tax according to current tax rate in Sweden (20.6%)	-343	-482
Tax effect of non-deductible costs	-39	-61
Tax effect of non-taxable income	363	544
Foreign withholding tax	-20	-22
Recognized tax expense	**-39**	**-21**

NOTE 7 Appropriations

SEK M	2024	2023
Group contributions received	139	141
Total	**139**	**141**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 9 Participations in group companies

Parent Company's holdings	Reg. office	Swedish Corp. Reg. No.	No. of shares	Percentage holding	Carrying amount 2024, SEK M	Carrying amount 2023, SEK M
Getinge Finance Holding AB	Göteborg	556473-1700	23,052,334	100	9,672	9,672
Getinge Sterilization AB	Halmstad	556031-2687	50,000	100	848	848
Getinge Business Support Services AB	Göteborg	556535-6317	1,000	100	1,031	1,031
Getinge Disinfection AB	Halmstad	556042-3393	25,000	100	208	118
Getinge Australia Pty Ltd	Australia		56,975	100	72	72
Getinge Danmark A/S	Denmark		10,000	100	41	41
Getinge IT Solutions ApS	Denmark		533,000	100	27	27
Getinge Finland Oy	Finland		-	-	-	0
Getinge Infection Control SAS	France		1,666,712	85	698	698
Getinge/Castle International Ltd	Greece		100	100	0	0
Getinge Treasury Ireland DAC	Ireland		2	100	-	-
Neuromedica SA	Spain		40,000	100	3	3
Getinge Shared Services Sp. z o.o.	Poland		60,600	100	29	29
Getinge Holding USA, Inc.	US		10,000	100	16,697	15,542
Getinge Polska Sp. z o.o.	Poland		2,109	35	13	13
Getinge Group Japan KK	Japan		800	100	243	243
Total carrying amount					**29,582**	**28,336**

The Parent Company's holding of shares in the subsidiaries constitutes the entire capital of the respective company, which also corresponds to 100% of the voting rights, unless otherwise stated.

Subsidiaries of sub-groups

Getinge Group, with operations in many countries, is organized into sub-groups in several categories, and accordingly, the legal structure cannot be reflected in a simpler manner in a tabular presentation.

Group companies directly or indirectly owned by Getinge AB (publ) are specified below. The ownership interest is 100% except in cases where the ownership interest is stated in parentheses.

Sweden
- Getinge Business Support Services AB, 556535-6317, Göteborg
- Getinge Disinfection AB, 556042-3393, Halmstad
- Getinge Finance Holding AB, 556473-1700, Göteborg
- Getinge Global Sales and Service AB, 559421-7928, Göteborg
- Getinge Logistics AB, 556547-8798, Halmstad
- Getinge Sterilization AB, 556031-2687, Halmstad
- Getinge Sverige AB, 556509-9511, Halmstad
- Getinge Treasury AB, 556535-6309, Göteborg
- Maquet Critical Care AB, 556604-8731, Solna
- Maquet Nordic AB, 556648-1163, Solna

Australia
- Getinge Australia Pty Ltd

Austria
- Getinge Österreich GmbH

Belgium
- Getinge Belgium NV

Brazil
- Getinge do Brasil Equipamentos Médicos Ltda

Canada
- Getinge Canada Ltd

China
- Getinge (Shanghai) Trading Co., Ltd
- Maquet (Shanghai) Medical Equipment Co., Ltd
- Maquet (Suzhou) Co., Ltd

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Note 9 Participations in group companies cont.

Colombia
- Getinge Colombia SAS

Czech Republic
- Getinge Czech Republic, s.r.o.

Denmark
- Getinge Cetrea A/S
- Getinge Danmark A/S
- Getinge IT Solutions ApS

Finland
- Getinge Finland Oy

France
- Fluoptics SAS
- Getinge France SAS
- Getinge Infection Control SAS
- Getinge Life Science France SAS
- Intervascular SAS
- LTA Medical
- Maquet SAS

Germany
- Getinge Deutschland GmbH
- Getinge Financial Services GmbH
- Getinge Holding B.V. & Co KG
- Getinge Holding GmbH
- Getinge IT Solutions GmbH
- Getinge Vertriebs Holding GmbH
- Irasun GmbH
- Maquet Cardiopulmonary GmbH
- Maquet GmbH
- Maquet Medical Systems AG
- MediKomp GmbH
- Pulsion Medical Systems SE (96%)

Greece
- Getinge/Castle International Ltd

Hong Kong
- Getinge Group Hong Kong Ltd

India
- Atrium Medical India Pvt Ltd
- Getinge India Pvt Ltd
- Getinge Medical India Pvt Ltd

Ireland
- Getinge Ireland Ltd.
- Getinge Treasury Ireland DAC
- Quadralene International Ltd.

Italy
- Getinge Italia Srl

Japan
- Getinge Group Japan KK

Mexico
- Maquet Mexicana, S. de R.L. de C.V.

Netherlands
- Applikon Biotechnology B.V.
- Getinge Holding Netherlands B.V.
- Getinge Netherlands B.V.
- Maquet Verwaltungs B.V.

Norway
- Getinge Norge AS

Poland
- Getinge IC Production Poland Sp. z o.o.
- Getinge Polska Sp. z o.o.
- Getinge Shared Services Sp. z o.o.

Portugal
- Getinge Group Portugal Unipessoal Lda

Russia
- Maquet LLC

Saudi Arabia
- Getinge Regional Headquarter

Serbia
- Getinge Group South East Europe d.o.o. Beograd

Singapore
- Getinge Singapore Pte. Ltd.
- Getinge South East Asia Pte. Ltd.

South Africa
- Maquet Southern Africa (Pty) Ltd

South Korea
- Getinge Medical Korea Co., Ltd

Spain
- Getinge Group Spain SL
- Neuromedica SA

Switzerland
- Getinge Schweiz AG

Taiwan
- Getinge Group Taiwan Co., Ltd.

Thailand
- Getinge (Thailand) Co., Ltd. (49%)

Türkiye
- Maquet Cardiopulmonary Medikal Teknik San.Tic.Ltd. Şti
- Getinge Medikal Sistemler San. Ve Tic. A.Ş.

Ukraine
- Maquet Ukraine LLC

United Arab Emirates
- Getinge Group Middle East FZ-LLC

United Kingdom
- Biocleanse Ltd
- Bioclear Ltd
- Dentisan Ltd
- Getinge Holding Ltd
- Getinge IT Solutions Ltd
- Getinge Ltd
- Quadralene Holdings Ltd
- Quadralene Ltd
- Teknon Ltd

USA
- Atrium Medical Corporation
- Datascope Corp.
- Getinge Aseptic Solutions, LLC
- Getinge Group Logistics Americas, LLC
- Getinge Holding USA, Inc.
- Getinge USA Sales, LLC
- Healthmark Industries Co., Inc.
- High Purity New England Inc.,
- Lunatronic Incorporated
- Maquet Cardiovascular LLC
- Maquet Cardiovascular US Sales, LLC
- Paragonix Technologies, Inc.
- Steritec Products Mfg. Co., Inc.
- Talis Clinical LLC
- Transplant Advocates LLC
- Ultra Clean Systems Inc.

Vietnam
- Getinge Vietnam Company Ltd

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 10 Interest-bearing liabilities

Interest-bearing long-term liabilities, SEK M	2024	2023
Bond loans	3,595	3,470
Total	**3,595**	**3,470**

All loans fall due for payment within five years.

Interest-bearing short-term liabilities, SEK M	2024	2023
Bond loans	1,374	570
Total	**1,374**	**570**

NOTE 11 Net interest-bearing debt

SEK M	2024	Change	2023
Interest-bearing short-term liabilities	1,374	804	570
Interest-bearing long-term liabilities	3,595	125	3,470
Less cash and cash equivalents	0	0	-1
Total	**4,969**	**929**	**4,039**

Net interest-bearing debt 2024, SEK M	Cash and cash equivalents	Interest-bearing liabilities	Total
Opening balance	**-1**	**4,040**	**-1,671**
Cash flow affecting net debt	0	929	1,670
Closing balance	**0**	**4,969**	**-1**

Net interest-bearing debt 2023, SEK M	Currency forwards	Interest-rate swaps	Total
Opening balance	**-1,671**	**2,544**	**873**
Cash flow affecting net debt	1,670	1,496	3,166
Closing balance	**-1**	**4,040**	**4,039**

NOTE 12 Accrued expenses and deferred income

SEK M	2024	2023
Salaries	68	60
Social security expenses	140	123
Interest expenses	30	34
Other	9	14
Total	**247**	**231**

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 13 Pledged assets and contingent liabilities

Pledged assets, SEK M
The Parent Company has no pledged assets.

Contingent liabilities, SEK M	2024	2023
Guarantees FPG/PRI	418	391
Other guarantees	5,173	2,457
Total	**5,591**	**2,848**

NOTE 14 Average number of employees

	2024	2023
Men	32	38
Women	45	42
Total	**77**	**80**

Distribution of senior executives at the closing date	2024	2023
Women:		
Board members of the Parent Company	2	3
Other members of the company's management, incl. CEO	1	1
Men:		
Board members of the Parent Company	8	8
Other members of the company's management, incl. CEO	2	3

NOTE 15 Employee costs

2024, SEK M	Board and CEO	Other	Total
Salaries and remuneration	-56	-90	-146
Social security expenses	-20	-46	-66
Pension expenses	-11	-23	-34
Total	**-87**	**-159**	**-246**

2023, SEK M	Board and CEO	Other	Total
Salaries and remuneration	-44	-102	-146
Social security expenses	-16	-41	-57
Pension expenses	-10	-20	-30
Total	**-70**	**-163**	**-233**

NOTE 16 Auditing

Fee to PwC, SEK M	2024	2023
Auditing assignment	-12	-9
Auditing activities other than auditing assignments	-1	-1
Other services	-1	-11
Total	**-14**	**-21**

Öhrlings PricewaterhouseCoopers AB has the auditing assignment for the Parent Company. Auditing assignments refer to auditing of the financial statements, statutory accounts and other required legal audit. Auditing activities other than auditing assignments include the review of sustainability report and review of interim reports. Other services referred to services in connection with acquisitions and other advisory services. Of other services SEK 1 M (0) was attributable to the registered auditing firm Öhrlings PricewaterhouseCoopers AB.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

NOTE 17 Proposed appropriation of profit

The following non-restricted equity in the Parent Company is at the disposal of the Annual General Meeting, SEK M:	
Share premium reserve	4,264
Retained earnings	17,117
Net profit for the year	1,627
Total	**23,008**

The Board and CEO propose that a dividend of SEK 4.60 per share shall be distributed to shareholders	1,253
to be carried forward	21,755
Total	**23,008**

NOTE 18 Events after the end of the reporting period

No significant events have occurred after the end of the reporting period.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Auditor's report

To the general meeting of the shareholders of Getinge AB (publ), corporate identity number 556408-5032

Report on the annual accounts and consolidated accounts

Opinions

We have performed an audit of the annual accounts and consolidated accounts of Getinge AB (publ) for the year 2024. The annual accounts and consolidated accounts of the company are included on pages 55–122 in this document with the exception of the Remuneration Report on pages 64–67.

In our opinion, the annual accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of the parent company as of December 31, 2024 and its financial performance and cash flow for the year then ended in accordance with the Annual Accounts Act. The consolidated accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of the group as of December 31, 2024 and their financial performance and cash flow for the year then ended in accordance with IFRS Accounting Standards, as adopted by the EU, and the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts and consolidated accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet for the parent company and group.

Our opinions in this report on the annual accounts and consolidated accounts are consistent with the content of the additional report that has been submitted to the parent company's audit committee in accordance with the Audit Regulation (537/2014) Article 11.

Basis for Opinions

We conducted our audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements. This includes that, based on the best of our knowledge and belief, no prohibited services referred to in the Audit Regulation (537/2014) Article 5.1 have been provided to the audited company or, where applicable, its parent company or its controlled companies within the EU.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Our audit approach

Focus and scope of the audit

We designed our audit by determining materiality and assessing the risks of material misstatement in the consolidated financial statements. In particular, we considered where management made subjective judgements; for example, in respect of significant accounting estimates that involved making assumptions and considering future events that are inherently uncertain. As in all of our audits, we also addressed the risk of override of internal controls by the Managing Director or Board of Directors, including among other matters consideration of whether there was evidence of bias that represented a risk of material misstatement due to fraud.

We tailored the scope of our audit in order to perform sufficient work to enable us to provide an opinion on the consolidated financial statements as a whole, taking into account the structure of the Group, the accounting processes and controls, and the industry in which the Group operates.

Materiality

The scope of our audit was influenced by our application of materiality. An audit is designed to obtain reasonable assurance whether the financial statements are free from material misstatement. Misstatements may arise due to fraud or error. They are considered material if individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the consolidated financial statements.

Based on our professional judgement, we determined certain quantitative thresholds for materiality, including the overall group materiality for the consolidated financial statements as a whole. These, together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures and to evaluate the effect of misstatements, both individually and in aggregate on the financial statements as a whole.

Key audit matter

Key audit matters of the audit are those matters that, in our professional judgment, were of most significance in our audit of the annual accounts and consolidated accounts of the current period. These matters were addressed in the context of our audit of, and in forming our opinion thereon, the annual accounts and consolidated accounts as a whole, but we do not provide a separate opinion on these matters.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Key audit matter	How our audit considered the key audit matter
Impairment test of intangible assets with indefinite life *With reference to Note 9.* Goodwill and other intangible assets represent a significant part of the Group's balance sheet. The company performs a yearly impairment test of the assets based on a calculation of the discounted future cash flow for the cash generating units in which goodwill and other intangible assets with indefinite life are reported. This impairment test is based on a high level of judgments and assumptions regarding future cash flows. Information is provided in Note 9 as to how the company's management has undertaken its assessments and provides information on important assumptions and sensitivity analyses. Key variables in the test are growth rate, cost trend and discount factor (cost of capital). As noted in the disclosures, no impairment need has been identified based on assumptions made.	In our audit, we have evaluated the calculation model applied by management. We have reconciled and evaluated key variables against forecasts and strategic plans for the business areas included in the financial plan approved by the Board of Directors. We have analyzed the accuracy on how previous years assumptions have been met as well as assessed any adjustments to assumptions compared to previous year, as a result from changes in the business and external factors. We have tested the sensitivity from changes in key variables to assess the risk for an impairment need to arise. We have considered and evaluated the additional goodwill from acquisitions made during the financial year. We have also assessed the disclosures included in the consolidated accounts.
Accounting for provisions relating to legal exposures *With reference to Note 15 and 25.* The assessment of provisions or contingent liabilities for legal exposures for specific significant disputes and claims from regulatory investigations is a significant area for the Group's financial statements. The assessment of relevant provisions for legal exposures is inherently associated with a high degree of uncertainty and subjectivity. The outcome of disputes and other claims may be difficult to predict, and the final outcome may deviate from initial assessments. During the year, negotiations with the Brazilian federal authority for internal control, transparency and anti-corruption, Comptroller General of the Union (CGU), have been ongoing linked to investigations relating to previous years. As stated in Note 15, these negotiations are still ongoing and in 2024 the Group made a provision linked to these negotiations.	In our audit, we have particularly focused our procedures on the assessment of underlying calculations for provisions and disclosures regarding ongoing negotiations with CGU. We have reviewed management's calculations and assessments of the legal exposures and obtained a statement from external legal advisors on relevant matters. We have assessed the reasonableness of management's assessments of required provisions, taking into account the information from legal counsel. We have obtained legal letters from external legal counsels and obtained management's assessment on other significant matters. We have also assessed the accuracy of the disclosures presented in the annual report.
Accounting for acquisitions and contingent considerations *With reference to Note 19 and 27.* Getinge has made an acquisition through Aseptic Solutions LLC and of Paragonix Technologies Inc during 2024. The acquisitions have resulted in additional goodwill and other intangible assets of SEK 6.3 billion. The acquisitions involve contingent considerations linked to future performance-based criteria. Liabilities for these additional considerations are measured at fair value through profit or loss. Assessments of future cash flows constitute an area of significant judgement. In light of the relative size and complexity of the acquisitions and the associated valuation of assets and liabilities, the accounting for acquisitions and contingent consideration constitutes a key audit matter for the 2024 audit.	In our audit, we have particularly focused on the acquisitions that Getinge has completed during the year. Our procedures include but are not limited to the following: We have assessed the appropriateness of the accounting for identified assets in relation to the criteria in IFRS 3, Business Combinations and IAS 38, Intangible Assets. We have reviewed the company's purchase price analyses against underlying acquisition agreements and reconciliation of opening balances. Our procedures have also included testing and evaluation of calculations and assumptions when identifying and measuring acquired assets and liabilities in purchase price analyses. We have assessed the measurement and accounting for contingent consideration in relation to accounting principles for financial instruments that are measured at fair value at the acquisition date and subsequent accounting at the balance sheet date. We have involved valuation specialists in assessing the appropriateness of valuation methods and relevant assumptions for determining the fair value of the contingent consideration and for acquisition analyses. We have also made reconciliations with accounting specialists in relation to the accounting of contingent consideration at the time of acquisition as well as in subsequent accounting. Finally, we have assessed the accuracy of the disclosures presented in the annual report

20250623150444

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Other information than the annual accounts

This document also contains other information than the annual accounts and consolidated accounts and is found on pages 1–31 and 169–185, the Remuneration Report on pages 64–67 and the Sustainability Reporting on pages 127–167. The Board of Directors and the Managing Director are responsible for this other information.

Our opinion on the annual accounts does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our audit of the annual accounts and consolidated accounts, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the annual accounts and consolidated accounts. In this procedure we also take into account our knowledge otherwise obtained in the audit and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibility of the Board of Directors and the Managing Director

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and consolidated accounts and that they give a fair presentation in accordance with the Annual Accounts Act and, as regards the consolidated accounts, according to IFRS Accounting Standards, as adopted by the EU, and the Annual Accounts Act. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts and consolidated accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts and consolidated accounts, the Board of Directors and the Managing Director are responsible for the assessment of the company and group's ability to continue as a going concern. They disclose, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is however not applied if the Board of Directors and the Managing Director intends to liquidate the company, cease operations or has no realistic alternative to doing any of this.

The Audit Committee shall, without prejudice to the Board of Director's responsibilities and tasks in general, among other things oversee the company's financial reporting process.

Auditor's responsibility

Our objectives are to obtain reasonable assurance about whether the annual accounts and consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts and consolidated accounts.

A further description of our responsibility for the audit of the annual accounts and consolidated accounts is available on Revisorsinspektionen's website: www.revisorsinspektionen.se/revisornsansvar. This description is part of the auditor's report.

Report on other legal and regulatory requirements

The auditor's examination of the administration of the company and the proposed appropriations of the company's profit or loss

Opinions

In addition to our audit of the annual accounts and consolidated accounts, we have also audited the administration of the Board of Directors and the Managing Director of Getinge AB (publ) for the year 2024 and the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

Basis for Opinions

We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent in relation of the parent company and group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Responsibility of the Board of Directors and the Managing Director

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company and group's type of operations, size and risks place on the size of the parent company's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the management of the company's affairs. This includes among other things continuous assessment of the company and group's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner. The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

Auditor's responsibility

Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors or the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

Introduction
Strategy
Corporate Governance Report
Financial statements
Administration Report
Guidelines for remuneration
Remuneration Report 2024
Proposed appropriation of profit
Group financial statements
Group notes
Parent Company financial statements
Parent Company notes
Auditor's report
Sustainability Report
Other information

Our objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

A further description of our responsibility for the audit of the administration can be found on the Auditor's Inspection's website: www.revisorsinspektionen.se/revisornsansvar. This description is part of the auditor's report.

The auditor's examination of the ESEF report

Opinions

In addition to our audit of the annual accounts and consolidated accounts, we have also examined that the Board of Directors and the Managing Director have prepared the annual accounts and consolidated accounts in a format that enables uniform electronic reporting (the ESEF report) pursuant to Chapter 16, Section 4(a) of the Swedish Securities Market Act (2007:528) for Getinge AB (publ) for the year 2024.

Our examination and our opinion relate only to the statutory requirements.

In our opinion, the ESEF report has been prepared in a format that, in all material respects, enables uniform electronic reporting.

Basis for Opinions

We have performed the examination in accordance with FAR's recommendation RevR 18 Examination of the ESEF report. Our responsibility under this recommendation is described in more detail in the Auditors' responsibility section. We are independent of Getinge AB (publ) in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of the Board of Director's and the Managing Director

The Board of Directors and the Managing Director are responsible for the preparation of ESEF report in accordance with the Chapter 16, Section 4(a) of the Swedish Securities Market Act (2007:528), and for such internal control that the Board of Directors and the Managing Director determine is necessary to prepare the ESEF report without material misstatements, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to obtain reasonable assurance whether the ESEF report is in all material respects prepared in a format that meets the requirements of Chapter 16, Section 4(a) of the Swedish Securities Market Act (2007:528), based on the procedures performed.

RevR 18 requires us to plan and execute procedures to achieve reasonable assurance that the ESEF report is prepared in a format that meets these requirements.

Reasonable assurance is a high level of assurance, but it is not a guarantee that an engagement carried out according to RevR 18 and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the ESEF report.

The firm applies International Standard on Quality Management 1, which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

The examination involves obtaining evidence, through various procedures, that the ESEF report has been prepared in a format that enables uniform electronic reporting of the annual accounts. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement in the report, whether due to fraud or error. In carrying out this risk assessment, and in order to design audit procedures that are appropriate in the circumstances, the auditor considers those elements of internal control that are relevant to the preparation of the ESEF report by the Board of Directors and the Managing Director, but not for the purpose of expressing an opinion on the effectiveness of those internal controls. The examination also includes an evaluation of the appropriateness and reasonableness of assumptions made by the Board of Directors and the Managing Director.

The procedures mainly include a validation that the ESEF report has been prepared in a valid XHTML format and a reconciliation of the ESEF report with the audited annual accounts and consolidated accounts.

Furthermore, the procedures also include an assessment of whether the consolidated statement of financial performance, financial position, changes in equity, cash flow and disclosures in the ESEF report have been marked with iXBRL in accordance with what follows from the ESEF regulation.

Öhrlings PricewaterhouseCoopers AB, was appointed as Getinge AB's (publ) auditor by the general meeting on April 22, 2024 and has been the company's auditor since April 17, 2008.

This is a translation of the Swedish language original. In the event of any differences between this translation and the Swedish language original, the latter shall prevail.

Gothenburg March 27, 2025
Öhrlings PricewaterhouseCoopers AB

Cecilia Andrén Dorselius
Authorized Public Accountant
Auditor in charge

Karin Olsson
Authorized Public Accountant

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information



Sustainability Report

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Contents

128 About the Report
129 Sustainability at Getinge
130 Materiality & Stakeholders
135 Sustainability Governance & Management
138 Environment
150 Social
160 Governance
162 Reporting principles
164 GRI index
168 Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

About the Report

The 2024 Annual and Sustainability Report for Getinge AB (publ) is submitted by the Board of Directors and describes the company's overall sustainability policies, strategic directions, actions, targets, key figures and results. Getinge's 2024 sustainability report's structure is inspired by the European Sustainability Reporting Standards.

The Sustainability Report has been created in accordance with the GRI Standards and Getinge's own reporting principles (see GRI index on pages 164–167) for the period from January 1 to December 31, 2024. Getinge's reporting cycle is annual. The report was reviewed by the company's auditor with limited assurance and it was published on March 27, 2025.

The sustainability report covers all subsidiaries in the Getinge Group (see pages 118–119), including those subsidiaries owned directly or indirectly by Getinge AB (publ). The reporting approach across all material topics and disclosures is consistent for all subsidiaries. Acquired companies are expected to start reporting according to Getinge's reporting manual no later than 24 months after the acquisition date, and are included in the reporting on an ongoing basis. When new acquisitions are included in the reporting, retroactive baseline values, including the baseline year, are included. Data on carbon scope 1, 2 and 3 emissions and energy consumption are not included for Quadralene. Quadralene was acquired in 2020 and reporting has been delayed due to relocation of the production facilities. Environmental data is not included in the report for Ultra Clean, Healthmark and Paragonix as they were acquired less than 24 months ago. Data on health and safety is not included for Paragonix. Data on carbon scope 1 and 2 emissions and energy consumption from High Purity New England (HPNE) are included in the 2024 report for the first time, but HPNE's scope 3 emissions are not included.

In 2024, the following restatements of information were made: efforts to further enhance the quality of Getinge's sustainability data have resulted in the restatement of some data regarding climate and energy for the period 2021–2024. The gas metric was restated for three legal entities in Germany, which transitioned to more granular measurement methodologies. The metrics related to gas and electricity for one legal entity were corrected and the reporting process was improved to reduce the risk of inaccuracies going forward. Scope 1 data for leased vehicles has been restated, as the new method is more coherent over the reporting period 2021–2024. Scope 2 data for leased spaces has been restated, as a number of production sites were double counted and already included in production figures.

The Sustainability Report also covers the statutory Sustainability Report for 2024 according to the Swedish Annual Accounts Act and constitutes of the following pages: About Getinge: 3, 56, Business Strategy: 12-31, Governance: 32–54, 135–137, Business Risk Management: 47–52, Anti-corruption: 160–161, Environment: 138–145, Employees: 150–156, Human Rights: 132, Social aspects: 150–159, EU Taxonomy: 146–148, and Board diversity policy: 36.

Limited assurance ('review') of the Sustainability Report

In 2024, the company's external auditor has been engaged to perform a limited assurance ('review') on the Sustainability Report. The relationship between Getinge and the appointed external auditor is described on page 36. The limited assurance has been performed in accordance with the International Standard on Assurance Engagements, ISAE 3000, see page 168 for details. The objective is to form a conclusion on whether anything has come to the auditor's attention that causes them to believe that the information in the Sustainability Report has not, in all material respects, been prepared in accordance with suitable criteria and the company's own reporting principles. The suitable criteria for the Sustainability Report consist of the GRI Sustainability Reporting Standards and Getinge's own reporting principles.

Contact for the Sustainability Report:

Catarina Paulson, Head of Corporate Sustainability

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information


General information

The first section of Getinge's sustainability report gives an overview of the company's sustainability framework, the process of identifying material topics and engaging with stakeholders, and the governance structures and management practices that guide the sustainability efforts. The information presented in this section outlines Getinge's sustainability approach and establishes the foundation for the company's reporting, ensuring transparency in addressing critical environmental, social, and governance (ESG) issues.

Sustainability at Getinge

Sustainability is an integral part of the company's strategy (see pages 13–15) to shape a future where healthcare is better, more efficient, and accessible. Together with partners and customers, the company strives to create a healthier and more sustainable future for patients, customers, and the planet. Getinge's sustainability efforts are anchored in three key pillars: innovation, responsibility, and engagement. Innovation means that the company works continually to develop innovative solutions including minimizing its environmental impact across the value chain. Responsibility is first and foremost about ensuring that quality is the highest priority in all steps of the products' life cycle. It also means conducting business in compliance with regulations and ethical principles. Engaged employees are critical to Getinge's success. This means that the company strives to create the best possible conditions for coworkers to thrive and reach their highest potential. Health and safety and ensuring employees feel included and equally valued are at the core of this engagement.

The following pages describe how impacts are identified through materiality assessment. Detailed information about each material topic, including policies, strategic direction, actions, targets, key figures, results, and performance data, can be found in the topical sections under the respective areas 'Environment', 'Social' and 'Governance'.



Introduction

Strategy

Corporate Governance Report

Financial statements

Sustainability Report

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

Other information

Materiality and stakeholders

PROCESS

The Corporate Sustainability Reporting Directive (CSRD) is incorporated in the Swedish Annual Accounts Act and will be mandatory for Getinge in 2025. In preparation the company initiated work on a preliminary double materiality assessment (DMA) based on the available draft for the European Sustainability Reporting Standards (ESRS) and by using guidance available from the European Financial Reporting Advisory group (EFRAG) in Q1 2024. The assessment covered all parts of the organization and group companies. However, it did not include acquisitions made during the reporting year, as the assessment was completed prior to these acquisitions in 2024. Moving forward, Getinge will continue to refine its approach as more guidance becomes available and best practices evolve.

The work during 2024 began by evaluating both actual and potential impacts of Getinge's operations on the environment and society across the value chain (inside-out). The focus on impact materiality ensures compliance with the GRI reporting requirements for 2024.

During the year, Getinge conducted activities related to a first DMA including a financial impact assessment (outside-in), focusing on sustainability-related risks and opportunities that could affect its business. Where possible, these risks were quantified and supplemented with qualitative analysis. The financial assessment methodology was aligned with the company Enterprise Risk Management (ERM) methodology and is part of the base for the DMA. Given that the 2024 Sustainability report is established according to GRI, only impacts are included in this report meaning that financial risks and opportunitites will be reported on starting 2025. In this initial assessment the stakeholder involvement was limited to internal subject-matter experts. To ensure accuracy and alignment, the results of the DMA were compared to previous materiality assessments, which had incorporated external stakeholder views and interests more broadly. The DMA update during 2025 is planned to incorporate external stakeholder involvement.



Considerations in materiality assessment

Positive/negative impacts: Both positive and negative impacts have been assessed.

Actual/potential impacts: Impacts have been identified as actual or potential. For actual negative impacts, scale, scope, and remediability have been the focus of the assessment. For potential negative impacts, likelihood has also been assessed. For positive impacts, scale, scope, and likelihood have been assessed.

Own operations/value chain: Impacts and risks were assessed for Getinge's own operations, and for the value chain (see page 133) where relevant and possible.

Risks/opportunities: An initial assessment of risks and opportunities was carried out aligned with the Enterprise Risk Management process.

Time horizons (short, medium and long term): Have been used as described in the ESRS standards and have been considered where possible.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

The process to determine the material topics included four steps:

1 Mapping the organization's context, strategy, business model and value chain

Getinge is a global organization providing products and solutions that aim to improve clinical results and optimize workflows in hospitals and life science institutions. Getinge's value chain includes a global supply chain with subcontractors that supply products including metals, plastics, electronics and finished components. The company's value chain also includes in-house research and development, production, marketing and sales, and logistics as well as customers, end users and end-of-life impact of the products. Getinge has about 12,000 employees, operations in 40 countries, sales in more than 135 countries and production facilities in Europe, Asia and Americas. The impact on the economy, environment and people in the value chain span over a wide range of areas. For more information see Strategy on pages 12-31.

2 Identification of actual and potential impacts

A desktop analysis was conducted to identify a gross list of actual and potential materiality impacts. This process utilized well-established frameworks, including global reporting standards (GRI and SASB), resources from the ILO, World Health Organization, the UN Global Compact, OECD Guidelines and the UN Guiding Principles on Business and Human Rights, as well as recognized indices (e.g. Environmental Performance Index, Transparency International). Tools such as the World Resources Institute Aqueduct (water scarcity) and Encore (business impact on nature/biodiversity) were also employed. The analysis was further informed by legal requirements, customer tender requests, and internal sources. Additionally, insights from previous materiality assessments, employee engagement surveys, customer ESG requests, and investor ratings were used to better understand the material aspects throughout the company's value chain.

3 Assessing the significance of the impacts and defining material topics

A cross functional project team was established to prepare for reporting according to CSRD, including conducting the double materiality assessment. Five dedicated workstreams were formed, with ESG topic owners and subject-matter experts collaborating to address impacts across environmental, social and governance dimensions. To assess impact materiality, scoring sheets were developed based on the sustainability matters covered in topical ESRS lists (sub-topic and sub-subtopics). Each workstream assessed the scale, scope, likelihood, and possibility to remediate the identified impacts. Both potential and actual impacts were analyzed in terms of short-, medium-, and long-term consequences. The initial findings from the workshops were then reviewed in additional workshops with Business Area management teams, leading to adjustments based on feedback.

4 Validation and decision on the material topics

In the final step, the list of material topics was cross-checked with previous materiality assessments incorporating feedback from workshops and stakeholder groups. The proposed material topics identified by subject matter experts were submitted to the Getinge Executive Team (GET) and the Board of Directors for a comprehensive review and validation. This process involved evaluating the relevance, alignment with the company's strategic priorities, and potential impacts across the organization and value-chain. Through this assessment, management ensured that the final material topics reflect a company-wide perspective.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Materiality assessment outcome

Getinge identified its actual and potential impacts on the environment and society (impact materiality assessment) and these are presented according to GRI standards in this report. Identified potential, actual, negative and positive impacts are further explained in each section pertaining to the material topic. The topics that have been identified as material are presented in the table below. Compared to 2023 year's report, the material topics have been updated to include water consumption. Human rights are included in each of the different material topics not as a separate material topic, and employee training has been removed from material topics.


	Material topics	Page
Environment	Climate and Energy	138
	Water consumption	142
	Circular economy: Resource use	144
Social	Occupational Health & Safety	151
	Inclusion and belonging (DEIB)	153
	Sustainable and responsible sourcing	157
	Patient safety and quality	159
Governance	Anti-corruption	160



Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Impacts on people and the environment across the value chain

Material impacts across the company's own operations and its value chain are illustrated below. The intention of the illustration is to provide an overview of the material impacts from the company's activities and it is not exhaustive. More detailed information on each material topic and where impacts occur in the value chain as well as policies, strategic direction and actions, targets, key figures, results, and performance data, can be found in the topical sections under 'Environment', 'Social' and 'Governance'.



Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Stakeholder groups and stakeholder dialogue

Maintaining an open dialogue with stakeholders is important to ensure that Getinge continues to integrate relevant sustainability aspects into its business model, strategy and daily operations. Input on stakeholder expectations and requirements is gathered through various channels such as: customer meetings and surveys, investor meetings, industry forums, supplier follow-ups and in dialogues and surveys with company employees. This engagement directly informs Getinge's strategic priorities and materiality assessment, helping to shape focus areas and decision-making. One example is that water has been added as a material topic in 2024. During the year, the stakeholder engagement was limited to internal subject-matter experts. To ensure accuracy and alignment, Getinge reviewed and compared with previous stakeholder dialogues, which had incorporated external stakeholder views and interests. Getinge's main stakeholders, their ESG expectations, and the way in which the company engages with them are listed in the table below.

External ESG Ratings

ESG ratings are sources of information and provide insights on the expectations from different stakeholders. The most relevant ESG ratings that have been considered include Sustainalytics, ISS ESG, MSCI and EcoVadis. Getinge is in continuous dialogue with financial stakeholders and rating agencies, to follow up on emerging ESG topics and to provide transparent communication.

Rating Agency	Results	Latest assessment
Sustainalytics	ESG Risk Rating 2024: 22.8 Medium Risk	Dec 2024
ISS ESG	Rating B- Governance Quality Score: 9 SDG Impact Rating: 5.9 Status: Prime	Jan 2025
MSCI	Rating B	Sept 2024
EcoVadis	Score 67	Feb 2025

Employees

Getinge's employees play a key role in enabling the company to successfully deliver on its business strategy.

ESG expectations
Employee surveys show that the expectations are: fair and safe treatment, meaningful work, fair wages, a sense of belonging and good development opportunities.

Engagement channels
- Daily interactions between managers and employees
- Employee materiality survey
- Meetings, interviews and workshops
- Education and training
- Employee Engagement Survey
- GetNet (internal digital platform)
- Speak-Up Line

Customers

Getinge has close relationships and a continuous dialogue with its customers. By actively listening to their feedback the company ensures the delivery of valuable products and services.

ESG expectations
Getinge has gradually experienced an increase in ESG-related questions from customers. Beyond quality and safety of products, customers place high importance on environmental considerations and value chain due diligence.

Engagement channels
- Meetings and interviews
- Analysis of tender specifications and requirements of purchasing organizations
- Financial and non-financial reporting including Getinge Capital Markets Day
- Product-related information and customer trainings
- Speak-Up Line
- Getinge.com

Business partners

Collaboration and dialogue with external experts are essential to enable positive contribution to society.

ESG expectations
Responsible business practices and partnership on strategic issues.

Engagement channels
- Meetings and interviews with suppliers and financial stakeholders
- ESG rating agencies
- Communication and training on Supplier Code of Conduct and Business Partner Code of Conduct
- Speak-Up Line
- Getinge.com

Investors and owners

Getinge has regular dialogues with investors.

ESG expectations
Beyond the company's financial performance (profitability) and economic efficiency as well as tangible and intangible assets, investors rank governance-related aspects highest.

Engagement channels
- Meetings and interviews
- Financial and non-financial reporting including Getinge Capital Markets Day
- Quarterly teleconferences and dedicated meetings with Sustainability analysts

Governments and regulators

Getinge is committed to complying with applicable regulations in the markets and in the geographic locations where it operates. A strong regulatory framework is vital to the company's success.

ESG expectations
Compliance with regulations and leadership on product quality.

Engagement channels
- Memberships in UN Global Compact and local Swedish Associations
- Industry associations Advamed and MedTech Europe
- Ongoing dialogues with regulators on certification/ registration of products

Affected communities and nature

Getinge acknowledges nature and communities as important silent stakeholders. By minimizing environmental impacts and supporting community well-being, the company wants to contribute to sustainable ecosystems and resilient societies.

ESG expectations
There are implicit expectations that Getinge will act responsibly across environmental, social, and governance dimensions. This includes protecting ecosystems and biodiversity, reducing environmental footprint, fostering social equity and community well-being, and maintaining ethical and transparent governance practices that prioritize long-term sustainability.

Engagement channels
- Scientific reports and tools. Examples of which are Encore, World Resource Institute Aqueduct, ILOSTAT, environment at a glance indicators (OECD), WASH, Forced Labor Observatory

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Sustainability Governance and Management

Corporate governance at Getinge is described in the Corporate Governance Report on pages 32–54. The main governing bodies as regards to sustainability governance are presented below.

Board of Directors


The Board of Directors holds the ultimate responsibility for material matters within the group, including sustainability and quality. It sets Getinge's sustainability targets, oversees the group's goals and strategies, risk management, M&A strategy, how the customer offering should be designed and the policy implementation – with the overall sustainability and quality approach integrated into all decisions. Parts of the preparatory work has been delegated by the board to relevant board committees.

The Board of Directors approves the group's annual materiality assessment which guides sustainability efforts, and is accountable for the group's reporting, including the sustainability report and its assurance by the auditors. The Board's primary role is supervisory, ensuring the governance and work of the Getinge Executive Team, monitoring, managing and overseeing impacts, risk and opportunities. This includes incorporating sustainability and quality into all decisions it makes on major acquisitions of companies and in the risk management process.

The members of the Board of Directors are considered, by the Nomination Committee, to possess competence and experience from the sustainability field, for example through one board member's previous assignment as chairman of a Sustainability Committee but also through other Board members' operational assignments in executive positions.

In December 2024, the Board participated in a training conducted by an external party in Responsible Business to further enhance their skills and expertise in overseeing related matters. The training focused on how the company ensures integrity in interactions with Healthcare Professionals and Healthcare Organisations. During 2024, the Board of Directors and the Ethics and Sustainability Committee addressed the material impacts outlined in this report.

Sustainability Governance organisation chart



Board Committees responsible for sustainability

The Ethics and Sustainability Committee, established in 2023 by the Board of Directors, works with ensuring a more in-depth follow up on the strategic integration of sustainability, including quality, and prepares policies, actions and targets, for decisions to be made by the Board of Directors. Additionally, as delegated by the Audit and Risk Committee, the Committee monitors reported sustainability information in both quarterly reports and the annual report and follows up on the auditor's review of the yearly sustainability report.

In 2024, the Ethics and Sustainability Committee received training in the material area "Consumer protection", i.e. product safety and quality, conducted by an external party. In addition to the Ethics and Sustainability Committee, the Board of Directors Remuneration Committee is responsible for the sustainability-related elements of the company's remuneration system. The Audit and Risk Committee is ultimately responsible for preparing the sustainability reporting and internal controls over sustainability reporting.

Executive Team

Getinge's CEO has the ultimate responsibility for the ongoing management and leadership of the Group, and is supported in this work by the Getinge Executive Team (GET), who holds the operational responsibility for integration of sustainability and quality

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

into the company's strategy, business model and operations. Within the Getinge Executive Team, the ultimate responsibility for Getinge's sustainability approach including monitoring, managing and overseeing impacts, risks and opportunities, rests with the Executive Vice President (EVP) Sustainability, Legal & Compliance.

Progress on implementation is reviewed as part of the recurring business and functional reviews. In addition, a quarterly meeting is held with the Sustainability Board, consisting of all members of the Getinge Executive Team, to enable focus on key topics.

Sustainability function

The Corporate Sustainability function, which is part of the overall Sustainability, Legal & Compliance team, is responsible for advancing the sustainability approach on an operational level.

To support this work a cross functional working group, the Sustainability Advisory group (SAG), has been established. A management team member from each business area and function has been appointed to SAG to ensure implementation of sustainability policies, actions and targets in all business areas and functions. SAG is chaired by the Head of Corporate Sustainability, each SAG member is responsible for ensuring that business area and functional management teams are adequately informed about the expected implementation of sustainability policies, actions and targets. Dedicated controls and procedures to follow up on the implementation are also ensured through a Sustainability Controller, integrated in the Finance function.

The Corporate Sustainability function is the subject matter expert of environmental matters as well as driver of key cross functional projects as decided by SAG.

The EVP Sustainability, Legal & Compliance oversees the work of the Corporate Sustainability function on material impacts, risks and opportunities, and follows up on its execution of the strategy. The outcome of this work is also reported by the EVP Sustainability, Legal & Compliance to the Ethics and Sustainability Committee and reported to the Board of Directors at least once a year.

Sustainability targets are prepared by the Corporate Sustainability function, as instructed by the Ethics and Sustainability Committee, and ultimately decided upon by the Board of Directors. The responsibility to follow up and monitor Getinge's progress lies with the Ethics and Sustainability Committee.

Ethics and Compliance function

The governance of ethics and compliance is led by the Ethics & Compliance function, part of the Sustainability, Legal & Compliance team. This function has adopted a risk-based approach to ensure that compliance programs are designed and implemented addressing relevant risk areas such as anti-bribery & corruption, healthcare compliance, human rights and trade sanctions. While the function provides day-to-day support for implementation, ultimate responsibility for implementation of the compliance programs lies with each respective business area and function. The Chief Ethics & Compliance Officer reports to the Board's Audit & Risk Committee, Ethics & Sustainability Committee as well at the Getinge Executive Team on a periodic basis.

Quality Compliance, Regulatory and Medical Affairs function

Quality and patient safety is a critical material topic for the company. A function for Quality Compliance, Regulatory & Medical Affairs has been established at group level, led by the Executive Vice President (EVP) Quality Compliance, Regulatory & Medical Affairs.

The function develops relevant policies, processes, and monitoring mechanisms to ensure the effectiveness of the quality management system as well as compliance with regulatory requirements. The ultimate operational responsibility for product quality and regulatory compliance lies with business area and functional management. Quality system audits are also carried out by each certificate holder in operations to ensure that the quality system meets the applicable external requirements. The responsibility to follow up and monitor Getinge's progress within quality related matters lies with the Ethics and Sustainability Committee.

Business areas and functions

Each of the business areas and functions including the global sales and service organization and corporate and group competence and support functions, are ultimately responsible for implementing policies, targets and actions. Alignment on an operational level is part of SAG and sustainability-related risks, opportunities and progress are regularly evaluated as part of this work. The business areas and functions are also responsible for integrating sustainability related considerations into their respective strategy and operational plan, which is presented to GET as well as the Board of Directors.

Policies and steering documents

The mandates and responsibilities of the Board of Directors and its Committees related to sustainability, including quality, as outlined in this section, are defined in the rules of procedure. Sustainability governance at Getinge is ultimately regulated by a sustainability policy adopted by the Board of Directors. The sustainability policy is part of Getinge's global policy framework.

Policy committments

The global policy framework comprises 16 global policies approved by Getinge's Board and related global directives. Getinge's global policies and directives are reviewed and updated at least every two years in response to the continuously evolving regulatory environment and stakeholder expectations. These documents provide additional guidance on specific areas and emphasize the company's commitment to responsible business ethics.

Getinge's Human Rights Policy states that all people should be treated with dignity and respect. The policy is based on the Universal Declaration of Human Rights, the United Nations Guiding Principles on Business and Human Rights, and the International Labor Organization's (ILO) Declaration on Fundamental Principles and Rights at Work, and applies to all employees and business relationships on behalf of Getinge.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Getinge's global policies and directives are available in 12 languages and are easily accessible to all employees via the internal communication platform, GetNet. Most of the policies are publicly available for other stakeholders on Getinge's website.

Two sustainability related policies in the framework were revised during the year: Global Anti-Trust & Fair Competition Policy and Global Intellectual Property Policy. Communication and training are provided to relevant employees to ensure that the requirements of the policy are met. Getinge's policies define the requirements and expectations of how to conduct oneself and how this can be translated into practice though daily actions and decisions.

Getinge has also developed and maintains a Business Partner Code of Conduct, which is an extension of Getinge's Code of Conduct and describes the ethical principles and requirements business partners are expected to comply with when doing business with Getinge.

Externally, the company is involved in several global initiatives related to responsible business ethics. Getinge is a signatory of the United Nations (UN) Global Compact and supports the ten principles on human rights, labor, environment, and anti-corruption.

Getinge also supports the 17 UN Sustainable Development Goals (SDGs) and Getinge's 2024 Annual Report identifies and describes those SDGs that best correspond to the company's impact on its business environment. In addition, Getinge has been a supporting member of the Swedish Anti-Corruption Institute since 2022 and actively participates in related networks.

Embedding policy commitments

All corporate functions and production units are responsible for complying with the Code of Conduct and achieving the sustainability targets in their line organizations. They are also responsible for evaluating sustainability-related risks in their operations, including but not limited to supplier responsibility, environment, occupational health & safety, anti-corruption, and labor & diversity. The corporate functions provide support, supervision and monitoring.

Processes to remediate negative impacts

Getinge is dedicated to providing open and transparent communication, internally and externally. All employees are encouraged to report any suspected or observed violations of the law or the corporate Code of Conduct. In this regard, Getinge encourages reporting to managers, HR and the global Ethics and Compliance team. Getinge also has a whistle-blower hotline – Getinge SpeakUp Line – available both internally and externally via the company's internal communication platform GetNet and the public website getinge.com. The platform for Getinge's Speak-Up Line has access to over 340 different languages, and Getinge currently uses around 60 different languages. Getinge has a strict non-retaliation policy and reports to senior executives the status of internal investigations on regular basis in various fora, such as the Ethics Committee, Audit & Risk Committee, during BA management meetings or regional Global Sales management meetings. By using these mechanisms, Getinge endeavors to identify, trace and take corrective action on complaints, following established routines and processes. Intended users of the Speak-Up Line are not involved in the design, review, operation or improvement of the hotline.

Mechanisms for seeking advice and raising concerns

Employees can seek advice from their direct managers, HR and/or the Ethics and Compliance department. Getinge's external whistle-blower hotline, Getinge Speak-Up Line, enables confidential reporting via a website or by telephone and is open to Getinge's employees, suppliers, distributors and other business partners. The Chief Ethics & Compliance Officer is responsible for ensuring that all reports of suspected Code of Conduct violations or non-compliance are correctly assessed, investigated, and acted upon.

The overall governing body for the internal investigations is the Ethics Committee, which is a forum on Getinge Executive Team-level. The Ethics Committee meets at least five times a year, prior to each Audit and Risk Committee meeting, and on a needs basis. The Chief Ethics & Compliance Officer is responsible for monitoring action plans and for providing updates on these to the Ethics Committee and the Board's Audit and Risk Committee. Relevant information is also provided to the Ethics and Sustainability Committee as deemed necessary.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

ENVIRONMENT

Climate and Energy

The big picture

The healthcare sector accounts for about 5% of global carbon emissions.[1] Climate change is directly linked to health, with rising temperatures and extreme weather contributing to the spread of diseases, respiratory conditions, and heat-related illnesses. This means that the healthcare sector needs to be involved in a systematic approach to deliver better health outcomes with a reduced carbon footprint.

Getinge is committed to reaching net zero emissions in line with its validated Science Based targets.

Getinge's Targets


Net-zero emissions by 2050

In 2020, Getinge committed to establish a climate target in accordance with the SBTi. The company's near and long-term targets were validated by the SBTi in 2023. The long-term target is net-zero emissions by 2050. The near-term targets are to reduce scope 1 & 2 emissions by at least 90% and scope 3 emissions by at least 25% by 2030 (base year 2021).

Energy

The company target is to reduce energy consumption by 20% by 2030 vs. 2021.

Relevant Sustainability Development Goals



1) https://www.thelancet.com/journals/lancplh/article/PIIS2542-5196(20)30121-2/fulltext

Impacts

Carbon emissions are prevalent at most stages of the company's value chain, with the majority of emissions arising from purchased goods and services, use of sold products and transportation of goods to and from production sites. Negative impacts in the value chain are described below.

Impacts Upstream
Scope 3 emissions

Sourcing:
Materials used in manufacturing that have high energy demands for extraction, refinement, or production (e.g., metals, electronics, plastics) increase the overall carbon footprint.

Certain suppliers rely on carbon-intensive energy sources, contributing significantly to scope 3 emissions.

Transportation:
Transporting materials between suppliers and manufacturers results in carbon emissions, with air freight representing the majority of these emissions.

Impacts Own Operations
Scope 1 & 2 emissions

Manufacturing:
Energy used for manufacturing and heating of production facilities and offices lead to carbon emissions in sites were fossil fuels are used.

Waste generation:
Manufacturing generates waste (e.g., production scrap), some of which requires energy-intensive disposal or end up in landfills, which often entails increased emissions.

Impacts Downstream
Scope 3 emissions

Transportation:
Transporting finished products from Getinge manufacturing sites to customers results in carbon emissions, particularly when air freight is used.

Energy consumption during use:
Products that require energy to operate, particularly sterilizers, contribute to increased energy demand and emissions, especially when customers rely on fossil-based electricity to generate steam.

End-of-life disposal:
Many of Getinge's products are incinerated at the end of their lifecycle due to safety regulations, leading to emissions and pollution. The absence of take-back programs or recycling systems further exacerbates these challenges.

Assessment of impacts and management of risks

Climate emissions are material for Getinge, as the healthcare sector contributes significantly to climate change. The long-term exposures to both physical and transition risks related to climate change exist mainly in the value chain. The main risks identified are the impact that extreme weather and rising sea levels may have on certain parts of the supply chain. An internal evaluation of exposure to physical risks is performed every year. For 2024 the evaluation concluded that the exposure to climate change in Getinge's own facilities remains relatively low.

Mitigation actions: To reduce the emissions from the company's value chain, net-zero targets have been established, and the carbon emission reduction targets were validated by SBTi in 2023. Actions that have reduced scope 1 and 2 emissions so far include shifting to renewable sources of energy in the company manufacturing sites and improving energy efficiency, while reducing air freight has contributed to reducing scope 3 emissions.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Policies

Getinge's Global Environmental Policy states the company's commitment to reducing its environmental impact across the value chain. The reduction of greenhouse gases is a primary focus in this policy. Getinge has ISO 14001 certifications at all production units (except for a small number of recent acquisitions). ISO 14001 provides a structured framework for management and emission reduction actions to be implemented and followed up at local level. Getinge's Standard Operating Procedure (SOP) for EcoDesign applies to hardware, accessories, spare parts, service, aftermarket, packaging and manuals. The procedure describes how the company addresses the environmental considerations in the Design Controls and Risk Management Process for Medical Devices and non-Medical Devices (local procedure), by using a standardized Life Cycle Assessment (LCA) methodology. This methodology contributes to the reduction of the environmental impact by providing information on the environmental footprint and the emission hotspots in the lifecycle of a product (including extraction of material, production, transport, product use and end-of-life treatment). Relevant employees are trained in using the LCA tool to ensure correct and consistent application.

Strategic direction and actions

The company is determined to measure and track carbon emissions across its full value chain, focusing on areas with greatest impact namely energy used in production, product development influencing choice of materials and energy efficiency in product use as well as choice of transport mode. Getinge will develop a transition plan for climate change.

Continuous improvement of data and calculation methods

Getinge has been working on emissions calculations for scope 1, 2 and 3 since 2021, constantly seeking to improve the measurements and calculations. The base year is 2021, which has been updated for the 2024 years' report and is adjusted to the base year of SBTi. 2024 is the first year that Getinge includes parts of scope 3 in the annual report. The full scope 1, 2 & 3 emissions are reported on since 2023, in the Climate Disclosure Report available on getinge.com.

Actions Upstream
Scope 3 emissions

Reducing emissions from purchased goods and services
Reducing emissions from purchased goods and services is challenging in the medtech industry due to the regulated nature of the industry. Despite this, Getinge is taking steps to reduce emissions with a focus on direct suppliers of goods that have a relatively high emission impact (metals, plastics and electronics). The aim is to obtain primary environmental data on products and alternatives, and to partner with existing suppliers to support their carbon emission reduction journeys.

The more significant impact will come from the work that has started in the three business areas to identify key EcoDesign opportunities by systematically challenging design, material and component selection as well as continuously aiming to reduce material flows. This includes replacing materials with lower-emission alternatives, e.g. biobased plastics that can replace fossil-based plastics. During 2024, Getinge reached one important milestone by developing a DPTE-BetaBag® where the beta port is made from renewable plastics replacing the previous fossil-based polycarbonate (PC).

Actions Own Operations
Scope 1 & 2 emissions

Reducing emissions from production
Scope 1 & 2 represented between 2-3% of the total carbon emissions in 2024. The emissions from energy used in manufacturing and heating of premises are the company's priority as they are directly controllable by the company. During 2024, the focus has been on improving energy efficiency, switching to alternative sources of energy and electricity, and reducing the use of fossil-fuels to the greatest extent possible.

Electrifying the car fleet
The electrification of the company's vehicle fleet continued in 2024 even though challenges regarding the charging infrastructure in some parts of the world still impacts the transition.

Actions Downstream
Scope 3 emissions

Decrease in emissions from goods transportation
Goods transportation emissions have continued to decrease during 2024 as a result of shifting transport modes from air freight to sea freight on several logistics routes most notably between Europe and US. This modal shift has resulted in a decrease of more than 30% since the base year.

Energy consumption during use of sold products
For products such as sterilizers and washer-disinfactors with high carbon emissions in the use phase, Getinge continuously explores ways to improve energy efficiency. A key approach is applying Eco-Design principles in product development.

Reducing emissions during use also depends on the rate at which customers transition from fossil-based to renewable sources of electricity. Getinge provides improved usage instructions and engages in active dialogue with customers to support emission reduction.

Energy efficiency remains a priority in product development. For example, the GEW 888 neo washer/dryer, launched in 2024, features a compact design and resource-efficient technology, reducing energy consumption by up to 25% compared to its predecessor, depending on configuration.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Scope 3 emissions

Scope 3 emissions, representing the majority of the total emissions, are mostly outside of the company's direct control. This means that actions to reduce emissions both up and downstream require more time and effort. The categories that will make the greatest difference in reducing emissions and achieving the company's near and long-term targets are: purchased goods and services, upstream and downstream goods transportation and emissions from the use of the sold products.

The above-mentioned categories of scope 3 emissions represented the majority of the total emissions during 2024 and will therefore be reported on in this annual report. For information about other scope 3 emissions categories please see the Getinge Climate Disclosure report.

Targets, key figures & results

Net-zero emissions by 2050

The long-term target is net-zero emissions by 2050. The near-term targets are to reduce scope 1 & 2 emissions by at least 90% and scope 3 emissions by at least 25% by 2030 (base year 2021). Scope 1 and 2 emissions in own production decreased with 20% during 2024 compared to last year, with the main contribution being the transfer to renewable electricity. For total scope 1 and 2 emissions, the transition from fossil fuel company vehicles to electric and hybrid vehicles accounts for the majority of the reduction. Regarding emissions from the value chain (scope 3), it is primarily in outbound transportation that the company can draw conclusions from changes in emissions. Here, the focus on replacing air transport with sea freight between the EU and the US, as well as reduced air transport in general, has resulted in a reduction of over 30% since the base year 2021. For emissions from purchased goods and the use of sold products, Getinge continues to work on improving data quality to be able to make better decisions on emission-reducing measures.

Energy

During 2024 Getinge has continued to reduce it's energy consumption in line with the target of reducing 20% of energy consumption compared with the base year 2021. For 2024, the energy consumption for productions sites amounted to 77 117 MWh, a -19% reduction compared with base year 2021. The reduction compared to 2023 is mainly due to reduction of gas usage in production. One site has, for example, invested in upgrading the heating loop and optimizing controls. The share of renewable energy amounts to 70% for 2024 (65% in 2023).

Emissions, ton CO_2eq*

Emissions from own production	2024	2023	2022	2021
Emissions from oil	81	93	88	94
Emissions from gas	3,720	3,990	3,602	5,187
Total Scope 1	**3,800**	**4,083**	**3,691**	**5,280**
Emissions from electricity	363	1,096	4,924	9,805
Emissions from district heating	0	0	97	210
Total Scope 2	**363**	**1,096**	**5,021**	**10,015**
Total Scope 1 and 2 from own production	**4,163**	**5,179**	**8,712**	**15,295**
Reduction from base year, ton CO_2eq	**-11,132**	**-10,117**	**-6,584**	
Reduction from base year (%)	**-73%**	**-66%**	**-43%**	
Reduction from previous year, ton CO_2eq	**-1,015**	**-3,533**	**-6,584**	
Reduction from previous year (%)	**-20%**	**-41%**	**-43%**	

Total direct GHG emissions (Scope 1)	2024	2023	2022	2021
Emissions from own production	3,800	4,083	3,691	5,280
Emissions from leased vehicles	8,910	11,449	11,149	12,838
Total Direct GHG emissions (Scope 1)	**12,710**	**15,532**	**14,840**	**18,118**
Total Indirect GHG emissions (Scope 2)				
Emissions from own production	363	1,096	5,021	10,015
Emissions from leased spaces	2,706	2,805	3,420	3,900
Total Indirect GHG emissions (Scope 2)	**3,069**	**3,901**	**8,441**	**14,766**

GHG emissions intensity	2024	2023	2022	2021
CO_2eq emissions from own production in relation to internal sales (MSEK)	0,256	0.327	0.543	0.871

*Efforts to further enhance the quality of Getinge's sustainability data have resulted in the restatement of some data regarding climate and energy for the period 2021–2023. The gas metric was restated for three legal entities in Germany, which transitioned to more granular measurement methodologies. The metrics related to gas and electricity for one legal entity were corrected and the reporting process was improved to reduce the risk of inaccuracies going forward. Scope 1 data for leased vehicles has been restated, as the new method is more coherent over the reporting period 2021–2023. scope 2 data for leased spaces has been restated, as a number of production sites were double counted and already included in production figures. One legal entity, High Purity New England, has been added through acquisition and data is updated for the period 2021–2024. All data is location based. Emission data is not included in the report for the following companies: Ultra Clean, Healthmark and Paragonix, as they were acquired less than 24 months ago.

Scope 3 emissions, ton CO_2eq**

Scope 3	2024	2023	2022	2021
3.1 Purchased goods and services	166,387	160,287	162,224	163,616
3.4 Upstream transportation and distribution	39,675	42,956	52,436	58,772
–Inbound transportation	7,803	7,669	8,952	10,764
–outbound transportation	31,872	35,287	43,485	48,008
3.11 Use of sold products	336,489	367,639	360,251	350,558

**Scope 3 emissions does not include acquisitions made after January 2022

20250623150052

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Energy consumption within the organization*

Energy consumption in production, MWh	2024	2023	2022	2021
Oil	297	342	326	345
Gas	29,319	31,072	29,113	37,103
Electricity	45,252	45,278	47,289	53,268
District heating	2,250	2,311	3,455	4,315
Total energy consumption from production	**77,117**	**79,004**	**80,183**	**95,031**
Reduction from base year 2021 (MWh)	**-17,914**	**-16,027**	**-14,848**	
Reduction from base year 2021 (%)	**-19%**	**-17%**	**-16%**	
Reduction from previous year (MWh)	**-1,887**	**-1,179**	**-14,848**	
Reduction from previous year (%)	**-2%**	**-1%**	**-16%**	
Energy intensity:				
Energy consumption from production (MWh/internal sales)	4.7	5.0	5.0	5.4

Renewable energy sources in production, MWh	2024	2023	2022	2021
Total energy consumption	**77,117**	**79,004**	**80,183**	**95,031**
Energy consumption from renewable sources	53,938	51,383	44,281	37,523
Percentage renewable energy sources	70%	65%	55%	39%
Total electricity consumption	**45,252**	**45,278**	**47,289**	**53,268**
Electricity consumption from renewable sources	42,705	41,290	33,608	28,254
Percentage renewable electricity	94%	91%	71%	53%
Total gas consumption	**29,319**	**31,072**	**29,113**	**37,103**
Gas consumption from renewable sources	8,984	7,791	8,094	6,837
Percentage renewable gas	31%	25%	28%	18%
Total district heating consumption	**2,250**	**2,311**	**3,455**	**4,315**
District heating consumption from renewable sources	2,250	2,302	2,580	2,432
Percentage renewable district heating	100%	100%	75%	56%

Gas and oil consumption, Nm^3	2024	2023	2022	2021
Gas consumption Nm^3 (Heat value 0,011 MWh/Nm^3)	2,665,946	2,832,463	2,653,908	3,382,216
Oil consumption Nm^3 (Heat value 9,95 MWh/Nm^3)	30	34	33	35

*Efforts to further enhance the quality of Getinge's sustainability data have resulted in the restatement of some data regarding climate and energy for the period 2021–2023. The gas metric was restated for three legal entities in Germany, which transitioned to more granular measurement methodologies. The metrics related to gas and electricity for one legal entity were corrected and the reporting process was improved to reduce the risk of inaccuracies going forward. One legal entity, High Purity New England, has been added through acquisition and data is updated for the period 2021–2024. All data is location based. Energy data is not included in the report for the following companies: Ultra Clean, Healthmark and Paragonix, as they were acquired less than 24 months ago.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

ENVIRONMENT

Water

The big picture

Globally, nearly four billion people experience severe water scarcity for at least one month each year[1]. Addressing water scarcity is not only crucial to secure access to water, but also essential for improving public health worldwide.


The value of water in hospitals and the life science industry cannot be underestimated, as it directly impacts health outcomes and scientific progress. Water is an indispensable resource, serving as the backbone for patient care, medical processes, and scientific research. In hospitals, it ensures hygiene, for example, by supporting instrument reprocessing, and maintaining a safe environment for patients and staff.

Furthermore, in the life science industry, access to high-quality water is crucial for laboratory accuracy, pharmaceutical production, biotechnology processes, and research and development, ensuring the integrity and reliability of scientific work. Water is also necessary in the production and testing of Getinge equipment and in the upstream supply chain.

Getinge's Target

The target is to reduce water consumption in sites located in water scarce areas by 20% by 2030 (base year 2021). The sites in scope for the target are those located in areas of high water stress defined as "extremely high" and "high" according to Aqueduct.[2]

Relevant Sustainability Development Goals



1) Water scarcity | UNICEF 2) WRI Water Risk Atlas tool Aqueduct

Impacts

The materiality assessment resulted in water consumption being added as a material topic for 2024.

Negative impacts in the valuechain are described in the boxes below.

Impacts Upstream	Impacts Own Operations	Impacts Downstream
Water is necessary in producing several materials purchased by Getinge, such as electronics, metals and plastics. Increased consumption of these materials results in increased consumption of water, potentially in areas with high water stress.	Getinge consumes water in larger amounts in the sites that manufacture sterilizers and washers. Withdrawal and consumption of water in areas classified as high water-stressed can put pressure on ecosystems and community access to water. Eight of the company's manufacturing sites are located in high water-stressed areas.	Water is needed to use some of the products Getinge puts on the market such as sterilizers and washers. If these products are used in customer sites located in high water-stressed areas the impact could be significant.

Policies

The company actively promotes resource efficiency in its entire value chain. The management of water follows the principles set out in both the sustainability and environmental policies and local environmental management systems. The sustainability policy describes sustainable innovations for better health which includes making products with reduced environmental impact.

Getinge's Global Environmental Policy includes the company's commitment to ensuring resource efficiency. The policy outlines the importance to continuously work to make manufacturing processes resource and water efficient, minimizing risk of pollution with the goal to optimize resource use throughout the company operations.

Getinge's process for EcoDesign includes requirements and criteria that shall be considered in the design phase such as selection of materials to be used and their environmental impact.

Getinge has ISO 14001 certifications at all production units (except for a small number of recently acquired units) to comply with all local regulation including safeguarding the use of water where relevant.

Strategic direction and actions

In 2024, the company used the World Resources Institute tool Acqueduct to understand which sites are located in water stressed areas. New targets to reduce water consumption in those sites were established.

With regards to the impact from use of products continuous work is done in the product development of sterilizers and washers to find solutions to reduce water consumption when these products are used. One example of this work is the GEW 888 neo washer/dryer launched in 2024. Depending on the customized configuration the new washer reduces the water consumption by up to 32% compared to the product it replaces.

20250623153053

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Targets, key figures & results

The target is to reduce water consumption in sites located in water scarce areas[1] by 20% by 2030 (base year 2021). The sites in scope for the target are those located in areas of high water stress defined as "extremely high" and "high" according to Aqueduct. Data is compiled monthly via a data management system and data is sourced from direct measurements, either via supplier invoices or via local measuring equipment or meters. Water is not recycled or reused. For water in high stress areas, the 2024 result shows a 3% increase compared to last year, mainly explained by increased production and testing in one site and one site where the property owner has amended the cost allocation of water between the tenants.

Water consumption in own production, m³	2024	2023	2022	2021
Total water consumption	188,481	175,826	162,499	202,835
Total water consumption in areas of:				
– *water risk (high according to Aqueduct)*	*40,565*	*43,016*	*40,272*	*58,849*
– *high water stress (extremely high and high according to Aqueduct)*	*97,710*	*95,188*	*88,413*	*109,370*

Water intensity	2024	2023	2022	2021
Total water consumption in m³ per net revenue (MSEK) in own operations	11.6	11.1	10.1	11.5

1) Source: WRI Water Risk Atlas tool Aqueduct.



Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

ENVIRONMENT

Circularity

The big picture

Currently, the secondary material consumed by the global economy is only 7.2% of all material used – a decrease from 9.1% over the past five years, due primarily to increasing virgin material extraction[1]. Changing the way products are made and how materials are used will have an important role in reusing and recycling, as well as reducing carbon emissions. One example is that by eliminating waste and pollution, greenhouse gas emissions can be reduced across the value chain[2].


According to the World Health Organization high income hospitals generate around 0,5kg of hazardous waste per bed per day and in high income countries the majority of waste (not including food waste) is plastic-based[3]. Working to reduce waste streams and improve material efficiency is therefore a priority for Getinge.

Getinge's Target

No waste to landfill by 2030

The target for the company towards 2030 is zero waste to landfill, excluding material required by local regulations to be landfilled.

Relevant Sustainability Development Goals



1) https://www.circularity-gap.world/2024 2) Ellen McArthur foundation
3) https://www.who.int/news-room/fact-sheets/detail/health-care-waste

Impacts

Getinge contributes to the generation of hospital waste as some of the products put on the market are disposable products. Many of the disposables come in contact with bodily fluids and are therefore classified as hazardous waste after being used. Packaging that is needed to transport products and to maintain the necessary sterility in many of products prior to their use, becomes waste after the product is used. Waste is also generated in manufacturing of Getinge products. Negative impacts in the valuechain are described in the boxes below.

Impacts Upstream	Impacts Own operations	Impacts Downstream
Production of single-use plastic consumables increases the demand for high-volume raw materials that strain ecosystems and contribute to waste after disposal. Being a manufacturer of both capital goods and consumables, requires energy and resource inputs, which contribute to emissions and resource depletion.	Getinge's production sites produce waste which is partly recycled, partly incinerated and when legally obliging sent to landfill. Waste handling requires energy and contributes to emissions and pollution.	Single-use plastic consumables generate significant waste, often ending up in incineration due to their contamination in use in hospitals, contributing to pollution and emissions. Packaging requires resources to be made such as wood, paper and plastics and the majority of the packaging becomes waste after being used for transporting goods.

Policies

Getinge's Global Environmental Policy states the company's commitment to ensuring resource efficiency. The policy outlines the importance to continuously work to make manufacturing processes resource and energy efficient, minimizing risk of pollution, emissions and waste with the goal to optimize resource use throughout the company operations. The environmental policy also includes Getinge's ambition to work with circularity. The company is dedicated to the principles of circularity and actively promotes resource efficiency, avoiding hazardous substances and waste in its entire value chain. The management of waste follows the principles set out in local environmental management systems. Getinge's process for EcoDesign includes requirements and criteria that shall be considered in the design phase such as: selection of materials to be used, reduction of material usage and the use of packaging materials as well as preparation of products for end of life and enabling reuse or recycling of material.

Getinge has ISO 14001 certifications at all production units (except for a small number of recently acquired units) to comply with all local regulation connected to waste handling.

Strategic direction and actions

Waste from own operations

Getinge is involved in waste management from its own operations, while also influencing the amount of waste generated by customers downstream through packaging and sale of single-use items, which are mainly made of plastic. The ambition is to follow the waste hierarchy aiming for prevention of waste. When this is not possible,

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

re-use and recycling are seen as the preferred alternatives and the last alternative is incineration. In some cases legislation rules that certain waste is to be landfilled. The company works together with waste handling companies treating the waste from operations to continuously find the best alternatives.

Waste from packaging

Product safety and clinical performance can never be compromised. This means that changing materials in the primary packaging is not an option unless the same level of safety and sterility can be maintained.

Product resource efficiency

Getinge has implemented Life Cycle Assessments (LCA) for products and conducted more than 10 full studies up to date. In addition, the EcoDesign SOP mandates that all new products are to be assessed according to this LCA methodology. The result from the studies aids in communicating the product's environmental impact, identifies the focus areas, optimizes resource use, provides a data-driven basis for informed decision making in product development and supports the EcoDesign process.

Targets, key figures & results

No waste to landfill by 2030

Responsible resource use and waste management are priorities across the company. By monitoring waste handling the company ensures the best options are chosen to ensure material efficiency. By 2030, the company aims to achieve zero waste to landfill, except for materials required by local regulations to be landfilled. Waste to landfill is estimated to 121 tons for 2024 (estimation for 2023 was 120 tons). Efforts to further enhance the quality of waste data are ongoing. The total amount of generated waste for 2024 increased slightly compared to 2023 and summed up to 2 988 tons. The increase mainly relates to one site with extraordinary handling for 2024, including repair of a road surface and cleaning activities on site.

Share of recycled waste from production	2024	2023	2022	2021
Recycling quote waste	50%	44%	47%	51%
Recycling quote waste (incl energy recovery)	90%	89%	91%	94%

Total waste (ton) from production	2024	2023	2022	2021
Waste to recycling	1,487	1,273	1,318	1,459
Waste not recycled	307	328	239	173
Waste energy recovery	1,195	1,283	1,239	1,209
Total generated waste	**2,988**	**2,884**	**2,797**	**2,841**

Non-hazardous waste (ton) from production	2024	2023	2022	2021
Non hazardous waste to recycling	1,425	1,219	1,275	1,397
Waste not recycled	254	274	201	115
Waste energy recovery	1,065	1,177	1,121	1,085
Total generated waste	**2,744**	**2,670**	**2,597**	**2,597**

Hazardous waste (ton) from production	2024	2023	2022	2021
Hazardous waste to recycling	62	54	43	62
Waste not recycled	53	54	38	58
Waste energy recovery	129	106	119	124
Total generated waste	**244**	**214**	**200**	**244**

Waste (ton) to landfill from production	2024	2023	2022	2021
Waste to landfill	121	120	n.a	n.a

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

EU Taxonomy

To identify Taxonomy-eligible activities an internal working group, supported by external expertise, has assessed the company's economic activities and investments against the Taxonomy Regulation and its delegated acts.

In addition to the two environmental objectives of Reduced Climate Impact and Adaptation to Climate Change, four new environmental objectives were added in 2023: 1) Sustainable use and protection of water and marine resources, 2) Transition to a circular economy, 3) Prevention and mitigation of environmental pollution and 4) Protection and restoration of biodiversity and ecosystems.

In accordance with the current EU guidance, issued in November 2024, Getinge has assessed the company's impact for the objective "Transition to a circular economy". The current assessment is that a number of products and product groups are covered by the environmental objective according to the criteria in the economic activity 1.2: "Manufacture of electrical and electronic equipment", which is presented in the table "Proportion of turnover" on page 147. The comparative figure for 2023 is set to zero, as the reporting for 2023 was based on a different interpretation of the principle. The capital expenditure (CapEx) and operating expenditure (OpEx) related to this activity have not yet been fully assessed.

Compliance with minimum safeguards must also be met and Getinge's position is that the group essentially meets these requirements. During 2024, work has been undertaken to formalise a human rights compliance program, including concluding the ongoing impact assessment throughout the value chain. As this assessment is not yet concluded Getinge will not claim meeting the minimum safeguards.

Getinge aims to, by 2030, reach net zero Scope 1 and Scope 2 emissions and reduce Scope 3 by 25% compared with the base year of 2021. Getinge has also set the target of having net-zero emissions throughout the entire value chain by 2050. As part of the actions to reduce scope 1 & 2 emissions investments mainly in energy efficiency equipment and electric cars have been made. Current amounts for the activities in question and the applied reporting policies are presented below.

Reporting data for turnover, CapEx and OpEx are based on separate account structures, therefore the risk for double counting is deemed low. Getinge is applying the International Financial Reporting Standards (IFRS), issued by the International Accounting Standards Board, as adopted by the EU.

Getinge has not yet developed a CapEx plan under the Taxonomy Regulation. As the "Draft Commission Notice on the interpretation and implementation of the EU Taxonomy Environmental Delegated act" was presented in late November 2024, Getinge will take this document in consideration and further validate during 2025 concerning the CapEx plan.

Annex II
Additional templates for economic activities that contribute to multiple objectives

	Proportion of CapEx/Total CapEX	
	Taxonomy-aligned per objective	Taxonomy-eligible per objective
CCM	0%	12%
CCA	%	%
WTR	%	%
CE	%	0%
PPC	%	%
WTR	%	%

Nuclear and fossil gas related activities

Row		
	Nuclear energy related activities	
1.	The undertaking carries out, funds or has exposures to research, development, demonstration and deployment of innovative electricity generation facilities that produce energy from nuclear processes with minimal waste from the fuel cycle.	NO
2.	The undertaking carries out, funds or has exposures to construction and safe operation of new nuclear installations to produce electricity or process heat, including for the purposes of district heating or industrial processes such as hydrogen production, as well as their safety upgrades, using best available technologies.	NO
3.	The undertaking carries out, funds or has exposures to safe operation of existing nuclear installations that produce electricity or process heat, including for the purposes of district heating or industrial processes such as hydrogen production from nuclear energy, as well as their safety upgrades.	NO
	Fossil gas related activities	
4.	The undertaking carries out, funds or has exposures to construction or operation of electricity generation facilities that produce electricity using fossil gaseous fuels.	NO
5.	The undertaking carries out, funds or has exposures to construction, refurbishment, and operation of combined heat/cool and power generation facilities using fossil gaseous fuels.	NO
6.	The undertaking carries out, funds or has exposures to construction, refurbishment and operation of heat generation facilities that produce heat/cool using fossil gaseous fuels.	NO

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

ENVIRONMENT - EU Taxonomy

Proportion of turnover from products or services associated with Taxonomy-aligned economic activities – disclosure covering year 2024

Financial year 2024		2024		Substantial contribution criteria						DNSH criteria ("Does Not Significantly Harm")									
Economic activities	Code(s)	Turnover	Proportion of turnover 2024	Climate change mitigation	Climate change adaptation	Water	Pollution	Circular economy	Biodiversity	Climate change mitigation	Climate change adaptation	Water	Pollution	Circular economy	Biodiversity	Minimum safeguards	Proportion of Taxonomy aligned (A.1) or eligible (A.2) turnover, year 2024	Category enabling activity	Category transitional activity
		SEK M	%	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y/N	Y/N	Y/N	Y/N	Y/N	Y/N	Y/N	%	E	T
A. TAXONOMY-ELIGIBLE ACTIVITIES																			
A.1. Environmentally sustainable activities (Taxonomy-aligned)																			
Turnover of environmentally sustainable activities (Taxonomy-aligned) (A.1)			0%														0%		
Of which Enabling			0%														0%		
Of which Transitional			0%														0%		
A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities)																			
1.2 Manufacture of electrical and electronic equipment	CE1.2	7,852	23%	N/EL	N/EL	N/EL	N/EL	EL	N/EL*										
Turnover of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		7,852	23%	0%	0%	0%	0%	23%	0%								0%		
A. Turnover of Taxonomy eligible activities (A.1+A.2)		**7,852**	**23%**	**0%**	**0%**	**0%**	**0%**	**23%**	**0%**								**0%**		

B. TAXONOMY-NON-ELIGIBLE ACTIVITIES

Turnover of Taxonomy-non-eligible activities[1]	26,907	77%
Total	**34,759**	**100%**

1) Refers to the group's net sales (turnover) for the 2024 financial year, which corresponds to the revenue arising in the normal operations recognized in accordance with IFRS 15. Refer also to Note 2 Net sales per revenue classification, in the financial reporting.
2) Getinge did not identify any revenue from Taxonomy-eligible economic activities in its operations for the 2023 fiscal year. The current guidance from EU was issued in November 2024, and the figures for 2023 was built on other interpretation of the principal..

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Proportion of CapEx from products or services associated with Taxonomy-aligned economic activities – disclosure covering year 2024

Financial year 2024		2024		Substantial contribution criteria						DNSH criteria ("Does Not Significantly Harm")									
Economic activities	Code(s)	CapEx	Proportion of CapEx 2024	Climate change mitigation	Climate change adaptation	Water	Pollution	Circular economy	Biodiversity	Climate change mitigation	Climate change adaptation	Water	Pollution	Circular economy	Biodiversity	Minimum safeguards	Proportion of Taxonomy aligned (A.1) or eligible (A.2.) CapEx, year 2023	Category enabling activity	Category transitional activity
		SEK M	%	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y/N	Y/N	Y/N	Y/N	Y/N	Y/N	Y/N	%	E	T
A. TAXONOMY-ELIGIBLE ACTIVITIES																			
A.1. Environmentally sustainable activities (Taxonomy-aligned)																			
CapEx of environmentally sustainable activities (Taxonomy-aligned) (A.1)			0%	%	%	%	%	%	%								0%		
Of which Enabling			%	%	%	%	%	%	%								%		
Of which Transitional			%	%													%		
A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities)																			
Transport by motorbikes, passenger cars and light commercial vehicles	CCM 6.5	275	5%	EL	N/EL	N/EL	N/EL	N/EL	N/EL								6%		
Renovation of existing buildings	CCM 7.2/ CE 3.2	3	0%	EL	N/EL	N/EL	N/EL	EL	N/EL								0%		
Installation, maintenance and repair of energy efficiency equipment	CCM 7.3	12	0%	EL	N/EL	N/EL	N/EL	N/EL	N/EL								1%		
Installation, maintenance and repair of charging stations for electric vehicles in buildings (and parking spaces attached to buildings)	CCM 7.4	0	0%	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0%		
Installation, maintenance and repair of instruments and devices for measuring, regulation and controlling energy performance of buildings	CCM 7.5	4	0%	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0%		
Installation, maintenance and repair of renewable energy technologies	CCM 7.6	14	0%	EL	N/EL	N/EL	N/EL	N/EL	N/EL								0%		
Acquisition and ownership of buildings	CCM 7.7	333	6%	EL	N/EL	N/EL	N/EL	N/EL	N/EL								11%		
CapEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		641	12%	12%	%	%	%	%	%								18%		
A. CapEx of Taxonomy eligible activities (A.1+A.2)[2]		**641**	**12%**	**12%**	%	%	%	%	%								**18%**		

B. TAXONOMY-NON-ELIGIBLE ACTIVITIES

CapEx of Taxonomy-non-eligible activities		4,680	88%
Total[1]		5,321	100%

1) Refers to capital expenditure (CapEx) related to investments in tangible assets, intangible assets and right-of-use assets under IFRS 16 (refer to Note 9 Intangible assets, Note 10 Tangible fixed assets and Note 11 Leases of the Annual Report). Assets arising through business acquisitions are included, except for goodwill which is not an identifiable intangible asset according to the definition in IAS 38.
2) Investments in energy-saving equipment have been judged to be Taxonomy-eligible according to activities 7.3, 7.4 and 7.5 in Annex 1 of the Taxonomy Regulation and investments in charging stations and right-of-use assets regarding electric cars are Taxonomy-eligible according to activity 7.3 and activity 6.5 in Annex 1. Investments in solar panels and right-of-use assets regarding premises and other investments in buildings are Taxonomy-eligible according to activities 7.6 and 7.7 in Annex 1.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Proportion of OpEx from products or services associated with Taxonomy-aligned economic activities – disclosure covering year 2024

Financial year 2024		2024		Substantial contribution criteria						DNSH criteria ("Does Not Significantly Harm")									
Economic activities	Code(s)	OpEx	Proportion of OpEx 2024	Climate change mitigation	Climate change adaptation	Water	Pollution	Circular economy	Biodiversity	Climate change mitigation	Climate change adaptation	Water	Pollution	Circular economy	Biodiversity	Minimum safeguards	Proportion of Taxonomy aligned (A.1) or eligible (A.2) OpEx, year 2023	Category enabling activity	Category transitional activity
		SEK M	%	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y; N; N/EL	Y/N	Y/N	Y/N	Y/N	Y/N	Y/N	Y/N	%	E	T
A. TAXONOMY-ELIGIBLE ACTIVITIES																			
A.1. Environmentally sustainable activities (Taxonomy-aligned)																			
OpEx of environmentally sustainable activities (Taxonomy-aligned) (A.1)			%	%	%	%	%	%	%								0%		
Of which Enabling			%	%	%	%	%	%	%								%		
Of which Transitional			%	%													%		
A.2 Taxonomy-Eligible but not environmentally sustainable activities (not Taxonomy-aligned activities)																			
OpEx of Taxonomy-eligible but not environmentally sustainable activities (not Taxonomy-aligned activities) (A.2)		0%	%	%	%	%	%	%	%								0%		
A. OpEx of Taxonomy eligible activities (A.1+A.2)		0%	%	%	%	%	%	%	%								0%		

B. TAXONOMY-NON-ELIGIBLE ACTIVITIES

OpEx of Taxonomy-non-eligible activities	1,547	100%
Total[1,2]	1,547	100%

1) Refers to operating expenditure (OpEx) attributable to costs for research and development, renovating buildings, short-term leases, maintenance and repairs and expense for tools.
2) Identified OpEx that are Taxonomy-eligible in 2024 amount to SEK 0 M.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

SOCIAL

Own employees

Employee engagement


The big picture

Employee engagement is essential to Getinge's success as it directly influences employee retention, business performance, and the company's ability to innovate. Engaged employees are more motivated, productive, and committed to the company's objectives.

Getinge's Target

The target for employee engagement is to reach an employee index score >70% measured through employee surveys.

Relevant Sustainability Development Goals



Impact

Although employee engagement is not included in the material topics, the company reports progress on engagement as it is interlinked with other material topics such as quality, inclusion and belonging, and health and safety. Training and development are important in this context to ensure employees are equipped with the necessary skills and knowledge for them to contribute effectively and grow within the organization.

Policies

Getinge's Global People Policy states that Getinge is committed to providing a fair and sustainable working environment for all employees. The objective of this policy is to define the company's position in relation to its people; reflecting human rights values both internally (making sure Getinge is a great place to work) and externally (when representing Getinge in business and other relations). The policy is valid for all Getinge companies, its subsidiaries and joint operations and applies to all employees and directors, as well as consultants and agency personnel who work at Getinge premises or under the direction of Getinge.

Strategic direction and actions

The company promotes employee engagement through regular feedback mechanisms, such as such as the global biannual employee survey. These surveys serve as a critical control mechanism, enabling the company to identify relevant focus areas and take timely actions based on employee feedback.

During 2024 Getinge has continued to support employee development through its comprehensive training programs, which are aligned with both employee needs and the company's strategic goals. Performance and career development are discussed annually between employees and their managers, with decisions guided by local regulations and internal governance documents.

In addition, Getinge has established a comprehensive framework for employee development, governed by key policies and procedures, including the Onboarding and Qualification SOP, the Competence, Awareness and Training directive and Product Training Certification Programs SOP. Training and development programs are delivered through both global and local initiatives, offered via face-to-face sessions or the company's e-learning platform.

The company ensures continuous monitoring and improvement of its training and development offerings. Getinge conducted 71,132 (66,270) hours of training globally in 2024, focusing on key areas such as Leadership and People Performance, Ethics and Compliance, Health and Safety, IT, Operations, and Continuous Improvement.


Targets, key figures & results

The target for employee engagement is to reach an employee index score >70% measured through employee surveys.

In 2024 the response rate was 78% (79%) and the engagement score was 71% (71%), meeting this target. The company remains committed to maintaining or exceeding this level of engagement in future surveys.

Reduced absence from work due to sick leave

The rate of sick leave in 2024 was: 2.6% (2023: 3.2%)



20250623150S7

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Occupational health and safety

The big picture

Safety at work is a basic human right. Ensuring a safe working environment protects employees from workplace hazards, enables improved productivity and reduces absenteeism. Working with Health & Safety also fosters a culture of trust and engagement. A culture of trust leads to increased employee satisfaction and engagement and can, in turn, foster innovation.

Getinge's target

Getinge's target is to reduce work-related accidents in relation to working hours (Work Related Accident Rate, WRAR) to less than 1 by 2025.

Relevant Sustainability Development Goals

Impacts

Getinge prioritizes health and safety measures which can positively impact the well-being of its employees. Safe working conditions can contribute to improved job satisfaction. Employees who feel cared for are more likely to be engaged, productive, and committed. Despite continous work to reduce risks, safety-related incidents do occur in the company mostly related to ergonomics. If the company or managers thereof would neglect health and safety measures the potential negative impact of workplace accidents, injuries, and occupational illnesses could increase.

Key potential negative impacts in the company's production sites include work-related accidents and ill health, with musculoskeletal disorders and psychosocial conditions being the most common in 2024. About 30% of the injuries in 2024 were directly linked to ergonomics.

Policies

Getinge's Code of Conduct mandates that all employees take responsibility for their safety and the safety of others. All employees, temporary workers and consultants must also comply with the mandatory requirements of Getinge's Global Policies, as well as adhering to local occupational health and safety standards. Getinge's global HR Policy and Code of Conduct encourage every employee to report, give feedback and avoid any hazardous situation. Getinge's Business Partner Code of conduct applies to suppliers and includes providing and maintaining a safe working environment. Health and safety are managed globally under Getinge's Health and Safety directive, with each workplace expected to follow the standards outlined by the directive. Each production site prepares and documents its own Occupational Health and Safety Policy in accordance with Getinge's directive. Employee consultation forums, such as safety committees, are set up in compliance with local laws. Getinge's management system was implemented in 2021 when the Global directive came into effect. The management system is not certified according to ISO or other standards.

The risk assessment process, guided by the Global Occupational Health and Safety Risk Assessment procedure, involves identifying hazards and assessing risks. It provides guidance for employees to identify potential risks and method to evaluate the level of criticality. The assessment is reviewed annually or whenever there are organizational changes. Getinge's incident management process requires that a thorough investigation of incidents, corrective and preventive actions be carried out and that insights are shared across the organization. Local occupational health services carry out risk analyses regularly. After any incident, risk analyses are reviewed to ensure proactive risk management. Work-related hazards that pose a risk of high-consequence injury are monitored through risk analysis and tracked in local management systems. The main risks during 2024 were ergonomics/manual handling and material handling.

To ensure up-to-date competence and a thorough understanding of health and safety risks, Getinge's global curricula for training and development covers health and safety awareness training.

A dedicated Speak-Up Line allows employees to report health and safety risks confidentially.

Strategic direction and actions

Getinge focuses on providing an incident-free workplace and fostering a safe culture with full worker engagement. In 2024, the company continued to work on improving the reporting system to support the company's goal of maintaining a structured, preventive approach to occupational health and safety. An important part of the approach is to have a safety-focused culture, as this enables employees to take ownership of their own and other employees' safety. Throughout the year, Getinge continued to roll out initiatives to reduce ergonomic-related injuries, such as introducing job rotation and implementing more frequent breaks.

0.92


Work-related accident rate (WRAR)

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Targets, key figures & results

Getinge's target is to reduce the work-related accident rate (WRAR) to less than 1 by 2025. In 2024, the WRAR was 0,92 (0,89), stable compared with last year and below Getinge's target. For contractors, the work-related accident rate decreased to 0,84 (1.11). Contractor cases are mainly attributed to falls/trip, material handling cases and ergonomics.

Types of work-related injuries, employees



Work-related injuries for employees[1]

Employees	2024	2023
Number of employees	11,791	11,385
Number of work-related fatalities	0	0
Number of fatalities due to work-related ill health	0	0
Number of high consequence work-related accidents	0	2
Number of work-related accidents	115	97
Number of work-related ill health	11	21
Number of lost workdays for work-related accident	1,100	1,282
Number of lost workdays for work-related ill health	577	786
Total work related high-consequences accident rate	0	0,02
Total work-related accident rate	0.92	0.89
Total work-related ill health rate	0.09	0.19

1) Health and safety data is not included for Paragonix, as it was acquired less than 24 months ago

Work-related injuries for contractors

Contractors	2024	2023
Number of temporary agency workers	631	691
Number of contractor workers	230	280
Number of work-related fatalities	0	0
Number of high consequence work-related accidents	0	0
Number of work-related accidents	10	12
Number of lost workdays for work-related accident	105	87
Total high consequence work-related accident rate	0	0
Total work-related accident rate	0.84	1.11



20250623150538

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Diversity, equity, inclusion & belonging (DEIB)


The big picture

Diversity, equity, inclusion, and belonging (DEIB) are essential for fostering innovation, creativity, and a positive workplace culture. A diverse and inclusive environment ensures that different perspectives are considered in decision-making, allowing the company to better serve its customers and remain competitive. Furthermore, a lack of diversity can lead to discriminatory practices, reduce employee well-being and hinder the advancement of underrepresented groups. Diversity does not mean only differences in gender, gender identity, but also differences in, for example, race, ethnicity, religion, age, marital or parental status, disability, sexual orientation, nationality, or other protected characteristics, backgrounds, experiences, perspectives, thoughts, interests, and ideas.

Getinge's Target

Getinge's primary target is to ensure equal employment opportunity and non-discrimination across all levels of the organization.

Relevant Sustainability Development Goals



Impacts

Getinge's culture promotes inclusive behavior with the ambition that all people can thrive in the workplace. Diversity in the company fosters innovative thinking and enhanced problem-solving by leveraging diverse skills and experiences. Training programs, development initiatives and regular individual development meetings between employees and managers helps ensure that career progression aligns with individual ambitions and demonstrated competence. Strong DEIB policies improve accountability to promote diversity and inclusion, which has a positive impact on employees.

The negative impacts are the potential for unconscious bias in recruitment, promotion, or performance reviews. In addition, lack of diversity in certain working groups and underrepresentation of certain demographic groups can lead to an inflexible culture that is unable to account for the interests of all stakeholders. Finally, if existing policies are not enforced, discrimination or harassment could occur.

Policies

Getinge's commitment to equal employment opportunities and an inclusive workplace is underscored by the company's Code of Conduct and Human Rights Policy, which affirm principles of diversity, inclusion, freedom of association, and workplace safety. These foundational policies provide a clear framework for the company's zero-tolerance stance on discrimination and harassment.

Building on the above mentioned framework, the People Policy and Diversity Directive outline specific expectations and practices to ensure fairness, respect, and dignity for all employees, regardless of gender, gender identity, race, ethnicity, religion, age, marital or parental status, disability, sexual orientation, nationality, or other protected characteristics.

Additionally, employees have access to a Diversity Behaviors instruction, offering guidance on fostering conscious inclusion, reducing discrimination risk, and intervening as bystanders when necessary. Processes for unbiased recruitment are in place to secure equal opportunities and non-discrimination in recruitment. The Getinge Speak-Up Line allows employees, as well as suppliers and partners, to report behavior that deviates from these guidelines ensuring that any issues are addressed transparently.

Strategic direction and actions

Diversity

Recognizing the importance of diverse perspectives in leadership, the company has implemented initiatives to develop a broader pool of diverse talent. By focusing on mentorship, leadership development, and individual development plans between managers and employees, the company ensures that a wide range of thoughts and ideas shape its future leadership.

Equity

Global paid family leave is a cornerstone of Getinge's commitment to equity. Introduced in 2022, the company offers at least 16 weeks of paid parental leave and 4 weeks of paid caregiver leave to all employees with over one year of service, regardless of gender. Local regulations may provide more generous terms.

Eliminating pay disparities based on gender promotes an inclusive workplace where all employees are valued equally for their contributions, regardless of their gender. Gender pay equity analysis[1] was conducted in several countries, including the UK, US, Australia, France, Sweden, and Germany, ensuring compliance with local legislation and corporate guidelines.

Inclusion and belonging

In 2024, Getinge placed a strong emphasis on competence development to advance its commitment to inclusion. Inclusive leadership plays a pivotal role in creating an environment where every employee feels valued and heard, regardless of their background or identity.

50/50

Gender representation in the Getinge Executive Team

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

By embedding diversity, inclusion, and belonging into leadership development, Getinge ensures that its leaders are not only capable of managing diverse teams effectively but also embody the values of inclusivity in their day-to-day leadership. This focus on competence development underscores the company's commitment to building a workplace that celebrates differences and fosters innovation through a wide range of perspectives.

A significant step was taken by integrating diversity and inclusive leadership into the company's Leading Leaders and Leading People training programs, with approximately 130 leaders taking part throughout the year. Diversity and inclusion have also been included into the Aspiring Leaders program attended by employees who are expected to take managerial roles in the near future. More than 170 employees attended this training during 2024.

Getinge has developed an e-learning course on unconscious bias, available to all employees, with a specific focus on managers. This course aims to raise awareness of the biases that can influence decision-making and interpersonal interactions, often unconsciously. By helping managers recognize how these biases can affect team dynamics, recruitment, and leadership decisions, the training promotes greater accountability and awareness. This initiative is a vital part of the company's broader efforts to create a more inclusive and equitable culture where every voice is heard and everyone can thrive.


Diversity and inclusion have also been embedded into the company culture approach "This is who we are" to cultivate a more inclusive and engaged workforce, which is essential to the long-term success of the company.

In addition, Getinge measured employee sentiment around DEIB through its employee surveys, which serves as a control mechanism to assess and address gaps in inclusion.

Targets, key figures & results

Getinge's primary target is to ensure equal employment opportunity and non-discrimination across all levels of the organization.

Gender representation



While progress has been slow, the company reported a consistent upward trend in female representation in 2024. Although the proportion of all female employees increased only marginally, the proportion of female managers increased 1% and the female representation in the executive team increased 5% compared to the previous year.

Additionally, Getinge continues to aim for improvements in regards to employee rating of the level of inclusion and belonging in the company. This is tracked through questions in the biannual employee engagement survey. For 2024 the inclusion score was 75 (74) and the belonging score was 69 (71).

Age intervals All employees	Female	Male	Other	Total
15-30	7%	7%	0%	14%
31-50	21%	34%	1%	55%
51-70	10%	20%	0%	30%
Invalid data	0%	0%	0%	0%
Total FTEs 2024	**38%**	**61%**	**1%**	**100%**
Total FTE 2023	38%	62%	0%	100%

Managers only	Female	Male	Other	Total
15-30	2%	1%	0%	3%
31-50	24%	39%	1%	64%
51-70	9%	23%	0%	33%
Invalid data	0%	0%	0%	0%
Total FTEs 2024	**35%**	**64%**	**2%**	**100%**
Total FTE 2023	34%	65%	0%	100%

The tables above present the gender and age distribution for all employees (Age intervals, All Employees) as well as for managers (Age intervals, Managers). All figures have been rounded to the nearest whole number full-time equivalents (FTE).

Confirmed incidents of discrimination and actions taken

During 2024, Getinge did not record any cases of discrimination that would be found substantiated as of the date of this reporting.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Employee metrics

FTExGender and Region	Female	Male	Other	*of which Americas*	*of which APAC*	*of which EMEA*	Total
FTE Permanent employees	4,250	7,059	115	*3,254*	*1,533*	*6,637*	11,423
FTE Temporary employees	195	170	3	*71*	*49*	*248*	368
FTE Full Time	4,175	7,064	115	*3,308*	*1,570*	*6,476*	11,354
FTE Part Time	270	165	2	*17*	*11*	*409*	437
Total FTEs 2024	**4,445**	**7,229**	**117**	***3,325***	***1,581***	***6,885***	**11,791**
Total FTE 2023	4,277	7,100	9	*3,027*	*1,607*	*6,752*	11,386

The number of employees at Getinge was 11,791 full-time equivalents (FTEs) at the end of the reporting period. All figures are rounded to the nearest whole number, but totals are calculated with decimals. Table "FTExGender and Region" shows the gender split across Permanent/Temporary, Full/Part time and the regional split. All numbers are in FTE.

The higher amount of "Other" compared to last reporting period comes from the acquired Paragonix Technologies where the gender of the employees was not captured adequately in the Human Resource Information System (HRIS). This will be corrected during 2025.

Difference to last period	FTEs	Comments
Increase from Dec 2023 to Dec 2024	+405	
Healthmark	+346	End of 2023 Healthmark was added to Getinge's system, however migration of the number of employees to the Human resources system was not finalized before the end of 2024.
Paragonix Technologies	+111	Getinge acquired Paragonix Technologies.
Other Changes excluding acquisitions of companies	-52	

The table "Difference to last period" presents the most marked differences to last year, including acquisitions of companies and/or assets.

Development of the FTE throughout the year is characterized by a slight increase during first half and then a steeper decrease during second half (ranging from 11,130 - 11,541 FTE when excluding acquisitions of Healthmark and Paragonix).

Changes from December 2023 to December 2024, including acquisitions of assets, split on Employee Cost Category.
Only major changes are mentioned.

Manufacturing & Service	+44	Changes in the number of Field Technicians in China, France, USA and Japan to match market demands. Applikon has down scaled production due to restructuring. HPNE also adjusted the capacity downwards. The DPTE Betabag® production capacity in Vendome has upscaled to accommodate the needs. Production has been increased in Türkiye, Germany and France to meet market demands. In USA there was a decrease due to efficiency and productivity programs. Insourcing of logistics activities in the USA led to an increase.
Sales	-114	During 2024 there was a steady decrease of personnel involved in sales activities, in direct sales personnel, sales support and customer service functions.
Administration	+24	The biggest change in administrative personnel comes from the insourcing of logistics project in US. Furthermore, the company increased the personnel in Getinge Shared Service Center to support increased task activity. Reduced employees in IT support and internal development in Germany.
R&D	-6	Personnel increased in Sweden at the same time as the R&D operations decreased in Germany and USA.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Workers who are not employees	FTEs	Comments
Difference to last period	-110	Decrease from Dec 2023 to Dec 2024
Manufacturing & Service	+6	The increase is primarily due to changes in various aspects of manufacturing.
Sales	-2	Minor changes across the globe.
Administration	-123	Decreases in Germany, Sweden and USA.
R&D	+8	Decrease in Sweden and increase in India and USA.

	New hires		Employee turnover	
KPIs for different groupings	Number (person)	Hire rate (%)	Number (person)	Turnover (%)
Female	405	9%	518	12%
Male	664	9%	794	11%
Other	144	65%	31	14%
15-30	331	22%	211	14%
31-50	692	11%	709	11%
51-70	181	5%	405	12%
Invalid data	9	16%	18	31%
Americas	459	14%	488	15%
APAC	208	13%	228	15%
EMEA	546	8%	627	9%
Total 2024	**1,213**	**10%**	**1,343**	**12%**
Total 2023	1,314	12%	1,278	11%

Parental leave	Started in 2024	Ended in 2024	Ended in 2023 and remained for at least 12 months	Retention rate
Female	137	89	75	86%
Male	147	138	85	93%
Other	0	0	0	n.a
Total 2024	**284**	**227**	**160**	**90%**
Total 2023	225	178	194	94%

Workers who are not employees

External workers at Getinge account for 861 full-time equivalents (FTE). All numbers are rounded to nearest whole. 631 FTE were shorter term temporary workers joining the company for secondment or as project support, upscaling of production, etc. 230 full-time equivalents are consultants & technical accounts that support on a project or on a need-to-support basis. Development of all the external workers during the period and between periods was relatively stable, varying from 861 to 1,037 FTE, but with a slightly decline from second half of 2024 (see the table to the left).

New employee hires and employee turnover

The table to the left shows the hires (including rehires) and terminations (both voluntary and involuntary) split by region, age and gender. All numbers are rounded to nearest whole.

The increased hire rate of the "Other" category primarily came from the acquisition of Paragonix Technologies and secondarily the Healthmark Industries Inc. where gender was not recorded in the system at the time of acquisition.

Parental leave

Entitlement to parental leave is governed by local rules, regulations and individual contracts and there is no data recorded centrally to provide an overview. Under Getinge's benefit plan, a total of 10,546 FTEs are entitled to parental leave, of whom 3,961 are women, 6,505 men and 81 others. The table "Parental leave" shows the number of employees that started maternity/paternity/parental leave during 2024, the number that returned and the number that were still employed at Getinge, 12 months after their return from this leave split by gender. The company has no records on employees not returning from parental leave.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

SOCIAL


Workers in the value chain

The big picture

Ensuring good working conditions and protecting worker rights throughout the whole value chain is important as it safeguards the well-being of individuals. In the value chain there is a risk that workers are exposed to unsafe environments and excessive working hours. In addition, when workers are exposed to unfair treatment it can result in significant stress and lack of job security impacting the workers' quality of life.

By prioritizing fair labor practices, workers can get access to better working conditions fostering a healthier and more equitable workforce.[1]

Relevant Sustainability Development Goals



1) https://www.ilo.org/publications/value-chain-development-decent-work-0

Impacts

The assessed impacts on workers in the value chain are limited to potential impacts. During the year a process has been implemented to better understand which of the potential impacts are actual impacts.

Getinge may contribute to poor working conditions in the value chain such as, but not limited to, excessive working hours, lack of health & safety, low wages, poor employment terms. In addition, workers' rights such as freedom of association or collective bargaining may be at risk. In the value chain there is also a potential risk of modern slavery and child labor or other human rights breaches.

Policies


The Business Partner Code of Conduct defines Getinge's ethical principles and requirements that stakeholders are expected to comply with when doing business with Getinge. The Business Partner Code of Conduct applies to suppliers, partners, contractors and subcontractors. Setting clear expectations on ethical business and responsible leadership is a prerequisite for a sustainable and fruitful collaboration. Responsible leadership is about daily decisions and as such it is critical that the Business Partner Code of Conduct is applied, that compliance is monitored, and continuous improvement undertaken. This monitoring is part of the auditing of suppliers.

Strategic direction and actions

During the year, Getinge initiated a comprehensive ESG due diligence process in the supply chain. The process is built around an analysis of ESG risks prevalent in the country of origin of the suppliers (human rights/anti-corruption) as well as ESG risks associated with the product, service or process purchased (health and safety/environment). The initiative has been launched in the majority of the company's legal entities.

Targets, key figures & results

The main objective of the ESG due diligence proces is to ensure that supply chain partners work in line with the Getinge Business Partner Code of Conduct. To achieve this, the company conducts supplier due diligence by first classifying suppliers based on risk, assessing whether identified risks are actual, and then implementing measures to mitigate them. During 2024, 65 legal entities were onboarded and more than 300 employee users trained, each tasked with implementing and overseeing the due diligence measures.



Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

SOCIAL

Patient safety and quality


The big picture

Getinge's offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. This means most of the company's products contribute directly or indirectly to public health. Product quality is an essential aspect in ensuring the safety of patients. Regulatory conformance of all products is mandatory in the highly regulated healthcare and life science industry.

Getinge's Targets

In 2024, Getinge replaced the Quality Index with two focused KPIs that reflect its commitment to quality: audit findings per audit (targeting regulatory compliance) and field actions per billion SEK net sales (assessing product quality). While field actions are safety-related measures with no defined target, Getinge aims for audit findings per audit for quality systems to remain below or equal to 1.5.

Relevant Sustainability Development Goals



Impacts

Poor quality can have severe consequences spanning operational, financial, legal and reputational. The most significant being harm to patients as defective medical devices can lead to adverse health consequences.

When product quality fails, already manufactured products and parts are at risk of becoming obsolete, resulting in unnecessary use of materials and natural resources and increased waste streams with negative environmental consequences.

Policies

Getinge is committed to delivering safe, high-quality products for its customers and patients. The Quality Management Systems (QMS) at all sites are certified to ISO 9001 or ISO 13485 standards, with additional compliance with national standards like 21 CFR 820, depending on market requirements. QMS implementation is based on a unified Quality Policy and a global framework consisting of nine Quality Directives. This ensures alignment with regulatory standards across all locations, supporting both product quality and regulatory compliance.

Through a structured corporate approach, Getinge continuously monitors compliance and the effectiveness of local QMS implementations, enabling the company to conduct targeted improvements across all areas.

Comprehensive training ensures that all employees understand quality principles, their significance, and Getinge's unified approach toward achieving quality. The company's commitment includes regular audits, with a focus on maintaining an agile, purpose-driven QMS.

Strategic direction and actions

During 2024, Getinge continued to work on important initiatives to optimize the QMS and deliver improved end-to-end quality outcomes. These initiatives and the associated investments in the QMS have been prioritized to support the company's operations related



commitments to FDA and equivalent government monitoring bodies worldwide. In 2024 Getinge transformed key QMS processes across the company with a special focus on management review, complaints process, and the field action process. Expected results from these changes are, for example, early alerts on where to improve, strengthen the quality culture to increase customer satisfaction, improve patient and user safety, reduce business risks and continue to nurture a learning organization.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Targets, key figures & results

In 2024, Getinge replaced the Quality Index with two focused KPIs that reflect its commitment to quality: audit findings per audit (targeting regulatory compliance) and field actions per billion SEK net sales (assessing product quality), where the KPI is based on number of initiated field actions. While field actions are safety-related measures with no defined target, Getinge aims for audit findings per audit to remain below or equal to 1.5.

Getinge's performance in 2024 included:

- Field actions per billion SEK (assessing product quality): 1.2 (2023: 1.9)
- Audit findings per audit for quality systems: 2.5 (2023: 1.3)
- Online customer trainings: 48,486 (2023: 45,553)

Field actions, which include recalls, corrections, and safety notifications, are essential for ensuring patient safety and regulatory compliance. In 2023, a higher number of field actions was initiated, mainly linked to the Cardiosave product. At the beginning of 2024 the number normalized. The number and type of field actions should be monitored to improve product quality and safety over time. However, it's important to clarify that the target should not be to reach a specific number of field actions but rather to reduce their occurrence. Getinge's focus is on improving product design, manufacturing processes, and post-market surveillance to address the underlying root causes of the field actions and thereby resolve problems and prevent future issues.

Audit findings are documented observations of nonconformance identified during an external audit against regulatory, quality, or procedural requirements. Getinge undergoes audits in accordance with industry practices and the requirements set by the FDA and equivalent governmental oversight bodies worldwide. The KPI for compliance metric increased slightly in 2024 compared to 2023 following a number of intensive quality audits at the beginning of the year.


Online-customer training includes various activities designed to train hospital staff in the proper and safe use of Getinge equipment. The KPI shows the number of times a customer has finalized an eLearning course or joined a training webinar, held by Getinge. In addition, the company offers extensive online training opportunities via getinge.com, simulations and workshops, and user trainings at customer site. The outcome for online customer training increased compared with 2023, mainly related to a customer activity in October 2024 – Getinge's Respiratory Care Week.

Incidents reported

In 2024, Getinge reported zero incidents of regulatory non-compliance concerning the health and safety impacts of products and services resulting in penalties or fines and one incident resulting in warnings. Compliance with CE certification ensures that all relevant products are evaluated for health and safety impacts.


All of Getinge's products are evaluated as regards to requirements for product and service information and labeling by either being subject to medical device market regulations or managed in Getinge's QMS. In 2024, Getinge reported one incident of non-compliance concerning product and service information and labelling resulting in penalties or fines and zero incidents resulting in warnings. Getinge did not have any incidents of non-compliance with regulations and/or voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship, in 2024.

Customer privacy remains a priority, and during 2024, Getinge received one complaint concerning a breach of customer privacy. The incident was caused by human error whereby e-mail addresses were added in the cc field rather than the blind cc field. Measures were taken to mitigate risks of similar incidents happening again. Getinge received no complaints in 2024 from regulatory bodies in relation to breaches of customer privacy. No leaks, theft or loss of customer data were detected in 2024.



Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Anti-corruption




The big picture

Corruption can divert financial resources away from healthcare services, leading to inadequate care and even loss of life[1]. Corruption increases inequalities in healthcare access and inefficient use of public funds. When resources are used wrongly, marginalized communities often suffer the most, as they rely heavily on public health services. Trust in healthcare systems is vital for effective public health. Corruption erodes this trust, making individuals less likely to seek care or follow medical advice. When patients believe that healthcare providers are corrupt, they may avoid necessary treatments, which can lead to worse health outcomes.

Getinge's Targets

Business Ethics & Responsible Leadership:
All employees are properly trained in Business ethics.

Relevant Sustainability Development Goals



1) https://www.who.int/activities/reducing-health-system-corruption/reducing-health-system-corruption

Impacts

Corruption leads to inefficiencies in healthcare delivery. It can inflate costs and reduce the quality of services, as funds are not used effectively. Implementing anti-corruption, anti-trust and healthcare compliance programs are important to ensure Getinge advocates for fair and transparent business practices and fostering a culture of accountability in healthcare systems.

The risk of corruption is significant especially in public procurement processes in emerging markets or markets where the tendering process is less mature and involves several business partners and intermediaries.

Distorted public procurement could be a result of corrupt practices. Public procurement stands for an increased risk and impact as this type of corruption leads to:

- Negative impact on the welfare of societies
- Potential misuse of public funds
- Potential negative impact on health equity

Policies

Getinge's Code of Conduct is at the core of Getinge's business. The Code of Conduct describes the main principles for conducting business in line with both laws and stakeholder expectations. One of the principles in Getinge's Code of Conduct is to always act with honesty, fairness and integrity. The principle states that employees should never act in a way that could manipulate the market or unfairly disadvantage colleagues, business partners or competitors. It also states that there should be no bribes, no corruption and no insider trading without exceptions.

Getinge's Global Anti-Bribery & Corruption Policy provides an overview of Getinge's commitment and principles against bribery and corruption. The policy applies to all employees, Board members and business partners acting on behalf of Getinge. The implementation is driven by global and local management, supported by the global Ethics & Compliance function. Getinge's Anti-Bribery and Corruption Policy is communicated to business

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

partners during contracting and onboarding processes. The policy and the Business Partner Code of Conduct are also referred to in contract templates.

The Global Anti-bribery & Corruption (ABC) program serves as a method and tool for ensuring that Getinge has adequate procedures in place, aimed at preventing the company from taking part in any corrupt business practices, and ensuring that the company adheres to applicable laws and regulations as well as relevant ethical norms including the Code of Conduct and global policies and directives. In addition, specific ethics & compliance programs have been designed for Healthcare Compliance and Anti-Trust to provide a risk-based framework for managing the risk of undue influence and unfair business practices.

Internal Controls, relevant for the ethics & compliance programs, have been integrated into the Getinge Internal Controls framework as relevant. The Corporate Internal Audit function conducts risk-based audits on the local implementation and provides recommendations for improving the effectiveness of the ethics & compliance programs.

Strategic direction and actions

Getinge uses a risk-based methodology in implementing its ethics and compliance programs and concentrates its efforts on high-risk areas. One of the high-risk areas is the interaction with healthcare professionals and participation in public procurement. Getinge has developed a formal protocol for conducting risk assessments and uses forensic expertise when necessary. The risk assessment process includes an evaluation of various criteria and risk factors such as those related to location, business activity, third-party interactions, products or services, internal control and audit outcomes.

Regional risk assessments have been conducted, encompassing a thorough review of country risk analysis, past audits, investigation findings, and risk assessments from site visits and stakeholder interviews. Findings indicate that a continued focus is necessary on interactions with healthcare professionals and organizations. As a major mitigation step taken over the past year, a Global Educational Grants portal was launched, along with a tool to register all interactions with healthcare professionals and organizations. In response to these findings, a detailed plan at each regional level has been developed to advance the implementation of identified mitigation actions. This includes updating relevant policies and delivering training on third-party management and monitoring practices.

Training and communication are essential components of Getinge's global ethics and compliance programs. The programs includes targeted training for Anti-bribery and corruption at all levels of the company, including employees, the Board and all members of the Getinge Executive Team. The global Ethics and Compliance team monitors all training to ensure that all employees receive relevant training at least once a year.

A specialized program, titled Responsible Leadership #ItStartsWithMe, was deployed in 2022 aiming to enhance business ethics awareness and a culture of compliance at all levels in Getinge. In 2024, the program was complemented with modules that are aimed for colleagues working in the factories.

The company has an ethics ambassador program with around 70 Ethics Ambassadors globally promoting business ethics and Responsible Leadership. The ethics ambassador program is a key initiative with the aim of spreading knowledge and supporting the organization in business ethics and compliance including Anti-Bribery and Corruption.

Targets, key figures & results

Business Ethics & Responsible Leadership:
Getinge's target is that all employees are properly trained in business ethics. Percentage of employees who completed online training in business ethics 2024: 90% (2023: 89%).

Confirmed incidents of corruption and actions taken
During 2024, Getinge did not record any cases of corruption that would be found substantiated as of the date of this reporting. No public corruption cases were brought against the company or its employees.

Legal actions for anti-competitive behavior, antitrust, and monopoly practices
No legal actions for anti-competitive behavior, antitrust, and monopoly practices arose in 2024.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Reporting principles

ENVIRONMENT

Climate and Energy

Boundaries: All greenhouse gas emissions are consolidated from entities over which Getinge has operational control (see pages 118–119 and pages 179–181).

The base year for calculation has been set to 2021 emission values, if not stated otherwise. The base year is updated for the 2024 report and is aligned with the baseline year in SBTi. Apart from adding one acquired unit (HPNE) and restatements presented in page 128, no changes in calculation method have been made.

Carbon dioxide (CO_2) is the predominant greenhouse gas included in the calculations. Emission factors applied to energy consumption for different energy resources are converted to MWh/CO_2eq. Getinge uses CO_2eq emission factors that may include small amounts of converted methane (CH_4) and N_2O, where applicable. Getinge does not report on other ozone depleting substances or greenhouse gases, neither on biogenic CO_2 emissions.

The inventory method has been used to account for reductions. Getinge strives to reach its targets to reduce GHG emissions without offsetting mechanisms to the extent possible. Getinge acknowledges that reducing CO_2 emissions with CO_2 offsetting is accepted by the GHG Protocol, but not by the SBTi.

Scope 1 and 2

GHG emissions are calculated based on the Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition).

Scope 1

Fuel combustion

Global Scope 1 emission factor for fuel combustion is from the Department for Business, Energy and Industrial Strategy 2021 Government GHG Conversion Factors for Company Reporting, in line with IPCC 2006 Guidelines for National Greenhouse Gas Inventories.

Calculation of emissions from vehicles

Getinge's fleet consists of 100% leased vehicles. Emissions from leased vehicles under the operational control of Getinge are calculated by multiplying contracted annual milage in km with CO_2eq emission factors per vehicle from vehicle manufacturers (in gCO_2eq / km). DEFRA's "UK Government Conversion Factors for Company Reporting" for the respective years 2021-2024 was applied in estimates.

Scope 2

Country-specific (location based) factors are sourced for electricity from AIB (2023) and IEA (2023), and for heating from Werner (2017). In addition, supplier specific factors have been analyzed locally to report emissions based on the location and market based methodology. The most recent and internationally recognized schemes are preferred. Due to incomplete data from suppliers, Getinge does not report its market based GHG emissions in 2024 but strives to obtain such data in the future.

Calculation of emissions from offices and warehouses

Emissions from owned and leased offices and warehouses are calculated by multiplying workplace area in m^2 with an average factor of energy consumption per year (kWh/m^2 per yr). For offices, this factor is 242.19 kWh/yr and for warehouses 96.88 kWh/yr^1. In the few cases in which data for consumption per office or warehouse is available, this has been used. The sum of calculated annual energy consumption per office/warehouse is then multiplied by country specific emission factors for the respective site. Emission factors: (IEA 2019) CO_2eq emissions per kWh of electricity and heat (gCO_2eq /kWh).

Scope 3

The calculation of the emissions from the three categories emitting the majority of the emissions – purchased goods and services (Category 3.1), upstream transportation and distribution (Category 3.4) and use of sold products (Category 3.11) are based on the Greenhouse Gas Protocol standards.

Category 3.1 – Purchased goods and services

The emissions represented in category 3.1 are based on the goods and services Getinge has purchased during the year.
These purchases were divided into five different categories:

- Plastics
- Metals
- Electronics and Electrical
- Other
- Purchased services

For plastics, metals and electronics, the calculations are based on both spend data and weight of the materials where available. Material emission factors used are the following: US Commodities and Industries v1.1, DEFRA UK database, EPA database and from Zero carbon product database and EcoInvent.

Category 3.4 Upstream transportation and distribution

For inbound transport Getinge gathers and estimates the weight for each product bought. For each order the region of the supplier and the end location of the goods are gathered. The start and end destination are then used for distance estimation. For inbound transport the split between means of transport is estimated. For outbound goods transport Getinge receives emission or transport reports from the freight forwarder. Transportation mode emission factors from the DEFRA UK database have been used for the calculations.

Category 3.11 – Use of sold products

The emissions calculated for use of sold products are based on expected energy consumption from Getinge's sold products during their lifetime. The activity data used has been the number of sold products that consume direct energy, that has been sold during the measurement period and the estimated energy profile for the sold products during its lifetime. Lifetime expectancy is calculated to be on average 10 years. The global electricity emission factor from "Our world in data" database has been used. Steam factors are from DEFRA UK. Please refer to Getinge Climate disclosure report 2023 for more details on calculations of other scope 3 emissions.

1) https://www.altenergymag.com/article/2019/07/benchmarking-commercial-building-energy-use-per-square-foot/31391
https://www.betterbuildingspartnership.co.uk/sites/default/files/media/attachment/REE8%202023%20Benchmarks_0.pdf

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Circularity

Waste

Waste data is measured quarterly and is based on invoices from suppliers or local data bases. Responsible use of resources and waste handling is in focus in all locations of operation. Getinge has ISO 14001 certifications at all production units (except for a small number of recently acquired units) to comply with all local regulation in this area and has set targets to increase recycling of its waste. The management of waste follows the principles set out in the environmental and sustainability policies and local environmental management systems. The development of generated waste volumes from production and modes of recycling are gathered quarterly in a central data management system for all production units.

Water

Water data is compiled monthly, either via supplier invoices or via local measuring equipment or meters. For assessing water risk and water stress level, the WRI Aqueduct database has been used.

METHODOLOGIES TO REPORT EMPLOYEE DATA

Employees

The presented data is extracted from the Getinge Global Human Resource Information System (HRIS). Data is reported as a snapshot of the end of the reporting period. Numbers are presented in full-time equivalents (FTE). FTE is defined as all employees that are either active or on paid leave, but excludes all employees on unpaid leave. Each relevant employee is then counted with their reported FTE value that represents their work time. Gender data is allowing for selecting other categories than "Male" or "Female". These are here presented combined under "Other" due to the low number of employees in these categories. Governance on gender classification is that it should be recorded in the system as stated in the employee's passport or any other country specific legal document. Region is defined based on the geographical place of the legal entity. Getinge doesn't centrally collect data on employees with guaranteed vs non-guaranteed hours, nor is this necessarily collected locally. Managers are defined as employees who have management responsibility over other employees – internally or externally. Getinge has no other minority data collected globally.

Workers who are not employees

The presented data is extracted from Getinge HRIS. Data is reported as a snapshot at the end of the reporting period. Numbers are presented in full-time equivalents (FTE).

New employee hires and employee turnover

The presented data is extracted from Getinge HRIS. Data is reported over the period of a year for people who were hired during 2024 or had their last day of employment in 2024. For both terminations and new hires, the numbers are presented in FTE. The definition is similar to that described under Employees with the following exceptions:

1. Only permanent employees are included in the retention rate. It excludes the small number of temporary employees. This is standard company practice to avoid impacting the data with terminations due to planned end of contract.
2. Getinge includes both employees who are active and on paid leave (as for Employees), but people on unpaid leave are also included to ensure all employees who are on unpaid leave for some reason during their period of notice are counted.

For data on gender, see the definition under Employees. Age group uses the recorded date of birth to calculate the age at the end of the reporting period. If date of birth is missing or incorrect, it is recorded as invalid in the above.

Parental leave

The presented data is extracted from Getinge HRIS. Data is reported over the period of a year for people going on leave or returning from leave.

Any kind of parental leave is by default handled locally according to local rules, regulations and contracts, hence the global data on this is limited. Any parental leave is to be recorded in the global HRIS system if it is either expected to last or actually lasts more than 14 calendar days. Multiple parental leaves for the same person are counted only once during the period, but as two leaves across reporting periods (e.g. if the person changes from paid to unpaid, etc.).

For data on gender, see the definition under Employees.

Diversity of governance bodies and employees

The presented data is extracted from Getinge HRIS. Data is reported as a snapshot of the end of the reporting period. Numbers are presented in FTE.

For data on gender, see the definition under Employees.

As regards to age groups, the recorded date of birth is used to calculate the age at the end of the reporting period. If the date of birth is missing or the age is outside the interval of 15–70, it is recorded as invalid in the above.

Health & Safety

High consequence work-related accident is defined as: A work-related accident that results in an injury from which the worker cannot, does not, or is not expected to recover fully to pre-injury health status within six months.

Work-related ill health is defined as: Any negative impact, such as abnormal conditions or disorders with a clear causal relationship between the ill health and the specific work environment or activity, other than one resulting from occupational health injuries arising from exposure to hazards at work.

Recordable injury is defined as: Any occupational injury that requires medical treatment more than simple first aid and occurs within a Getinge site perimeter, or while on business travel and which includes an employee or a contractor normally based at that site.

Work-related accident rate (WRAR): The number of accidents that resulted in absence of more than one day per 200,000 hours worked. Number of total hours worked: employees: 25,002,684 hours, workers who are not employees: 2,380,596 hours.

Contractors are defined as:

- short term temporary workers who join the company as temporary cover or, for example, to support projects or scale up production.
- associated consultants and technical consultants who provide support on a project- or need basis.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

GRI Content Index

Statement of Use: Getinge has reported in accordance with the GRI Standards for the period from January 1 to December 31, 2024
GRI 1 used: GRI 1 Foundation 2021
Applicable GRI Sector standards: none

GRI Standard	Disclosure Title	Pages	Omission
GENERAL DISCLOSURES			
GRI 2 General Disclosures 2021			
1. The organization and its reporting practices			
2-1	Organizational details	34-35, 56	
2-2	Entities included in the organization's sustainability reporting	118-119, 128	
2-3	Reporting period, frequency and contact point	128	
2-4	Restatements of information	128	
2-5	External assurance	128, 168	
2. Activities and workers			
2-6	Activities, value chain and other business relationships	3, 12-31, 56, 133	
2-7	Employees	155-156, 163	**Not applicable.** Getinge does not report on GRI 2-7, b iii (non-guaranteed hours employees, and a breakdown by gender and by region) as such employee relations are not present.
2-8	Workers who are not employees	156, 163	
3. Governance			
2-9	Governance structure and composition	32-46, 135-137	**Not applicable.** GRI 2-9 c vi, Getinge's highest governance body is not composed based on these parameters.
2-10	Nomination and selection of the highest governance body	35-37	
2-11	Chair of the highest governance body	39	
2-12	Role of the highest governance body in overseeing the management of impacts	135-137	**The information is incomplete.** GRI 2-12 b i, Getinge does not follow a formalized procedure for the engagement process between stakeholders and the highest governance body.
2-13	Delegation of responsibility for managing impacts	38, 135-137	

GRI Standard	Disclosure Title	Pages	Omission
Governance, cont.			
2-14	Role of the highest governance body in sustainability reporting	135-137	
2-15	Conflicts of interest	36-37, 39-41	
2-16	Communication of critical concerns	135-137	**Information unavailable.** GRI 2-16 b, Getinge does not consolidate data about this specific type of communication.
2-17	Collective knowledge of the highest governance body	36-37, 135-137	
2-18	Evaluation of the performance of the highest governance body	37	**Information unavailable.** The evaluation carried out does not specifically monitor the organization's impact on the economy, environment, or people.
2-19	Remuneration policies	64-67, 105-106	
2-20	Process to determine remuneration	38, 64-67, 105-106	
2-21	Annual total compensation ratio	64-67, 105-106	**The information is incomplete.** Getinge does not yet consolidate this information at Group level.
4. Strategy, policies and practices			
2-22	Statement on sustainable development strategy	7, 13-16, 129	
2-23	Policy commitments	135-137	**The information is incomplete.** GRI 2-23 a ii, iii and b ii. Reported information does not fully cover all requirements, but Getinge strives to obtain such information in future reports.
2-24	Embedding policy commitments	136-137	
2-25	Processes to remediate negative impacts	137	
2-26	Mechanisms for seeking advice and raising concerns	137	

20250623150064

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

GRI Standard	Disclosure Title	Pages	Omission
Strategy, policies and practices, cont.			
2-27	Compliance with laws and regulations	56-60, 136-137	**The information is incomplete.** GRI 2-27 a ii, b, d. Getinge does not yet consolidate this information at Group level.
2-28	Membership associations	134, 137	
5. Stakeholder engagement			
2-29	Approach to stakeholder engagement	130-131	
2-30	Collective bargaining agreements		**Information unavailable.** Getinge complies with local regulation in all countries of operation but does not collect country specific information on collective bargaining agreements on a global level.
MATERIAL TOPICS			
GRI 3 Material Topics 2021			
1. The organization and its reporting practices			
3-1	Process to determine material topics	130-132	
3-2	Material topics	132	
GRI Topic Specific Disclosures			
Governance			
GRI 205 Anti-corruption 2016			
GRI 3-3	Management of material topics	130-132, 135-137	
205-1	Operations assessed for risks related to corruption	160-161	**The information is incomplete.** GRI 205-1 a, The percentage of operations assessed for corruption risks is not available for 2023.
205-2	Communication and training about anti-corruption policies and procedures	160-161	**The information is unavailable.** Getinge does not currently measure the percentage of governance body members and business partners that have received training on anti-corruption, broken down by region (GRI 205-2 a,b,c,d). The percentage of employees who received anti-corruption training by category is not available for 2023 (GRI 205-2(e)).
205-3	Confirmed incidents of corruption and actions taken	160-161	

GRI Standard	Disclosure Title	Pages	Omission
Governance, cont.			
GRI 206 Anti-competitive behavior 2016			
GRI 3-3	Management of material topics	130-132, 160-161	
206-1	Legal actions for anti-competitive behavior, anti-trust and monopoly practices	161	
Own	Employee Training on Business Ethics	161	
GRI Topic Specific Disclosures			
Social			
GRI 401 Employment 2016			
GRI 3-3	Management of material topics	130-132, 150-156	
401-1	New employee hires and employee turnover	155-156	
401-3	Parental leave	156	**The information is incomplete.** 401-3 e. Getinge does not currently have records on employees not returning from parental leave.
Own	Sick Leave	150	
GRI 403 Occupational Health and Safety 2018			
GRI 3-3	Management of material topics	130-132, 151-152	
403-1	Occupational health and safety management system	151-152	
403-2	Hazard identification, risk assessment, and incident investigation	151-152	
403-3	Occupational health services		**Information unavailable.** Due to regional variances, Getinge doesn't currently collect data on occupational health services at global level.
403-4	Worker participation, consultation, and communication on occupational health and safety		**Information unavailable.** Due to regional variances, Getinge currently doesn't collect data on occupational health and safety jointed manager-worker committees at global level.
403-5	Worker training on occupational health and safety	151-152	

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

GRI Standard	Disclosure Title	Pages	Omission
Social, cont.			
403-6	Promotion of worker health		**Information unavailable.** Due to regional variances, Getinge currently does not collect data from all sites of operation on workers' access to non-occupational medical and healthcare services, nor information on any voluntary health promotion services and programs.
403-7	Prevention and mitigation of occupational health and safety impacts directly linked by business relationships	151-152	
403-8	Workers covered by an occupational health and safety management system	151-152, 163	**The information is incomplete.** 403-8 a ii and iii. Getinge currently does not report on information from internal or external audits of the occupational health and safety management system at its workplaces.
403-9	Work-related injuries	151-152, 163	**The information is incomplete.** 403-9 a v, b v: Getinge does not currently report the local number of hours worked. 403-9 c ii, iii Getinge also does not report the actions taken or underway to eliminate work-related hazards and minimize risks.
403-10	Work-related ill health	151-152, 163	**The information is incomplete.** Getinge does not collect data on work-related ill health from contractors as it is under external employer responsibility.
GRI 405 Diversity and Equal Opportunity 2016			
GRI 3-3	Management of material topics	130-132, 153-154	
405-1	Diversity of governance bodies and employees	39-41, 43-44, 153-154	
GRI 406 Non-discrimination 2016			
GRI 3-3	Management of material topics	130-132, 153-154	
406-1	Incidents of discrimination and corrective actions taken	154	

GRI Standard	Disclosure Title	Pages	Omission
Social, cont.			
GRI 416 Customer Health and Safety 2016			
GRI 3-3	Management of material topics	130-132, 158-159	
416-1	Assessment of the health and safety impacts of product and service categories	158-159	
416-2	Incidents of non-compliance concerning the health and safety impacts of products and services	158-159	
GRI 417 Marketing and labeling 2016			
GRI 3-3	Management of material topics	130-132, 158-159	
417-1	Requirements for product and service information and labeling	158-159	
417-2	Incidents of non-compliance concerning product and service information and labeling	158-159	
417-3	Incidents of non-compliance concerning marketing communications	158-159	
GRI 418 Customer privacy 2016			
GRI 3-3	Management of material topics	130-132, 158-159	
418-1	Substantiated complaints concerning breaches of customer privacy and losses of customer data	158-159	
Own	Regulatory compliance (audit findings/audit for quality systems)	159	
Own	Product quality (field actions per SEK billion in net revenue)	159	
Own	Customer Training	159	

Introduction

Strategy

Corporate Governance Report

Financial statements

Sustainability Report

About the Report

Sustainability at Getinge

Materiality and stakeholders

Sustainability governance and management

Environment

Social responsibility

Governance

Reporting principles

GRI content index

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

Other information

GRI Standard	Disclosure Title	Pages	Omission
GRI Topic Specific Disclosures			
Environment			
GRI 302 Energy 2016			
GRI 3-3	Management of material topics	130-132, 138-141	
302-1	Energy consumption within the organization	140-141, 162-163	
302-3	Energy intensity	141	
302-4	Reduction of energy consumption	141, 162-163	
GRI 305 Emissions 2016			
GRI 3-3	Management of material topics	130-132, 138-141	
305-1	Direct (Scope 1) GHG emissions	140, 162-163	**The information is incomplete.** Getinge does not report on other ozone depleting substances or greenhouse gases (other than CO_2e) or on biogenic carbon emissions.
305-2	Indirect (Scope 2) GHG emissions	140, 162-163	**The information is incomplete.** Due to incomplete data from suppliers, Getinge is not reporting its market-based GHG emissions in 2024, but strives to obtain such data in the future.
305-3	Other indirect (Scope 3) GHG emissions	140, 162-163	**The information is incomplete.** Getinge reports on 3.1, 3.4 and 3.11. Detailed report on all scope 3 emissions is included in the Getinge Climate Disclosure report.
305-4	GHG emissions intensity	140, 162-163	
305-5	Reduction of GHG emissions	140, 162-163	

GRI Standard	Disclosure Title	Pages	Omission
Environment; cont.			
Own	Reduction of water consumption in sites with water scarcity	143, 163	
GRI 306 Waste 2020			
GRI 3-3	Management of material topics	130-132, 144-145	
306-1	Waste generation and significant waste-related impacts	144-145	
306-2	Management of significant waste-related impacts	144-145, 163	**The information is incomplete.** GRI 306-2 b, c. Getinge does not consolidate data about this process.
306-3	Waste generated	144-145, 163	
306-4	Waste diverted from disposal	144-145, 163	**The information is incomplete.** Getinge does not aggregate detailed data on local recycling schemes and treatments of waste at production sites on a global level, but complies with local legal environmental requirements in all countries of production.
306-5	Waste directed to disposal	144-145, 163	**The information is incomplete.** GRI 306-5 a, b, c. Getinge reports incineration without energy recovery, landfilling and other disposal operations under the item not recycled. GRI 306-5 d. Getinge does not aggregate detailed data on local recycling schemes and treatments of waste at production sites on a global level, but complies with local legal environmental requirements in all countries of production.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
About the Report
Sustainability at Getinge
Materiality and stakeholders
Sustainability governance and management
Environment
Social responsibility
Governance
Reporting principles
GRI content index
Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report
Other information

Auditor's Limited Assurance Report on Getinge AB (publ)'s Sustainability Report and statement on the Statutory Sustainability Report

To the annual general meeting of Getinge AB (publ), corporate identity number 556408-5032

Introduction

We have been engaged by the Board and Group Management of Getinge AB (publ) ("Getinge") to undertake a limited assurance of Getinge AB (publ)'s Sustainability Report for the year 2024. The company has defined the scope of its sustainability report on page 128. The statutory sustainability report is further defined on page 128.

Responsibilities of the Board and Group Management

The Board of Directors and Group Management are responsible for the preparation of the Sustainability Report, including the statutory sustainability report, in accordance with the applicable criteria and the Annual Accounts Act in the previous version that applied before 1 July 2024. The criteria are described on page 128 of the Sustainability Report and consists of the parts of the sustainability reporting framework issued by the GRI (Global Reporting Initiative) Sustainability Reporting Standards which are applicable to the Sustainability Report, as well as the accounting and calculation principles that the company has developed. This responsibility also includes the internal control which is deemed necessary to establish a sustainability report that does not contain material misstatement, whether due to fraud or error.

Responsibilities of the auditor

Our responsibility is to express a conclusion on the Sustainability Report based on the limited assurance procedures we have performed and to provide a statement on the statutory sustainability report. Our assignment is limited to the historical information that is presented and thus does not include future-oriented information.

We conducted our limited assurance engagement in accordance with ISAE 3000 (revised) *Assurance Engagements Other than Audits or Reviews of Historical Financial Information*. A limited assurance engagement consists of making inquiries, primarily of persons responsible for the preparation of the Sustainability Report and applying analytical and other limited assurance procedures. We have conducted our examination regarding the statutory sustainability report in accordance with FAR's recommendation RevR 12, *the Auditor's Opinion on the Statutory Sustainability Report*. A limited assurance engagement and an examination according to RevR 12 have a different focus and a considerably smaller scope compared to the focus and scope of an audit in accordance with International Standards on Auditing and generally accepted auditing standards in Sweden.

The audit firm applies ISQM 1 (International Standard on Quality Management), which requires the firm to design, implement and operate a system of quality management including policies or procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements. We are independent in relation to Getinge according to generally accepted auditing standards in Sweden and have fulfilled our professional ethics responsibility according to these requirements.

The procedures performed in a limited assurance engagement and an examination according to RevR 12 do not allow us to obtain such assurance that we become aware of all significant matters that could have been identified if an audit was performed. The conclusion based on a limited assurance engagement and an examination in accordance with RevR 12, therefore, does not provide the same level of assurance as a conclusion based on an audit has.

Our procedures are based on the criteria defined by the Board of Directors and the Group Management as described above. We consider these criteria as suitable for the preparation of the Sustainability Report.

We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our conclusion below.

Conclusion

Based on the limited assurance procedures we have performed, nothing has come to our attention that causes us to believe that the Sustainability Report is not prepared, in all material respects, in accordance with the criteria defined by the Board of Directors and Group Management.

A Statutory Sustainability Report has been prepared.

Gothenburg, March 27, 2025

Öhrlings PricewaterhouseCoopers AB

Cecilia Andrén Dorselius
Authorized Public Accountant
Auditor in charge

Karin Olsson
Authorized Public Accountant

This is a translation of the Swedish language original. In the event of any differences between this translation and the Swedish language original, the latter shall prevail.



Other information

Contents

170–171	The Getinge share
172–173	Multi-year overview
176–178	Reconciliation of alternative performance measures
179–181	Group companies
182–183	Definitions
184	Annual General Meeting and Nomination Committee
184	Financial information
185	Reading guide and distribution policy
185	Contact

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

The Getinge share

Getinge's Class B share has been listed on Nasdaq Stockholm since 1993. The share is included in the Nasdaq Nordic Large Cap segment and the OMXS30 index. On December 31, 2024, the number of shareholders was 59,381. The percentage of foreign-owned shares amounted to 30.1%. Institutional owners accounted for 62.9% of the share capital, of which Swedish institutional owners accounted for 37.7%.

SEK **4.60**
Proposed dividend per share for the fiscal year 2024

-19.1%
Development in Getinge's share value in 2024

SEK **181.55**
Getinge's share price at year-end 2024

Share trend and liquidity

At year-end, Getinge's share was listed at SEK 181.55, which was a decrease by -19.1% (3.7) during the year. The highest price paid in 2024 was SEK 240.20 (April 29), the lowest was SEK 164.35 (November 21). At year-end, market capitalization amounted to SEK 49.4 billion. During the year, 211.9 million shares (203.3) were traded.

Share capital

At year-end 2024, the share capital in Getinge totaled to SEK 136,184,786.50 distributed among 272,369,573 shares. All shares carry the same dividend entitlement. One Class A share carries ten votes and one Class B share carries one vote.

Dividend policy

The Board of Directors of Getinge has adopted a dividend policy entailing that future dividends will be adjusted in line with Getinge's profit level, financial position and future development potential. The aim is for the dividend to correspond to 30–50% of net income. During the last five years, the dividend payout ratio has been an average of 46.9%, including the proposed dividend.


Sell-side analysts covering Getinge

ABG Sundal Collier, Carnegie, DNB Markets, Equita, Handelsbanken, J.P. Morgan, Kepler Cheuvreux, Morgan Stanley, Morningstar, Nordea, Pareto Securities, Redburn and SEB Enskilda.

Getinge's peers

Getinge's peers consist of the listed companies named in the section for each business area in this Annual Report.

Performance 2020–2024



Source: Monitor Holdings

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Development of share capital

	Transaction	No. of shares after transaction	Share capital after transaction, SEK
1990	Formation	500	50,000
1992	Split 50:1, par value SEK 100 to SEK 2	25,000	50,000
1992	Private placement	5,088,400	10,176,800
1993	Private placement	6,928,400	13,856,800
1995	Non-cash issue	15,140,544	30,281,088
1996	Bonus issue 2:1	45,421,632	90,843,264
2001	New issue 1:9 at SEK 100	50,468,480	100,936,960
2003	Split 4:1, par value SEK 2 to SEK 0.50	201,873,920	100,936,960
2008	New issue 1:16 at SEK 120	214,491,404	107,245,520
2009	New issue 1:9 at SEK 83.5	238,323,377	119,161,689
2017	New issue 1:7 at SEK 127	272,369,573	136,184,787

Getinge's largest shareholders on December 31, 2024

	Class A shares	Class B shares	% of capital	% of votes
Carl Bennet AB	18,217,200	36,802,969	20.20%	50.19%
Fjärde AP-fonden		21,007,390	7.71%	4.81%
AMF Pension & Fonder		11,782,460	4.33%	2.70%
Carnegie Fonder		11,664,757	4.28%	2.67%
Swedbank Robur Fonder		9,659,015	3.55%	2.21%
Vanguard		8,866,076	3.26%	2.03%
Incentive AS		8,830,666	3.24%	2.02%
BlackRock		8,818,388	3.24%	2.02%
Handelsbanken Fonder		7,616,677	2.80%	1.75%
Lannebo Kapitalförvaltning		6,053,120	2.22%	1.39%
Other	0	123,048,855	45.18%	28.20%
Total	**18,217,200**	**25,4152,373**	**100.00%**	**100.00%**

Share capital distribution

	Class A	Class B	Total
No. of shares	18,217,200	254,152,373	272,369,573
No. of votes	182,172,000	254,152,373	436,324,373
% of capital	7%	93%	100%
% of votes	42%	58%	100%


Five largest countries – capital, %



Ownership structure 2024

Ägarfördelning efter innehav	Antal aktier	% of capital	% of votes	Ownership	Ownership (%)
1 - 100	1,087,307	0.40%	0.25%	32,098	54.05%
101 - 200	1,159,683	0.43%	0.27%	7,633	12.85%
201 - 500	2,955,648	1.09%	0.68%	8,766	14.76%
501 - 1 000	3,663,731	1.35%	0.84%	4,952	8.34%
1 001 - 2 000	4,368,984	1.60%	1.00%	3,030	5.10%
2 001 - 5 000	5,677,916	2.08%	1.30%	1,797	3.03%
5 001 - 10 000	3,873,018	1.42%	0.89%	541	0.91%
10 001 - 20 000	3,472,650	1.27%	0.80%	247	0.42%
20 001 - 50 000	4,158,492	1.53%	0.95%	135	0.23%
50 001 - 100 000	3,927,489	1.44%	0.90%	53	0.09%
100 001 - 200 000	6,538,650	2.40%	1.50%	45	0.08%
200 001 - 500 000	10,335,753	3.79%	2.37%	34	0.06%
500 001 - 1 000 000	10,874,367	3.99%	2.49%	16	0.03%
1 000 001 - 2 000 000	18,558,122	6.81%	4.25%	14	0.02%
2 000 001 - 5 000 000	24,853,600	9.12%	5.70%	9	0.02%
5 000 001 - 10 000 000	55,412,264	20.34%	12.70%	7	0.01%
10 000 001 - 20 000 000	23,447,217	8.61%	5.37%	2	0.00%
20 000 001 -	76,027,559	27.91%	55.00%	2	0.00%
Anonymous ownership	11,977,123	4.40%	2.75%	0	0.00%
Total	**272,369,573**	**100.00%**	**100.00%**	**59,381**	**100.00%**

Ownership by category – capital, %



Shareholder information

Financial information about Getinge is available on the company's website. Questions regarding this annual report and other financial communications can be directed to the investor relations function at the company, as indicated on the website.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Multi-year overview

Group

Amounts in SEK M unless otherwise stated	2024	2023	2022	2021	2020
Order situation					
Order intake	34,232	30,894	29,621	28,258	30,568
Net sales	34,759	31,827	28,252	27,049	29,819
of which, international sales, %	98.2	98.0	98.1	98.2	97.3
EBITDA	5,275	5,829	5,653	6,185	7,251
Adjusted EBITA	4,869	3,887	4,281	5,212	5,724
Operating profit/loss (EBIT)	2,854	3,736	3,526	4,371	4,784
Net financial items	-571	-393	-154	-183	-299
Profit/loss after financial items	2,282	3,343	3,472	4,188	4,485
Taxes	-628	-915	-956	-1,187	-1,213
Net profit/loss for the year	**1,654**	**2,428**	**2,516**	**3,000**	**3,273**
Margin measures					
EBITDA margin, %	15.2	18.3	20.0	22.9	24.3
Adjusted EBITA margin, %	14.0	12.2	15.1	19.3	19.2
Operating margin (EBIT), %	8.2	11.7	12.8	16.2	16.0
Personnel					
Number of employees, December 31	11,791	11,739	11,082	10,729	10,818
Balance sheet					
Intangible assets	39,242	30,670	27,010	24,148	22,085
Tangible assets	3,902	3,723	3,532	3,060	2,956
Right-of-use assets	1,795	1,486	1,336	1,060	1,017
Financial assets	817	1,061	1,048	1,217	1,526
Inventories	6,590	6,416	6,232	4,767	4,513
Other receivables	8,610	7,503	7,198	6,227	6,862
Cash and cash equivalents	2,961	2,728	5,676	4,076	6,056
Total assets	**63,918**	**53,586**	**52,032**	**44,555**	**45,014**
Equity	33,210	30,403	30,453	25,176	21,486
Provisions for pensions, interest-bearing	2,700	2,664	2,454	3,378	3,359
Leasing liabilities	1,800	1,479	1,314	1,036	990
Other interest-bearing liabilities	12,207	6,597	4,510	3,270	9,216
Other provisions[1]	4,502	3,245	4,539	3,782	3,077
Other non-interest-bearing liabilities[1]	9,498	9,198	8,761	7,912	6,886
Total equity and liabilities	**63,918**	**53,586**	**52,032**	**44,555**	**45,014**

Amounts in SEK M unless otherwise stated	2024	2023	2022	2021	2020
Net debt, including pension liabilities	10,467	8,012	2,602	3,609	7,509
Net debt, excluding pension liabilities	7,766	5,348	148	231	4,150
Cash flow					
Cash flow from operating activities	4,577	2,957	3,367	6,560	7,199
Cash flow per share, SEK	16.8	10.9	12.4	24.1	26.4
Net investments in non-current assets	-1,294	-1,334	-1,106	-614	-983
Return indicators					
Return on operating capital, %	31.1	10.2	13.0	17.3	16.3
Return on equity, %	5.2	7.8	8.9	12.9	16.1
Financial indicators					
Equity/assets ratio, %	52.0	56.7	58.5	56.5	47.7
Net debt/equity ratio, multiple	0.32	0.26	0.09	0.14	0.35
Operating capital, average	40,952	36,560	31,510	28,561	32,374
Equity December 31	33,210	30,403	30,453	25,176	21,486
Data per share, amounts in SEK unless otherwise stated					
Earnings per share	6.01	8.86	9.15	10.90	11.89
Market price, December 31	181.55	224.30	216.30	395.10	192.10
Dividend	4.60[2]	4.40	4.25	4.00	3.00
Dividend yield, %	2.53	1.96	1.96	1.01	1.56
Price/earnings ratio	30.19	25.32	23.64	36.25	16.16
Dividend as profit percentage, %	76.50	49.68	46.45	36.70	25.23
Equity per share, SEK	121.93	111.63	111.81	92.43	78.88
Average number of shares (million)	272.4	272.4	272.4	272.4	272.4
Number of shares December 31 (million)	272.4	272.4	272.4	272.4	272.4

1) As from 2024, contingent considerations have been reclassified from Other provisions to Other non-interest-bearing liabilities. Previous years have been restated.
2) Dividend proposed by the Board of Directors.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Business areas

ACUTE CARE THERAPIES, SEK M	2024	2023	2022	2021	2020
Order intake	17,719	16,375	16,108	15,335	19,208
Net sales	17,948	16,529	15,285	15,527	18,719
Adjusted gross profit	10,417	9,660	9,174	9,596	11,536
Margin, %	*58.0*	*58.4*	*60.0*	*61.8*	*61.6*
Adjusted EBITDA	4,474	4,023	4,274	5,272	6,833
Margin, %	*24.9*	*24.3*	*28.0*	*34.0*	*36.5*
Depreciation, amortization and write-downs of tangible and intangible assets	-920	-905	-872	-828	-1,002
Adjusted EBITA	3,554	3,117	3,402	4,444	5,831
Margin, %	*19.8*	*18.9*	*22.3*	*28.6*	*31.1*

LIFE SCIENCE, SEK M	2024	2023	2022	2021	2020
Order intake	4,601	4,148	3,932	4,120	3,413
Net sales	4,552	4,325	4,026	3,558	2,854
Adjusted gross profit	1,808	1,527	1,548	1,492	1,176
Margin, %	*39.7*	*35.3*	*38.5*	*41.9*	*41.2*
Adjusted EBITDA	818	620	801	870	522
Margin, %	*18.0*	*14.3*	*19.9*	*24.5*	*18.3*
Depreciation, amortization and write-downs of tangible and intangible assets	-271	-190	-151	-141	-128
Adjusted EBITA	608	430	650	729	393
Margin, %	*13.4*	*9.9*	*16.1*	*20.5*	*13.8*

SURGICAL WORKFLOWS, SEK M	2024	2023	2022	2021	2020
Order intake	11,912	10,371	9,581	8,803	7,948
Net sales	12,258	10,974	8,981	7,965	8,246
Adjusted gross profit	5,185	4,346	3,639	3,304	3,163
Margin, %	*42.3*	*39.6*	*40.5*	*41.5*	*38.4*
Adjusted EBITDA	1,728	1,304	1,127	949	495
Margin, %	*14.1*	*11.9*	*12.5*	*11.9*	*6.0*
Depreciation, amortization and write-downs of tangible and intangible assets	-638	-583	-577	-559	-622
Adjusted EBITA	1,090	721	549	390	-127
Margin, %	*8.9*	*6.6*	*6.1*	*4.9*	*-1.5*

The group's 20 largest markets

	2024		2023		2022	
Net sales	SEK M	%	SEK M	%	SEK M	%
US	13,929	40.1%	11,897	36.8%	10,143	35.9%
China	2,844	8.2%	2,836	8.9%	2,610	9.2%
Germany	1,904	5.5%	1,859	5.8%	1,631	5.8%
France	1,611	4.6%	1,483	4.7%	1,251	4.4%
Japan	1,207	3.5%	1,241	3.9%	1,254	4.4%
United Kingdom	1,177	3.4%	1,100	3.5%	949	3.4%
Italy	1,041	3.0%	980	3.1%	849	3.0%
Spain	771	2.2%	738	2.3%	649	2.3%
Canada	770	2.2%	731	2.3%	606	2.1%
Australia	715	2.1%	643	2.0%	592	2.1%
Sweden	617	1.8%	632	2.0%	549	1.9%
India	561	1.6%	491	1.5%	534	1.9%
Netherlands	544	1.6%	518	1.6%	496	1.8%
Switzerland	440	1.3%	423	1.3%	284	1.0%
Denmark	400	1.2%	345	1.1%	265	0.9%
Brazil	395	1.1%	305	1.0%	274	1.0%
Belgium	363	1.0%	342	1.1%	296	1.0%
Hong Kong	345	1.0%	377	1.2%	354	1.2%
Austria	302	0.9%	283	0.9%	228	0.8%
Saudi Arabia	286	0.8%	182	0.6%	175	0.6%

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

The ten largest markets by business area

ACUTE CARE THERAPIES	2024 SEK M	2024 %	2024 #	2023 SEK M	2023 %	2023 #	2022 SEK M	2022 %	2022 #
US	8,377	46.7%	1	7,517	45.5%	1	6,845	44.8%	1
China	2,040	11.4%	2	1,830	11.1%	2	1,592	10.4%	2
Germany	848	4.7%	3	797	4.8%	3	720	4.7%	3
Japan	541	3.0%	4	578	3.5%	4	628	4.1%	4
Italy	525	2.9%	5	534	3.2%	5	485	3.2%	5
France	485	2.7%	6	467	2.8%	6	422	2.8%	6
Canada	454	2.5%	7	421	2.5%	7	373	2.4%	7
Spain	396	2.2%	8	393	2.4%	8	350	2.3%	8
India	372	2.1%	9	314	1.9%	10	344	2.2%	9
United Kingdom	364	2.0%	10	317	1.9%	9	314	2.1%	10

LIFE SCIENCE	2024 SEK M	2024 %	2024 #	2023 SEK M	2023 %	2023 #	2022 SEK M	2022 %	2022 #
US	1,738	38.2%	1	1,470	34.0%	1	1,343	33.4%	1
France	517	11.3%	2	455	10.5%	2	379	9.4%	3
Germany	290	6.4%	3	291	6.7%	4	316	7.8%	4
United Kingdom	275	6.0%	4	219	5.1%	5	203	5.0%	5
China	210	4.6%	5	408	9.4%	3	433	10.8%	2
Denmark	172	3.8%	6	121	2.8%	9	69	1.7%	11
Ireland	132	2.9%	7	151	3.5%	6	105	2.6%	8
Belgium	129	2.8%	8	125	2.9%	8	109	2.7%	7
Italy	116	2.5%	9	96	2.2%	11	67	1.7%	12
Japan	114	2.5%	10	94	2.2%	12	103	2.6%	9

SURGICAL WORKFLOWS	2024 SEK M	2024 %	2024 #	2023 SEK M	2023 %	2023 #	2022 SEK M	2022 %	2022 #
US	3,913	31.1%	1	2,710	24.7%	1	1,954	21.8%	1
Germany	765	6.2%	2	771	7.0%	2	595	6.6%	2
France	609	5.0%	3	561	5.1%	6	450	5.0%	5
China	594	4.8%	4	599	5.5%	3	585	6.5%	3
Japan	552	4.5%	5	569	5.2%	4	524	5.8%	4
United Kingdom	538	4.4%	6	563	5.1%	5	432	4.8%	6
Australia	456	3.7%	7	388	3.5%	8	339	3.8%	8
Sweden	414	3.4%	8	429	3.9%	7	363	4.0%	7
Italy	401	3.3%	9	350	3.2%	9	296	3.3%	9
Spain	357	2.9%	10	335	3.0%	10	253	2.8%	10

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Acquisition history

Year	Company	Business	Country	Sales	
2024	Paragonix Technologies, Inc	Organ transport products and services	US	SEK	826 M
2024	Technology and intellectual property rights from Intact Solutions LLC	Technology aseptic processing, bioprocessing	US	-	-
2023	Healthmark Industries Co. Inc.	Provider of innovative instrument care and infection control consumables	US	SEK	1,321 M
2023	High Purity New England Inc.	Company in the areas of custom single-use solutions for bioprocessing applications	US	SEK	389 M
2023	Ultra Clean Systems Inc.	Manufacturer of ultrasonic cleaning technologies used in hospitals and surgery centers to decontaminate surgical instruments	US	SEK	90 M
2022	Fluoptics SAS	Leader in fluorescence imaging	FR	SEK	45 M
2022	Irasun GmbH	Develops products for venous drainage and temperature control	DE	-	-
2021	Talis Clinical LLC	High Acuity cloud-based software solutions	US	SEK	57 M
2021	Development assets from Verrix	Biological indicators	US	-	-
2020	Applikon Biotechnology BV	Life Science bioreactor system	NL	SEK	350 M
2020	Quadralene Holdings Ltd	Disinfection	GB	SEK	75 M
2017	Carus HMS GmbH	Integrated workflow solutions	DE	SEK	20 M
2017	Simm Company and Surgeon Aids	Distributor	TH	SEK	75 M
2016	AccuMed	Production facility for medical textiles	DR	SEK	100 M
2016	1st Call Mobility Ltd	Medical-device solutions for bariatric patients	GB	SEK	100 M
2015	GOA Teknoloji Danismanlik Elektronik	Low temperature sterilization technology	TR	SEK	20 M
2014	Pulsion AG	Systems for hemodynamic monitoring	DE	SEK	300 M
2014	Altrax Group Ltd	Systems for traceability and quality assurance for sterilization	GB	SEK	35 M
2014	Cetrea A/S	Systems for resource planning	DK	SEK	30 M
2014	Austmel Pty Ltd	Sterilization and thermal processes	AU	SEK	80 M
2013	LAAx Inc.	Cardiac and vascular surgery	US	SEK	8 M
2013	Trans Medikal Devices Inc.	Manufacture of sterilizers and distribution of disinfectors	TR	SEK	55 M
2013	STS East LLC	Service	US	SEK	25 M
2012	Product rights from Avalon Laboratories	Cardiopulmonary	US	-	-
2012	Eirus Medical	Critical Care	SE	-	-
2012	Acare Medical Science Ltd	Healthcare beds	CH	SEK	135 M
2012	USCI	Distributor	JP	SEK	150 M
2012	Tecno Hospitalia	Distributor	CO	SEK	4 M
2012	Therapeutic Support Systems (TSS)	Wound care	US	SEK	1,600 M
2012	Steritec Products Mfg Inc.	Consumables	US	SEK	70 M
2011	Blanchet Medical Service	Service	FR	SEK	3 M
2011	Atrium Medical Inc	Products for the cardiovascular market	US	USD	200 M
2011	Combimobil AB	Rehabilitation aids	SE	SEK	2 M
2011	Pumedica	Distributor	CH	SEK	70 M
2011	IDS Medical Equipment	Distributor	SG	SEK	25 M
2011	Mak Saglik	Distributor	TR	SEK	20 M
2011	STS Holding West	Service	US	SEK	20 M
2010	Odelga	Service	AT	SEK	25 M
2008	Datascope	Cardiac assist and vascular surgery	US	USD	231 M
2008	Cardio Research Pty Ltd.	Distributor	AU	AUD	5.1 M
2008	Subtil Crepieux	Service	FR	EUR	8 M
2008	Getus Services Ltd	Service	NZ	NZD	1.1 M
2008	Olmed AB	Distributor	SE	SEK	70 M

Year	Company	Business	Country	Sales	
2008	Boston Scientific's Cardiac and Vascular surgery divisions	Endoscopic vessel harvesting (EVH), anastomosis, stabilizers and instruments for surgery on beating hearts and vascular implants	US	SEK	1,733 M
2007	NS Nielsen Equipment A/S	Distributor	DK	-	-
2006	Huntleigh Technology	Special mattresses for pressure-ulcer treatment, beds for intensive, specialist and elderly care vein thrombosis prophylaxis and equipment for fetal and vascular diagnostics.	UK	SEK	2,675 M
2006	Comercio E Industria Medicia	Consumables for open-heart surgery	BR	SEK	25 M
2006	CTY GmbH	Telemedicine specializing in products and solutions for hospitals' IT infrastructure focused on the operating room.	DE	SEK	20 M
2006	Getinge Czech Republic	Distributor	CZ	SEK	10 M
2005	Lancer UK	Distributor	UK	SEK	104 M
2005	La Calhène	Isolator technology and electron sterilization technology	FR	EUR	40 M
2004	Dynamed	Distributor	CA	SEK	85 M
2004	BHM Medical Inc.	Patient management products for the care and elderly care segments	CA	SEK	206 M
2003	MAQUET AG	Distributor	CH	CHF	4.9 M
2003	Siemens LSS	Ventilators and anesthesia equipment for the hospital market	SE	EUR	230 M
2003	Jostra GmbH	Equipment and consumables for cardiac surgery	DE	EUR	90 M
2003	Copharm B.V.	Distributor	NL	EUR	10 M
2002	Heraeus Medical	Surgical lamps, ceiling service units and therapy accessories and gas distribution for operating rooms	DE	EUR	52 M
2001	ALM	Surgical lamps	FR	FRF	490 M
2000	Maquet	Surgical tables	DE	EUR	155 M
2000	Parker Bath	Bathing systems for the semi-institutional care market	UK	SEK	150 M
2000	Lenken Healthcare	Distributor	IE	SEK	65 M
2000	Gestion Techno-Medic	Patient lifting systems	CA	SEK	22 M
1999	Lunatronic Aps	Comprehensive IT solutions for the maintenance of sterilization departments	DK	DKK	15 M
1999	MPT Corp.	Washer disinfectors for the life science market	US	SEK	35 M
1998	Egerton Hospital Equipment	Specialist beds and anti-decubitus mattresses for hospitals and care facilities	UK	SEK	45 M
1998	Royal Linden B.V.	Infection control	NL	SEK	60 M
1998	Medibo	Patient lifting and pressure-ulcer treatments	BE	SEK	28 M
1998	OMASA	Infection control	IT	SEK	100 M
1998	SMI/BBC	Infection control	FR	SEK	75 M
1998	Kemiterm	Water distillers pure-steam generators for pharmaceutical industry	DK	DKK	25 M
1998	Pegasus	Anti-decubitus products for hospitals and elderly care	UK	SEK	350 M
1996	MDT/Castle	Infection control	US	-	-
1996	Van Dijk Medizintechnik GmbH	Infection control	DE	SEK	30 M
1995	Arjo	Products for aging care related to hygiene and patient management	SE	SEK	1,538 M
1994	Lancer	Disinfection products	FR	FRF	70 M

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Reconciliation of alternative performance measures

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the group's performance. The alternative performance measures are not to be considered a substitute for, but rather a supplement to, the financial statements prepared in accordance with IFRS.

The alternative performance measures recognized are not calculated in accordance with IFRS but are provided since Getinge believes that they are important to investors' assessments of the group and the Getinge share. These performance measures are widely used by investors, securities analysts and other stakeholders as supplementary measures of the earnings trend and financial position. Getinge's performance measures that are not defined in accordance with IFRS are not necessary comparable with similar measures presented by other companies and have certain limitations as analysis tools.

THE GROUP'S PRIMARY PERFORMANCE MEASURES

Adjusted gross profit, SEK M	2024	2023
Gross profit	16,153	14,495
Add-back of:		
Depreciation, amortization and write-downs of tangible and non-acquired intangible assets	960	1,029
Other items affecting comparability	297	154
Adjustment for write-downs included in other items affecting comparability	-	-146
Adjusted gross profit	**17,409**	**15,533**

Adjusted EBITDA, SEK M	2024	2023
Operating profit/loss (EBIT)	**2,854**	**3,736**
Add-back of:		
Depreciation, amortization and write-downs of tangible and non-acquired intangible assets	1,823	1,859
Amortization and write-down of acquired intangible assets	320	234
Other items affecting comparability	797	-325
Acquisition and restructuring costs	898	242
Adjustment for write-downs included in other items affecting comparability and restructuring costs	-46	-172
Adjusted EBITDA	**6,646**	**5,574**

EBITA, SEK M	2024	2023
Operating profit/loss (EBIT)	**2,854**	**3,736**
Add-back of:		
Amortization and write-down of acquired intangible assets	320	234
EBITA	**3,174**	**3,970**

Adjusted EBITA, SEK M	2024	2023
Operating profit/loss (EBIT)	**2,854**	**3,736**
Add-back of:		
Amortization and write-down of acquired intangible assets	320	234
Other items affecting comparability	797	-325
Acquisition and restructuring costs	898	242
Adjusted EBITA	**4,869**	**3,887**

Adjusted EBIT, SEK M	2024	2023
Operating profit/loss (EBIT)	**2,854**	**3,736**
Add-back of:		
Other items affecting comparability	797	-325
Acquisition and restructuring costs	898	242
Adjusted EBIT	**4,549**	**3,653**

20250623150700

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Adjusted net profit for the year, SEK M	2024	2023
Net profit for the year	**1,654**	**2,428**
Add-back of:		
Amortization and write-down of acquired intangible assets	320	234
Other items affecting comparability	797	-325
Acquisition and restructuring costs	898	242
Tax items affecting comparability	–	–
Tax on add-back items	-459	-60
Adjusted net profit for the year	**3,211**	**2,519**

The calculation of adjusted earnings per share, before and after dilution, attributable to the Parent Company's shareholders, is based on the following information:

Earnings (numerator), SEK M	2024	2023
Adjusted net profit for the year	**3,211**	**2,519**
Adjusted net profit for the year attributable to non-controlling interest	-16	-16
Adjusted net profit for the year attributable to the Parent Company shareholders, which form the basis for calculation of adjusted earnings per share	**3,195**	**2,503**
Number of shares (denominator)		
Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands)	272,370	272,370
Adjusted earnings per share, SEK	**11.73**	**9.19**

Net debt/equity ratio, multiple	2024	2023
Net interest-bearing debt, SEK M	10,467	8,012
Equity, SEK M	33,230	30,403
Net debt/equity ratio[1)]	**0.32**	**0.26**

1) Net interest-bearing debt in relation to equity.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

ADJUSTED EBITA PER SEGMENT

Adjusted EBITA, 2024, SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Group functions and other	Total
Operating profit (EBIT)	**2,065**	**526**	**703**	**-440**	**2,854**
Add back of:					
Amortization and write-down of acquired intangible assets	170	46	104	–	320
Other items affecting comparability	604	–	193	–	797
Acquisition and restructuring costs	715	35	91	57	898
Adjusted EBITA	**3,554**	**608**	**1,090**	**-383**	**4,869**

Adjusted EBITA, 2023, SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Group functions and other	Total
Operating profit (EBIT)	**3,215**	**395**	**675**	**-549**	**3,736**
Add back of:					
Amortization and write-down of acquired intangible assets	145	32	56	–	234
Other items affecting comparability	-279	–	-46	–	-325
Acquisition and restructuring costs	36	3	35	167	242
Adjusted EBITA	**3,117**	**430**	**721**	**-381**	**3,887**

Other items affecting comparability, 2024, SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Group functions and other	Total
Provision for investigations with CGU in Brazil, Acute Care Therapies	289	–	–	–	289
Provision for investigations with CGU in Brazil, Surgical Workflows	–	–	193	–	193
Provision for field actions for Cardiosave, Acute Care Therapies	297	–	–	–	297
Other	18	–	–	–	18
Total	**604**	**–**	**193**	**–**	**797**

Other items affecting comparability, 2023, SEK M	Acute Care Therapies	Life Science	Surgical Workflows	Group functions and other	Total
Write down of R&D	146	–	–	–	146
Insurance compensation	-450	–	–	–	-450
Dissolution of provision for contingent consideration	–	–	-46	–	-46
Other	25	–	–	–	25
Total	**-279**	**–**	**-46**	**–**	**-325**

202506231507l

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Group companies

HEAD OFFICE

Getinge AB (publ)
Lindholmspiren 7A
SE-417 56 Göteborg
Tel: +46 10 335 0000
President: Mattias Perjos

Australia

Getinge Australia Pty Ltd
Suite 701, Level 7, 11 Help St
AU-Chatswood, NSW 2067
Tel: +61 18 0043 8464
President: Kartik Natarajan

Austria

Getinge Österreich GmbH
Lemböckgasse 49 Haus 2,
Stiege D, EG
AT-1230 Wien
Tel: +43 1 8651 4870
President: Raghed Hanna

Belgium

Getinge Belgium NV
Alfons Gossetlaan 17
BE-1702 Groot-Bijgaarden
Tel: +32 24 67 8585
President: Raghed Hanna

Brazil

Getinge do Brasil Equipamentos Médicos Ltda
Avenida Manuel Bandeira, 291 – Bloco B – Conjunto 33 e 34
BR-05317-020 São Paulo
Tel: +55 11 2608 7400
President: Aurélio Carmona

Canada

Getinge Canada Ltd
90 Matheson Blvd. W, Suite 300
CA-L5R 3R3, Mississauga, ON
Tel: +1 905 752 3300
President: Dave Blair

China

Maquet (Shanghai) Medical Equipment Co., Ltd
20F, Building 1, 188 Ruby Road,
Changning District
CN-201 103 Shanghai
Tel: +86 21 6197 3999
President: Echo Mao

Maquet (Suzhou) Co., Ltd
No 158 Fangzhou Road,SIP
CN-215 024 Suzhou
Tel: +86 512 6283 9880
President: Shukun Liu

Colombia

Getinge Colombia SAS
Carrera 16 # 95 70
CO-110221 Bogotá, D.C.
Tel: +571 743 8124
President: Rodrigo Aurelio Garcia

Czech Republic

Getinge Czech Republic, s.r.o.
Na Strži 1702/65
CZ-140 00 Praha 4-Nusle
Tel: +420 225 092 302
President: Jiri Lacina

Denmark

Getinge Cetrea A/S
Brendstrupgårdsvej 21 F
DK-8200 Aarhus N
Tel: +45 26 397 990
President: Charlotte Enlund

Getinge IT Solutions ApS
Dampfærgevej 21, 2.
DK-2100 Copenhagen
Tel: +45 33 338 855
President: Charlotte Enlund

Getinge Danmark A/S
Tonsbakken 16-18,
DK-2740 Skovlunde
Tel: +45 45 932 727
President: Magnus Back

Finland

Getinge Finland Oy
Vuoritorntuntie 22
FI-02200 Espoo
Tel: +35 896 824 120
President: Magnus Back

France

Getinge France SAS
Carnot Plaza,
14/16 avenue Carnot
FR-91300 Massy
Tel: +33 238 258 888
President: Sylvain Touron

Getinge Infection Control SAS
30 Boulevard De L'Industrie
FR-31170 Tournefeuille
Tel: +33 561 151 111
President: Sebastien Blanche

Getinge Life Science France SAS
1 Rue du Comté de Donegal
FR-41100 Vendome
Tel: +33 561 151 111
President: Julien Albuy-Meyer & Michael Raphael

LTA Medical
27 rue Albert Einstein
FR-93 000 Bobigny
Tel: +33 756 152 048
President: Jérome Polenne

Intervascular SAS
270 Voie Ariane - ZI Athélia 1
FR-13600 La Ciotat
Tel: +33 442 084 646
President: Jocelyn Lebrun

Maquet SAS
Parc de Limère – Avenue de la Pomme de Pin
FR-45074 Orléans
Tel: +33 238 258 888
President: Jérome Baron

Fluoptics SAS
44 Rue Des Berges
FR-38000 Grenoble
Tel: +33 485 870 660
President: Laurence Baudel-Vanbeek

Germany

Getinge IT Solutions GmbH
Südportal 5
DE-22848 Norderstedt
Tel: +49 4051 435 0
President: Dr. Matthias Rath

Getinge Deutschland GmbH
Kehler Str. 31
DE-76437 Rastatt
Tel: +49 7222 932 0
President: Raghed Hanna

Irasun GmbH
Lichtenbergstr. 8
DE-85748 Garching bei München
Tel: +49 176 43 6663 46
President: Fabian König & Florian Altinger

Maquet Cardiopulmonary GmbH
Kehler Str. 31
DE-76437 Rastatt
Tel: +49 7222 932 0
President: Dr. Dieter Engel

Maquet GmbH
Kehler Str. 31
DE-76437 Rastatt
Tel: +49 7222 932 0
President: Sebastian Hügli

Getinge Holding B.V. & Co KG
Kehler Str. 31
DE-76437 Rastatt
Tel: +49 7222 932 0
President: Matthias Gelsok

Pulsion Medical Systems SE
Hans-Riedl-Str. 21
DE-85622 Feldkirchen
Tel: +49 894 599 140
President: Stephan Haft

MediKomp GmbH
Kehler Str. 31
DE-76437 Rastatt
Tel: +49 7222 932 0
President: Özgür Yildiz

Getinge Financial Services GmbH
Kehler Str. 31
DE-76437 Rastatt
Tel: +49 7222 932 0
President: Matthias Gelsok

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Hong Kong
Getinge Group Hong Kong Ltd
26/F, Port 33, 33 Tseuk Luk Street
HK-San Po Kong, Kowloon, Hong Kong
Tel: +852 2207 6111
President: CM Leung

India
Getinge Medical India Pvt Ltd
Times Square Building, 9th floor, E Wing, Mathuradas Vasanji Road, Marol, Andheri East
IN-400059 Mumbai
Tel: +91 22 6233 2100
President: Aruna Nayak

Getinge India Pvt Ltd
Times Square Building, 9th floor, E Wing, Mathuradas Vasanji Road, Marol, Andheri East
IN-400059 Mumbai
Tel: +91 74 0009 4775
President: Sunil Dinanath Joshi

Ireland
Getinge Ireland Ltd.
B6 Calmount Park, Ballymount, Dublin 12
IE-D12NA03 Dublin
Tel: +353 1 425 0032
President: Amy Rothwell

Italy
Getinge Italia Srl
Via Guido Gozzando, 14
IT-20092 Cinisello Balsamo (MI)
Tel: +39 02 611 135 1
President: Roberto Chareun

Japan
Getinge Group Japan KK
Sphere Tower Tennoz 7F, 2-2-8 Higashi-shinagawa, Shinagawa-ku
JP-140-0002 Tokyo
Tel: +81 3 5463 8310
President: Yuko Nagasawa

Mexico
Maquet Mexicana, S. de R.L. de C.V.
Montecito 38, piso 10 ofna 33, Col Nápoles, Alcaldía Benito Juárez
MX-03810 Mexico City
Tel: +52 55 9000 8970
President: Rodrigo Aurelio Garcia

Netherlands
Getinge Netherlands B.V.
Olympia 4
NL-1213 NT Hilversum
Tel: +31 35 303 5000
President: Raghed Hanna

Applikon Biotechnology B.V.
Heertjeslaan 2
NL-2629 JG Delft
Tel: +31 10 20 83 555
President: Eric Goossens

New Zealand
Maquet New Zealand Pty Ltd (Branch)
Level 2, Building B, 600 Great South Road
NZ-Auckland 1051
Tel: +61 1800 438 464
President: Kartik Natarajan

Norway
Getinge Norge AS
Enebakkveien 150
NO-0680 Oslo
Tel: +47 230 35 200
President: Magnus Back

Poland
Getinge IC Production Poland Sp. z o.o.
ul. Szkolna 30
PL-62-064 Plewiska
Tel: +48 61 630 99 00
President: Jakub Cegiela

Getinge Polska Sp. z o.o.
ul. Żwirki i Wigury 18
PL-02-092 Warszawa
Tel: +48 22 882 06 44
President: Szymon Kawalko

Getinge Shared Service Sp. z o.o.
Powstańców Wielkopolskich 13 F (Budynek D)
PL-30-707 Kraków
Tel: +48 12 385 42 22
President: Agnieszka Obuchowska

Portugal
Getinge Group Portugal Unipessoal Lda
Edifício Zenith, Rua Dr. Antonio Loureiro Borges nº 9/9º - 3º andar
PT-1495-131 Alges Miraflores
Tel: +351 214 189 815
President: Marcio Mazon

Russia
Maquet LLC
Office Park Comcity, 22nd km Kievskoe highway, 6 bld 1
RU-108811 Moscow
Tel: +7 495 514 0055
President: Anna Mednikova

Saudi Arabia
Getinge Regional Headquarter
Building No: 7793, West Umm Al Hamam District
SA-12329 Riyadh
Tel: +966 563 333 417
President: Georges El Obeid

Serbia
Getinge Group South East Europe d.o.o. Beograd
Bulevar Vojvode Bojovica 6-8
RS-11000 Belgrade
Tel: +420 225 092 302
President: Jiri Lacina

Singapore
Getinge Singapore Pte. Ltd.
20 Bendemeer Road #06-04
BS Bendemeer Centre
SG-339914 Singapore
Tel: +65 6 296 1992
President: Marimuthu Anbuchezhian

Getinge South East Asia Pte. Ltd.
20 Bendemeer Road #06-01/02
BS Bendemeer Centre
SG-339914 Singapore
Tel: +65 6 296 1992
President: Teodor Johansson

South Africa
Maquet Southern Africa (Pty) Ltd
4 Bridle Close, Woodmead
Office Park, Van Reenen Ave
ZA-2196 Sandton, Johannesburg
Tel: +27 11 656 3306
President: Salah Malek

South Korea
Getinge Medical Korea Co., Ltd.
13F KeumKang Building, 304, Bongeunsa-ro, Gangnam-gu
KR-06143 Seoul
Tel: +82 25 58 2271
President: Hyun Dong Kim

Spain
Getinge Group Spain SL
C/Marie Curie 5, edificio Alfa Planta 6 Of 6.2
ES-28521 Rivas Vacia Madrid
Tel: +34 91 678 1652
President: Marcio Mazon

Sweden
Getinge AB (publ)
Lindholmspiren 7A
SE-417 56 Göteborg
Tel: +46 10 335 0000
President: Mattias Perjos

Getinge Disinfection AB
Ljungadalsgatan 11
SE-352 46 Växjö
Tel: +46 10 335 9800
President: Jonas Andersson, interim

Getinge Finance Holding AB
Lindholmspiren 7A
SE-417 56 Göteborg
Tel: +46 10 335 0000
President: Daniel Bengtsson Ireman

Getinge Logistics AB
Ekebergsvägen 26
SE-305 75 Getinge
Tel: +46 10 335 0000
President: Christian Lambrant

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Getinge Business Support Services AB
Lindholmspiren 7A
SE-417 56 Göteborg
Tel: +46 10 335 0000
President: Pelle Nilsson

Getinge Sterilization AB
Ekebergsvägen 26
SE-305 75 Getinge
Tel: +46 10 335 0000
President: Maria Ek

Getinge Sverige AB
Ekebergsvägen 26
SE-305 75 Getinge
Tel: +46 10 335 0000
President: Magnus Back

Getinge Treasury AB
Lindholmspiren 7A
SE-417 56 Göteborg
Tel: +46 10 335 0000
President: Mimmi Lykken Ljungdahl

Maquet Critical Care AB
Röntgenvägen 2
SE-171 54 Solna
Tel: +46 10 335 7300
President: Cecilia Sjöstedt

Switzerland

Getinge Schweiz AG
Quellenstr. 41b
CH-4310 Rheinfelden
Tel: +41 61 836 47 70
President: Raghed Hanna

Taiwan

Getinge Group Taiwan Co., Ltd.
Rm. 08, 6F., No. 288, Sec. 6, Civic Blvd., Xinyi Dist.
TW-110417 Taipei City
Tel: +886 2 8161 6588
President: Tina Wang

Thailand

Getinge (Thailand) Co., Ltd.
5 Soi Krungthepkreetha 4 (B.Grimm)
Huamark, Bangkapi
TH-10240 Bangkok
Tel: +66 02 704 4388
President: Kulissara Tunyong

Türkiye

Getinge Medikal Sistemler San. Ve Tic. A.Ş.
Allianz Plaza Küçükbakkalköy
Mah. Kayışdağı Cad. No:1
Kapı no:96
TR-34752 Ataşehir / Istanbul
Tel: +90 216 444 66 78
President: Vecihe Özek

Maquet Cardiopulmonary Medikal Teknik San.Tic.Ltd.Şti
Serbest Bölge R
Ada,108/1,109/1,110/1,111/1
Parseller 1 Cadde Dış Kapı No:8
TR-07070 Antalya
Tel: +90 242 249 90 30
President: Murat Calik

United Arab Emirates

Getinge Group Middle East FZ-LLC
1901N, 19th Floor, Dubai Science Park (DSP) Towers-North
AE-214742 Dubai
Tel: +971 4 447 0963
President: Salah Malek

United Kingdom

Getinge IT Solutions Ltd
Unit 3 St Modwen Park,
Andressey Way, Chaddesden
GB-DE61 6YH Derby
Tel: +44 1773 814730
President: Stéphane Le Roy

Getinge Ltd
Unit 3 St Modwen Park,
Andressey Way, Chaddesden
GB-DE61 6YH Derby
Tel: +44 1773 814730
President: Amy Rothwell

Applikon Biotechnology B.V. (UK Branch)
Unit 3 St Modwen Park,
Andressey Way, Chaddesden
GB-DE61 6YH Derby
Tel: +44 345 337 3306
President: Eric Goossens

Quadralene Ltd
Unit 3 St Modwen Park,
Andressey Way, Chaddesden
GB-DE61 6YH Derby
Tel: +44 133 229 2500
President: Robert Newsome

US

Atrium Medical Corporation
40 Continental Blvd.
US-03054, Merrimack, NH
Tel: +1 603 880 1433
President: Chad Carlton

Datascope Corp.
45 Barbour Pond Drive
US-07470 Wayne, NJ
Tel: +1 888 627 8383
President: Cynthia Hougum

Steritec Products Mfg. Co., Inc.
74 Inverness Drive East
US-80112 Englewood, CO
Tel: +1 303 660 4201
President: Bryan Leo

Getinge Group Logistics Americas, LLC
45 Barbour Pond Drive
US-07470 Wayne, NJ
Tel: +1 551 427 1052
President: Frank Kozar

Getinge Aseptic Solutions, LCC
201 Housatonic Avenue
US-06776 Milford, CT
Tel: +1 860 350 1900
President: Benoit Portier

Paragonix Technologies, Inc.
950 Winter Street, 2nd Floor
US-02451 Waltham, MA
Tel: +1 781 428 4153
President: Lisa Anderson

Talis Clinical LLC
650 Mondial Parkway
US-44241 Streetsboro, OH
Tel: +1 234 284 2400
President: Gary Colister

Getinge USA Sales, LLC
45 Barbour Pond Drive
US-07470 Wayne, NJ
Tel: +1 973 709 7000
President: Patricia Fitch

Maquet Cardiovascular LLC
45 Barbour Pond Drive
US-07470 Wayne, NJ
Tel: +1 973 709 7000
President: Cynthia Hougum

Ultra Clean Systems Inc.
110 Douglas Road East
US-34677 Oldsmar, FL
Tel: +1 727 512 9576
President: Christopher Devlin

High Purity New England Inc.,
2 Thurber Blvd.
US-02917 Smithfield, RI
Tel: +1 401 349 4477
President: Sean Herdlein

Healthmark Industries Co., Inc.
18600 Maylyn Blvd.
US-48026-3496 Fraser, MI
Tel: +1 800 521 6224
President: Steven Basile

Vietnam

Getinge Vietnam Company Ltd
Floor 6, Yoco Building,
41 Nguyen Thi Minh Khai,
Ben Nghe Ward, District 1
VN-Ho Chi Minh City
Tel: +84 28 3824 3391
President: Teodor Johansson

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Definitions

Financial terms

Adjusted EBIT: Operating profit (EBIT) with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITA: EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITDA: EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted earnings per share: Adjusted net profit for the year attributable to Parent Company's shareholders in relation to average number of outstanding shares.

Adjusted gross profit: Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

Adjusted net profit: Net profit for the year with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income statement items.

Adjusted profit before tax: Profit before tax with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

Capital goods: Durable products that are not consumed when used.

Cash flow per share: Cash flow from operating activities divided by the average number of outstanding shares.

Currency transaction effect: Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.

Dividend yield: Dividend in relation to the market share price on December 31.

Earnings per share: Net profit for the year attributable to Parent Company's shareholders in relation to average number of outstanding shares.

EBIT: Operating profit.

EBITA: Operating profit (EBIT) with add-back of amortization and write-down of acquired intangible assets.

EBITA margin: EBITA in relation to net sales.

EBITDA: Operating profit (EBIT) with add-back of amortization, depreciation and write-downs.

EBITDA margin: EBITDA in relation to net sales.

Equity/assets ratio: Equity in relation to total assets.

Equity per share: Equity in relation to the number of outstanding shares at the end of the period.

Gross margin: Gross profit in relation to net sales.

Interest-coverage ratio: Adjusted EBITDA in relation to net interest.

Items affecting comparability: Comprises acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.

Net debt/equity ratio: Net interest-bearing debt in relation to equity.

Operating capital: Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

Operating liabilities: Accounts payable, other provisions and other non-interestbearing liabilities (contract liabilities, non-interest-bearing provisions for pensions, accrued expenses and deferred income as well as other liabilities).

Operating margin: Operating profit (EBIT) in relation to net sales.

Operating receivables: Accounts receivable and other current receivables (contract assets, prepaid expenses and accrued income, and other receivables).

Organic change: A financial change adjusted for currency, acquisitions and divestment of operations.

P/E ratio: Share price (final price) in relation to earnings per share.

Recurring revenue: Products that are continuously consumed as well as service, spare parts and similar items.

Return on equity: Profit after tax in relation to average equity.

Return on operating capital: Adjusted EBIT in relation to operating capital.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Sustainability terms

Double materiality assessment: The process of identifying an organization's impacts on people and the environment and the sustainability-related financial risks and opportunities for the organization. The results are also used to determine whether a sustainability topic is to be included in the company's sustainability report.

ESRS: European Sustainability Reporting Standards.

Employee engagement: The engagement score in Getinge's employee survey.

Online customer training: The number of training courses held for customers. The total number of times a customer has completed an e-learning course or participated in a training webinar.

REC (Renewable Energy Certificates): Used to certify that electricity was generated from renewable sources.

Scope 1 & 2: Carbon emissions from production (in ton CO_2 equivalents). Scope 1 includes emissions from oil and gas consumption and emissions from Getinge's vehicle fleet. Scope 2 includes emissions from electricity, heating, cooling and emissions from leased spaces.

Medical terms

Anesthesia: A procedure where patients are put into a state of unconsciousness so that they do not feel pain during, for example, surgery.

Aseptic handling: Refers to a controlled process where a product undergoes disinfection in a washer and is stored and handled as to maintain its level of purity.

Bioreactor: A container used for the development and production of biopharmaceuticals and food.

Cardiopulmonary: Something that relates to or belongs to both the heart and lungs.

Cardiovascular: Pertaining or belonging to both heart and blood vessels.

DPTE'-BetaBag: A bag that ensures contamination-free transfer of components.

ECMO: Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine that exchanges oxygen and carbon dioxide, like an artificial lung.

Endoscope: Equipment for visual examination of the body's cavities, such as the stomach.

Endovascular: Vascular treatment using catheter technologies.

GMP: Good Manufacturing Practice is an international guideline for production and quality assurance in the pharmaceutical industry.

Graft: Artificial vascular implant.

Hemodynamic monitoring: Monitoring the balance between blood pressure and blood flow.

Isolator: Sterile space for antiseptic handling of, for example, pharmaceuticals.

Low-temperature sterilization: A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments used in minimal invasive surgery.

Monoclonal antibodies: Identical antibodies derived from a single cell.

Stent: A tube for endovascular widening of blood vessels.

Sterilizer: A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.

Vascular intervention: A medical procedure conducted through vascular puncturing instead of using an open surgery method.

Ventilator: Medical device to help patients breathe.

Washer: Machine that cleans and disinfects medical equipment.

Geographic areas

Americas: North, South and Central America.

APAC: Asia and Pacific (excluding Middle East).

EMEA: Europe, Middle East and Africa.

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Annual General Meeting and Nomination Committee

Annual General Meeting

The Annual General Meeting will be held on April 22, 2025, in Kongresshallen at Hotel Tylösand, Halmstad, Sweden. Detailed information about participation and postal voting is available on the company's website, https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2025/.

Registration

Shareholders wishing to participate at the Annual General Meeting must:

- be recorded in the share register kept by Euroclear Sweden AB on April 10, 2025, and
- notify the company of their intention to participate not later than April 14, 2025

Shareholders who wish to participate in person may register in the following ways:

- On Getinge's website: https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2025/.
- By post to:
  Getinge AB (publ)
  "AGM 2025"
  c/o Euroclear Sweden AB
  PO Box 191, SE-101 23 Stockholm, Sweden
- By telephone: +46 (0) 10 335 08 18
  (weekdays between 9:00 a.m.–4:00 p.m.)

Shareholders who wish to participate in the Annual General Meeting by postal vote should cast their postal vote in accordance with instructions available on Getinge's website, https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2025/.

Nominee-registered shares

Shareholders whose shares are registered in the name of a nominee through a bank or other nominee must be entered in their own name in the share register maintained by Euroclear Sweden AB on April 10, 2025 in order to be entitled to participate in the AGM. Shareholder must inform the nominee well in advance of this date.

For shareholders represented by proxy, power of attorney must be issued, which should be sent before the AGM. A proxy form can be downloaded from https://www.getinge.com/int/company/corporate-governance/general-meetings/annual-general-meeting-2025/. Anyone representing a legal entity must show a certified copy of the registration certificate or equivalent authorization documents stating the authorized signatory.

Nomination Committee

Getinge AB's interim report for the third quarter of 2024 contained instructions for shareholders on how to proceed to submit proposals to Getinge's Nomination Committee and how to propose motions to be addressed at the Annual General Meeting.

Dividend

The Board of Directors and CEO propose that a dividend of SEK 4.60 (4.40) per share, a combined total of SEK 1,253 M (1,198), shall be paid for 2024.

The proposed record date is April 24, 2025. Euroclear Sweden AB expects to distribute the dividend to shareholders on April 29, 2025.

Financial information

Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website www.getinge.com.

The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.getinge.com. A printed copy of the Annual Report can also be ordered at www.getinge.com.

Financial information

Preliminary dates for financial information are as follows:

- April 22, 2025: Q1 Report 2025
- April 22, 2025: Annual General Meeting
- July 18, 2025: Q2 Report 2025
- October 21, 2025: Q3 Report 2025
- January 27, 2026: Q4 Report 2025
- March 2026: 2025 Annual Report

Introduction
Strategy
Corporate Governance Report
Financial statements
Sustainability Report
Other information
The Getinge share
Multi-year overview
Reconciliation of alternative performance measures
Group companies
Definitions
Annual General Meeting and Nomination Committee
Financial information
Reading guide and distribution policy
Contact

Reading guide and distribution policy

Reading guide

- The Getinge Group is referred to as Getinge in the Annual Report.
- Figures in parentheses pertain to operations in 2023, unless otherwise specified.
- Swedish kronor (SEK) is used throughout (sometimes abbreviated as SEK or kr).
- Millions of Swedish kronor are abbreviated SEK M.
- All figures pertain to SEK M, unless otherwise specified.
- For practical reasons, numbers are rounded off in the Annual Report, therefore it can occur that notes and tables do not sum up.
- Information provided in the Annual Report concerning markets, competition and future growth constitutes Getinge's assessment based on both external information and material compiled internally.

Distribution policy

The Annual Report is available for download at www.getinge.com. A printed version of the report can also be ordered from the website. The decision not to automatically send a printed version to the company's shareholders is based on the ambition to reduce Getinge's negative impact on the environment.

Contact

Getinge AB (publ)
Lindholmspiren 7A
P.O. Box 8861
SE-402 72, Gothenburg
Sweden

Tel: +46 (0)10 335 00 00
E-mail: info@getinge.com
www.getinge.com

GETINGE

Getinge AB (publ)
Lindholmspiren 7A
P.O. Box 8861
SE-402 72, Gothenburg
Sweden

Tel: +46 (0)10 335 00 00
E-mail: info@getinge.com
www.getinge.com